Probe name,Rating in cell,Rating in organism,Number of Ratings,Unsuitable,URL,Target name,Target class,Target subclass,Published on,Uniprot ID,InChI key,SMILES,PAINS,Toxicophore,ChEMBL ID,canSAR ID,Reference (PMID),Mechanism of action,Potency value,Potency assay,Potency value in cells,Potency assay (cells),Potency in cells,Organism,Dose,Control compound
Please cite the Chemical Probes Portal
SGC0946,3.8,0.0,4.0,No,https://www.chemicalprobes.org/sgc0946,DOT1L,Epigenetic,Protein methyltransferase,2015-10-02,Q8TEK3,IQCKJUKAQJINMK-HUBRGWSESA-N,CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2cc(Br)c3c(N)ncnc32)[C@H](O)[C@@H]1O,No,No,CHEMBL3087498,828356,"www.doi.org/10.1038/ncomms2304, http://www.ncbi.nlm.nih.gov/pubmed/23250418",Inhibitor,0.06 nM,SPR; IC50 = 0.3 nM in enzymatic assay,8.8 nM,in-cell western assay assessing methylation of protein substrate in MCF10A cells,IC50,,,SGC0649
EPZ020411,2.7,2.7,3.0,No,https://www.chemicalprobes.org/epz020411,PRMT6,Epigenetic,Protein methyltransferase,2015-11-05,Q96LA8,QMDKVNSQXPVCRD-RQNOJGIXSA-N,CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@H](OCCC3CCOCC3)C2)cc1,No,No,CHEMBL3589039,469025,"www.doi.org/10.1021/acsmedchemlett.5b00071, http://www.ncbi.nlm.nih.gov/pubmed/?term=26101569",Inhibitor,0.010 uM,Inhibition of 3H-SAM-dependent labeling of peptide substrate and quantification of 3H-labeled peptide.,0.0637 uM,H3R2 methylation in PRMT6-overexpressing A375 cells.,IC50,Other,5 mg/mL,
I-BRD9,3.0,0.0,3.0,No,https://www.chemicalprobes.org/i-brd9,BRD9,Epigenetic,Bromodomain,2016-07-29,Q9H8M2,WRUWGLUCNBMGPS-UHFFFAOYSA-N,CCn1cc(-c2cccc(C(F)(F)F)c2)c2sc(C(=N)NC3CCS(=O)(=O)CC3)cc2c1=O,No,No,CHEMBL3769507,541825,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00256, https://www.ncbi.nlm.nih.gov/pubmed/25856009",Antagonist,BRD9 7.3,"TR-FRET, and BROMOscan profiling with N-methyl Kac mimetic: BRD9 pKD = 8.7.",,"In HUT-78 cells, chemoproteomic competitive binding assays showed I-BRD9 was >625-fold selective for BRD9 over BRD3",,,,Not available
CFI-400945,1.7,1.7,3.0,No,https://www.chemicalprobes.org/cfi-400945,PLK4,Protein kinase,Other,2015-12-10,O00444,DADASRPKWOGKCU-FVTQAUBDSA-N,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2,No,No,CHEMBL3408947,829372,"http://www.sciencedirect.com/science/article/pii/S1535610814002219, http://www.ncbi.nlm.nih.gov/pubmed/25043604",ATP-competitive inhibitor,0.26 nM,In vitro kinase assay IC50 = 2.8 nM,12.3 nM,Inhibition of PLK4 autophosphorylation in PLK4-overexpressing cells.,EC50,Other,2.4-20 mg/kg,
BIX-02565,3.0,2.0,2.0,No,https://www.chemicalprobes.org/bix-02565,RPS6KA3,Protein kinase,AGC,2021-02-02,P51812,ZHMXXVNQAFCXKK-QGZVFWFLSA-N,C[C@@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21,No,No,CHEMBL1933288,592803,"www.doi.org/10.1016/j.bmcl.2011.10.029, www.doi.org/10.1124/jpet.111.189365, https://pubmed.ncbi.nlm.nih.gov/22056746/, https://pubmed.ncbi.nlm.nih.gov/22128344/",Inhibitor,1 nM,,20 nM,Inhibition of substrate phosphorylation,IC50,Other,"1,3, 10 (IV) mg/Kg; , 30, 100, 300 (PO) mg/Kg",
PRT062607,3.7,3.7,3.0,No,https://www.chemicalprobes.org/prt062607,SYK,Protein kinase,TK,2015-12-10,P43405,TXGKRVFSSHPBAJ-JKSUJKDBSA-N,NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1,No,No,CHEMBL2177736,267014,"www.doi.org/10.1124/jpet.111.188441, http://www.ncbi.nlm.nih.gov/pubmed/22040680",Inhibitor,2.1 nM,"Radiometric assay; in a FRET-based assay, IC50 = 6 nM",0.16-0.4 uM,Inhibition of protein substrate phosphorylation in B cells,IC50,Other,30 mg/kg,
KU-60019,2.0,1.7,3.0,No,https://www.chemicalprobes.org/ku-60019,ATM,Protein kinase,Atypical,2015-12-10,Q13315,SCELLOWTHJGVIC-BGYRXZFFSA-N,C[C@H]1CN(CC(=O)Nc2ccc3c(c2)Cc2cccc(-c4cc(=O)cc(N5CCOCC5)o4)c2S3)C[C@@H](C)O1,No,Yes,CHEMBL2140173,856836,"www.doi.org/10.1158/1535-7163.MCT-09-0519, http://www.ncbi.nlm.nih.gov/pubmed/19808981",Inhibitor,6.3 nM,,,Dose-dependent inhibition of protein substrate phosphorylation in U87 glioma cells,,,,
GNE7915,3.0,3.0,3.0,No,https://www.chemicalprobes.org/gne7915,LRRK2,Protein kinase,TKL,2015-12-10,Q5S007,XCFLWTZSJYBCPF-UHFFFAOYSA-N,CCNc1nc(Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F,No,No,CHEMBL2178134,379695,"www.doi.org/10.1021/jm301020q, http://www.ncbi.nlm.nih.gov/pubmed/22985112",Competitive inhibitor,1 nM,,9 nM,Inhibition of autophosphorylation,IC50,Other,0.5 mg/kg,
CCT241533,3.7,2.0,3.0,No,https://www.chemicalprobes.org/cct241533,CHEK2,Protein kinase,CAMK,2015-12-10,O96017,HZASIAXCPXTISQ-NVXWUHKLSA-N,COc1cc2nc(-c3cc(F)ccc3O)nc(N[C@@H]3CNC[C@H]3C(C)(C)O)c2cc1OC,No,No,CHEMBL1236782,432350,"www.doi.org/10.1158/0008-5472.CAN-10-1252, http://www.ncbi.nlm.nih.gov/pubmed/21239475",ATP-competitive inhibitor,1.16 nM,Radiometric assay; IC50 in kinase assay = 3 nM,,"In HT-29 and HeLa cells, CCT24133 inhibited phosphorylation of CHEK2 substrates more than CHEK1 substrates.",,Other,,
VE-821,2.7,0.0,3.0,No,https://www.chemicalprobes.org/ve-821,ATR,Protein kinase,Atypical,2015-12-10,Q13535,DUIHHZKTCSNTGM-UHFFFAOYSA-N,CS(=O)(=O)c1ccc(-c2cnc(N)c(C(=O)Nc3ccccc3)n2)cc1,No,No,CHEMBL1766779,1808649,"http://www.nature.com/nchembio/journal/v7/n7/full/nchembio.573.html, http://pubs.acs.org/doi/abs/10.1021/jm101488z, http://www.ncbi.nlm.nih.gov/pubmed/21490603, http://www.ncbi.nlm.nih.gov/pubmed/21413798",ATP-competititve inhibitor,13 nM,,,VE-821 dose-dependently inhibited ATR substrate phosphorylation in cells,,,,
PF-4800567,2.0,1.0,3.0,No,https://www.chemicalprobes.org/pf-4800567,CSNK1E,Protein kinase,CK1,2015-12-10,P49674,AUMDBEHGJRZSOO-UHFFFAOYSA-N,Nc1ncnc2c1c(COc1cccc(Cl)c1)nn2C1CCOCC1,No,No,CHEMBL2069623,1644683,"https://doi.org/10.1124/jpet.109.151415, http://www.ncbi.nlm.nih.gov/pubmed/19458106",ATP-competitive inhibitor,32 nM,In vitro kinase assay,0.13 uM,Inhibition of protein substrate phosphorylation; CSNK1D IC50 = 2.65 uM,IC50,Other,100 mg/kg,
AZ191,3.0,0.0,3.0,No,https://www.chemicalprobes.org/az191,DYRK1B,Protein kinase,CMGC,2015-12-10,Q9Y463,ZYVXTMKTGDARKR-UHFFFAOYSA-N,COc1cc(N2CCN(C)CC2)ccc1Nc1nccc(-c2cn(C)c3cnccc23)n1,No,No,CHEMBL3421968,466178,"http://www.biochemj.org/content/457/1/43.long, http://www.ncbi.nlm.nih.gov/pubmed/24134204",Inhibitor,17 nM,in vitro radioactivity-based substrate phosphorylation assay,,"In cells, AZ191 dose-dependently inhibited DYRK1B > DYRK1A substrate phosphorylation.",,,,
JIB-04,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/jib-04,,,,2016-12-15,,YHHFKWKMXWRVTJ-OQKWZONESA-N,Clc1ccc(N/N=C(\c2ccccc2)c2ccccn2)nc1,No,Yes,CHEMBL1982368,1354531,,,,,,,,,,
LY294002,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ly294002,,,,2016-12-15,,CZQHHVNHHHRRDU-UHFFFAOYSA-N,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,No,No,CHEMBL98350,1394412,,,,,,,,,,
AMI-1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ami-1,,,,2017-03-07,,MOUNHKKCIGVIDI-UHFFFAOYSA-L,O=C(Nc1ccc2c(O)cc(S(=O)(=O)[O-])cc2c1)Nc1ccc2c(O)cc(S(=O)(=O)[O-])cc2c1.[Na+].[Na+],No,No,CHEMBL3109656,723373,,,,,,,,,,
XMD17-109,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/xmd17-109,,,,2016-12-15,,XVBGRTMNFNMINE-UHFFFAOYSA-N,CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C1CCCC1)c1ccccc1C(=O)N2C,No,No,CHEMBL2381340,927800,,,,,,,,,,
DZNep,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dznep,,,,2017-02-03,,OMKHWTRUYNAGFG-IEBDPFPHSA-N,Nc1nccc2c1ncn2[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,No,No,CHEMBL154745,1117457,,,,,,,,,,
Chaetocin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chaetocin,,,,2017-02-03,,PZPPOCZWRGNKIR-PNVYSBBASA-N,CN1C(=O)[C@@]23C[C@]4([C@]56C[C@@]78SS[C@@](CO)(C(=O)N7[C@H]5Nc5ccccc56)N(C)C8=O)c5ccccc5N[C@@H]4N2C(=O)[C@]1(CO)SS3,No,Yes,CHEMBL1089316,915616,,,,,,,,,,
Epiblastin A,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/epiblastin,,,,2020-12-05,,ZWNKKZSRANLVEW-UHFFFAOYSA-N,Nc1nc(N)c2nc(-c3cccc(Cl)c3)c(N)nc2n1,No,No,,2922952,"http://www.cell.com/cell-chemical-biology/abstract/S2451-9456(16)30085-X, http://www.cell.com/cell-reports/abstract/S2211-1247(16)30362-X?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS221112471630362X%3Fshowall%3Dtruehttp://www.cell.com/cell-reports/abstract/S2211-1247(16)30362-X?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS221112471630362X%3F, https://www.ncbi.nlm.nih.gov/pubmed/27049670, https://www.ncbi.nlm.nih.gov/pubmed/27149845",,,,,,,,,
JAK3i,2.3,2.3,3.0,No,https://www.chemicalprobes.org/jak3i,JAK3,Protein kinase,TK,2016-09-09,P52333,KNLROUBMVYVLGX-UHFFFAOYSA-N,C=CC(=O)Nc1ccc(F)c(-c2ncnc3[nH]cc(C(=O)OCC)c23)c1,Yes,Yes,CHEMBL4209692,1788744,"http://www.nature.com/nchembio/journal/v12/n5/full/nchembio.2056.html, http://www.ncbi.nlm.nih.gov/pubmed/27018889",Irreversible inhibitor,0.43 nM,"JAK3 in vitro kinase assay with JAK3 kinase domain (Invitrogen), 100 uM ATP, 30 minute pre-incubation and 30 minute incubation with substrate (JAK3Tide) + 32P ATP.",3.7 nM,"IL-2-induced proliferation of CD4+ T-cell blasts from mouse. Briefly, CD4 T-cell blasts were stimulated with 50 units/mL of rhIL-2, incubated for 24 hours, and then proliferation was assessed by 24-hour tritiated thymidine uptake.  
Multiple assays downstream of IL-2 were performed with some variation in IC50: 47 nM for formation of pSTAT5 (FACS), 3.1 nM for upregulation of IL-2Ralpha (CD25) at 24-hours post-IL-2 stimulation, 6.8 nM for IFN-gamma production 24-hours post-IL-2 stimulation.",IC50,Other,40 mg/kg,Compound 2 from Smith et al. 2016 (propionamide of JAK3i)
eCF309,3.0,0.0,3.0,No,https://www.chemicalprobes.org/ecf309,MTOR,Protein kinase,Atypical,2016-10-17,P42345,PSICWGWNIOOULV-UHFFFAOYSA-N,CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC,No,Yes,CHEMBL3800481,129518,http://pubs.rsc.org/en/content/articlelanding/md/2016/c5md00493d#!divAbstract,ATP-competitive inhibitor,15 nM,"MTOR kinase activity relative to DMSO was determined by measuring 33P incorporation on its substrate (poly[Glu,Tyr]4:1) by Reaction Biology Corp., USA. 
eCF309 was tested at 10 different doses with 3-fold serial dilution starting from 10 Î¼M.",<30nM; 8-72 nM,"To verify that eCF309 inhibits both mTORC1 and mTORC2 signalling in cells by inhibition of the mTOR catalytic domain, phosphorylation of downstream targets of both complexes were assessed in MCF7 breast cancer cells by Western blot. Phosphorylation levels of the p70 ribosomal S6 kinase 1 (P70S6K) and its substrate S6 were analysed as substrates of mTORC1, and phospho-AKT (Y473) as an mTORC2 substrate. eCF309 mediated a dose-dependent reduction of the pP70S6K, pS6 and pAKT levels in MCF7 cells, achieving almost complete inhibition of the phosphorylation of these targets at 30 nM. 
 
Antiproliferative activity of eCF309 against cancer cell lines was also evaluated using the PrestoBlue reagent. EC50 = 8 nM in MCF7 cells, 37 nM in PC3 cells; 72 nM in MDA-MB-231 cells. As expected by an mTOR inhibitor, eCF309 reduced cell proliferation in these cell lines by cell cycle arrest.","IC50, EC50",,,
Tandutinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tandutinib,,,,2016-12-09,,UXXQOJXBIDBUAC-UHFFFAOYSA-N,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,No,No,CHEMBL124660,848749,,,,,,,,,,
Quercetin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/quercetin,,,,2016-12-09,,REFJWTPEDVJJIY-UHFFFAOYSA-N,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Yes,Yes,CHEMBL50,1305802,,,,,,,,,,
Dinaciclib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dinaciclib,,,,2016-12-09,,PIMQWRZWLQKKBJ-SFHVURJKSA-N,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,No,No,CHEMBL2103840,256723,,,,,,,,,,
Epigallocatechin-3-gallate (ECGC),0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/epigallocatechin-3-gallate-ecgc,,,,2016-12-09,,WMBWREPUVVBILR-WIYYLYMNSA-N,O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1,Yes,Yes,CHEMBL297453,498738,,,,,,,,,,
Resveratrol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/resveratrol,,,,2016-12-09,,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,No,No,CHEMBL165,96102,,,,,,,,,,
Suramin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/suramin,,,,2016-12-09,,FIAFUQMPZJWCLV-UHFFFAOYSA-N,Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1,No,No,CHEMBL265502,1009853,,,,,,,,,,
Trifluoperazine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/trifluoperazine,,,,2016-12-09,,ZEWQUBUPAILYHI-UHFFFAOYSA-N,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,No,No,CHEMBL422,1899498,,,,,,,,,,
Fluoxetine glucuronide,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/fluoxetine-glucuronide,,,,2016-12-09,,RRKRXIFOHFBLHY-YEZSYGFXSA-M,CN(CCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1)[C@@H]1O[C@H](C(=O)[O-])[C@@H](O)[C@H](O)[C@H]1O.[Na+],No,No,,3312909,,,,,,,,,,
Doxorubicin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/doxorubicin,,,,2016-12-09,,AOJJSUZBOXZQNB-TZSSRYMLSA-N,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Yes,Yes,CHEMBL53463,791569,,,,,,,,,,
Vandetanib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/vandetanib,,,,2016-12-09,,UHTHHESEBZOYNR-UHFFFAOYSA-N,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,No,No,CHEMBL24828,233726,,,,,,,,,,
Axitinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/axitinib,,,,2016-12-09,,RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,No,No,CHEMBL1289926,1927385,,,,,,,,,,
NVP-TAE 226,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nvp-tae-226,,,,2016-12-09,,UYJNQQDJUOUFQJ-UHFFFAOYSA-N,CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl,No,No,CHEMBL458997,512994,,,,,,,,,,
PD173955,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pd173955,,,,2016-12-09,,VAARYSWULJUGST-UHFFFAOYSA-N,CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1,No,No,CHEMBL386051,158055,,,,,,,,,,
AST 487,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ast-487,,,,2016-12-09,,ODPGGGTTYSGTGO-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,No,No,CHEMBL574738,764849,,,,,,,,,,
Vorinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/vorinostat,,,,2017-04-10,,WAEXFXRVDQXREF-UHFFFAOYSA-N,O=C(CCCCCCC(=O)Nc1ccccc1)NO,No,Yes,CHEMBL98,1113023,,,,,,,,,,
G-5555,3.7,2.7,3.0,No,https://www.chemicalprobes.org/g-5555,"PAK1, PAK2, PAK3","Protein kinase, Protein kinase, Protein kinase","STE, STE, STE",2016-11-29,"Q13153, Q13177, O75914",ZBCMHWUFWQFPLV-VVOJOOEHSA-N,CNc1ncc2cc(-c3ccc(-c4cccc(C)n4)cc3Cl)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1,No,No,CHEMBL3770443,660740,"http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00398, https://www.ncbi.nlm.nih.gov/pubmed/?term=26713112",ATP-competitive inhibitor,3.7 nM,Measuring the phosphorylation of a FRET peptide substrate (Ser/Thr19) labeled with Coumarin and Fluorescein,69 nM,pMEK (S298) phosphorylation assay using EBC-1 cells,IC50,Other,"10, 20, and 30 mg/kg","(R)-6-(2-Chloro-4-(4-methyl-2-oxopyridin-1(2H)-yl)phenyl)- 2-(methylamino)-8-(morpholin-2-ylmethyl)pyrido[2,3-d]- pyrimidin-7(8H)-one"
Sunitinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/sunitinib,,,,2016-12-09,,WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,Yes,No,CHEMBL535,154683,,,,,,,,,,
XL-647,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/xl-647,,,,2016-12-09,,HVXKQKFEHMGHSL-QKDCVEJESA-N,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,No,No,CHEMBL3544983,535317,,,,,,,,,,
Apomorphine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apomorphine,,,,2016-12-09,,VMWNQDUVQKEIOC-CYBMUJFWSA-N,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,Yes,Yes,CHEMBL53,1185273,,,,,,,,,,
Ebselen,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ebselen,,,,2016-12-09,,DYEFUKCXAQOFHX-UHFFFAOYSA-N,O=c1c2ccccc2[se]n1-c1ccccc1,No,Yes,CHEMBL51085,65636,,,,,,,,,,
Digitoflavone,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/digitoflavone,,,,2016-12-09,,IQPNAANSBPBGFQ-UHFFFAOYSA-N,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Yes,Yes,CHEMBL151,1241698,,,,,,,,,,
Apigenin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apigenin,,,,2016-12-09,,KZNIFHPLKGYRTM-UHFFFAOYSA-N,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,No,No,CHEMBL28,1161291,,,,,,,,,,
Curcumin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/curcumin,,,,2016-12-09,,ZIUSSTSXXLLKKK-KOBPDPAPSA-N,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,No,Yes,CHEMBL116438,1795385,,,,,,,,,,
Dipyridamole,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dipyridamole,,,,2016-12-09,,IZEKFCXSFNUWAM-UHFFFAOYSA-N,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,No,No,CHEMBL932,681918,,,,,,,,,,
Crizotinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/crizotinib,,,,2016-12-09,,KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,No,No,CHEMBL601719,259783,,,,,,,,,,
Amiodarone,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/amiodarone,,,,2016-12-09,,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,No,No,CHEMBL633,322374,,,,,,,,,,
Linifanib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/linifanib,,,,2016-12-09,,MPVGZUGXCQEXTM-UHFFFAOYSA-N,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,No,No,CHEMBL223360,1920436,,,,,,,,,,
Dovitinib lactate,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dovitinib-lactate,,,,2016-12-09,,QDPVYZNVVQQULH-UHFFFAOYSA-N,CC(O)C(=O)O.CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1.O,No,No,CHEMBL4297063,711445,,,,,,,,,,
"5,7-Dihydroxyflavone",0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/57-dihydroxyflavone,,,,2016-12-09,,RTIXKCRFFJGDFG-UHFFFAOYSA-N,O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12,No,No,CHEMBL117,1115786,,,,,,,,,,
NVP-TAE684,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nvp-tae684,,,,2016-12-09,,QQWUGDVOUVUTOY-UHFFFAOYSA-N,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,No,No,CHEMBL509032,868137,,,,,,,,,,
JNJ-28312141,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/jnj-28312141,,,,2016-12-09,,GUBJNPWVIUFSTR-UHFFFAOYSA-N,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,No,No,CHEMBL1908842,591760,,,,,,,,,,
Ilorasertib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ilorasertib,,,,2016-12-09,,WPHKIQPVPYJNAX-UHFFFAOYSA-N,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,No,No,CHEMBL1980297,644156,,,,,,,,,,
Intedanib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/intedanib,,,,2016-12-09,,XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,No,Yes,CHEMBL502835,817948,,,,,,,,,,
PF-562271,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pf-562271,,,,2016-12-09,,MZDKLVOWGIOKTN-UHFFFAOYSA-N,CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,No,No,CHEMBL1084546,631801,,,,,,,,,,
Kenpaullone,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kenpaullone,,,,2016-12-09,,QQUXFYAWXPMDOE-UHFFFAOYSA-N,O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1,No,No,CHEMBL296586,1185198,,,,,,,,,,
CHEMBL1908393,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl1908393,,,,2016-12-09,,SEJGTFPOEJWEGG-UHFFFAOYSA-N,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)NC5=CCC(F)C=C5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,No,No,,3100290,,,,,,,,,,
Fedratinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/fedratinib,,,,2016-12-09,,JOOXLOJCABQBSG-UHFFFAOYSA-N,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,No,No,CHEMBL1287853,729057,,,,,,,,,,
Kinome_1198,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome1198,,,,2016-12-09,,MVJMMLFMPWITEJ-UHFFFAOYSA-N,N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1,No,Yes,CHEMBL1987034,212832,,,,,,,,,,
SU14813,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/su14813,,,,2016-12-09,,CTNPALGJUAXMMC-PMFHANACSA-N,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,No,No,CHEMBL1721885,449255,,,,,,,,,,
JNJ-7706621,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/jnj-7706621,,,,2016-12-09,,KDKUVYLMPJIGKA-UHFFFAOYSA-N,Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F,No,No,CHEMBL191003,1799601,,,,,,,,,,
KW-2449,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kw-2449,,,,2016-12-09,,YYLKKYCXAOBSRM-JXMROGBWSA-N,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,No,No,CHEMBL1908397,1708627,,,,,,,,,,
Kinome_1194,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome1194,,,,2016-12-09,,OWRXHGAFWZFFCW-UHFFFAOYSA-N,CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl,No,No,CHEMBL1993661,455055,,,,,,,,,,
Kinome_2079,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome2079,,,,2016-12-09,,JZTOUVBEZONDKA-UHFFFAOYSA-N,Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1,No,No,CHEMBL1974328,1720177,,,,,,,,,,
PF-03814735,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pf-03814735,,,,2016-12-09,,RYYNGWLOYLRZLK-UHFFFAOYSA-N,CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12,No,No,CHEMBL1983111,593029,,,,,,,,,,
CHEMBL2062936,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl2062936,,,,2016-12-09,,FUMCKNCUEAQHCV-XYPYZODXSA-N,O[C@H]1CC[C@H](Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1,Yes,No,CHEMBL2062936,1543298,,,,,,,,,,
Kinome_1054,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome1054,,,,2016-12-09,,ZGZVRPRSFXRGCF-UHFFFAOYSA-N,COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC,No,No,CHEMBL1991078,593085,,,,,,,,,,
Chlorpromazine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chlorpromazine,,,,2016-12-09,,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,No,No,CHEMBL71,1233755,,,,,,,,,,
Indometacin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/indometacin,,,,2016-12-09,,CGIGDMFJXJATDK-UHFFFAOYSA-N,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,No,No,CHEMBL6,1616755,,,,,,,,,,
Kinome_1199,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome1199,,,,2016-12-09,,GCBJDOWIQHMCMR-UHFFFAOYSA-N,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1,No,No,CHEMBL396523,1705658,,,,,,,,,,
ZINC04335977,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/zinc04335977,,,,2016-12-09,,KRIUNPBAQZGFQA-UHFFFAOYSA-N,Oc1c2ccccc2c2c3c(cccc13)N=N2,No,Yes,CHEMBL1725279,1049783,,,,,,,,,,
CX5011,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/cx5011,,,,2016-12-09,,HJGFPNFAFSFDNN-UHFFFAOYSA-N,C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cncnc23)c1,No,No,CHEMBL1682283,1798236,,,,,,,,,,
A-674563,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/674563,,,,2016-12-08,,BPNUQXPIQBZCMR-IBGZPJMESA-N,Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12,No,No,CHEMBL379218,1807394,,,,,,,,,,
Staurosporine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/staurosporine,,,,2016-12-09,,HKSZLNNOFSGOKW-FYTWVXJKSA-N,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,No,No,CHEMBL388978,624063,,,,,,,,,,
IPA-3,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ipa-3,,,,2017-01-04,,RFAXLXKIAKIUDT-UHFFFAOYSA-N,Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12,No,Yes,CHEMBL472940,1503412,,,,,,,,,,
Amitriptyline,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/amitriptyline,,,,2016-12-09,,KRMDCWKBEZIMAB-UHFFFAOYSA-N,CN(C)CCC=C1c2ccccc2CCc2ccccc21,Yes,No,CHEMBL629,1253640,,,,,,,,,,
6-Bromoindirubin-3'-oxime,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/6-bromoindirubin-3-oxime,,,,2016-12-09,,DDLZLOKCJHBUHD-WAVHTBQISA-N,O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O,Yes,Yes,CHEMBL409450,1322637,,,,,,,,,,
Enzastaurin hydrochloride,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/enzastaurin-hydrochloride,,,,2016-12-09,,UUADYKVKJIMIPA-UHFFFAOYSA-N,Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,No,Yes,CHEMBL2107337,826365,,,,,,,,,,
Kinome_635,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome635,,,,2016-12-09,,KSOVGRCOLZZTPF-UHFFFAOYSA-N,Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1,Yes,No,CHEMBL1967878,521608,,,,,,,,,,
Kinome_1202,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome1202,,,,2016-12-09,,ZVWRFVCNQOECJS-UHFFFAOYSA-N,Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1,No,No,CHEMBL1988838,292199,,,,,,,,,,
CHEMBL3115681,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3115681,,,,2016-12-09,,VADOZMZXXRBXNY-UHFFFAOYSA-N,CN1CCN(c2ccc(Nc3ncc4cc(C#N)c(=O)n(C5CCCC5)c4n3)cc2)CC1,Yes,No,CHEMBL3115681,462817,,,,,,,,,,
Lestaurtinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/lestaurtinib,,,,2016-12-09,,UIARLYUEJFELEN-LROUJFHJSA-N,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,No,No,CHEMBL603469,578962,,,,,,,,,,
Kinome_1901,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kinome1901,,,,2016-12-09,,BSFNGHCTZDCQBF-UHFFFAOYSA-N,NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12,No,No,CHEMBL2001751,698309,,,,,,,,,,
4-anilinopyrimidine 8c,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/4-anilinopyrimidine-8c,,,,2016-12-09,,LYNBNVBMAGDJRW-UHFFFAOYSA-N,O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1,No,No,CHEMBL243088,1493914,,,,,,,,,,
Gw8510,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gw8510,,,,2016-12-09,,GCYXEGSPUDSZJY-PTNGSMBKSA-N,O=C1Nc2ccc3ncsc3c2/C1=C/Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1,No,Yes,CHEMBL1276446,352155,,,,,,,,,,
4-anilinopyrimidine 15a,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/4-anilinopyrimidine-15a,,,,2016-12-09,,YMIJUBCSOKSFRU-UHFFFAOYSA-N,O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1,No,No,CHEMBL244378,1699687,,,,,,,,,,
Thioridazine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/thioridazine,,,,2016-12-09,,KLBQZWRITKRQQV-UHFFFAOYSA-N,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,No,No,CHEMBL479,1583578,,,,,,,,,,
CYC-116,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/cyc-116,,,,2016-12-09,,GPSZYOIFQZPWEJ-UHFFFAOYSA-N,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,Yes,No,CHEMBL482967,1709990,,,,,,,,,,
Flavopiridol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/flavopiridol,,,,2016-12-09,,BIIVYFLTOXDAOV-YVEFUNNKSA-N,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,No,No,CHEMBL428690,1905588,,,,,,,,,,
BMS-387032,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bms-387032,,,,2016-12-09,,OUSFTKFNBAZUKL-UHFFFAOYSA-N,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,No,No,CHEMBL296468,1596650,,,,,,,,,,
CHEMBL1649761,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl1649761,,,,2016-12-09,,JPYQFPGTGGLOMD-UHFFFAOYSA-N,NC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,No,No,CHEMBL1649761,1643156,,,,,,,,,,
SCHEMBL3814469,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/schembl3814469,,,,2016-12-09,,BQDHCGJUSXMIIS-UHFFFAOYSA-N,COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC.Cl,No,No,,3312912,,,,,,,,,,
Ellagic acid,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ellagic-acid,,,,2016-12-09,,AFSDNFLWKVMVRB-UHFFFAOYSA-N,O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23,Yes,Yes,CHEMBL6246,1305685,,,,,,,,,,
C646,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/c646,,,,2016-12-13,,AYQYIBVVCJFCAE-KSEXSDGBSA-N,CC1=NN(c2ccc(C(=O)O)cc2)C(=O)/C1=C\Cc1ccc(Cc2cc(C)c(C)cc2[N+](=O)[O-])o1,Yes,No,CHEMBL3421960,654302,,,,,,,,,,
Dorsomorphin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dorsomorphin,,,,2016-12-15,,XHBVYDAKJHETMP-UHFFFAOYSA-N,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1,No,No,CHEMBL478629,252407,,,,,,,,,,
Entospletinib,3.7,3.3,3.0,No,https://www.chemicalprobes.org/entospletinib,SYK,Protein kinase,TK,2021-02-17,P43405,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,Yes,No,CHEMBL3265032,390013,"http://pubs.acs.org/doi/abs/10.1021/jm500228a, https://www.ncbi.nlm.nih.gov/pubmed/?term=24779514",Inhibitor,7.7 nM,SYK enzymatic assay (Lance-based assay),26 nM,MSD assay detecting the substrate pBLNK,EC50,Other,"0.4 (IV), 1 (PO) mg/Kg",
Ki-20227,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ki-20227,,,,2017-03-02,,SHPFDGWALWEPGS-UHFFFAOYSA-N,COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1,No,No,CHEMBL1908396,592278,,,,,,,,,,
K00564a,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/k00564a,,,,2021-02-18,,MLKHXLFEYOOYEY-NVNXTCNLSA-N,Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21,Yes,No,CHEMBL104279,1588377,,,,,,,,,,
Lck inhibitor,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/lck-inhibitor,,,,2017-03-02,,FMETVQKSDIOGPX-UHFFFAOYSA-N,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1,Yes,No,CHEMBL47940,1889063,,,,,,,,,,
SL0101,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/sl0101,,,,2017-03-02,,SXOZSDJHGMAEGZ-IGKKHSBFSA-N,CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O,No,No,CHEMBL240954,716875,,,,,,,,,,
XL019,2.3,2.7,3.0,No,https://www.chemicalprobes.org/xl019,JAK2,Protein kinase,TK,2021-01-07,O60674,ISOCDPQFIXDIMS-HSZRJFAPSA-N,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)[C@H]1CCCN1,Yes,No,CHEMBL2208034,524806,"http://www.sciencedirect.com/science/article/pii/S0960894X12012747, https://www.ncbi.nlm.nih.gov/pubmed/?term=23127890",Inhibitor,2.2 nM JAK2; 214 nM JAK3; 134 nM JAK1,Chemiluminescence activity based assay (ATP hydrolysis),386.4 nM pSTAT1; 695 nM pSTAT3,Immunoblotting detection of pSTAT1 and pSTAT3,IC50,Other,30-300 mg/Kg,
ENMD-2076,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/enmd-2076,,,,2017-02-01,,BLQYVHBZHAISJM-CMDGGOBGSA-N,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,No,No,CHEMBL482968,1907784,,,,,,,,,,
Foretinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/foretinib,,,,2017-02-01,,CXQHYVUVSFXTMY-UHFFFAOYSA-N,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,No,No,CHEMBL1230609,916365,,,,,,,,,,
Ninetedanib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ninetedanib,,,,2017-02-01,,XZXHXSATPCNXJR-UHFFFAOYSA-N,COC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,No,Yes,CHEMBL2136735,826661,,,,,,,,,,
PD166285,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pd166285,,,,2017-02-01,,IFPPYSWJNWHOLQ-UHFFFAOYSA-N,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,No,No,CHEMBL49120,614800,,,,,,,,,,
Dasatinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dasatinib,,,,2017-02-01,,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,No,No,CHEMBL1421,501089,,,,,,,,,,
Tozasertib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tozasertib,,,,2017-02-01,,GCIKSSRWRFVXBI-UHFFFAOYSA-N,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,No,No,CHEMBL572878,567748,,,,,,,,,,
UPF1069,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/upf1069,,,,2017-01-31,,JJWMRRNGWSITSQ-UHFFFAOYSA-N,O=C(COc1cccc2c(=O)[nH]ccc12)c1ccccc1,No,No,CHEMBL4089840,1302916,,,,,,,,,,
Entrectinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/entrectinib,,,,2017-02-01,,HAYYBYPASCDWEQ-UHFFFAOYSA-N,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,No,No,CHEMBL1983268,849266,,,,,,,,,,
Famitinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/famitinib,,,,2017-02-01,,GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,No,No,CHEMBL1278146,265157,,,,,,,,,,
Navitoclax,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/navitoclax,,,,2017-01-31,,JLYAXFNOILIKPP-KXQOOQHDSA-N,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,No,Yes,CHEMBL443684,997861,,,,,,,,,,
NS-018,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ns-018,,,,2017-02-01,,UQTPDWDAYHAZNT-AWEZNQCLSA-N,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1,No,No,CHEMBL4303389,147527,,,,,,,,,,
Rebastinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/rebastinib,,,,2017-02-01,,WVXNSAVVKYZVOE-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,No,No,CHEMBL1738757,848780,,,,,,,,,,
Sorafenib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/sorafenib,,,,2017-02-01,,MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,No,No,CHEMBL1336,429624,,,,,,,,,,
PJ34,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pj34,,,,2017-01-31,,UYJZZVDLGDDTCL-UHFFFAOYSA-N,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,No,No,CHEMBL372303,1321633,,,,,,,,,,
Aloisine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/aloisine,,,,2017-02-01,,WVMANZPBOBRWCB-UHFFFAOYSA-N,CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12,No,No,CHEMBL306498,1264460,,,,,,,,,,
U18666A,2.7,2.0,3.0,No,https://www.chemicalprobes.org/u18666a,NPC1,Other,Intracellular Cholesterol Transporter,2020-11-26,O15118,GZFYZYBWLCYBMI-MYZJJQSMSA-N,CCN(CC)CCO[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1.Cl,No,Yes,CHEMBL2354929,202015,"https://elifesciences.org/content/4/e12177, https://www.ncbi.nlm.nih.gov/pubmed/26646182",Inhibitor,,,30 nM,Cholesterol esterification and proteolytic cleavage of SREBP-2,Ki,Other,10 mg/Kg,Compound A
Maritoclax,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/maritoclax,,,,2017-03-13,,QYPJBTMRYKRTFG-UHFFFAOYSA-N,O=C(c1ccccc1O)c1[nH]c(Cl)c(Cl)c1-n1c(C(=O)c2ccccc2O)cc(Cl)c1Cl,No,No,CHEMBL3393621,466403,,,,,,,,,,
2-MT 63,2.7,2.7,3.0,No,https://www.chemicalprobes.org/2-mt-63,TEK,Protein kinase,TK,2017-03-13,Q02763,HHKGVQGXRGQBBA-UHFFFAOYSA-N,CNc1ncnc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)ccc3N(C)CCCN(C)C)c2)n1,No,No,CHEMBL373882,886037,"http://pubs.acs.org/doi/abs/10.1021/jm061107l, https://www.ncbi.nlm.nih.gov/pubmed/17253678",Inhibitor,30 nM,Homogenous time-resolved fluorescence assays detecting enzyme activity using peptide substrates.,62 nM,"In EA.hy926 cells, the compound inhibited Ang-1-induces TIE2 autophosphorylation in a plate-based immunassay.",IC50,Other,"1 mg/kg (IV), 10 mg/kg (oral)",
Ischemin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ischemin,,,,2017-03-07,,UUECJWRVDTUDCB-ISLYRVAYSA-N,Cc1cc(/N=N/c2cc(S(=O)(=O)O)c(C)cc2C)c(N)cc1O,Yes,Yes,CHEMBL1615026,1453644,,,,,,,,,,
Iniparib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/iniparib,,,,2017-03-02,,MDOJTZQKHMAPBK-UHFFFAOYSA-N,NC(=O)c1ccc(I)c([N+](=O)[O-])c1,No,Yes,CHEMBL1170047,24483,,,,,,,,,,
Chelerythrine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chelerythrine,,,,2017-03-02,,LLEJIEBFSOEYIV-UHFFFAOYSA-N,COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC,No,No,CHEMBL13045,1688064,,,,,,,,,,
Apogossypol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apogossypol,,,,2017-03-02,,PBJKWGWHZVXBGU-UHFFFAOYSA-N,Cc1cc2c(C(C)C)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)cc2c1O,Yes,Yes,CHEMBL551288,572876,,,,,,,,,,
HA14-1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ha14-1,,,,2017-03-02,,SXJDCULZDFWMJC-UHFFFAOYSA-N,CCOC(=O)C1=C(N)Oc2ccc(Br)cc2C1C(C#N)C(=O)OCC,No,No,CHEMBL288542,1596359,,,,,,,,,,
BXI-61,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bxi-61,,,,2017-03-02,,HYTMVPCGCCQGST-JGUILPGDSA-N,CCOc1ccc2nc3cc(/N=N/c4ccc(N)nc4N)ccc3c(N)c2c1.Cl,Yes,Yes,CHEMBL1987594,234445,,,,,,,,,,
TW37,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tw37,,,,2017-03-02,,PQAPVTKIEGUPRN-UHFFFAOYSA-N,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O,Yes,Yes,CHEMBL217354,839902,,,,,,,,,,
UMI-77,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/umi-77,,,,2017-03-02,,WUGANDSUVKXMEC-UHFFFAOYSA-N,O=C(O)CSc1cc(NS(=O)(=O)c2ccc(Br)cc2)c2ccccc2c1O,Yes,No,CHEMBL1331211,1829299,,,,,,,,,,
Bcl-2 Inhibitor,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bcl-2-inhibitor,,,,2017-03-02,,YPSXFMHXRZAGTG-UHFFFAOYSA-N,COc1ccc(N=O)c(CCc2cc(OC)ccc2N=O)c1,No,Yes,,3312891,,,,,,,,,,
Bromosporine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bromosporine,,,,2017-03-02,,UYBRROMMFMPJAN-UHFFFAOYSA-N,CCOC(=O)Nc1cc(-c2ccc(C)c(NS(C)(=O)=O)c2)nn2c(C)nnc12,No,No,CHEMBL3133807,115590,,,,,,,,,,
Adenosine dialdehyde,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/adenosine-dialdehyde,,,,2017-03-07,,ILMNSCQOSGKTNZ-NKWVEPMBSA-N,Nc1ncnc2c1ncn2[C@@H](C=O)O[C@@H](C=O)CO,No,Yes,CHEMBL2374428,1146558,,,,,,,,,,
MDL 28842,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mdl-28842,,,,2017-03-07,,NAWIFPQLACUTSO-MXGDDHKLSA-N,Nc1ncnc2c1ncn2[C@@H]1O/C(=C\F)[C@@H](O)[C@@H]1O,No,Yes,CHEMBL2051969,1144457,,,,,,,,,,
Methylstat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/methylstat,,,,2017-03-07,,MUJOCHRZXRZONW-FOCLMDBBSA-N,COC(=O)/C=C/C(=O)N(O)CCCCNCc1ccc(COC(=O)Nc2cccc3ccccc23)cc1,No,Yes,CHEMBL3347630,719521,,,,,,,,,,
Tranylcypromine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tranylcypromine,,,,2017-03-07,,AELCINSCMGFISI-DTWKUNHWSA-N,N[C@@H]1C[C@H]1c1ccccc1,No,No,CHEMBL1179,45808,,,,,,,,,,
MB-3,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mb-3,,,,2017-03-07,,ZJZCTCNQTXBBFZ-PLMZOXRSSA-N,C/C(=C(\CCO)SCCC(=O)c1ccc(C)cc1)N(C=O)Cc1cnc(C)nc1N.Cl,No,Yes,,3312903,,,,,,,,,,
Salicylate,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/salicylate,,,,2017-03-07,,YGSDEFSMJLZEOE-UHFFFAOYSA-M,O=C([O-])c1ccccc1O,No,No,,2880280,,,,,,,,,,
APHA,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apha,,,,2017-03-07,,JAXSELKSZJMFSA-UHFFFAOYSA-N,O=C(O)CCC(=O)Nc1ccc(Cc2ccncc2)cc1,No,No,,3312911,,,,,,,,,,
Quisinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/quisinostat,,,,2017-03-07,,PAWIYAYFNXQGAP-UHFFFAOYSA-N,Cn1cc(CNCC2CCN(c3ncc(C(=O)NO)cn3)CC2)c2ccccc21,No,Yes,CHEMBL2105763,256735,,,,,,,,,,
Panobinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/panobinostat,,,,2017-03-07,,FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,Yes,Yes,CHEMBL483254,1710013,,,,,,,,,,
Pandacostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pandacostat,,,,2017-03-07,,KGDMFBRXTHKRPA-GRCJMCHGSA-N,O=C(/C=C/c1ccc(C(=O)N/N=C/c2ccc(O)c(O)c2O)cc1)NO,Yes,Yes,CHEMBL1213457,1718170,,,,,,,,,,
Pyroxamide,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pyroxamide,,,,2017-03-07,,PTJGLFIIZFVFJV-UHFFFAOYSA-N,O=C(CCCCCCC(=O)Nc1cccnc1)NO,No,Yes,CHEMBL353581,1123828,,,,,,,,,,
R306465,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/r306465,,,,2017-03-07,,MUTBJZVSRNUIHA-UHFFFAOYSA-N,O=C(NO)c1cnc(N2CCN(S(=O)(=O)c3ccc4ccccc4c3)CC2)nc1,No,Yes,CHEMBL609583,169499,,,,,,,,,,
SBHA,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/sbha,,,,2017-03-07,,IDQPVOFTURLJPT-UHFFFAOYSA-N,O=C(CCCCCCC(=O)NO)NO,No,Yes,CHEMBL320497,30287,,,,,,,,,,
Pivanex,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pivanex,,,,2017-03-07,,GYKLFBYWXZYSOW-UHFFFAOYSA-N,CCCC(=O)OCOC(=O)C(C)(C)C,No,Yes,CHEMBL100014,28056,,,,,,,,,,
GSK-5959,2.3,0.0,3.0,No,https://www.chemicalprobes.org/gsk-5959,BRPF1,Epigenetic,Bromodomain,2017-04-04,P55201,LTUGYAOMCKNTGG-UHFFFAOYSA-N,COc1ccccc1C(=O)Nc1cc2c(cc1N1CCCCC1)n(C)c(=O)n2C,No,No,CHEMBL1522313,190291,"http://pubs.acs.org/doi/abs/10.1021/ml5002932, https://www.ncbi.nlm.nih.gov/pubmed/?term=25408830",Antagonist,0.08 uM,"Time-resolved fluorescence resonance energy transfer (TR-FRET) binding assay, pIC50=7.1.",0.98 uM,NanoBRET assay; pIC50=6.0,IC50,,,
MS7972,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ms7972,,,,2017-04-04,,MIGJEXKBUJPKJF-UHFFFAOYSA-N,CC(=O)n1c2c(c3ccccc31)CCCC2=O,No,No,CHEMBL1236441,1119325,,,,,,,,,,
Obatoclax,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/obatoclax,,,,2017-03-02,,RFTSSZJZXOSICM-GRSHGNNSSA-N,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,No,No,CHEMBL408194,1500972,,,,,,,,,,
Gossypol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gossypol,,,,2017-03-02,,QBKSWRVVCFFDOT-UHFFFAOYSA-N,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,Yes,Yes,CHEMBL51483,754444,,,,,,,,,,
AT-101,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/101,,,,2017-03-02,,KLDXJTOLSGUMSJ-JGWLITMVSA-N,O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12,No,No,CHEMBL1200660,56967,,,,,,,,,,
Antimycin A,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/antimycin,,,,2017-03-02,,UIFFUZWRFRDZJC-SBOOETFBSA-N,CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C,No,Yes,CHEMBL211501,793808,,,,,,,,,,
BXI-72,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bxi-72,,,,2017-03-02,,PRDFBSVERLRRMY-UHFFFAOYSA-N,CCOc1ccc(-c2nc3cc(-c4nc5cc(N6CCN(C)CC6)ccc5[nH]4)ccc3[nH]2)cc1,No,No,CHEMBL343002,565476,,,,,,,,,,
MIM1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mim1,,,,2017-03-02,,RGGFUBMUOVFZEF-LDRVEFRDSA-N,Cc1cs/c(=N\C2CCCCC2)n1/N=C/c1ccc(O)c(O)c1O,Yes,Yes,CHEMBL3265288,1556735,,,,,,,,,,
BH3I-1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bh3i-1,,,,2017-03-02,,COHIEJLWRGREHV-XFFZJAGNSA-N,CC(C)C(C(=O)O)N1C(=O)/C(=C/c2ccc(Br)cc2)SC1=S,Yes,Yes,CHEMBL335265,1320297,,,,,,,,,,
LJI308,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/lji308,,,,2017-03-02,,YUYJEQHNWKQNBT-UHFFFAOYSA-N,Oc1c(F)cc(-c2cnccc2-c2ccc(N3CCOCC3)cc2)cc1F,No,No,CHEMBL3604794,1868394,,,,,,,,,,
Saracatinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/saracatinib,,,,2017-03-02,,OUKYUETWWIPKQR-UHFFFAOYSA-N,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,No,No,CHEMBL217092,766308,,,,,,,,,,
5-methyl thioadenosine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/5-methyl-thioadenosine,,,,2017-03-07,,WUUGFSXJNOTRMR-IOSLPCCCSA-N,CSC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,No,No,CHEMBL277041,1171526,,,,,,,,,,
Sinefungin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/sinefungin,,,,2017-03-07,,LMXOHSDXUQEUSF-YECHIGJVSA-N,Nc1ncnc2c1ncn2[C@@H]1O[C@H](C[C@@H](N)CC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O,No,No,CHEMBL1214186,1823000,,,,,,,,,,
Embelin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/embelin,,,,2017-03-07,,IRSFLDGTOHBADP-UHFFFAOYSA-N,CCCCCCCCCCCC1=C(O)C(=O)C=C(O)C1=O,Yes,Yes,CHEMBL221137,1241811,,,,,,,,,,
Plumbagin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/plumbagin,,,,2017-03-07,,VCMMXZQDRFWYSE-UHFFFAOYSA-N,CC1=CC(=O)c2c(O)cccc2C1=O,Yes,Yes,CHEMBL295316,30007,,,,,,,,,,
Resminostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/resminostat,,,,2017-03-07,,FECGNJPYVFEKOD-VMPITWQZSA-N,CN(C)Cc1ccc(S(=O)(=O)n2ccc(/C=C/C(=O)NO)c2)cc1,No,Yes,CHEMBL4296717,1583363,,,,,,,,,,
Givinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/givinostat,,,,2017-03-07,,YALNUENQHAQXEA-UHFFFAOYSA-N,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,No,Yes,CHEMBL1213492,350456,,,,,,,,,,
Dacinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dacinostat,,,,2017-03-07,,BWDQBBCUWLSASG-MDZDMXLPSA-N,O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO,No,Yes,CHEMBL356066,1902688,,,,,,,,,,
Oxamflatin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/oxamflatin,,,,2017-03-07,,IVTKCTFTVKYWIQ-WEVVVXLNSA-N,O=C(/C=C/C#Cc1ccc(NS(=O)(=O)c2ccccc2)cc1)NO,No,Yes,CHEMBL314389,1496674,,,,,,,,,,
Abexinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/abexinostat,,,,2017-03-07,,MAUCONCHVWBMHK-UHFFFAOYSA-N,CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12,No,Yes,CHEMBL2103863,256658,,,,,,,,,,
Belinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/belinostat,,,,2017-03-07,,NCNRHFGMJRPRSK-MDZDMXLPSA-N,O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,No,Yes,CHEMBL408513,1322821,,,,,,,,,,
Pracinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pracinostat,,,,2017-03-07,,JHDKZFFAIZKUCU-ZRDIBKRKSA-N,CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC,No,Yes,CHEMBL1851943,1718108,,,,,,,,,,
Scriptaid,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/scriptaid,,,,2017-03-07,,JTDYUFSDZATMKU-UHFFFAOYSA-N,O=C(CCCCCN1C(=O)c2cccc3cccc(c23)C1=O)NO,No,Yes,CHEMBL96051,1487542,,,,,,,,,,
Trichostatin A,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/trichostatin,,,,2017-03-07,,RTKIYFITIVXBLE-QEQCGCAPSA-N,CC(/C=C/C(=O)NO)=C\[C@@H](C)C(=O)c1ccc(N(C)C)cc1,No,Yes,CHEMBL99,1317329,,,,,,,,,,
Butyrate,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/butyrate,,,,2017-03-07,,MFBOGIVSZKQAPD-UHFFFAOYSA-M,CCCC(=O)[O-].[Na+],No,No,CHEMBL62381,1190,,,,,,,,,,
Valproic acid,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/valproic-acid,,,,2017-03-07,,NIJJYAXOARWZEE-UHFFFAOYSA-N,CCCC(CCC)C(=O)O,No,Yes,CHEMBL109,45378,,,,,,,,,,
Fisetin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/fisetin,,,,2017-03-07,,XHEFDIBZLJXQHF-UHFFFAOYSA-N,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12,Yes,Yes,CHEMBL31574,1234742,,,,,,,,,,
Piceatannol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/piceatannol,,,,2017-03-07,,CDRPUGZCRXZLFL-OWOJBTEDSA-N,Oc1cc(O)cc(/C=C/c2ccc(O)c(O)c2)c1,Yes,Yes,CHEMBL69863,1066438,,,,,,,,,,
Apabetalone,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apabetalone,,,,2017-03-07,,NETXMUIMUZJUTB-UHFFFAOYSA-N,COc1cc(OC)c2c(=O)[nH]c(-c3cc(C)c(OCCO)c(C)c3)nc2c1,No,No,CHEMBL2393130,1857922,,,,,,,,,,
Diflusinal,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/diflusinal,,,,2017-03-20,,HUPFGZXOMWLGNK-UHFFFAOYSA-N,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,No,No,CHEMBL898,1065883,,,,,,,,,,
Gefitinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gefitinib,,,,2017-03-21,,XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,No,No,CHEMBL939,337949,,,,,,,,,,
Butein,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/butein,,,,2017-03-07,,AYMYWHCQALZEGT-ORCRQEGFSA-N,O=C(/C=C/c1ccc(O)c(O)c1)c1ccc(O)cc1O,Yes,Yes,CHEMBL128000,1166678,,,,,,,,,,
Isoliquiritigenin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/isoliquiritigenin,,,,2017-03-07,,DXDRHHKMWQZJHT-FPYGCLRLSA-N,O=C(/C=C/c1ccc(O)cc1)c1ccc(O)cc1O,No,Yes,CHEMBL129795,1116690,,,,,,,,,,
BIC1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bic1,,,,2017-03-07,,KDPSGIFCBZTBEZ-UHFFFAOYSA-N,Cn1c(=S)n(CCSc2nc3ccccc3[nH]2)c2ccccc21,No,Yes,CHEMBL1738777,1508966,,,,,,,,,,
Brusatol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/brusatol,,,,2017-03-17,,ZZZYHIMVKOHVIH-MWFXHRFLSA-N,COC(=O)[C@@]12OC[C@@]34[C@H]1[C@@H](OC(=O)C=C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)=C(O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,No,Yes,CHEMBL450464,720663,,,,,,,,,,
Garcinol,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/garcinol,,,,2017-03-20,,QDKLRKZQSOQWJQ-SMDXAGPFSA-N,C=C(C)[C@@H](CC=C(C)C)C[C@@]12C[C@@H](CC=C(C)C)C(C)(C)[C@@](CC=C(C)C)(C(=O)C(C(=O)c3ccc(O)c(O)c3)=C1O)C2=O,Yes,Yes,CHEMBL502489,898879,,,,,,,,,,
PCI-34051,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pci-34051,,,,2017-04-10,,AJRGHIGYPXNABY-UHFFFAOYSA-N,COc1ccc(Cn2ccc3ccc(C(=O)NO)cc32)cc1,No,Yes,CHEMBL2170177,1358819,,,,,,,,,,
Apicidin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apicidin,,,,2017-04-11,,JWOGUUIOCYMBPV-GMFLJSBRSA-N,CCC(=O)CCCCC[C@@H]1NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2cn(OC)c3ccccc23)NC1=O,No,No,CHEMBL430060,902928,,,,,,,,,,
CI-994,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ci-994,,,,2017-04-11,,VAZAPHZUAVEOMC-UHFFFAOYSA-N,CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1,No,Yes,CHEMBL235191,1170255,,,,,,,,,,
Depudecin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/depudecin,,,,2017-04-11,,DLVJMFOLJOOWFS-VJIFSZOSSA-N,C=C[C@@H](O)[C@@H]1O[C@H]1/C=C/[C@@H]1O[C@@H]1[C@@H](C)O,No,Yes,CHEMBL1213459,51775,,,,,,,,,,
HC Toxin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/hc-toxin,,,,2017-04-11,,GNYCTMYOHGBSBI-KVUCBBCISA-N,C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](CCCCCC(=O)C2CO2)NC(=O)[C@@H](C)NC1=O,No,Yes,,3312889,,,,,,,,,,
Mocetinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mocetinostat,,,,2017-04-11,,HRNLUBSXIHFDHP-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,No,Yes,CHEMBL272980,244348,,,,,,,,,,
Entinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/entinostat,,,,2017-04-11,,INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,No,Yes,CHEMBL27759,1888264,,,,,,,,,,
Rottlerin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/rottlerin,,,,2017-06-27,,DEZFNHCVIZBHBI-ZHACJKMWSA-N,CC(=O)c1c(O)c(C)c(O)c(Cc2c(O)c3c(c(C(=O)/C=C/c4ccccc4)c2O)OC(C)(C)C=C3)c1O,No,No,CHEMBL34241,754171,,,,,,,,,,
TH287,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/th287,,,,2017-07-08,,URWCXPXBBITYLR-UHFFFAOYSA-N,CNc1cc(-c2cccc(Cl)c2Cl)nc(N)n1,No,No,CHEMBL3781316,1061093,,,,,,,,,,
Nutlin-2,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nutlin-2,,,,2017-06-02,,PVRYEWOXWGDQHA-URLMMPGGSA-N,CCOc1cc(OC)ccc1C1=N[C@@H](c2ccc(Br)cc2)[C@@H](c2ccc(Br)cc2)N1C(=O)N1CCN(CCO)CC1,No,No,CHEMBL407632,847292,,,,,,,,,,
MI-219,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mi-219,,,,2017-06-02,,UNXQGBMZYKHQCO-NVHWNKAKSA-N,CC(C)(C)C[C@H]1N[C@@H](C(=O)NCC[C@H](O)CO)[C@H](c2cccc(Cl)c2)[C@@]12C(=O)Nc1cc(Cl)c(F)cc12,No,No,CHEMBL572933,724668,,,,,,,,,,
MCL0527-3,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mcl0527-3,,,,2017-06-02,,RLUGRMMSGGKTPV-UHFFFAOYSA-N,Nc1sc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)c1C(=O)NC1CCCCC1,Yes,No,CHEMBL2385521,203147,,,,,,,,,,
RO5353,4.0,4.0,2.0,No,https://www.chemicalprobes.org/ro5353,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,UOVSZRTTWLJPHE-HNXAPSNLSA-N,COc1cc(C(N)=O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@]2(C(=O)Nc3cc(Cl)sc32)[C@H]1c1cccc(Cl)c1F,No,No,CHEMBL3109040,851760,"http://pubs.acs.org/doi/abs/10.1021/ml400359z, https://www.ncbi.nlm.nih.gov/pubmed/24900784",Antagonist,7 nM,HTRF assay,0.007 uM,"Antiproliferative activity (MTT assay) averaged across multiple p53 wild-type cells (SJSA-1, HCT-116, RKO). RO5353 is 1023-fold selective for p53 wild type compared with p53 mutant cells.",IC50,Other,10 mg/kg (oral),
4-PBHA,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/4-pbha,,,,2017-04-11,,NNGMKDJOKUWNGN-NMMPVGNLSA-N,Cl.N#C[C@@H]1CS[C@H]2C[C@](N)(C3CCCC3)C(=O)N21,No,Yes,CHEMBL558956,1078674,,,,,,,,,,
S63845,4.0,3.0,4.0,No,https://www.chemicalprobes.org/s63845,MCL1,Other,BCL2 family,2017-04-24,Q07820,ZFBHXVOCZBPADE-SSEXGKCCSA-N,Cc1c(-c2c(-c3ccc(F)o3)sc3ncnc(O[C@H](Cc4ccccc4OCc4ccnn4CC(F)(F)F)C(=O)O)c23)ccc(OCCN2CCN(C)CC2)c1Cl,Yes,No,CHEMBL4439276,2959159,"https://www.nature.com/nature/journal/v538/n7626/full/nature19830.html, www.doi.org/10.1021/acs.jmedchem.0c01234, https://www.ncbi.nlm.nih.gov/pubmed/27760111, https://pubmed.ncbi.nlm.nih.gov/33146521/",BH3 mimetic Inhibitor,MCL1: 0.19 nM,"Surface plasmon resonance assay; in FP assay, S63845 had Ki <1.2 nM for MCL1.",< 10 nM,"In MCL1-dependent, H929 cells, S63845 had an IC50 <10 nM in apoptosis assays. In HeLa cells, S63845 disrupted MCL1 complex formation with BAX and BAK (co-immunoprecipitation experiments). BAX- and BAK-deficient cells are resistant to S63845.",IC50,Other,"25 mg/kg, Reviewer suggested dose: 6.25-25 mg/Kg IV",
Nutlin-1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nutlin-1,,,,2017-06-02,,IYDMGGPKSVWQRT-UHFFFAOYSA-N,COc1ccc(C2=NC(c3ccc(Cl)cc3)C(c3ccc(Cl)cc3)N2C(=O)N2CCN(C(C)=O)CC2)c(OC(C)C)c1,No,No,CHEMBL1818538,865782,,,,,,,,,,
Nutlin-3A,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nutlin-3a,,,,2017-06-02,,BDUHCSBCVGXTJM-WUFINQPMSA-N,COc1ccc(C2=N[C@@H](c3ccc(Cl)cc3)[C@@H](c3ccc(Cl)cc3)N2C(=O)N2CCNC(=O)C2)c(OC(C)C)c1,No,No,CHEMBL191334,813911,,,,,,,,,,
PB12,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pb12,,,,2017-06-02,,QZJRNGXHRQJBJH-UHFFFAOYSA-N,O=C(O)c1[nH]c2cc(Cl)ccc2c1-c1c(-c2ccccc2)ncn1Cc1ccc(Cl)cc1,No,No,CHEMBL1233798,432336,,,,,,,,,,
PB11,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pb11,,,,2017-06-02,,FLEPRYJBTOPZTM-UKILVPOCSA-N,CC(C)C[C@@]1(C(=O)NCCc2ccncc2)N=CN(CC2CC2)[C@H]1c1ccc(Cl)cc1,No,No,CHEMBL3407580,391134,,,,,,,,,,
AM-8735,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/am-8735,,,,2017-06-06,,HMKAZNCSHAJLSA-HIJQLYNKSA-N,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,No,No,CHEMBL3125537,777492,"http://pubs.acs.org/doi/abs/10.1021/jm401767k, https://www.ncbi.nlm.nih.gov/pubmed/24548297",,,,,,,,,
RO2468,3.0,3.5,2.0,No,https://www.chemicalprobes.org/ro2468,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,CGCOPBXAGSCZNX-FNQJWKMRSA-N,COc1cc(C(N)=O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@]2(C(=O)Nc3cc(Cl)ncc32)[C@H]1c1cccc(Cl)c1F,No,Yes,CHEMBL3109042,872752,"http://pubs.acs.org/doi/abs/10.1021/ml400359z, www.doi.org/10.1016/j.bmc.2014.05.072, https://www.ncbi.nlm.nih.gov/pubmed/24900784, https://www.ncbi.nlm.nih.gov/pubmed/24997575",Antagonist,6 nM,HTRF assay.,0.015 uM,"Average anti-proliferative activity across multiple p53-positive cell lines (SJSA-1, HCT-116, RKO). RO2468 was 742-fold more potent against p53 wild-type than p53-mutant cell types.",IC50,Other,10 mg/Kg QD,
NMS-P118,3.0,3.5,2.0,No,https://www.chemicalprobes.org/nms-p118,PARP1,Other post-translational modification,PARP,2017-06-14,P09874,ARYVAQSYRLZVQD-UHFFFAOYSA-N,NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2,No,No,CHEMBL3606021,121519,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00680, https://www.ncbi.nlm.nih.gov/pubmed/26222319",Inhibitor,0.009 uM,SPR binding assay,0.04 uM,"In HeLa cells, hydrogen peroxide-induced PAR production was quantified.",IC50,Other,10 mg/kg,
Epothilone,0.0,0.0,0.0,No,https://www.chemicalprobes.org/epothilone,TUBB,Structural protein,Cytoskeleton,2017-07-20,P07437,QXRSDHAAWVKZLJ-PVYNADRNSA-N,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,No,Yes,CHEMBL94657,615771,,,,,,,,,,
RH02007,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/rh02007,,,,2017-06-22,,XZFYSTPLSPZNKJ-UHFFFAOYSA-N,Cc1ccc(C)n1-c1ccc(C(=O)ON2C(=O)CCC2=O)cc1,Yes,No,,3312902,,,,,,,,,,
NSC83143,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc83143,,,,2017-06-22,,ZFEXNHYQHDJAGL-UHFFFAOYSA-N,CCC1=C(c2cc(Cl)c3ccccc3c2OCC(=O)O)OC(CC)(C(=O)c2cc(Cl)c3ccccc3c2OCC(=O)O)CC1,No,No,,3312905,,,,,,,,,,
NSC135098,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc135098,,,,2017-06-22,,CGLMQIIIQWNAMG-UHFFFAOYSA-N,CCOC(=O)C1C(O)=C(P(=O)(C2=C(O)C(C(=O)OCC)C(c3ccc(OC(C)=O)cc3)C(C(=O)O)C2=O)N(CCCl)CCCl)C(=O)C(C(=O)O)C1c1ccc(OC(C)=O)cc1,No,Yes,,3313081,,,,,,,,,,
Acid Green 3,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/acidÂ greenÂ 3,,,,2017-06-22,,XKTMIJODWOEBKO-UHFFFAOYSA-M,CCN(Cc1cccc(S(=O)(=O)[O-])c1)c1ccc(C(=C2C=CC(=[N+](CC)Cc3cccc(S(=O)(=O)[O-])c3)C=C2)c2ccccc2)cc1.[Na+],Yes,Yes,CHEMBL1333604,933654,,,,,,,,,,
Decernotinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/decernotinib,,,,2017-06-26,,ASUGUQWIHMTFJL-QGZVFWFLSA-N,CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,No,No,CHEMBL3039513,113802,,,,,,,,,,
KT5720,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/kt5720,,,,2017-06-27,,ZHEHVZXPFVXKEY-LYGOBDSISA-N,CCCCCCOC(=O)[C@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,No,No,CHEMBL4450227,3145847,,,,,,,,,,
ONC201,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/onc201,,,,2017-07-18,,VLULRUCCHYVXOH-UHFFFAOYSA-N,Cc1ccccc1CN1C(=O)C2=C(CCN(Cc3ccccc3)C2)N2CCN=C12,No,No,CHEMBL4297310,233041,,,,,,,,,,
Cotransin,2.3,0.0,3.0,No,https://www.chemicalprobes.org/cotransin,SEC61A1,Integral membrane protein,General secrectory pathway,2017-06-23,P61619,LTYNXERAWVCPAH-OHRKNAERSA-N,CC(C)C[C@@H]1NC(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)OC(=O)[C@H](C)N(C)C1=O,No,Yes,,2958985,"https://www.nature.com/nature/journal/v436/n7048/full/nature03821.html, https://www.ncbi.nlm.nih.gov/pubmed/16015336",Inhibitor,,"In synthetic proteoliposomes containing only SEC61 and SR, 10 uM cotransin inhibited VCAM1 translocation but not pre-prolactin. In in vitro transcription/translation assays in reticulocyte lysate with rough endoplasmic reticulum (ER) and microsomes (TNT assays), 10 uM cotransin VCAM1 glycosylation but not translation, and had comparable activity on fusion proteins containing the N-terminal signal sequence from VCAM1. 25 uM cotransin also disrupted cross-linking between ER proteins and Sec61alpha.",,"In COS-7 cells, 2 uM cotransin inhibited a small subset of secretory and membrane proteins (i.e., VCAM1 and P-selectin). These phenotype was mimicked by depletion of the Sec61 complex.",,,,Nor-cotransin
Gossypetin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gossypetin,,,,2017-06-22,,YRRAGUMVDQQZIY-UHFFFAOYSA-N,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2c(O)c(O)cc(O)c12,Yes,Yes,CHEMBL253570,1401932,,,,,,,,,,
DSHS00884,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dshs00884,,,,2017-06-22,,VWFIHGWHMXSTAO-UHFFFAOYSA-N,C=CCn1c(S)nnc1CSc1ccccc1[N+](=O)[O-],No,No,CHEMBL1595621,1200722,,,,,,,,,,
NSC117907,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc117907,,,,2017-06-22,,JPOAXWSMFOLMQH-UWWJMHSNSA-N,O=C(O)c1cc(N=C2C=CC(=C(c3ccccc3)c3ccc(Nc4ccc(Cl)c(C(=O)O)c4)cc3)C=C2)ccc1Cl,No,No,,3312910,,,,,,,,,,
NSC216029,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc216029,,,,2017-06-22,,QKJRDUVFCNBDGG-YKXMQWBGSA-N,C=CC1=C(C)C(=O)N/C1=C\c1[nH]c(Cc2[nH]c(/C=C3/NC(=O)C(C(C)SC(C)=O)=C3C)cc2CCC(=O)O)c(CCC(=O)O)c1C,No,Yes,,3312907,,,,,,,,,,
Cerdulatinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/cerdulatinib,,,,2017-06-26,,BGLPECHZZQDNCD-UHFFFAOYSA-N,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,Yes,No,CHEMBL4116008,328588,,,,,,,,,,
Pacritinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pacritinib,,,,2017-06-26,,HWXVIOGONBBTBY-ONEGZZNKSA-N,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,No,No,CHEMBL2035187,646856,,,,,,,,,,
GW788388,2.5,3.0,2.0,No,https://www.chemicalprobes.org/gw788388,TGFBR1,Protein kinase,TKL,2021-02-05,P36897,SAGZIBJAQGBRQA-UHFFFAOYSA-N,O=C(NC1CCOCC1)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1,No,No,CHEMBL202887,410745,"www.doi.org/10.1038/sj.ki.5002717, www.doi.org/10.1021/jm0509905, https://www.ncbi.nlm.nih.gov/pubmed/18075500, https://www.ncbi.nlm.nih.gov/pubmed/16570917",Inhibitor,18 nM,ALK5 Fluorescence Polarization Binding Assay with intracellular kinase domain from ALK5.,93 nM,"TGF-beta-dependent signaling assay. In 293T cells expressing constitutively active (ca) ALK5, TbetaRII, BMPRII, or ACTRII, 10 uM GW788388 inhibited autophosphorylation of ALK5 and TbetaRII. In U2OS cells expressing caALK1, caALK2, caALK3, caALK4, caALK5, caALK6, or caALK7, GW788388 dose-dependently inhibited only TGF-beta-dependent signaling (ALK4, ALK5, and ALK7; assessed indirectly through Smad-responsive luciferase activity).",IC50,Other,"2 mg/kg, 4 mg/kg",
TH588,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/th588,,,,2017-07-08,,PNMYJIOQIAEYQL-UHFFFAOYSA-N,Nc1nc(NC2CC2)cc(-c2cccc(Cl)c2Cl)n1,No,No,CHEMBL3782004,1157610,,,,,,,,,,
S-crizotinib,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/s-crizotinib,,,,2017-07-08,,KTEIFNKAUNYNJU-LBPRGKRZSA-N,C[C@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,No,No,CHEMBL1825141,255181,,,,,,,,,,
GSK-J1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gsk-j1,,,,2017-07-08,,AVZCPICCWKMZDT-UHFFFAOYSA-N,O=C(O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,No,No,CHEMBL3188597,207430,,,,,,,,,,
Thio-2,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/thio-2,,,,2017-07-08,,KWUZCAVKPCRJPO-UHFFFAOYSA-N,CCNc1ccc(-c2nc3ccc(C)cc3s2)cc1,No,No,,3312908,,,,,,,,,,
Thioflavin S,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/thioflavin-s,,,,2017-07-08,,TZALECNALKOBPY-UHFFFAOYSA-N,Cc1ccc2c(sc(-c3ccc4c(c3)sc(-c3ccc(N(C)C)cc3)[n+]4C)[n+]2C)c1S(=O)(=O)[O-],Yes,No,,3313069,,,,,,,,,,
FRAX1036,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/frax1036,,,,2017-07-08,,RYCBSFIKWACFBY-UHFFFAOYSA-N,CCn1c(=O)c(-c2ccc(-c3cncc(C)n3)cc2Cl)cc2cnc(NCCC3CCN(C)CC3)nc21,No,No,CHEMBL3770186,744970,,,,,,,,,,
TG10129,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tg10129,,,,2017-07-08,,JVDOKQYTTYUYDV-UHFFFAOYSA-N,Cc1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,Yes,No,CHEMBL1995703,698084,,,,,,,,,,
MLN8054,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mln8054,,,,2017-07-08,,HHFBDROWDBDFBR-UHFFFAOYSA-N,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,No,No,CHEMBL259084,575044,,,,,,,,,,
Apoptozole,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/apoptozole,,,,2017-07-08,,ZIMMTPFXOMAJTQ-UHFFFAOYSA-N,COc1ccc(-c2nc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)n(Cc3ccc(C(N)=O)cc3)c2-c2ccc(OC)cc2)cc1,No,No,CHEMBL3416503,908308,,,,,,,,,,
Pifithrin-mu,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pifithrin-mu,,,,2017-07-08,,ZZUZYEMRHCMVTB-UHFFFAOYSA-N,NS(=O)(=O)C#Cc1ccccc1,No,No,CHEMBL1241268,8743,,,,,,,,,,
Pifithrin-alpha,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pifithrin-alpha,,,,2017-07-08,,HAGVCKULCLQGRF-UHFFFAOYSA-N,Br.Cc1ccc(C(=O)Cn2c3c(sc2=N)CCCC3)cc1,Yes,No,CHEMBL556353,1244293,,,,,,,,,,
Pifithrin-beta,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/pifithrin-beta,,,,2017-07-08,,IMUKUMUNZJILCG-UHFFFAOYSA-N,Cc1ccc(-c2cn3c4c(sc3n2)CCCC4)cc1,No,No,CHEMBL193504,1118708,,,,,,,,,,
MCB-613,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/mcb-613,,,,2017-07-08,,MMBSCBVEHMETSA-GDAWTGGTSA-N,CCC1C/C(=C\c2cccnc2)C(=O)/C(=C/c2cccnc2)C1,Yes,No,CHEMBL1452264,1433969,,,,,,,,,,
K4F,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/k4f,,,,2017-07-08,,LUYWAGVRXKSNLL-DEOSSOPVSA-N,CC1(C)OC(=O)N(c2ccc(C(=O)Nc3cccc4cccnc34)cc2)[C@H]1c1ccccc1,No,No,CHEMBL2381958,528188,,,,,,,,,,
CHEMBL3414768 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3414768,,,,2017-07-08,,FDQXEDMRIBACLZ-UHFFFAOYSA-N,NC(=O)c1cccc(NC(=O)C2=C(C(=O)O)CCC2)c1,No,No,CHEMBL3414768,1221513,,,,,,,,,,
CHEMBL2179989,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl2179989,,,,2017-07-08,,GNFSYBNDPOBXLJ-PLNGDYQASA-N,NC(=O)c1cccc(NC(=O)/C=C\C(=O)O)c1,No,Yes,CHEMBL2179989,1054590,,,,,,,,,,
CHEMBL3092538 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3092538,,,,2017-07-08,,HWTVYWVFOWWESR-GFCCVEGCSA-N,C[C@@H](NC(=O)CCc1nc2ccccc2c(=O)[nH]1)c1ccccn1,No,No,CHEMBL3092538,1550908,,,,,,,,,,
CHEMBL483348,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl483348,,,,2017-07-08,,HRYKZAKEAVZGJD-UHFFFAOYSA-N,Cc1nc2c(c(=O)[nH]1)CSCC2,No,No,CHEMBL483348,8926,,,,,,,,,,
CHEMBL3092523 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3092523,,,,2017-07-08,,VBHDTUSGPSUCNL-KRWDZBQOSA-N,COC(=O)[C@H](Cc1ccccc1)NC(=O)CCc1nc2ccccc2c(=O)[nH]1,No,No,CHEMBL3092523,114471,,,,,,,,,,
CHEMBL3092539 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3092539,,,,2017-07-08,,HWTVYWVFOWWESR-LBPRGKRZSA-N,C[C@H](NC(=O)CCc1nc2ccccc2c(=O)[nH]1)c1ccccn1,No,No,CHEMBL3092539,1550909,,,,,,,,,,
CHEMBL3416132,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3416132,,,,2017-07-08,,NMZRTRAYSHQMPR-UHFFFAOYSA-N,O=C1NCCc2ccc(Cl)cc21,No,No,CHEMBL3416132,14467,,,,,,,,,,
NSC-93392,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc-93392,,,,2017-07-08,,ZHXIMGYEMBZGOI-UHFFFAOYSA-N,O=c1cc(-c2ccc(F)cc2)oc2ccccc12,No,No,CHEMBL53738,1065940,,,,,,,,,,
CHEMBL3589281 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3589281,,,,2017-07-08,,DTMHAFMUJHYVGK-UHFFFAOYSA-N,CN1CCCc2c1cc(-c1ccccc1)[nH]c2=O,No,No,CHEMBL3589281,1107538,,,,,,,,,,
A-620223,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/620223,,,,2017-07-08,,KXSIHXHEHABEJX-UHFFFAOYSA-N,CCCN1CCC(c2nc3cccc(C(N)=O)c3[nH]2)CC1,No,No,CHEMBL452800,1308630,,,,,,,,,,
Phthalazinone,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/phthalazinone,,,,2017-07-08,,IJAPPYDYQCXOEF-UHFFFAOYSA-N,Oc1nncc2ccccc12,No,No,CHEMBL124706,89399,,,,,,,,,,
GJW,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gjw,,,,2017-07-08,,ZLYVTQGSZRQZLA-UHFFFAOYSA-N,O=c1[nH]c2cc(CN3CCCC3)ccc2n2cccc12,No,No,CHEMBL571234,1181168,,,,,,,,,,
BZC,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/bzc,,,,2017-07-08,,NVVWVYYHTKCIAE-UHFFFAOYSA-N,COc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)c1,No,No,CHEMBL134022,1166997,,,,,,,,,,
AMG-458,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/amg-458,,,,2017-07-08,,GLBZSOQDAOLMGC-UHFFFAOYSA-N,COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1,No,No,CHEMBL460472,817363,,,,,,,,,,
Enzastaurin,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/enzastaurin,,,,2017-07-08,,AXRCEOKUDYDWLF-UHFFFAOYSA-N,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,No,Yes,CHEMBL300138,795308,,,,,,,,,,
Flavone,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/flavone,,,,2017-07-08,,VHBFFQKBGNRLFZ-UHFFFAOYSA-N,O=c1cc(-c2ccccc2)oc2ccccc12,No,No,CHEMBL275638,1109148,,,,,,,,,,
Chloroquine,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chloroquine,,,,2017-07-08,,WHTVZRBIWZFKQO-UHFFFAOYSA-N,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,No,No,CHEMBL76,1305871,,,,,,,,,,
AJ4,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/aj4,,,,2017-07-08,,PPOQMSJVMJCEAI-UHFFFAOYSA-N,Cc1cc(=O)[nH]c2cc(-c3ccccc3F)ccc12,No,No,CHEMBL2381633,1146534,,,,,,,,,,
CHEMBL2179988 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl2179988,,,,2017-07-08,,GNFSYBNDPOBXLJ-SNAWJCMRSA-N,NC(=O)c1cccc(NC(=O)/C=C/C(=O)O)c1,No,Yes,CHEMBL2179988,1054589,,,,,,,,,,
CHEMBL3593715,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3593715,,,,2017-07-08,,NZSKSXWSNJEOQY-UHFFFAOYSA-N,O=c1[nH]c(N2CCN(Cc3ccncc3)CC2)nc2c1CCCC2,No,No,CHEMBL3593715,1570026,,,,,,,,,,
CHEMBL3092521 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3092521,,,,2017-07-08,,INPZIMSQNZGLHQ-JTQLQIEISA-N,CC[C@@H](CO)NC(=O)CCc1nc2ccccc2c(=O)[nH]1,No,No,CHEMBL3092521,1284750,,,,,,,,,,
CHEMBL3092544,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl3092544,,,,2017-07-08,,YAXDRRKYLDEMKO-INIZCTEOSA-N,CC[C@H](NC(=O)CCc1nc2ccccc2c(=O)[nH]1)c1ccccc1,No,No,CHEMBL3092544,1653084,,,,,,,,,,
3-Aminobenzoic Acid,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/3-aminobenzoic-acid,,,,2017-07-08,,XFDUHJPVQKIXHO-UHFFFAOYSA-N,Nc1cccc(C(=O)O)c1,No,No,CHEMBL307782,56288,,,,,,,,,,
CHEMBL1688212 ,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl1688212,,,,2017-07-08,,YWPMKTWUFVOFPL-UHFFFAOYSA-N,O=C1NCCc2ccccc21,No,No,CHEMBL1688212,3985,,,,,,,,,,
NSC-22356,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc-22356,,,,2017-07-08,,ISZWRZGKEWQACU-UHFFFAOYSA-N,O=c1cc(-c2cccc(O)c2)oc2ccccc12,No,No,CHEMBL147552,1068678,,,,,,,,,,
CHEMBL301624,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/chembl301624,,,,2017-07-08,,PVFGJHYLIHMCQD-UHFFFAOYSA-N,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)ccc12,Yes,Yes,CHEMBL301624,1172273,,,,,,,,,,
NSC-123414,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/nsc-123414,,,,2017-07-08,,SQVXWIUVAILQRH-UHFFFAOYSA-N,COc1ccc(-c2cc(=O)c3ccc(O)cc3o2)cc1,No,No,CHEMBL16751,1161709,,,,,,,,,,
IWR-1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/iwr-1,,,,2017-07-08,,ZGSXEXBYLJIOGF-ALFLXDJESA-N,O=C(Nc1cccc2cccnc12)c1ccc(N2C(=O)[C@H]3[C@H]4C=C[C@H](C4)[C@H]3C2=O)cc1,No,Yes,CHEMBL562310,344422,,,,,,,,,,
AG-014376,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ag-014376,,,,2017-07-08,,PISBNXWDAGANOP-UHFFFAOYSA-N,CN(C)Cc1ccc(-c2cc3cccc4c3n2CCNC4=O)cc1,No,No,CHEMBL361489,1499401,,,,,,,,,,
KU-0058948,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ku-0058948,,,,2017-07-08,,HGEPGGJUGUMFHT-UHFFFAOYSA-N,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCCNCC1,No,No,CHEMBL380648,1903925,,,,,,,,,,
KU-58684,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ku-58684,,,,2017-07-08,,YQSZNYLPVBOGPO-UHFFFAOYSA-N,O=C1CCC(=O)N1c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,No,No,CHEMBL196444,1696288,,,,,,,,,,
CEP-6800,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/cep-6800,,,,2017-07-08,,SDXBGOVSVBZDFL-UHFFFAOYSA-N,NCc1ccc2[nH]c3c4c(c5c(c3c2c1)C(=O)NC5=O)CCC4,No,Yes,CHEMBL247374,1401652,,,,,,,,,,
LFM-A13,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/lfm-a13,,,,2017-07-08,,UVSVTDVJQAJIFG-VURMDHGXSA-N,C/C(O)=C(\C#N)C(=O)Nc1cc(Br)ccc1Br,No,Yes,CHEMBL228043,99599,,,,,,,,,,
4-Bromo-Benzamide,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/4-bromo-benzamide,,,,2017-07-08,,ZRWNRAJCPNLYAK-UHFFFAOYSA-N,NC(=O)c1ccc(Br)cc1,No,No,CHEMBL339059,56360,,,,,,,,,,
WLH,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/wlh,,,,2017-07-08,,SQCWABLHLAOJBR-UHFFFAOYSA-N,CN1CCN(c2nc3c(c(=O)[nH]2)CCCC3)CC1,No,No,CHEMBL3593716,1107542,,,,,,,,,,
RUSKI-41,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ruski-41,,,,2020-03-05,,LPTGUSPVGHUCQF-UHFFFAOYSA-N,C=CCNCC(=O)N1CCc2sccc2C1COc1ccc(Cl)c(C)c1,No,No,,3312888,doi.org/10.1021/acschembio.6b00896,,,,,,,,,
Ogerin,3.0,3.0,1.0,No,https://www.chemicalprobes.org/ogerin,GPR68,GPCR,Proton Sensing GPCR,2020-05-29,Q15743,MDGIEDNDSFMSLP-UHFFFAOYSA-N,Nc1nc(NCc2ccccc2)nc(-c2ccccc2CO)n1,No,No,CHEMBL4548689,2968794,"www.doi.org/10.1038/nature15699, https://www.ncbi.nlm.nih.gov/pubmed/26550826",Positive Allosteric Modulator,,,4.92,Glo cAMP assay analyzed using a 4-parameter logistic model for agonist activity (agonist: pH),pKbB,Other,10 mg/Kg,ZINC32547799
BAY-885,2.7,0.0,3.0,No,https://www.chemicalprobes.org/bay-885,MAPK7,Protein kinase,CMGC,2020-05-17,Q13164,QXURFIGBRGWPQD-UHFFFAOYSA-N,CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1,No,No,CHEMBL4445670,2920850,"https://doi.org/10.1021/acs.jmedchem.8b01606, https://www.ncbi.nlm.nih.gov/pubmed/30563338",Inhibitor,35 nM (@250 uM ATP),High-throughput TR-FRET-based kinase inhibition assay was used to identify potential ERK5 inhibitors,115 nM,Active in cellular mechanistic luciferase assay demonstrating on-target cell activity,IC50,,,BAY-693
MLi-2,3.0,2.5,2.0,No,https://www.chemicalprobes.org/mli-2,LRRK2,Protein kinase,TKL,2020-05-17,Q5S007,ATUUNJCZCOMUKD-OKILXGFUSA-N,C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1,No,No,CHEMBL4098877,137938,"www.doi.org/10.1021/acs.jmedchem.7b00045, https://www.ncbi.nlm.nih.gov/pubmed/28245354",Inhibitor,1.8 nM,MSD and Invitrogen assay,3.5 nM,LRRK2 G2019S SH-SY5Y human neuroblastoma cell line was used for the LRRK2 pSer935 phosphorylation measurements.,IC50,Other,"30 mg/Kg Oral, 2 mg/Kg IV",MLi-2-NC
RUSKI-43,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ruski-43,,,,2020-03-05,,AEENEMOEBJOKGN-UHFFFAOYSA-N,CCC(C)CNCC(=O)N1CCc2sccc2C1COc1cccc(C)c1,No,No,CHEMBL3133036,1861430,DOI.ORG/10.1021/acschembio.6b00896,,,,,,,,,
TP-024,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tp-024,GPR52,GPCR, A orphan G protein-coupled receptor ,2020-05-29,Q9Y2T5,TYXSIXOYTBHZFA-UHFFFAOYSA-N,Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O,No,No,CHEMBL4082756,136711,"https://doi.org/10.1016/j.bmc.2017.03.064, https://doi.org/10.1124/jpet.117.242925, https://www.ncbi.nlm.nih.gov/pubmed/28433511, https://www.ncbi.nlm.nih.gov/pubmed/28851764",Agonist,,,93 nM in human; 141 nM in Mouse; 134 nM in Rat,CHO-Bases cAMP assay,IC50,Other,10 to 30 mg/Kg in Rat,TP-024n
 (R)-Zinc-3573,3.0,0.0,1.0,No,https://www.chemicalprobes.org/r-zinc-3573,MRGPRX2,GPCR,Mast cell-specific receptor,2020-05-29,Q96LB1,XKBSPAZCFAIBJL-OAHLLOKOSA-N,CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1,No,No,CHEMBL4520293,2968796,"www.doi.org/10.1038/nchembio.2334, www.doi.org/10.1038/nchembio.2490, www.doi.org/10.1038/nrd.2017.77, https://www.ncbi.nlm.nih.gov/pubmed/28288109, https://www.ncbi.nlm.nih.gov/pubmed/29045379, https://www.ncbi.nlm.nih.gov/pubmed/28417990",Agonist,,,760nM and 1000nM,"PRESTO-Tango arrestin recruitment, FLIPR calcium assay",EC50,,,ZINC72453574
TP-004,2.5,2.5,2.0,No,https://www.chemicalprobes.org/tp-004,METAP2,Other,Methionine Aminopeptidase,2020-06-23,P50579,BNTAEJNPQLMGDJ-LLVKDONJSA-N,Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12,No,No,CHEMBL3799512,1780427,"https://doi.org/10.1016/j.bmcl.2016.04.072, https://doi.org/10.1016/j.bmcl.2016.04.073, https://pubmed.ncbi.nlm.nih.gov/27155900, https://pubmed.ncbi.nlm.nih.gov/27136719",Reversible Inhibitor,5nM with Mn; 31nM with Co,Biochemical Activity,15 nM,Accumulation of NMet14-3-3 in HUVEC cells,EC50,Other,"30 mg/Kg, 10 mg/Kg, 5 mg/Kg",TPn-004
WM-1119 ,3.0,3.0,2.0,No,https://www.chemicalprobes.org/wm-1119,KAT6A,Other,Lysine Acetyltransferase,2020-07-09,Q92794,QLXULUNLCRKWRD-UHFFFAOYSA-N,O=C(NNS(=O)(=O)c1ccccc1F)c1cc(F)cc(-c2ccccn2)c1,No,Yes,CHEMBL4456585,2843004,"www.doi.org/10.1021/acs.jmedchem.9b02071, www.doi.org/10.1038/s41586-018-0387-5, https://pubmed.ncbi.nlm.nih.gov/32118427, https://pubmed.ncbi.nlm.nih.gov/30069049",HAT inhibitor,"6.3 nM IC50, 2 nM KD",,0.250 uM,"Cell cycle analysis, Western",IC50,Other,"2.9 (IV) mg/kg, 33 (PO) mg/kg","Compound 187, Compound 188, Compound 189"
BI-1935,4.0,4.0,1.0,No,https://www.chemicalprobes.org/bi-1935,EPHX2,Other,Epoxide Hydrolase 2,2020-05-24,P34913,KMESAVNRPDKZCQ-UHFFFAOYSA-N,CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O,No,No,CHEMBL4516982,2913055,"https://doi.org/10.1016/j.bmcl.2010.09.095, https://doi.org/10.1517/13543776.2010.484804, https://pubmed.ncbi.nlm.nih.gov/20934334/, https://pubmed.ncbi.nlm.nih.gov/20429668/",Inhibitor,7 nM,biochemical h-sEH binding assay,< 1 nM,cellular Hep G2-DHET assay,IC50,Other,"1.2 mg/Kg IV, 3 mg/Kg PO",
BI-2545,3.7,3.7,3.0,No,https://www.chemicalprobes.org/bi-2545,ENPP2,Other,Phosphodiesterase,2020-05-24,Q13822,ZDOBSAPHUUUOHX-OSYLJGHBSA-N,O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1,No,No,CHEMBL4165749,752127,"www.doi.org/10.1021/acsmedchemlett.7b00312, https://pubmed.ncbi.nlm.nih.gov/29259743/",Inhibitor,2.2 nM (human); 3.4 nM (rat),LPA measurement,29 nM (human) ; 96 nM (rat),Whole blood assay,IC50,Other,"10 mg/Kg PO, 1 mg/Kg IV",BI-3017
M-808,2.3,2.0,3.0,No,https://www.chemicalprobes.org/m-808,MEN1,Epigenetic,Scaffold Protein ,2020-07-09,O00255,BTSUNSRQYLVGIS-ADTYUTHVSA-N,COC(=O)N[C@H]1CCC[C@@H]1[C@](CN1CCC1)(c1cccc(F)c1)C1CCN(CC2CN(c3ccc(S(=O)(=O)C4CN(C(=O)/C=C/CN5CCCCC5)C4)cc3)C2)CC1,No,Yes,CHEMBL4438797,2959399,"https://doi.org/10.1021/acs.jmedchem.0c00547, https://pubmed.ncbi.nlm.nih.gov/32338903/",Covalent Inhibitor,2.6 nM,FP assay,1 nM in MV4;11; 4 nM in MOLM-13,Cell Growth inhibition,IC50,Other,"10 mg/Kg (not effective), 25 mg/Kg",
CMLD-2,2.0,0.0,2.0,No,https://www.chemicalprobes.org/cmld-2,ELAVL1,Other,RNA Binding Protein,2020-07-16,Q15717,PROGRNRRJJYCNX-UHFFFAOYSA-N,COc1ccc(C(CC(=O)N2CCCC2)c2c(OC)cc(OC)c3c(-c4ccccc4)cc(=O)oc23)cc1,No,No,CHEMBL1499653,770107,"www.doi.org/10.1021/cb500851u, www.doi.org/10.1038/s41598-017-07787-4, www.doi.org/10.1038/s41598-019-43894-0, https://pubmed.ncbi.nlm.nih.gov/25750985/, https://pubmed.ncbi.nlm.nih.gov/28855578, https://pubmed.ncbi.nlm.nih.gov/31089242",Inhibitor,0.35 uM,"FP assay, AlphaLISA assay, SPR",,"RNP IP, luciferase-based reporter assays, and cytotoxicity assays.",,,,NC-3
AMG 176,3.0,2.5,2.0,No,https://www.chemicalprobes.org/amg-176-0,MCL1,Other,BCL2 family	,2020-07-10,Q07820,JQNINBDKGLWYMU-GEAQBIRJSA-N,CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3,No,No,CHEMBL4446378,2945470,"www.doi.org/10.1158/2159-8290.CD-18-0387, www.doi.org/10.1158/1078-0432.CCR-19-1397, www.doi.org/10.1016/j.blre.2020.100672, https://pubmed.ncbi.nlm.nih.gov/30254093/, https://pubmed.ncbi.nlm.nih.gov/31937611/, https://pubmed.ncbi.nlm.nih.gov/32204955/",Antagonist,60 pM,Time-resolved fluorescence resonance energy transfer binding assays,,"Split Luciferase Complementation Assay, immunoblot 
(these experiments were performed with close analogue AM-8621",,Other,"30 and 60 mg/Kg , 50 and 100 mg/Kg",
TP-020,2.0,3.0,1.0,No,https://www.chemicalprobes.org/tp-020,MGAT2,Other post-translational modification,N-acetylglucosaminyltransferase,2020-09-24,Q10469,VSZRYLHBOKTNBO-UHFFFAOYSA-N,Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1,No,No,CHEMBL4455357,3150984,"https://doi.org/10.1371/journal.pone.0150976, https://doi.org/10.1016/j.bmc.2015.06.003, https://pubmed.ncbi.nlm.nih.gov/26938273/, https://pubmed.ncbi.nlm.nih.gov/26100443/",Inhibitor,7.8 nM (human) 2.4 nM  (Mouse),Enzymatic Assay,160 nM,Cell Based Assay,IC50,Other,0.1-1-3-10-30 mg/Kg,TP-020n
XMD8-87,2.0,0.0,3.0,No,https://www.chemicalprobes.org/xmd8-87,TNK2,Protein kinase,TK,2020-10-13,Q07912,LGLHCXISMKHLIK-UHFFFAOYSA-N,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2,No,No,CHEMBL1672987,517482,"www.doi.org/10.1016/j.chembiol.2011.05.010, www.doi.org/10.1158/0008-5472.CAN-15-0817, https://pubmed.ncbi.nlm.nih.gov/21802008/, https://pubmed.ncbi.nlm.nih.gov/26677978/",ATP competitive inhibitor,"15, 35.4 nM","Ambit binding assay (KD), Invitrogen Kinase assay",38 nM (D163E); ; 113 nM (R806Q),Phosphorylation inhibition assay,IC50,,,
MBM-55,3.0,2.5,2.0,No,https://www.chemicalprobes.org/mbm-55,NEK2,Protein kinase,Ser/Thr Protein Kinase,2020-10-22,P51955,CGECJCJUHCZZGO-UHFFFAOYSA-N,CN(C)CCn1cc(-c2ccn3c(-c4ccc(C(N)=O)c(OCc5cccc(F)c5)c4)cnc3c2)cn1,No,No,CHEMBL4062453,750570,"www.doi.org/10.1016/j.ejmech.2016.12.026, https://pubmed.ncbi.nlm.nih.gov/28039836/",Inhibitor,1 nM,HTRFÂ® KinEASEâ¢-STK (Cisbio Assays),530 nM (MGC-803); 840 nM (HCT-116); 7130 nM (Bel-7402),cell cycle analysis by flow cytometry,IC50,Other,1 mg/Kg,cpd 28a
GSK2973980A ,3.0,3.0,2.0,No,https://www.chemicalprobes.org/gsk2973980a,DGAT1,Other,Diacylglycerol O-acyltransferase,2020-10-23,O75907,OTKTZEZTFCAULO-DEOSSOPVSA-N,O=C(O)C[C@]1(CC(F)(F)F)CCc2cc(-c3cnc(NC(=O)Nc4ccc(F)c(F)c4)cn3)ccc2C1=O,No,No,CHEMBL4173715,788421,"www.doi.org/10.1021/acsmedchemlett.7b00450, https://www.journaljpri.com/index.php/JPRI/article/view/19787, https://pubmed.ncbi.nlm.nih.gov/29456796/",Inhibitor,"3.3 (human), 13 (rat) nM",Radiometric lipid extraction assay (enzymatic assay),75 nM,Inhibition of TG synthesis.,IC50,Other,"1, 3, 10 mg/Kg",
PF-06869206,3.0,3.0,2.0,No,https://www.chemicalprobes.org/pf-06869206,SLC34A1,Other,SLC Family,2020-10-20,Q06495,ATFQBBCQZKVZJN-QMMMGPOBSA-N,Cc1[nH]c2c(N3CCO[C@H](CO)C3)c(C#N)c(C(F)(F)F)nc2c1Cl,No,No,CHEMBL4175607,1685260,"www.doi.org/10.1021/acsmedchemlett.8b00013, www.doi.org/10.1152/ajprenal.00146.2020, https://pubmed.ncbi.nlm.nih.gov/29795756/, https://pubmed.ncbi.nlm.nih.gov/32744087/",Selective inhibitor,350 nM,Displacement of tritiated compound 6b from NaPi2a Membranes,1.4 uM,Dose dependent inhibition of NaPi2a in OK cells,IC50,Other,"1 mg/Kg IV, 5 mg/Kg PO, 50 mg/Kg PO",
NCT-505,2.0,2.0,2.0,No,https://www.chemicalprobes.org/nct-505,ALDH1A1,Other,aldehyde dehydrogenase,2020-10-22,P00352,XMNLWOQHMQRHDV-UHFFFAOYSA-N,CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2N2CCC(C#N)(c3ccccc3)CC2)CC1,No,No,CHEMBL4206892,753008,"www.doi.org/10.1021/acs.jmedchem.8b00270, https://pubmed.ncbi.nlm.nih.gov/29767973/",Inhibitor,7 nM,ALDH Enzymatic Assays,30 nM MIA PaCa-2; 33 nM OV-90; 123 nM HT-19,Aldefluor Cell-Based Assays.,IC50,Other,"2 mg/Kg IV, 10 mg/Kg PO",
PF-04457845,2.0,4.0,1.0,No,https://www.chemicalprobes.org/pf-04457845,FAAH,Lipid metabolism,Serine Hydrolase,2020-11-30,O00519,BATCTBJIJJEPHM-UHFFFAOYSA-N,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,No,No,CHEMBL1651534,516958,"www.doi.org/10.1021/ml100190t, https://pubmed.ncbi.nlm.nih.gov/21666860/",Covalent Inhibitor,"7.2 nM (human), 7.4 nM (Rat)",glutamate dehydrogenase-coupled FAAH assay,3.2 nM,Measurement of FAAH Activity using 3H-labelled substrate,IC50,Other,"1 mg/Kg PO, 0.5 mg/Kg IV",PF-04875474
Tanespimycin (17-AAG),0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tanespimycin-17-aag,,,,2020-12-02,,AYUNIORJHRXIBJ-TXHRRWQRSA-N,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,Yes,Yes,CHEMBL109480,866964,,,,,,,,,,
A-1331852,2.0,2.0,2.0,No,https://www.chemicalprobes.org/1331852,BCL2L1,Other,Apoptosis Regulator,2021-02-01,Q07817,QCQQONWEDCOTBV-UHFFFAOYSA-N,Cc1c(-c2ccc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)cnn1CC12CC3CC(CC(C3)C1)C2,No,Yes,CHEMBL3793424,937342,"www.doi.org/10.1021/acsmedchemlett.9b00568, www.doi.org/10.1126/scitranslmed.aaa4642, https://pubmed.ncbi.nlm.nih.gov/33062160/, https://pubmed.ncbi.nlm.nih.gov/25787766/",Inhibitor,0.01 nM,BCL-XL TR-FRET,6.3 nM,"BCellTiter-Glo cell viability assay; induction of apoptosis in BCL-XLâdependent Molt-4 cells, does not affect MEF cells lacking BAK or BAX CL-XLâBIM and BCL-2âBIM complexes in Molt-4 cells",EC50,Other,5-30 mg/Kg,
BAY-850,3.0,0.0,3.0,No,https://www.chemicalprobes.org/bay-850,ATAD2,Epigenetic,ATPase,2021-03-28,Q6PL18,BSISGUIVBKDTQO-QIKYYPRYSA-N,COc1cc(Cl)c(C(=O)N[C@@H](CN[C@H]2CC[C@@H](N)CC2)Cc2ccc(C#N)cc2)cc1-c1ccc(CN[C@H](C)c2ccc(C)cc2)o1,No,No,CHEMBL4536031,3194987,"www.doi.org/10.1021/acschembio.7b00708, https://pubmed.ncbi.nlm.nih.gov/29043777/",Inhibitor,"22-166 nM (T), 157 nM (A), 115 nM (B),  85 nM (M)","TR-FRET (T), Alphascreen (A), BROMOscan (B), MST (M)",5.8-5.9,Growth Inhibition Assay,pGI50,,,BAY-460
Vimirogant,3.0,3.0,2.0,No,https://www.chemicalprobes.org/vimirogant,RORC,Transcription factor,NR1 nuclear hormone receptors,2021-05-20,P51449,XUYMIRYNRKXKOR-HMHJJOSWSA-N,CCS(=O)(=O)c1ccc(CNC(=O)c2cnc3c(c2)CN(C[C@H]2CC[C@H](C(F)(F)F)CC2)[C@H]3C(C)C)nc1,No,No,CHEMBL4172726,788372,"www.doi.org/10.1002/cmdc.201700278, www.doi.org/10.1080/13543776.2017.1262350, https://pubmed.ncbi.nlm.nih.gov/28590087/, https://pubmed.ncbi.nlm.nih.gov/27852111/",Inhibitor,3.7 nM,radio-ligand RORÎ³ binding scintillation proximity assay,17 nM,,IC50,Other,15-100 mg/Kg,
Tris-DBA palladium,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/tris-dba-palladium,,,,2021-05-27,,CYPYTURSJDMMMP-WVCUSYJESA-N,O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Pd].[Pd],No,Yes,,3313089,,,,,,,,,,
D-NMAPPD,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/d-nmappd,,,,2021-05-27,,XUSDVLHKNBOGJY-UHFFFAOYSA-N,CCCCCCCCCCCCCC(=O)NC(CO)C(O)c1ccc([N+](=O)[O-])cc1,No,Yes,CHEMBL2142864,296713,,,,,,,,,,
2-hydroxymyristic acid,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/2-hydroxymyristic-acid,,,,2021-05-27,,JYZJYKOZGGEXSX-UHFFFAOYSA-N,CCCCCCCCCCCCC(O)C(=O)O,No,Yes,CHEMBL2004471,1052019,,,,,,,,,,
GPR120-IN-1,2.7,2.0,3.0,No,https://www.chemicalprobes.org/gpr120-in-1,FFAR4,GPCR,Free fatty acid receptor,2021-10-06,Q5NUL3,WUJVPELCYCESAP-UHFFFAOYSA-N,O=C(O)CC1CCC2(CC1)CCN(c1cc(OC(F)(F)F)ccc1Cl)CC2,No,No,CHEMBL3919973,1877870,"www.doi.org/10.1038/nm.3614, https://pubmed.ncbi.nlm.nih.gov/24997608/",Agonist,,,7.6,Fluorometric calcium assay using FLIPR methodology,pEC50,Other,30 mg/Kg,
NI-42,1.7,2.5,3.0,No,https://www.chemicalprobes.org/ni-42,"BRPF1, BRD1, BRPF3","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2017-01-30,"P55201, O95696, Q9ULD4",ZLTQCDRXWXUYHJ-UHFFFAOYSA-N,[C-]#[N+]c1ccc(S(=O)(=O)Nc2ccc3c(c2)cc(C)c(=O)n3C)cc1,No,No,,2977301,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01583, https://www.ncbi.nlm.nih.gov/pubmed/28068087",Antagonist,"40 nM, 7.9 nM, 140 nM, 210 nM, 48 nM, 760 nM, 940 nM, 260 nM, 2000 nM","ITC, Bromoscan assay, Alphascreen activity assays",,"An indexed cell panel of 211 cancer cell lines (CLIMB panel) was treated with NI-42 for 72 h and observed modest and selective inhibition of proliferation of certain AML cell lines (OCI-AML2, Nomo-1, THP-1, KG-1, MV-4-11) with GI50s 1-10 uM.",,Mouse,"3 mg/kg (oral), 1 mg/kg (IV)",NI-198
STO609,2.7,0.0,3.0,No,https://www.chemicalprobes.org/sto609,"CAMKK1, CAMKK2","Kinase, Kinase","Other, Other",2015-12-10,"Q8N5S9, Q96RR4",MYKOWOGZBMOVBJ-UHFFFAOYSA-N,O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21,No,No,CHEMBL1182777,1514280,"www.doi.org/10.1074/jbc.M201075200, http://www.ncbi.nlm.nih.gov/pubmed/11867640",ATP-competitive inhibitor,"250 nM, 380 nM, 47 nM, 120 nM","Autophosphorylation of CaM-KKÎ± and -Î², in vitro kinase assays",,"In HeLa cells transfected with CAMK, STO609 dose-dependently inhibited CAMK substrate phosphorylation.",,,,
BMS-265246,2.0,2.0,3.0,No,https://www.chemicalprobes.org/bms-265246,"CDK1, CDK2","Kinase, Kinase","CMGC, CMGC",2015-12-10,"P06493, P24941",SCFMWQIQBVZOQR-UHFFFAOYSA-N,CCCCOc1c(C(=O)c2c(F)cc(C)cc2F)c[nH]c2nncc1-2,No,No,CHEMBL310840,1597130,"www.doi.org/10.1158/1535-7163.MCT-10-0720, www.doi.org/10.1016/S0960-894X(03)00381-0, http://www.ncbi.nlm.nih.gov/pubmed/21216932, https://www.ncbi.nlm.nih.gov/pubmed/12824044",ATP-competitive inhibitor,"6 nM, 9 nM",In Vitro Kinase Inhibition,293-492 nM,"In high-content imaging experiments, BMS-265246 led to G2-arrest phenotypes",EC 50,,,
WH-4-023,1.8,1.3,5.0,No,https://www.chemicalprobes.org/wh-4-023,"LCK, SRC","Kinase, Kinase","TK, TK",2015-12-10,"P06239, P12931",NBTNHSGBRGTFJS-UHFFFAOYSA-N,COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)c(OC)c1,Yes,No,CHEMBL213100,861456,"www.doi.org/10.1021/jm060435i, http://www.ncbi.nlm.nih.gov/pubmed/16884310",Inhibitor,"0.6 nM, 1 nM",Kinase enzymatic activity,61 nM,Inhibition of IL-2 secretion,IC 50,Rat,5 mg/kg,
SCH772984,4.0,3.3,3.0,No,https://www.chemicalprobes.org/sch772984,"MAPK1, MAPK3","Kinase, Kinase","CMGC, CMGC",2015-12-10,"P28482, P27361",HDAJDNHIBCDLQF-RUZDIDTESA-N,O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1,No,No,CHEMBL3590107,945181,"http://cancerdiscovery.aacrjournals.org/content/early/2013/06/26/2159-8290.CD-13-0070, http://www.ncbi.nlm.nih.gov/pubmed/23614898",ATP-competitive inhibitor,"4 nM, 0.24 nM, 1 nM","Kinase assay, Temperature-dependent fluorescence binding assay",<500 nM,SCH772984 dose-dependently inhibited substrate phosphorylation in cells.,EC 50,,,
IMP-1088,3.0,2.0,3.0,No,https://www.chemicalprobes.org/imp-1088,"NMT1, NMT2","Other post-translational modification, Other post-translational modification","Acyltransferase, Acyltransferase",2021-05-18,"P30419, O60551",SOXNKJCQBRQUMS-UHFFFAOYSA-N,Cc1nn(C)c(C)c1CCOc1c(-c2ccc3c(c2)c(CN(C)C)nn3C)ccc(F)c1F,No,No,CHEMBL4445137,2888176,"www.doi.org/10.1016/j.chembiol.2019.03.006, www.doi.org/10.1038/s41557-018-0039-2, https://pubmed.ncbi.nlm.nih.gov/31006618/, https://pubmed.ncbi.nlm.nih.gov/29760414/",Inhibitor,"< 1 nM, 0.210 nM","Fluorogenic detection of the CoASH (NMT inhibition assay), SPR","17 nM (C), 5.8 nM","Inhibition of virus-induced CPE, Inhibition of single-cycle replication in HeLa cells infected with RV-A16",IC 50,,,IMP-994
LXR-623,2.5,4.0,2.0,No,https://www.chemicalprobes.org/lxr-623,"NR1H2, NR1H3","NHR, NHR","NR1 Subfamily, NR1 Subfamily",2020-07-16,"P55055, Q13133",KYWWJENKIMRJBI-UHFFFAOYSA-N,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,No,No,CHEMBL456237,160497,"www.doi.org/10.1186/1479-5876-6-59, www.doi.org/10.1194/jlr.M900037-JLR200, www.doi.org/10.1093/eurheartj/ehr136, www.doi.org/10.1016/j.ccell.2016.09.008, www.doi.org/10.1021/jm800799q, https://pubmed.ncbi.nlm.nih.gov/18925943/, https://pubmed.ncbi.nlm.nih.gov/19318684/, https://pubmed.ncbi.nlm.nih.gov/21606082/, https://pubmed.ncbi.nlm.nih.gov/27746144/, https://pubmed.ncbi.nlm.nih.gov/18973288/",Partial Agonist,"179 nM, 24 nM",Radio Labelled binding assay,"GAL4 LXRÎ± 6.66 uM (53), GAL4 LXRÎ² 3.67 uM (73); GAL4 LXRÎ± 6.66 uM (53); ABAC1 0.53 uM (100); C-Efflux 1.27 uM (140); SREBP1 2.11 uM (58); Lipid acc. 1.91 uM (35)","Huh-7 human hepatoma cell based Gal4 LXRÎ± or LXRÎ² transactivation assay, Cell functional assay for gene expression.","EC50 , (% effect)",Other,"30 (r), 50 (m) mg/kg/day, 15, 50 mg/Kg (R), 20, 60, and 120 mg/kg/day (ham), 50 mg/Kg (mon)Rab",
WZ4003,3.0,2.0,3.0,No,https://www.chemicalprobes.org/wz4003,"NUAK1, NUAK2","Kinase, Kinase","CAMK, CAMK",2015-12-10,"O60285, Q9H093",SDGJBAUIGHSMRI-UHFFFAOYSA-N,CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,No,No,CHEMBL4303523,616919,"www.doi.org/10.1042/BJ20131152, http://www.ncbi.nlm.nih.gov/pubmed/24171924",Inhibitor,"20 nM, 100 nM","Kinase assay, Kinase Assay",,"In HEK-293 cells, WZ4003 dose-dependently inhibited NUAK protein substrate phosphorylation.",,,,
ML323,3.3,0.0,3.0,No,https://www.chemicalprobes.org/ml323,"USP1, WDR48","Other post-translational modification, Other post-translational modification","Deubiquitinase, Deubiquitinase",2016-10-14,"O94782, Q8TAF3",VUIRVWPJNKZOSS-UHFFFAOYSA-N,Cc1cnc(-c2ccccc2C(C)C)nc1NCc1ccc(-n2ccnn2)cc1,No,No,CHEMBL3182437,207292,"http://pubs.acs.org/doi/10.1021/jm5010495, http://www.nature.com/nchembio/journal/v10/n4/full/nchembio.1455.html, http://www.ncbi.nlm.nih.gov/pubmed/25229643, https://www.ncbi.nlm.nih.gov/pubmed/24531842",Allosteric inhibitor,76 nM,"USP1/UAF1 activity was monitored in a fluorometric ubiquitinârhodamine110 assay. 
ML323 also showed IC50s of 174 nM and 820 nM in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) and monoubiquitinated PCNA (Ub-PCNA) as substrates, respectively.",,"Activity-based profiling with hemagglutinin (HA)-tagged ubiquitin vinyl methyl ester (HA-Ub-VME) in HEK293T cells revealed that ML323 could selectively and dose-dependently inhibit the labeling of USP1. ML323 also increased mUb of PCNA and FANCD2 in H596 cells, recapitulating results obtained with shRNA targeting USP1.",,,,NCGC-959
BAY-826,3.0,3.0,1.0,No,https://www.chemicalprobes.org/bay-826,"TIE1, TEK, DDR1, DDR2","Kinase, Kinase, Kinase, Kinase","TK, TK, TK, TK",2020-06-15,"P35590, Q02763, Q08345, Q16832",MPASHPJAIUOWCK-UHFFFAOYSA-N,Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1,No,No,CHEMBL3907057,2933235,"www.doi.org/10.1111/jnc.13877, https://pubmed.ncbi.nlm.nih.gov/27787897/",Inhibitor,"0.9 nM, 1.6 nM, 0.45 nM, 0.4 nM, 1.3","KINOMEscan, In house kinase assay","2.7 nM, 0.7 nM, 3.0 nM, 4.5 nM",Functional cellular assays: NanoBRET assay,IC 50,Rat,"25, 50, 100 mg/Kg",BAY-309
HG-9-91-01,3.0,1.7,3.0,No,https://www.chemicalprobes.org/hg-9-91-01,"SIK1, SIK2, SIK3","Kinase, Kinase, Kinase","CAMK, CAMK, CAMK",2015-12-10,"P57059, Q9H0K1, Q9Y2K2",UYUHRKLITDJEHB-UHFFFAOYSA-N,COc1ccc(N(C(=O)Nc2c(C)cccc2C)c2cc(Nc3ccc(N4CCN(C)CC4)cc3)ncn2)c(OC)c1,Yes,No,CHEMBL4553284,2945471,"www.doi.org/10.1073/pnas.1215450109, http://www.ncbi.nlm.nih.gov/pubmed/23033494",ATP-competitive inhibitor,"0.92 nM, 6.6 nM, 9.6 nM",In vitro kinase assay,,Inhibition of protein substrate phosphorylation in macrophages,,,,
BI-D1870,2.0,1.0,3.0,No,https://www.chemicalprobes.org/bi-d1870,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6","Kinase, Kinase, Kinase, Kinase","AGC, AGC, AGC, AGC",2015-12-10,"Q15418, Q15349, P51812, Q9UK32",DTEKTGDVSARYDS-UHFFFAOYSA-N,CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C,No,No,CHEMBL573107,1913977,"www.doi.org/10.1042/BJ20061088, http://www.ncbi.nlm.nih.gov/pubmed/17040210",ATP-competitive inhibitor,"31 nM RPS6KA1, 18 nM, 24 nM, 15 nM",In Vitro Kinase assay @ 100 uM ATP,1 uM,"In HEK-293 cells, BI-D1870 inhibited phosphorylation of RPS6KA protein substrates but not those for several off-target kinases",IC50,,,
PF-3758309,2.5,2.5,4.0,No,https://www.chemicalprobes.org/pf-3758309,"PAK1, PAK4, PAK5, PAK6","Kinase, Kinase, Kinase, Kinase","STE, STE, STE, STE",2015-12-10,"Q13153, O96013, Q9P286, Q9NQU5",AYCPARAPKDAOEN-LJQANCHMSA-N,Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,No,No,CHEMBL3128043,651981,"www.doi.org/10.1073/pnas.0911863107, http://www.ncbi.nlm.nih.gov/pubmed/20439741",ATP-competitive inhibitor,"13.7 nM, PAK4 18.7 nM, 2.7 nM, 4.5 nM, 18.1 nM, 17.1 nM","Biochemical Assay, ITC, SPR",1.3 nM,Inhibition of PAK protein substrate phosphorylation,IC50,Mouse,7.5-30 mg/kg,
AC710,2.0,2.0,2.0,No,https://www.chemicalprobes.org/ac710,"CSF1R, FLT3, KIT, PDGFRB, PDGFRA","Kinase, Kinase, Protein kinase, Kinase, Kinase","TK, TK, TK, TK, TK",2020-11-27,"P07333, P36888, P10721, P09619, P16234",JVCWPUFNLFSKFS-UHFFFAOYSA-N,CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C,No,No,CHEMBL2206278,850277,"http://pubs.acs.org/doi/abs/10.1021/ml300214g, https://www.ncbi.nlm.nih.gov/pubmed/?term=24900421",Inhibitor,"0.5 nM, 0.6 nM, 1 nM, 1.3 nM",Competition binding assay (KinomeScan),"10.5 nM, 2 nM, 1.2 nM, 7.7 nM",Phosphorylation MSD assay,IC50,Mouse,"3, 10, 30 mg/Kg",
IMP-1710,3.3,0.0,3.0,No,https://www.chemicalprobes.org/imp-1710,UCHL1,Other,Peptidase C12 family,2021-06-22,P09936,FYMVGXGSNIVSKY-NRFANRHFSA-N,C#Cc1cnc2[nH]cc(-c3cccc4c3CCN4C(=O)[C@@H]3CCCN3C#N)c2c1,No,Yes,,3313091,"www.doi.org/10.1021/jacs.0c04527, https://pubmed.ncbi.nlm.nih.gov/32579346/",Covalent Inhibitor,38 nM,Fluorescence polarization (FP) assay using Ub-Lys-TAMRA,110 nM,Homogeneous time-resolved fluorescence (HTRF) assay in Cal51 cells,IC50,,,cpd 3
SGC-CBP30,3.3,0.0,3.0,No,https://www.chemicalprobes.org/sgc-cbp30,"EP300, CREBBP","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2015-11-03,"Q09472, Q92793",GEPYBHCJBORHCE-SFHVURJKSA-N,COc1ccc(CCc2nc3cc(-c4c(C)noc4C)ccc3n2C[C@H](C)N2CCOCC2)cc1Cl,No,No,CHEMBL3622373,767103,"www.doi.org/10.1021/ja412434f, www.doi.org/10.1073/pnas.1501956112, http://www.ncbi.nlm.nih.gov/pubmed/?term=24946055, http://www.ncbi.nlm.nih.gov/pubmed/?term=26261308",Antagonist,"47 nM, 38 nM",Biolayer interference.,,"In HeLa cells, SGC-CBP30 displaced CREBBP from chromatin in a FRAP assay.",,,,SGC-CBP30N (BDOIA513)
XAV939,1.3,0.0,3.0,No,https://www.chemicalprobes.org/xav939,"TNKS, TNKS2, PARP1, PARP2","Other post-translational modification, Other post-translational modification, Other post-translational modification, Other post-translational modification","PARP, PARP, PARP, PARP",2016-07-29,"O95271, Q9H2K2, P09874, Q9UGN5",KLGQSVMIPOVQAX-UHFFFAOYSA-N,Oc1nc(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2,No,No,CHEMBL1086580,1246871,"http://www.nature.com/nature/journal/v461/n7264/full/nature08356.html, http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00990, http://www.ncbi.nlm.nih.gov/pubmed/19759537, https://www.ncbi.nlm.nih.gov/pubmed/?term=28001384",Inhibitor,"99 nM, 93 nM",CY5-labeled XAV939 binding assay,,"In HEK293 cells, XAV939 inhibited SuperTopFlash-luciferase reporter expression (Wnt/B-catenin-dependent expression).",,,,LDW643
AZ6102,3.0,3.0,3.0,No,https://www.chemicalprobes.org/az6102,"TNKS, TNKS2","Other post-translational modification, Other post-translational modification","PARP, PARP",2016-07-29,"O95271, Q9H2K2",WCPTUQOMNJBIET-CALCHBBNSA-N,Cc1cc(N2C[C@H](C)N[C@H](C)C2)ncc1-c1ccc(-c2nc(=O)c3ccn(C)c3[nH]2)cc1,No,No,,2879308,"http://pubs.acs.org/doi/abs/10.1021/ml5003663, http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00990, http://www.ncbi.nlm.nih.gov/pubmed/?term=25815142, https://www.ncbi.nlm.nih.gov/pubmed/?term=28001384",NAD+ competitive inhibitor,"3 nM, 100 nM, 1 nM, 0.6 nM","Scintillation Proximity Assay (SPA): The assay was designed to measure compound inhibition of Tankyrase-1 autoPARsylation (Tankyrase-1 was both enzyme and substrate in this assay)., In vitro ADP ribosylation assays",0.005 uM,Inhibition of the Wnt pathway as demonstrated in a TCF TOPflash reporter assay in DLD-1 cells.,"IC 50, IC50",Other,25 mg/kg IV (mouse),
BAY-985,3.0,2.3,3.0,No,https://www.chemicalprobes.org/bay-985,"TBK1, IKBKE","Kinase, Kinase","Ser/Thr Protein Kinase, Ser/Thr Protein Kinase",2020-05-16,"Q9UHD2, Q14164",HZRJHVDNTDBTOZ-QGZVFWFLSA-N,C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1,No,No,CHEMBL4537673,2937943,"www.doi.org/10.1021/acs.jmedchem.9b01460, https://www.ncbi.nlm.nih.gov/pubmed/31859507",Inhibitor,"2 nM, 18 nM","Low ATP-TR-FRET-based kinase activity inhibition assays using recombinant human enzymes., High ATP-TR-FRET-based kinase activity inhibition assays using recombinant human enzymes., Low ATP- TR-FRET-based kinase activity inhibition assays using recombinant human enzymes.","312 nM, 1735 nM","NanoBRET; 
anti-proliferative activity;  
no activity in MDA-MB-231 xenograft.",IC50,Mouse,"0.3 mg/Kg IV, up to 200 mg/Kg",BAY-440
L-Moses,2.5,2.0,6.0,No,https://www.chemicalprobes.org/l-moses,"KAT2B, KAT2A","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2017-03-13,"Q92831, Q92830",MSFPLTWUFWOKBX-IFXJQAMLSA-O,Cc1[nH]nc2c3ccccc3c(N[C@@H](C)[C@H](c3ccccc3)N(C)C)n[n+]12,No,No,,2843266,"http://onlinelibrary.wiley.com/doi/10.1002/anie.201610816/abstract, https://www.ncbi.nlm.nih.gov/pubmed/27966810",Antagonist,"48 nM, 47 nM, 126 nM, 220 nM, 550 nM","BROMOscan, PCAF HTRF assay, ITC with PCAF Bromodomain construct, ITC with GCN5 Bromodomain",256 nM,Displacement of PCAF-Brd from H3.3-nanoLuc in live HEK-293 cells using the nanoBRET assay,EC 50,Mouse,10 mg/kg,D-Moses
DS-437,2.0,1.0,3.0,No,https://www.chemicalprobes.org/ds-437,"PRMT5, PRMT7","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2016-08-08,"O14744, Q9NVM4",CACMCLIHCDTJHL-IDTAVKCVSA-N,CCNC(=O)NCCSC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O,No,No,CHEMBL3577854,1868908,"http://pubs.acs.org/doi/abs/10.1021/ml500467h, http://www.ncbi.nlm.nih.gov/pubmed/?term=25893041",SAM competitive inhibitor,"5900 nM, 25000 nM, 6000 nM, 37000 nM","Enzyme inhibition assay-SPA, In SPR binding assays with H4 peptide (PRMT5-Mep50), In SPR binding assays with H2B peptide (PRMT7)","1000 nM, 8000 nM","In MB-MDA231 cells, DS-437 inhibited protein substrate methylation (SmD and SmB proteins).",IC 50,,,
JW55,1.0,1.0,3.0,No,https://www.chemicalprobes.org/jw55,"TNKS, TNKS2","Other post-translational modification, Other post-translational modification","PARP, PARP",2016-07-29,"O95271, Q9H2K2",ZJZWZIXSGNFWQQ-UHFFFAOYSA-N,COc1ccc(C2(CNC(=O)c3ccc(NC(=O)c4ccco4)cc3)CCOCC2)cc1,No,No,CHEMBL3753077,475947,"http://cancerres.aacrjournals.org/content/72/11/2822.long, http://www.sciencedirect.com/science/article/pii/S0960894X15303310, http://www.ncbi.nlm.nih.gov/pubmed/22440753, http://www.ncbi.nlm.nih.gov/pubmed/?term=26706174",Inhibitor,"1900 nM, 830 nM",Biochemical PARylation assays,470 nM,"In Wnt-3a-induced HEK293 cells, JW55 inhibited SuperTop-luciferase reporter expression.",IC 50,,,
MS436,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ms436,BRD4,Epigenetic,Bromodomain,2020-12-03,O60885,DZTGIRNXWSZBIM-QURGRASLSA-N,Cc1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)c(N)cc1O,Yes,Yes,CHEMBL3086883,1860952,"http://pubs.acs.org/doi/abs/10.1021/jm401334s, https://www.ncbi.nlm.nih.gov/pubmed/?term=24144283",Inhibitor,85 nM BD1; 340 nM BD2,in vitro fluorescent anisotropy binding assay,"3.8 nM, 4.9 uM","Inhibition of NF-ÎºB pathway (NO assay), ELISA assay",IC 50,,,
GSK2801,2.3,2.0,3.0,No,https://www.chemicalprobes.org/gsk2801,"BAZ2A, BAZ2B","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2016-07-29,"Q9UIF9, Q9UIF8",KHWCPNJRJCNVRI-UHFFFAOYSA-N,CCCOc1ccn2c(C(C)=O)cc(-c3ccccc3S(C)(=O)=O)c2c1,No,No,CHEMBL3739699,1780119,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00209, http://www.ncbi.nlm.nih.gov/pubmed/25799074",Antagonist,"257 nM, 400 nM, 136 nM, 430 nM","Isothermal Titration Calorimetry and Biolayer interferometry, Biochemical FRET assay",,"In a cellular FRAP assay (U2OS cells), 1 uM GSK2801 displaced GFP-BAZ2A from acetylated chromatin.",,Mouse,30 mg/kg,"GSK8573, with activity against BRD9"
Bafetinib,2.8,2.5,4.0,No,https://www.chemicalprobes.org/bafetinib,"ABL1, LYN","Kinase, Kinase","TK, TK",2015-12-10,"P00519, P07948",ZGBAJMQHJDFTQJ-DEOSSOPVSA-N,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,No,No,CHEMBL206834,861358,"http://www.bloodjournal.org/content/106/12/3948.long?sso-checked=true, http://www.ncbi.nlm.nih.gov/pubmed/16105974",Inhibitor,"5.8 nM, 19 nM",Kinase Profiler,"11 nM, 22 nM","In K562 and 293T cells, bafetinib dose-dependently inhbited BCR-ABL autophosphorylation and phosphorylation of its substrates. IC50 was 11 nM in K562 cells and 22 nM in 293T cells., IC50 was 11 nM in K562 cells and 22 nM in 293T cells.",IC 50,Mouse,30 mg/kg,
LP99,2.0,0.0,3.0,No,https://www.chemicalprobes.org/lp99,"BRD9, BRD7","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2016-07-29,"Q9H8M2, Q9NPI1",LVDRREOUMKACNJ-BKMJKUGQSA-N,Cc1cc(=O)n(C)c2cc(N3C(=O)CC[C@H](NS(=O)(=O)CC(C)C)[C@H]3c3ccc(Cl)cc3)ccc12,No,No,CHEMBL3753082,661124,"http://onlinelibrary.wiley.com/doi/10.1002/anie.201501394/abstract;jsessionid=4E4574D7F79F4604CC4AD2E5F443B79D.f01t03, https://www.ncbi.nlm.nih.gov/pubmed/25864491",Antagonist,"99 nM, 909 nM",Isothermal Calorimetry,"3300 nM, 3700 nM","In HEK293 cells, LP99 disrupted BRD7-NanoLuc--H3.3-HaloTag and BRD9-NanoLuc--H4-HaloTag interaction. LP99 also disrupted BRD9-chromatin interaction as detected by fluorescence recovery after photobleaching assays.",IC 50,,,"2S,3R-enantiomer"
THAL-SNS-032,3.7,0.0,3.0,No,https://www.chemicalprobes.org/thal-sns-032,"CDK9, CDK10","Kinase, Kinase","CMGC, CMGC",2020-11-12,"P50750, Q15131",BXDZOYLPNAIDOC-UHFFFAOYSA-N,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5c4C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)s2)o1,No,Yes,CHEMBL4587232,3239852,"www.doi.org/10.1038/nchembio.2538, https://pubmed.ncbi.nlm.nih.gov/29251720/",Degrader (PROTAC),,,"50 nM, 250 nM","Western Blot, Western Blot assessing CDK10 protein level; CDK10 demonstrated partial degradation, but required longer exposure to the compound to achieve full degradation",EC 50,,,
KH-CB19,3.0,2.0,3.0,No,https://www.chemicalprobes.org/kh-cb19,"CLK1, CLK4, DYRK1A","Kinase, Kinase, Kinase","CMGC, CMGC, CMGC",2015-12-10,"P49759, Q9HAZ1, Q13627",CXJCGSPAPOTTSF-VURMDHGXSA-N,CCOC(=O)c1c(/C(C#N)=C\N)c2ccc(Cl)c(Cl)c2n1C,No,Yes,CHEMBL1236620,1336958,"http://www.sciencedirect.com/science/article/pii/S1074552110004448, http://www.ncbi.nlm.nih.gov/pubmed/21276940",Inhibitor,"19.7 nM, 530 nM, 55 nM","Phosphorylation reactions were monitored using a coupled-enzyme assay in which ADP production is coupled to NADH oxidation by pyruvate kinase (PK) and lactate dehydrogenase (LDH), enzymatic activity assay",,"KH-CB19 dose-dependently inhibited CLK1 protein substrate phosphorylation (SRp75, SRp55, and SRp20) in HMEC-1 cells. Dose response of KH-CB19 was tested using SRp75 and SRp55, and phosphorylation levels of these two proteins in TNF-Î±âstimulated cells were significantly reduced at increasing concentration of the inhibitor.",,,,
I-CBP112,3.0,2.0,3.0,No,https://www.chemicalprobes.org/i-cbp112,"EP300, CREBBP","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2015-11-03,"Q09472, Q92793",YKNAKDFZAWQEEO-IBGZPJMESA-N,CCC(=O)N1CCOc2c(cc(-c3ccc(OC)c(OC)c3)cc2OC[C@H]2CCCN(C)C2)C1,No,No,CHEMBL3774655,689769,"www.doi.org/10.1158/0008-5472.CAN-15-0236, http://www.ncbi.nlm.nih.gov/pubmed/26552700",Antagonizes interaction with acetylated lysine,"167 nM, 151 nM, 170 nM","ITC, Biolayer interferometry
I-CBP112 displaced acetylated lysine peptides from CBP",600 nM,"In cells, I-CBP112 interfered with CBP interaction with acetylated lysine-containing proteins in FRAP and BRET assays.","IC 50, IC50",Mouse,3 mg/mL,
Luminespib,4.0,3.7,3.0,No,https://www.chemicalprobes.org/luminespib,"HSP90AA1, HSP90AB1","Other post-translational modification, Other post-translational modification","Chaperone , Chaperone ",2020-05-11,"P07900, P08238",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,No,No,CHEMBL252164,563431,"www.doi.org/10.1158/0008-5472.CAN-07-5256, www.doi.org/10.3109/10428194.2012.698278, www.doi.org/10.1021/jm701018h, www.doi.org/10.1021/jm9004708, www.doi.org/10.1186/bcr1996, www.doi.org/10.1158/1078-0432.CCR-05-0518, https://www.ncbi.nlm.nih.gov/pubmed/18413753, https://www.ncbi.nlm.nih.gov/pubmed/22646928, https://www.ncbi.nlm.nih.gov/pubmed/22753713, https://www.ncbi.nlm.nih.gov/pubmed/18020435, https://www.ncbi.nlm.nih.gov/pubmed/20055425, https://www.ncbi.nlm.nih.gov/pubmed/18430202, https://www.ncbi.nlm.nih.gov/pubmed/16203796",Inhibitor,"7.8 nM, 21 nM",Fluorescence polarisation (FP) competitive binding assay,from 2.3 to 39 nM in various tumour cells; (*Growth Inhibition 50%),"Extensive evidence is available to validate depletion of client proteins (eg kinases CDK4, RAF and ERBB2/HER2 and transcription factors such as the estrogen and androgen receptor) together with increased expression of HSF1-regulated genes such as HSP72 and HSP27 as on-target molecular effects of HSP90 inhibitors) Eccles et al. 2008 (DOI: 10.1158/0008-5472.CAN-07-5256) and Banerji et al. 2005 (DOI: 10.1158/1078-0432.CCR-05-0518)",GI50*,Mouse,50 mg/Kg,
BLU9931,3.7,4.0,3.0,No,https://www.chemicalprobes.org/blu9931,FGFR4,Protein kinase,TK,2017-03-14,P22455,TXEBNKKOLVBTFK-UHFFFAOYSA-N,C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1,No,Yes,CHEMBL4068896,666346,"http://cancerdiscovery.aacrjournals.org/content/5/4/424.long, https://www.ncbi.nlm.nih.gov/pubmed/?term=25776529",Covalent inhibitor,0.6 X 10^5/(mol/L) s,"Omnia assay technology (Life Technologies); Incubation of recombinant FGFR4 with BLU9931 led to covalent modification of the receptor at Cys552, confirmed by mass shift and proteomics. In enzyme activity assays FGFR4 IC50=3 nM.",,"In the FGFR4-dependent cell line MDA-MB-453, BLU9931 potently and dose-dependently inhibited phosphorylation of FGFR4 substrates (FRS2, MAPK, AKT).",,Other,"10, 30 and 100 mg/kg",
MK-5108,4.0,4.0,3.0,No,https://www.chemicalprobes.org/mk-5108,AURKA,Kinase,cell cycle-regulated kinase,2015-12-10,O14965,LCVIRAZGMYMNNT-UHFFFAOYSA-N,O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1,No,No,CHEMBL3182444,387296,"http://mct.aacrjournals.org/content/9/1/157.long, http://www.ncbi.nlm.nih.gov/pubmed/20053775",ATP-competitive inhibitor,0.064 nM,Kinase Profiler Assay,,"In cells, MK-5108 inhibited AURKA autophosphorylation and the accumulation of phosphoH3 in response to DNA damage.",,,,
GNE-781,4.0,4.0,2.0,No,https://www.chemicalprobes.org/gne-781,"CREBBP, EP300","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2020-11-25,"Q92793, Q09472",CQCWHSDMJBAGDC-UHFFFAOYSA-N,CNC(=O)N1CCc2c(c(N3CCCc4cc(-c5cnn(C)c5)c(C(F)F)cc43)nn2C2CCOCC2)C1,Yes,No,CHEMBL4097025,788110,"www.doi.org/10.1021/acs.jmedchem.7b00796, https://pubmed.ncbi.nlm.nih.gov/28892380/",Inhibitor,"0.94 nM, 1.2 nM",Time-Resolved Fluorescence Resonance Energy Transfer Assays,"6.2 nM, 6.6 nM","CBP BRET assay, MYC Expression inhibition","IC 50, EC 50",Other,"1 mg/Kg IV, 5 mg/Kg PO, 5-10-30 mg/Kg PO BID, Reviewer suggested: max 30 mg/Kg",
LSN-3213128,4.0,4.0,1.0,No,https://www.chemicalprobes.org/lsn-3213128,ATIC,Other,formyltransferase and cyclohydrolase,2020-10-22,P31939,DSUZLJDXUJUTGI-LLVKDONJSA-N,O=c1[nH]ccc2cc(F)c(NS(=O)(=O)c3ccc(N4CC[C@@H](O)C4)s3)cc12,No,No,CHEMBL4063104,1880818,"www.doi.org/10.1021/acs.jmedchem.7b01046, www.doi.org/10.1038/s41598-018-33453-4, https://pubmed.ncbi.nlm.nih.gov/29072452/, https://pubmed.ncbi.nlm.nih.gov/30337562/",Inhibitor,16 Â± 11 nM,Enzymatic Assay,19 Â± 8 nM,ZMP accumulation in Vitro Assay,IC50,Mouse,"1 mg/Kg (IV), 10 mg/Kg (PO)",
CGI1746,4.0,4.0,3.0,No,https://www.chemicalprobes.org/cgi1746,BTK,Kinase,TK,2015-12-10,Q06187,JIFCFQDXHMUPGP-UHFFFAOYSA-N,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1,No,No,CHEMBL1230541,885852,"http://www.nature.com/nchembio/journal/v7/n1/full/nchembio.481.html, http://www.ncbi.nlm.nih.gov/pubmed/21113169",ATP-competitive inhbitor,"1.5 nM, 1.9 nM","Lanthascreen assay, In vitro kinase assay",~2.9 nM,Average IC50 for several assay is given. Assays included inhibition of autophosphorylation and protein substrate phosphorylation.,IC50,Mouse,100 mg/kg,
25CN-NBOH,4.0,3.7,3.0,No,https://www.chemicalprobes.org/25cn-nboh,"HTR2A, HTR2C, HTR2B","GPCR, GPCR, GPCR","Serotonin Receptor, Serotonin Receptor",2020-06-17,"P28223, P28335, P41595",VWEDZTZAXHMZIL-UHFFFAOYSA-N,COc1cc(CCNCc2ccccc2O)c(OC)cc1C#N,Yes,No,,2968795,"www.doi.org/10.3389/fphar.2018.00017, www.doi.org/10.1007/s00213-018-5118-y, www.doi.org/10.1007/s00213-014-3739-3, www.doi.org/10.1016/j.neuropharm.2016.03.038, www.doi.org/10.1124/jpet.117.239905, www.doi.org/10.1021/cn400216u, https://pubmed.ncbi.nlm.nih.gov/29467649, https://pubmed.ncbi.nlm.nih.gov/30448990, https://pubmed.ncbi.nlm.nih.gov/25224567, https://pubmed.ncbi.nlm.nih.gov/27020041, https://pubmed.ncbi.nlm.nih.gov/28360333, https://pubmed.ncbi.nlm.nih.gov/24397362/",Agonist,"0.81 nM, 42 nM (2C), 30 nM","Radioligand competition binding assay performed using: [3H]LSD (data shown), [3H]Cimbi-36, ([3H]ketanserin), ([3H]mesulergine)","2.4 nM, 350 nM",IP-One homogeneous time-resolved fluorescence assay,EC 50,Mouse,0.1 to 10 mg/Kg,
Linsitinib,4.0,4.0,3.0,No,https://www.chemicalprobes.org/linsitinib,"IGF1R, INSR, INSRR","Kinase, Kinase, Kinase","TK, TK, TK",2017-06-27,"P08069, P06213, P14616",PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,No,No,CHEMBL1091644,431871,"http://www.future-science.com/doi/abs/10.4155/fmc.09.89?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov, https://www.ncbi.nlm.nih.gov/pubmed/21425998",Inhibitor,"35 nM, 75 nM","In-house ELISA assays, R&D systems commercial assays","24 nM, 39 nM","In LISN cells, inhibition of IGF-1-dependent IGF1R autophosphorylation - quantified via ELISA., in Hepa1 cells, inhibition of INSR autophosphorylation - quantified via ELISA.",IC50,Other,"5 mg/kg, 50-75 mg/Kg Oral (Reviewer Suggested)",
dBET6,4.0,3.7,3.0,No,https://www.chemicalprobes.org/dbet6,BRD4,Epigenetic,Bromodomain,2020-11-23,O60885,JGQPZPLJOBHHBK-UFXYQILXSA-N,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCCCCCCNC(=O)COc1cccc3c1C(=O)N(C1CCC(=O)NC1=O)C3=O)c1nnc(C)n1-2,No,Yes,CHEMBL4303781,982743,"www.doi.org/10.1073/pnas.1712363115, www.doi.org/10.1016/j.molcel.2017.06.004, www.doi/org/10.1038/s41589-018-0055-y, https://pubmed.ncbi.nlm.nih.gov/29764999/, https://pubmed.ncbi.nlm.nih.gov/28673542/, https://pubmed.ncbi.nlm.nih.gov/29892083/",Degrader (PROTAC),14 nM BRD4,BRD4 (BD1) AlphaScreen assay,10-50 nM,"Degradation of BRD4 BD1/2 assessed by EGFP/mCherry reporter assay, Dual Luciferase Assay, CETSA; Western blot (BRD2, BRD3, BRD4)",DC50,Mouse,"10 mg/Kg, Reviewers suggest: 7.5 mg/Kg BID",
QC6352,4.0,4.0,3.0,No,https://www.chemicalprobes.org/qc6352,KDM4C,Epigenetic,Protein Demethylase,2020-10-22,Q9H3R0,XSMABFRQESMONQ-SFHVURJKSA-N,CN(c1ccccc1)c1ccc2c(c1)CCC[C@H]2CNc1cnccc1C(=O)O,No,No,CHEMBL4216044,231616,"www.doi.org/10.1021/acsmedchemlett.7b00220, www.doi.org/10.1158/0008-5472.CAN-17-1754, https://pubmed.ncbi.nlm.nih.gov/28835804/, https://pubmed.ncbi.nlm.nih.gov/28883001/",Inhibitor,35 Â± 8 nM,enzymatic screening assay (AlphaScreen and LANCE),"3.5 Â± 1 nM, 1.3 Â± 0.3  nM",Western blot of histone mark; UHPLCâMSMS analysis; cell proliferation methods,EC50,Mouse,"5 , 10, 25, 50 mg/Kg",
AZD3988,4.0,4.0,3.0,No,https://www.chemicalprobes.org/azd3988,DGAT1,Other,Diacylglycerol O-acyltransferase,2020-10-23,O75907,NGEBYTLALFOQKI-HDJSIYSDSA-N,O=C(O)C[C@H]1CC[C@H](c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1,No,No,CHEMBL2036730,522930,"www.doi.org/10.1016/j.bmcl.2012.04.117, https://pubmed.ncbi.nlm.nih.gov/22608962/",Inhibitor,"0.6 nM, 0.5 nM, 1.1 nM","Enzymatic activity for human homolog, Enzymatic activity for rat homolog, Enzymatic activity for mouse homolog",0.5 nM,Inhibition of triacylglycerol (TAG) synthesis,IC50,Other,"0.5 (M), 2 (R), 1 (D) mg/kg IV, 1 (M), 5 (R), 1 (D) mg/kg PO, Reviewer suggest: 20 mg/Kg (M), 0.5-5 mg/Kg (R)",
LNP-023,4.0,4.0,1.0,No,https://www.chemicalprobes.org/lnp-023,CFB,Other,Serine Protease,2020-07-10,P00751,RENRQMCACQEWFC-UGKGYDQZSA-N,CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@H](c2ccc(C(=O)O)cc2)C1,No,No,CHEMBL4594448,2870759,"www.doi.org/10.1073/pnas.1820892116, www.doi.org/10.1021/acs.jmedchem.9b01870, www.doi.org/10.1053/j.seminhematol.2018.02.002, https://pubmed.ncbi.nlm.nih.gov/30926668/, https://pubmed.ncbi.nlm.nih.gov/32073845/, https://pubmed.ncbi.nlm.nih.gov/30032754/",Inhibitor,"7.9 nM, 12 nM","SPR, Half-maximal inhibition of human FB in TR-FRET based competition binding assay (FB-comp)","130 nM, 110 nM, 150 nM","inhibition of AP-induced MAC formation in 50% human and mouse serum, inhibition of AP-induced MAC formation in 50% serum, inhibition of AP-induced MAC formation in 50% whole blood",IC50,Other,"1 to 30 mg/Kg (R), 0.1 to 10 mg/Kg (D), 1 (IV), 10 (PO) mg/Kg (m)",
HTL14242,4.0,4.0,1.0,No,https://www.chemicalprobes.org/htl14242,GRM5,GPCR,Metabatropic Glutamate Receptor,2021-03-05,P41594,FQAXDSVNYVVQSE-UHFFFAOYSA-N,N#Cc1cc(Cl)cc(-c2cc(-c3ccc(F)cn3)ncn2)c1,No,No,CHEMBL3603923,1380420,"www.doi.org/10.1021/acs.jmedchem.5b00892, https://pubmed.ncbi.nlm.nih.gov/26225459/",Negative Allosteric Modulator,9.3,[3H]-M-MPEP Binding Assay,0.6 nM,IPone assay,IC50,Other,"5, 10, 30 mg/Kg",
SD-36,4.0,4.0,2.0,No,https://www.chemicalprobes.org/sd-36,STAT3,Transcription factor,Signal transducer and transcription activator,2020-06-04,P40763,JKCSCHXVWPSGBG-OPKPGBGESA-N,NC(=O)CC[C@H](NC(=O)[C@@H]1CC[C@@H]2CCN(C(=O)CCCCCC#Cc3cccc4c3CN(C3CCC(=O)NC3=O)C4=O)C[C@H](NC(=O)c3cc4cc(C(F)(F)P(=O)(O)O)ccc4[nH]3)C(=O)N12)C(=O)NC(c1ccccc1)c1ccccc1,No,Yes,CHEMBL4452527,2960889,"www.doi.org/10.1021/acs.jmedchem.9b01530, www.doi.org/10.1016/j.ccell.2019.10.002, https://pubmed.ncbi.nlm.nih.gov/31747516/, https://pubmed.ncbi.nlm.nih.gov/31715132/",Degrader (PROTAC),"11 nM, 44 nM","Fluorescence polarization binding assay, biolayer interferometry sensorgrams","10 nM, 60 nM, 28 nM","Luciferase reporter assay, Western blot observing reduced levels of STAT3 and pSTAT3Y705 after 16 h","IC50, DC50",Mouse,"25 mg/Kg, 50 mg/Kg, 100 mg/Kg",SD-36Me
GLPG0974,4.0,4.0,1.0,No,https://www.chemicalprobes.org/glpg0974,FFAR2,GPCR,Free fatty acid receptor,2021-01-12,O15552,MPMKMQHJHDHPBE-RUZDIDTESA-N,C[C@]1(C(=O)N(CCCC(=O)O)Cc2cccc(Cl)c2)CCN1C(=O)c1csc2ccccc12,No,No,CHEMBL3353541,527015,"www.doi.org/10.1021/jm5012885, www.doi.org/10.1074/jbc.M115.687939, https://pubmed.ncbi.nlm.nih.gov/25380412, https://pubmed.ncbi.nlm.nih.gov/26518871/",Antagonist,,,"9 nM, 27-43 nM, 483 nM","CaFlux assay, Neutrophil Migration Assay (NMA) in buffer (27 nM) and plasma (43 nM), Whole Blood CD11b activation-specific epitope (AE) Assay",IC50,Rat,"1 mg/Kg IV, 5-30 mg/Kg PO",
AM-6761,4.0,4.0,3.0,No,https://www.chemicalprobes.org/am-6761,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,HNLHOKSDTBAERS-CWIPYCOQSA-N,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ncc(CC(=O)O)s2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)c(F)c1,No,No,CHEMBL3236357,908112,"http://pubs.acs.org/doi/abs/10.1021/jm401911v, https://www.ncbi.nlm.nih.gov/pubmed/24601644",Antagonist,0.1 nM 0% HS; 0.8 nM 15% HS,HTRF-based neutralization assay with and without Human Serum (HS),16 nM,cell proliferation assays (EdU using SJSA-1 tumor cells),IC50,Other,"0.5 mg/Kg (IV), 5 mg/Kg (PO)",
PT2399,4.0,4.0,1.0,No,https://www.chemicalprobes.org/pt2399,EPAS1,Transcription factor,Hypoxia-Inducible Factor,2020-07-28,Q99814,MXUSGDMIHGLCNC-HNNXBMFYSA-N,N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)C(F)F)c3c2CC(F)(F)[C@H]3O)c1,No,Yes,CHEMBL4165848,138474,"www.doi.org/10.1021/acs.jmedchem.8b01196, www.doi.org/10.1038/nature19796, www.doi.org/10.1038/nature19795, https://pubmed.ncbi.nlm.nih.gov/30289716/, https://pubmed.ncbi.nlm.nih.gov/27595394/, https://pubmed.ncbi.nlm.nih.gov/27595393/",Antagonist,"< 5 nM, 42 nM","Scintillation Proximity Assay (SPA), Isothermal Calorimetry (ITC)","6 nM, 14 nM","Luciferase Assay, VEGF ELISA Assay",EC50,Other,"10 mg/Kg PO, 3 mg/Kg IV",
TAK-981,4.0,4.0,2.0,No,https://www.chemicalprobes.org/tak-981,"SAE1, UBA2","Enzyme, Enzyme","SUMOylation Enzyme, SUMOylation Enzyme",2021-03-16,"Q9UBE0, Q9UBT2",LXRZVMYMQHNYJB-UNXOBOICSA-N,Cc1sc(C(=O)c2cncnc2N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)cc1[C@@H]1NCCc2ccc(Cl)cc21,No,No,CHEMBL4862901,3313066,"www.doi.org/10.1021/acs.jmedchem.0c01491, https://pubmed.ncbi.nlm.nih.gov/33631934/",Inhibitor,1 nM,The E1-E2 HTRF transthiolation (HTRF),"15 nM; (32 - 46 nM, 0 - 8 h)","SUMO2/3 immunofluorescent Assay assessing the ratio of SUMO2/3 in the nuclear versus cytoplasm (treatment is followed by immediate washout and readings at 0 and 8 h), SUMO2/3 immunofluorescent Assay assessing the ration of SUMO2/3 in the nuclear versus cytoplasm (treatment is followed by immediate washout and readings at 0 and 8 h)",IC 50,Rat,"1 (IV), 10 (PO) mg/Kg",
PFI-1,4.0,4.0,3.0,No,https://www.chemicalprobes.org/pfi-1,"BRD2, BRD4, BRD3, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2015-07-16,"P25440, O60885, Q15059, Q58F21",TXZPMHLMPKIUGK-UHFFFAOYSA-N,COc1ccccc1S(=O)(=O)Nc1ccc2c(c1)CN(C)C(=O)N2,No,No,CHEMBL2179387,1545950,"www.doi.org/10.1158/0008-5472.CAN-12-3292, http://www.ncbi.nlm.nih.gov/pubmed/23576556",Antagonist,"BD1 107.9, BD2 143.9 nM, 98 nM, BD1 47.4 nM, BD2 194.6 nM, 220 nM, BD1 80 nM,  BD2 76.3 nM, BD1 85.5, BD2 220 nM","ITC assays, alpha screen assay, alpha screen assays",,"In U2OS cells, PFI-1 was active in a FRAP assay at 1-5 uM.",,,,
TUG-469,3.5,3.5,2.0,No,https://www.chemicalprobes.org/tug-469,FFAR1,GPCR,Free fatty acid receptor,2021-01-12,O14842,RUPXKSLKGSSZCP-UHFFFAOYSA-N,Cc1ccccc1-c1cccc(CNc2ccc(CCC(=O)O)cc2)c1,No,No,CHEMBL1773261,1819526,"www.doi.org/10.1021/ml100106c, www.doi.org/10.1021/jm3002026, www.doi.org/10.1007/s00210-013-0899-3, https://www.ncbi.nlm.nih.gov/pubmed/24900217, https://pubmed.ncbi.nlm.nih.gov/22724451/, https://pubmed.ncbi.nlm.nih.gov/23861168/",Agonist,,,19 nM,"Calcium efflux assay, dynamic mass redistribution (DMR) assay",EC50,Mouse,10 mg/Kg,
AMG900,3.7,3.7,3.0,No,https://www.chemicalprobes.org/amg900,"AURKA, AURKB, AURKC","Kinase, Kinase, Kinase","cell cycle-regulated kinase, cell cycle-regulated kinase, cell cycle-regulated kinase",2015-12-10,"O14965, Q96GD4, Q9UQB9",IVUGFMLRJOCGAS-UHFFFAOYSA-N,Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1,No,No,CHEMBL2140408,735997,"www.doi.org/10.1158/0008-5472.CAN-10-3001, http://www.ncbi.nlm.nih.gov/pubmed/20935223",ATP-competitive inhibitor,"5 nM, 4 nM, 1 nM",enzyme inhibition assay,6.5-8.2 nM,"In HeLa cells, IC50s were measured in substrate phosphorylation assays using quantitative cell imaging. The IC50 varied slightly by substrate.","IC 50, IC50",Mouse,3.75-15 mg/kg,
PT2385,3.7,3.7,3.0,No,https://www.chemicalprobes.org/pt2385,EPAS1,Transcription factor,Hypoxia-Inducible Factor,2020-09-23,Q99814,ONBSHRSJOPSEGS-INIZCTEOSA-N,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2,No,No,CHEMBL4173075,1787649,"https://doi.org/10.1021/acs.jmedchem.8b01196, https://doi.org/10.1158/0008-5472.CAN-16-0473, https://pubmed.ncbi.nlm.nih.gov/30289716/, https://pubmed.ncbi.nlm.nih.gov/27635045/",Antagonist,"< 50 nM, 12 Â± 5 nM, 167 nM","ITC Binding Affinity, Scintillation proximity assay with PAS-B* domain, Measured by MST","27 Â± 6 nM, 42-44 nM","Luciferase assay, Expression of HIF-2 target genes in 786-O cells (constitutively active HIF-2Î± and nonfunctional HIF-1Î±) after treatment with PT2385 at various concentrations; Co-IP of ARNT, VEGFa ELISA",IC50,Other,"3 mg/Kg (IV), 10 mg/Kg (PO)",9a
RG7388,3.7,3.7,3.0,No,https://www.chemicalprobes.org/rg7388,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,TVTXCJFHQKSQQM-LJQIRTBHSA-N,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,No,No,CHEMBL2402737,872228,"http://pubs.acs.org/doi/abs/10.1021/jm400487c, https://www.ncbi.nlm.nih.gov/pubmed/23808545, https://www.ncbi.nlm.nih.gov/pubmed/26998348",Antagonist,"6 nM, 9.79 nM","Homogenous time-resolved fluorescence binding assay., Biacore binding assay",30 nM,"Average from three p53-positive cancer cell lines (SJSA1, RKO, and HCT116) in MTT assay. RG7388 was 344-fold more potent in this assay against p53-positive cells compared with p53-negative cells.",IC50,Mouse,50 mg/kg (oral); 5 mg/kg (IV),
AZD1152,3.7,3.7,3.0,No,https://www.chemicalprobes.org/azd1152,AURKB,Kinase,cell cycle-regulated kinase,2015-12-10,Q96GD4,GBJVVSCPOBPEIT-UHFFFAOYSA-N,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O,No,Yes,CHEMBL415049,842171,"http://www.bloodjournal.org/content/110/6/2034.long?sso-checked=true, http://pubs.acs.org/doi/abs/10.1021/jm061335f, http://www.ncbi.nlm.nih.gov/pubmed/17495131, http://www.ncbi.nlm.nih.gov/pubmed/17373783",Inhibitor,<1 nM,"AZD1152 (Compound 5), the prodrug for Compound 34 (AZD1152-HQPA), inhibits AURKB in vitro with an IC50 < 0.001 uM.",<1 nM,In-cell (SW620 cells) protein substrate phosphorylation (phospho Histone 3),IC50,Mouse,150 mg/kg,
BYL-719,4.0,4.0,3.0,No,https://www.chemicalprobes.org/byl-719,PIK3CA,Lipid kinase,Class I,2015-12-10,P42336,STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,No,No,CHEMBL2396661,299737,"www.doi.org/10.1016/j.bmcl.2013.05.007, http://www.ncbi.nlm.nih.gov/pubmed/23726034",ATP-competitive inhibitor,5 nM,In vitro kinase assay,74 nM,Substrate phosphorylation in Rat1-myr-p110alpha cells,IC50,Rat,1 mg/kg,
BTZO-1,4.0,2.0,2.0,No,https://www.chemicalprobes.org/btzo-1,MIF,Other post-translational modification,Tautomerase,2020-05-25,P14174,GBAKVEWPYUIGHN-UHFFFAOYSA-N,O=c1nc(-c2ccccn2)sc2ccccc12,No,No,CHEMBL4516611,2857979,"www.doi.org/10.1016/j.chembiol.2010.10.011, https://pubmed.ncbi.nlm.nih.gov/21168764/",ARE Activator,"68.6 nM, 147 nM","SPA binding assay with human protein, SPA binding assay with rat protein","MEC1.5 16 nM, MEC2.0 820 nM","ARE-Luc Reporter Assay (Activation of ARE (antioxidant response element)-mediated cytoprotective gene expression): 
MEC1.5: Necessary concentration to give a 50% increase in the viability of rat cardiocytes, ARE-Luc Reporter Assay (Activation of ARE (antioxidant response element)-mediated cytoprotective gene expression): 
MEC2.0: Necessary concentration to double luciferase activity in pGL3-ARE-Luc reporter plasmid-transfected H9c2 cells","MEC1.5, MEC2.0",,,"BTZO-3, BTZO-4"
AX15836,4.0,2.0,3.0,No,https://www.chemicalprobes.org/ax15836,MAPK7,Kinase,CMGC,2016-12-05,Q13164,HTFNVAVTYILUCF-UHFFFAOYSA-N,CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(S(C)(=O)=O)c1ccccc1C(=O)N2C,No,No,CHEMBL4541479,2954220,"http://www.pnas.org/content/113/42/11865, https://www.ncbi.nlm.nih.gov/pubmed/?term=27679845",ATP-competitive inhibitor,8 nM,KiNativ (www.kinativ.com),9 nM,"KiNativ - in cell assay 
The compound was tested in PBMCs, endothelial cells, and oncogenic cell lines. 
In HeLa cells, AX15836 inhibited EGF-dependent ERK5 autophosphorylation.",Kd,Mouse,50 mg/kg,
CPI-169,4.0,2.3,3.0,No,https://www.chemicalprobes.org/cpi-169,"EZH2, EZH1","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2016-08-08,"Q15910, Q92800",LHGUZCKPFXXVPV-GOSISDBHSA-N,CCS(=O)(=O)N1CCC([C@@H](C)n2c(C)c(C(=O)NCc3c(OC)cc(C)[nH]c3=O)c3ccccc32)CC1,No,No,CHEMBL3605457,741335,"http://www.sciencedirect.com/science/article/pii/S1074552114003421, http://www.ncbi.nlm.nih.gov/pubmed/?term=25457180",SAM competitive inhibitor,"0.24 nM, 6.4 nM","PRC2 enzyme inhibition assay (Y641N-EZH2 IC50=0.5 nM), PRC2 enzyme inhibition assay",41 nM,ELISA-based detection of inhibition of protein substrate (H3K27) methylation,"EC 50, EC50",Mouse,50-200 mg/kg,
SR-318,4.0,2.0,1.0,No,https://www.chemicalprobes.org/sr-318,"MAPK14, MAPK11","Kinase, Kinase","CMGC, CMGC",2020-06-02,"Q16539, Q15759",HXNUFFCHRIWTRZ-UHFFFAOYSA-N,Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1,No,No,CHEMBL4436748,2897459,"www.doi.org/10.1021/acs.jmedchem.9b01227, https://pubmed.ncbi.nlm.nih.gov/31702918",Type II Inhibitor,"5 nM, 32 nM",Radiometric activity assay ProQinase,"3.7 nM, 10 nM",NanoBRET,IC50,,,SR-321
PF-3845,4.0,2.0,1.0,No,https://www.chemicalprobes.org/pf-3845,FAAH,Lipid metabolism,Serine Hydrolase,2020-11-30,O00519,NBOJHRYUGLRASX-UHFFFAOYSA-N,O=C(Nc1cccnc1)N1CCC(Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,No,No,CHEMBL1651524,516940,"http://www.sciencedirect.com/science/article/pii/S1074552109000805, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692831",Covalent Inhibitor,"Kinact 3.3 nM, 230 nM",enzyme-coupled assay with oleamide as a substrate,18 nM,TLC of radio-labelled fatty acid conversions,IC50,Other,"10 mg/Kg IP, 1-30 mg/Kg PO",
BI-3802,4.0,3.0,3.0,No,https://www.chemicalprobes.org/bi-3802,BCL6,Transcription factor,Transcriptional Repressor,2021-01-20,P41182,GXTJETQFYHZHNB-GASCZTMLSA-N,CNC(=O)COc1cc2cc(Nc3nc(N4C[C@@H](C)C[C@@H](C)C4)ncc3Cl)ccc2n(C)c1=O,No,No,CHEMBL4640049,2897538,"www.doi.org/10.1016/j.celrep.2017.08.081, www.doi.org/10.1038/s41586-020-2925-1, https://pubmed.ncbi.nlm.nih.gov/28930682/, https://pubmed.ncbi.nlm.nih.gov/33208943/",Degrader,â¤ 3 nM,BCL6::BCOR Ulight TR-FRET,20 nM DC50; 43 nM IC50; 80% Dmax,"BCL6::NCOR LUMIER, Antiproliferative assay, western blot of BCL6 in (Farage cells) capillary electrophoresis measuring BCL6 levels in DLBCL cell lines","IC50, DC50, Dmax",Mouse,"10 mg/Kg, 100 mg/Kg",BI-5273
GSK2982772,4.0,3.3,3.0,No,https://www.chemicalprobes.org/gsk2982772,RIPK1,Kinase,TKL,2020-10-21,Q13546,LYPAFUINURXJSG-AWEZNQCLSA-N,CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21,No,No,CHEMBL4071864,135972,"www.doi.org/10.1021/acs.jmedchem.6b01751, https://pubmed.ncbi.nlm.nih.gov/28151659/",Inhibitor,"16 nM, 1 nM","FP binding assay, ADP-Glo Assay","2 nM, 0.5 nM","Human whole blood stimulation assay measuring the inhibition of cytokine MIP-1Î², RIP1-dependent inflammatory cytokine MIP-1Î² production.",IC50,Other,"1.1 (R) - 1.2 (M) mg/Kg, 2.1 (R) - 1.9 (M) mg/Kg, Reviewer suggested 5-50 mg/Kg PO",
OICR-9429,4.0,2.0,3.0,No,https://www.chemicalprobes.org/oicr-9429,WDR5,Structural protein,WD40-repeat proteins,2015-10-02,P61964,DJOVLOYCGXNVPI-UHFFFAOYSA-N,CN1CCN(c2ccc(-c3cccc(CN4CCOCC4)c3)cc2NC(=O)c2c[nH]c(=O)cc2C(F)(F)F)CC1,No,No,CHEMBL3798846,832481,"www.doi.org/10.1038/nchembio.1859, http://www.ncbi.nlm.nih.gov/pubmed/26167872",Antagonist,93 nM,"ITC 
OICR-9429 disrupts WDR5 interaction with a peptide from WDR5-interacting protein Kdisp = 64 nM.",223 nM,OICR-9429 disrupted WDR5-MLL interaction as well as C/EBPalpha p30-WDR5 interaction in cells.,IC50,,,OICR-0547
CM11,4.0,0.0,3.0,No,https://www.chemicalprobes.org/cm11,VHL,Other post-translational modification,E3 ubiquitin ligase,2020-03-05,P40337,WGJCHHJGGFCCRS-DEYDLUNASA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCCOCC(=O)N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)NCc2ccc(-c3scnc3C)cc2)C(C)(C)C)C(C)(C)C)cc1,No,No,CHEMBL4740486,2960864,"www.doi.org/10.1038/s41467-017-00954-1, https://www.ncbi.nlm.nih.gov/pubmed/29018234",Degrader (PROTAC),10 nM,ITC,10-100 nM,Western blot,DC50,,,"CMP98 (cis-cis) - inactive epimer on each side, CMP99 (cis-trans) - inactive epimer on one side, act as VHL inhibitor but not degrader"
TH5427,4.0,0.0,2.0,No,https://www.chemicalprobes.org/th5427,NUDT5,Epigenetic,Nudix Hydrolase,2020-06-12,Q9UKK9,QXCXMVYVUHVFLP-UHFFFAOYSA-N,Cn1c(=O)c2c(nc(N3CCNCC3)n2Cc2nnc(-c3ccc(Cl)c(Cl)c3)o2)n(C)c1=O,No,No,,2888018,"www.doi.org/10.1038/s41467-017-02293-7, www.doi.org/10.3390/cancers11091337, https://pubmed.ncbi.nlm.nih.gov/29343827, https://pubmed.ncbi.nlm.nih.gov/31510016",Inhibitor,29 nM,MG assay,2100 nM,ITDRF CETSA,EC50,,,
ARCC-4,4.0,0.0,1.0,No,https://www.chemicalprobes.org/arcc-4,AR,Transcription factor,Nuclear Hormone Receptor	,2020-11-30,P10275,DUPAJELXESPTNF-PPZGWQTASA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCCOc2ccc(-c3ccc(N4C(=S)N(c5ccc(C#N)c(C(F)(F)F)c5)C(=O)C4(C)C)cc3)cc2)C(C)(C)C)cc1,No,Yes,CHEMBL4540528,3199231,"www.doi.org/10.1038/s42003-018-0105-8, https://pubmed.ncbi.nlm.nih.gov/30271980/",Degrader (PROTAC),,,5 nM; 98%; 36 nM (IC50),"Western Blot, RL binding Assay (lysate), Cell Proliferation Assay","DC50, Dmax, IC50",,,cpd 3
GSK481,4.0,0.0,3.0,No,https://www.chemicalprobes.org/gsk481,RIPK1,Kinase,TKL,2017-02-16,Q13546,KNOUWGGQMADIBV-KRWDZBQOSA-N,CN1C(=O)[C@@H](NC(=O)c2cc(Cc3ccccc3)on2)COc2ccccc21,No,No,CHEMBL3785703,128444,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01898, https://www.ncbi.nlm.nih.gov/pubmed/?term=26854747",Inhibitor,0.8 nM,ADP-Glo activity assay,10 nM,Human monocytic leukemia U937 cells in a necroptosis assay which measures the ability to block the necrotic cell death induced by treatment with TNF and the caspase inhibitor zVAD.fmk.,IC50,,,"5-benzyl-N-[(3R)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide"
FS-694,4.0,0.0,1.0,No,https://www.chemicalprobes.org/fs-694,MAPK14,Kinase,CMGC,2020-05-17,Q16539,JWZSSEWMVYKYKW-UHFFFAOYSA-N,O=C(NCCN1CCOCC1)c1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)c(NC(=O)c4ccccc4)c3)cc1CC2,No,No,CHEMBL2316207,923369,"https://doi.org/10.1021/jm301539x, https://doi.org/10.1002/anie.201701185, https://www.ncbi.nlm.nih.gov/pubmed/23270382, https://www.ncbi.nlm.nih.gov/pubmed/28397331",Inhibitor Type IÂ½,"0.2 nM, 1.5 nM","Elisa, Cell free DiscoverX",14.9 nM Alpha; 16.9 nM Beta,NanoBRET,IC50,,,FM-743
BSJ-03-123,4.0,0.0,3.0,No,https://www.chemicalprobes.org/bsj-03-123,CDK6,Kinase,CMGC,2020-11-12,Q00534,LUHCYAOYQIFNRN-UHFFFAOYSA-N,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(CCOCCOCCOCCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cn3)nc2n(C2CCCC2)c1=O,No,Yes,,3312897,"www.doi.org/10.1016/j.chembiol.2018.11.006, https://pubmed.ncbi.nlm.nih.gov/30595531/",Degrader (PROTAC),"8.7 nM, 41.6 nM","In vitro kinase inhibition assay CDK6/CyclinD1, In vitro kinase inhibition assay CDK4/CyclinD1",,Cellular Thermal Shift Assay,,,,BSJ-Bump
MLT-748,4.0,0.0,1.0,No,https://www.chemicalprobes.org/mlt-748,MALT1,Other,Peptidase C14B,2020-06-17,Q9UDY8,XKQLNDPUQSZBJW-QGHHPUGFSA-N,CO[C@H](C)[C@H](OC)c1c(NC(=O)Nc2cnc(-n3nccn3)c(Cl)c2)cnc2cc(Cl)nn12,No,No,,2888113,"www.doi.org/10.1038/s41589-018-0222-1, https://pubmed.ncbi.nlm.nih.gov/30692685/",Allosteric inhibitor,"5 nM, 42 nM, 13 nM","MALT1 peptide cleavage inhibition, SPR for WT, SPR for mutant W580S",69 nM,"MALT1 Cleavage inhibition of BCL10, Immunoblotting densitometry",EC50,,,
MI-77301,3.8,3.8,4.0,No,https://www.chemicalprobes.org/mi-77301,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,IDKAKZRYYDCJDU-HBMMIIHUSA-N,CC(C)(C)C[C@@H]1N[C@@H](C(=O)N[C@H]2CC[C@H](O)CC2)[C@H](c2cccc(Cl)c2F)[C@]12C(=O)Nc1cc(Cl)ccc12,No,No,CHEMBL2381408,775664,"http://cancerres.aacrjournals.org/content/74/20/5855.long, https://www.ncbi.nlm.nih.gov/pubmed/25145672",Antagonist,0.88 nM,Fluorescence polarization binding assay with MDM2 protein and p53 peptide.,0.092 uM,"In SJSA-1 cells, MI-77301 inhibited cell growth. Comparable results were found in multiple cell lines that express p53.",IC50,Mouse,25-200 mg/kg,
SGC707,3.8,2.7,4.0,No,https://www.chemicalprobes.org/sgc707,PRMT3,Epigenetic,Protein methyltransferase,2015-10-02,O60678,DMIDPTCQPIJYFE-UHFFFAOYSA-N,O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1,No,No,CHEMBL4072005,1385905,"www.doi.org/10.1002/anie.201412154, http://www.ncbi.nlm.nih.gov/pubmed/25728001",Allosteric Inhibitor,"53 nM, 85n M, 31 nM, 66 nM","ITC, SPR, Scintillation proximity assay, LC-MS detection assay under balanced conditions.",1300 nM,"In CELL Hunter Assay in HEK293 cells, and IC50 = 225 nM in a cellular protein substrate methylation assay.",EC50,Mouse,30 mg/mL,XY1
BMS-911543,3.7,3.7,3.0,No,https://www.chemicalprobes.org/bms-911543,JAK2,Kinase,TK,2016-07-29,O60674,JCINBYQJBYJGDM-UHFFFAOYSA-N,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,No,No,CHEMBL3545215,466885,"www.doi.org/10.1021/acsmedchemlett.5b00226, http://www.ncbi.nlm.nih.gov/pubmed/26288683",ATP-competitive inhibitor,0.48 nM,"IC50=1.1 nM
Potency was determined with ATP=Km for each JAK kinase using Caliper LabChip","60 nM, 61 nM, 990 nM","JAK2-dependent cell lines SET-2 IC50=60 nM, JAK 1/3 IL-2-mediated, T-cell proliferation assay
SET-2 and BaF3-V617F proliferation are dependent on JAK2.",IC50,Other,1-100 mg/kg,Not available
AG-270,3.7,3.7,3.0,No,https://www.chemicalprobes.org/ag-270,MAT2A,Other post-translational modification,Methionine Adenosyltransferase,2021-05-20,P31153,HSVRUECLQUGTDS-UHFFFAOYSA-N,COc1ccc(-c2c(Nc3ccccn3)[nH]c3c(C4=CCCCC4)c(-c4ccccc4)nn3c2=O)cc1,No,No,CHEMBL4573938,3232522,"www.doi.org/10.1021/acs.jmedchem.0c01895, www.doi.org/10.1016/j.ccell.2020.12.010, https://pubmed.ncbi.nlm.nih.gov/33829783/, https://pubmed.ncbi.nlm.nih.gov/33450196/",Allosteric Inhibitor,"14 nM, 91 %",Enzymatic MAT2A inhibition assay,"20 nM, 257 nM","72 h Cell MTAP-null SAM assay, MTAP-null cell proliferation",IC50,Other,10-200 mg/Kg,AGI-38053
T0901317,3.7,4.0,3.0,No,https://www.chemicalprobes.org/t0901317,"NR1H2, NR1H3","NHR, NHR","NR1 Subfamily, NR1 Subfamily",2017-07-18,"P55055, Q13133",SGIWFELWJPNFDH-UHFFFAOYSA-N,O=S(=O)(c1ccccc1)N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1,No,No,CHEMBL62136,324605,"http://science.sciencemag.org/content/289/5484/1524.long, http://genesdev.cshlp.org/content/14/22/2831.full.pdf+html, www.doi.org/10.1016/j.bmcl.2009.02.039, www.doi.org/10.1016/j.jpba.2020.113420, https://www.ncbi.nlm.nih.gov/pubmed/10968783, https://www.ncbi.nlm.nih.gov/pubmed/11090131, https://pubmed.ncbi.nlm.nih.gov/19264481/, https://pubmed.ncbi.nlm.nih.gov/32593849/",Agonist,"20 nM, 10 nM, 8 nM","Scintillation proximity assay, FRET-based co-activator (SRC-1) recruitment assay measuring agonist activity","85 nM, 75 nM",Cell-based reporter gene assay,EC 50,Mouse,"10 mg/Kg PO, 20 mg/Kg IP, 50 mg/Kg IP",
AZD2014,3.7,4.0,3.0,No,https://www.chemicalprobes.org/azd2014,MTOR,Kinase,Atypical,2015-12-10,P42345,JUSFANSTBFGBAF-IRXDYDNUSA-N,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,No,No,CHEMBL2336325,597831,"www.doi.org/10.1016/j.bmcl.2013.01.019, www.doi.org/10.1158/1535-7163.MCT-15-0365, http://www.ncbi.nlm.nih.gov/pubmed/23375793, https://www.ncbi.nlm.nih.gov/pubmed/26358751",ATP-competitive inhibitor,2.8 nM,"Inhibition of mTOR kinase was evaluated in a high-throughput assay using Î± screen capture complex technology (Perkin-Elmer) with a recombinant truncated FLAG-tagged mTOR (amino acids 1362â2549, expressed in HEK293 cells).",80 nM,"Inhibition of substrate phosphorylation also yielded IC50 = 0.2 uM (pS6). Levels of phosphorylation were assessed using an Acumen laser scanning cytometer. In MDAMB468 cells, AZD2014 yielded an average IC50=210 nM for mTORC1 substrate ribosomal protein S6 and 78 nM for the MTORC2 substrate AKT. Comparable results were obtained in MCF7 cells.",IC50,Other,"4 uM/kg (rat), 7.5-15 mg/kg (mouse)",
BGJ-398,3.7,3.3,3.0,No,https://www.chemicalprobes.org/bgj-398,"FGFR1, FGFR2, FGFR3, FGFR4","Kinase, Kinase, Kinase, Kinase","TK, TK, TK, TK",2015-12-10,"P11362, P21802, P22607, P22455",QADPYRIHXKWUSV-UHFFFAOYSA-N,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,Yes,No,CHEMBL1852688,764774,"www.doi.org/10.1021/jm2006222, http://www.ncbi.nlm.nih.gov/pubmed/21936542",Inhibitor,"0.9 nM, 1.4 nM, 1 nM, 60 nM",Kinase assay,5 nM,ELISA-based detection of protein substrate phosphorylation in BaF3 cells,IC50,Mouse,"5 IV, 20 PO mg/Kg",
GNF-5837,3.7,3.0,3.0,No,https://www.chemicalprobes.org/gnf-5837,"NTRK1, NTRK2, NTRK3","Kinase, Kinase, Kinase","TK, TK, TK",2020-11-17,"P04629, Q16620, Q16288",YYDUWLSETXNJJT-MTJSOVHGSA-N,Cc1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1Nc1ccc2c(c1)NC(=O)/C2=C\c1ccc[nH]1,No,No,CHEMBL2037226,856218,"www.doi.org/10.1021/ml200261d, www.doi.org/10.1530/ERC-17-0201, https://www.ncbi.nlm.nih.gov/pubmed/?term=24900443, https://pubmed.ncbi.nlm.nih.gov/29563190/",Inhibitor,"8 nM, 12 nM, NA",HTRF Assay,"11 nM, 9 nM, 7 nM","cellular Ba/F3 assays, anti-proliferation assay",IC 50,Other,50-100 mg/Kg,
UCSF4226,3.7,3.3,3.0,No,https://www.chemicalprobes.org/ucsf4226,MTNR1B,GPCR,Melatonin Receptor,2020-05-29,P49286,BLNNXJOEJRKHAM-UHFFFAOYSA-N,COc1ccc(Br)c(CNc2cccnc2)c1,No,No,,2857978,"www.doi.org/10.1038/s41586-020-2027-0, https://www.ncbi.nlm.nih.gov/pubmed/32040955",Agonist,63 nM,Radioligand binding,7.1 nM,Glo cAMP assay,EC50,Mouse,30 ug,ZINC1848444290
A-770041,3.7,3.3,3.0,No,https://www.chemicalprobes.org/770041,LCK,Kinase,TK,2020-11-25,P06239,ZMNWFTYYYCSSTF-SOAUALDESA-N,COc1cc(-c2nn([C@H]3CC[C@H](N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C,No,No,CHEMBL197603,913014,"www.doi.org/10.1016/j.bmcl.2005.09.039, www.doi.org/10.1124/jpet.105.089169, https://pubmed.ncbi.nlm.nih.gov/16216497/, https://pubmed.ncbi.nlm.nih.gov/16014572/",Inhibitor,147 nM @ 1 mM ATP,Enzymatic inhibition assay,80 nM,Inhibition of Concanavalin A-induced cytokine production in Whole Blood,EC50,Other,"10 mg/Kg PO, 5 mg/Kg IV",
EPZ-5676,3.7,3.3,3.0,No,https://www.chemicalprobes.org/epz-5676,DOT1L,Epigenetic,Protein methyltransferase,2015-10-02,Q8TEK3,LXFOLMYKSYSZQS-XKHGBIBOSA-N,CC(C)N(C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C1CC(CCc2nc3cc(C(C)(C)C)ccc3[nH]2)C1,No,No,CHEMBL3087499,851884,"www.doi.org/10.1182/blood-2013-04-497644, http://www.ncbi.nlm.nih.gov/pubmed/23801631",Inhibitor,0.08 nM,SAM competition assay,3 nM,ELISA to detect protein substrate methylation,IC50,Other,"20 mg/kg (mice), 1 mg/kg (rat)",
EPZ011989,3.7,4.0,3.0,No,https://www.chemicalprobes.org/epz011989,"EZH2, EZH1","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2015-10-02,"Q15910, Q92800",XQFINGFCBFHOPE-WXUXXXNLSA-N,CCN(c1cc(C#CCN2CCOCC2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)[C@H]1CC[C@H](N(C)CCOC)CC1,No,No,CHEMBL3672841,945437,"www.doi.org/10.1021/acsmedchemlett.5b00037, http://www.ncbi.nlm.nih.gov/pubmed/26005520",Inhibitor,"6 nM, <3 nM, 103 nM, 45 nM","ELISA-based protein substrate methylation assay., Biochemical Assay",< 100 nM,Protein substrate methylation in WSU-DLCL2 cells,IC50,Other,"30 mg/kg - 300 mg/kg (R), 125 - 1000 mg/kg (M)",
Romidepsin,3.7,3.0,3.0,No,https://www.chemicalprobes.org/romidepsin,"HDAC1, HDAC2, HDAC3, HDAC8","Epigenetic, Epigenetic, Epigenetic, Epigenetic","HDAC, HDAC, HDAC, HDAC",2017-04-11,"Q13547, Q92769, O15379, Q9BY41",OHRURASPPZQGQM-GCCNXGTGSA-N,C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,No,No,CHEMBL343448,680376,"http://www.sciencedirect.com/science/article/pii/S0014482798940277?via%3Dihub, http://cancerres.aacrjournals.org/content/62/17/4916.long, http://www.nature.com/nchembio/journal/v6/n3/full/nchembio.313.html, https://www.ncbi.nlm.nih.gov/pubmed/9633520, https://www.ncbi.nlm.nih.gov/pubmed/12208741, https://www.ncbi.nlm.nih.gov/pubmed/20139990",Noncovalent inhibitor,"36 nM, 0.015, 47 nM, 0.038 nM, 0.15 nM","HDAC-inhibitory activity was evaluated by using HDACs prepared from 293T cells, In biochemical enzyme assays with synthetic substrates, FK-228 potently and selectively inhibited class I HDACs",0.038 - 6.36 nM,"In M-8 and HeLa cells, histone acetylation increased upon treatment with FK-228. 
Inhibition of cell viability in Hut-78 and Karpas-266 cell lines.",IC50,,,
CHIR-99021,3.7,4.0,3.0,No,https://www.chemicalprobes.org/chir-99021,"GSK3A, GSK3B","Kinase, Kinase","CMGC, CMGC",2015-07-16,"P49840, P49841",AQGNHMOJWBZFQQ-UHFFFAOYSA-N,Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1,No,No,CHEMBL412142,418517,"www.doi.org/10.2337/diabetes.52.3.588, http://www.ncbi.nlm.nih.gov/pubmed/12606497",ATP-competitive inhibitor,"6.7 nM, 10 nM",Cell-free kinase assay,763 nM,"In CHO-IR and primary rat hepatocytes, CHIR-99021 activated glycogen synthase",EC 50,,,
Skepinone-L,3.7,3.0,3.0,No,https://www.chemicalprobes.org/skepinone-l,MAPK14,Kinase,CMGC,2017-03-15,Q16539,HXMGCTFLLWPVFM-GOSISDBHSA-N,O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21,No,No,CHEMBL2152944,380624,"http://www.nature.com/nchembio/journal/v8/n2/full/nchembio.761.html, http://pubs.acs.org/doi/abs/10.1021/jm300327h, https://www.ncbi.nlm.nih.gov/pubmed/22198732, https://www.ncbi.nlm.nih.gov/pubmed/22676210",ATP-competitive inhibitor,"1.5 nM, 5 nM","Ambit Biosciences binding assay, In enzyme activity assays","40 nM, 25 nM","In whole blood assay, Inhibition of HSP27 phosphorylation",IC50,Mouse,,
GSK583,3.7,3.3,3.0,No,https://www.chemicalprobes.org/gsk583,RIPK2,Kinase,TKL,2017-03-09,O43353,XLOGLWKOHPIJLV-UHFFFAOYSA-N,CC(C)(C)S(=O)(=O)c1ccc2nccc(Nc3n[nH]c4ccc(F)cc34)c2c1,No,No,CHEMBL3823499,129909,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b00211, https://www.ncbi.nlm.nih.gov/pubmed/27109867",ATP competitive inhibitor,5 nM,A fluorescent polarization based binding assay was developed to quantitate interaction of novel test compounds at the ATP binding pocket of RIPK2 by competition with a fluorescently labeled ATP competitive ligand.,"237 nM, 133 nM, 18 nM","Human and rat whole blood assays:  MDP (muramyl dipeptide, NOD2 specific activating ligand) stimulated TNFalpha release measured in whole blood. HEK cells: MDP stimulated IL-8 release measured in HEK cells overexpressing NOD2. (human whole blood assay); 133 nM (rat whole blood assay); 18 nM (HEK cells), Human and rat whole blood assays:  MDP (muramyl dipeptide, NOD2 specific activating ligand) stimulated TNFalpha release measured in whole blood. HEK cells: MDP stimulated IL-8 release measured in HEK cells overexpressing NOD2., HEK cells: MDP stimulated IL-8 release measured in HEK cells overexpressing NOD2",IC50,Other,"2 mg/kg oral, 1 mg/kg IV crossover (mouse and rat)",
GDC-0879,3.7,2.5,3.0,No,https://www.chemicalprobes.org/gdc-0879,BRAF,Kinase,TKL,2015-12-10,P15056,DEZZLWQELQORIU-RELWKKBWSA-N,OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1,No,Yes,CHEMBL525191,1606527,"http://cancerres.aacrjournals.org/content/69/7/3042.long, http://www.ncbi.nlm.nih.gov/pubmed/19276360",ATP-competitive inhibitor,63 nM,In vitro substrate phosphorylation assay,,,,Mouse,25 mg/kg,
XMD-12,3.7,3.0,3.0,No,https://www.chemicalprobes.org/xmd-12,"AURKA, AURKB, AURKC","Kinase, Kinase, Kinase","cell cycle-regulated kinase, cell cycle-regulated kinase, cell cycle-regulated kinase",2020-10-14,"O14965, Q96GD4, Q9UQB9",DFQAJLQXPSPNJE-UHFFFAOYSA-N,CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(N4CCC(O)CC4)cc3)ncc21,Yes,No,CHEMBL4649424,2879300,"https://doi.org/10.1021/cb200305u, https://pubmed.ncbi.nlm.nih.gov/21992004/",Inhibitor,"5.6 nM, 18.4 nM, 24.6 nM",Invitrogen biochemical assay,16.7 nM,"Dose-dependently inhibited Aurora A autophosphorylation monitored by 
T288 residue in HeLa S3 cell, completely inhibited Aurora A at 250 nM. 
Dose-dependently inhibited Aurora B autophosphorylation monitored by 
T232 residue in HeLa S3 cell, completely inhibited Aurora A at 250 nM. 
Dose-dependently inhibited HCT116/HT29/HeLa cell growth with EC50 of 9.5 nM, 55 nM and 16.7 nM respectively. 
Compound phenotypes were compared to literature. The cellular effects were correlated 
with in vitro biochemical activities.",EC 50,,,
EI1,3.7,2.0,3.0,No,https://www.chemicalprobes.org/ei1,EZH2,Epigenetic,Protein methyltransferase,2016-08-08,Q15910,PFHDWRIVDDIFRP-UHFFFAOYSA-N,CCC(CC)n1ccc2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(C#N)cc21,No,No,CHEMBL3414574,209990,"http://www.pnas.org/content/109/52/21360.long, http://www.ncbi.nlm.nih.gov/pubmed/?term=23236167",SAM competitive inhibitor,"13 nM, 15 nM","PRC2 enzyme inhibition assays against wild-type EZH2, PRC2 enzyme inhibition assays against Y641F EZH2.",,"In G401, WSU-DLCL2, and GA10 cells, EI1 dose-dependently decreased H3K27 methylation (substrate). In mouse embryonic fibroblasts, EI1 phenocopied genetic depletion of Ezh2.",,,,
PF-CBP1,3.7,0.0,3.0,No,https://www.chemicalprobes.org/pf-cbp1,"EP300, CREBBP","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2017-03-13,"Q09472, Q92793",CGWBJJZOKGZCSJ-UHFFFAOYSA-N,CCCOc1ccc(CCc2nc3cc(-c4c(C)noc4C)ccc3n2CCN2CCOCC2)cc1,No,No,CHEMBL3963965,706267,"http://www.cell.com/cell-chemical-biology/fulltext/S1074-5521(15)00420-2, http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01022, https://www.ncbi.nlm.nih.gov/pubmed/26670081, https://www.ncbi.nlm.nih.gov/pubmed/27682507",Antagonist,"363 nM, 190 nM, 130 nM","FRET, Isothermal titration calorimetry",49 %,We performed single-cell transcriptional profiling on the Fluidigm microfluidic platform (macrophages) and Affymetrix microarrays (neurons) at a single dose (1 uM). Transcriptional changes in macrophages phenocopy CBP knockdown with siRNA but not BRD4 knockdown. PF-CBP1 modulates the expression of genes that are known targets for CBP in neurons.,Residual activity,,,ISOX-INACT (isolipophilic inactive isomer)
dBRD9,3.7,0.0,3.0,No,https://www.chemicalprobes.org/dbrd9,BRD9,Epigenetic,Bromodomain,2020-11-30,Q9H8M2,AIOCFZJGGGEWDK-UHFFFAOYSA-N,COc1cc(-c2cn(C)c(=O)c3cnccc23)cc(OC)c1CN(C)CC(=O)NCCOCCOCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,No,Yes,,3313067,"www.doi.org/10.1002/anie.201611281, www.doi.org/10.1021/acs.jmedchem.8b01413, https://pubmed.ncbi.nlm.nih.gov/28418626/",Degrader (PROTAC),104 nM,AlphaScreen,"5 nM, 90 nM","Immunoblotting, ATPlite Viability Assay, HiBiT, Immunoblotting",EC50,,,
THZ531,3.7,0.0,3.0,No,https://www.chemicalprobes.org/thz531,"CDK12, CDK13","Kinase, Kinase","CMGC, CMGC",2020-10-14,"Q9NYV4, Q14004",RUBYHLPRZRMTJO-MOVYNIQHSA-N,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1,No,Yes,CHEMBL4163879,836733,"www.doi.org/10.1038/nchembio.2166, www.doi.org/10.1016/j.bbrc.2019.10.052, https://pubmed.ncbi.nlm.nih.gov/27571479/, https://pubmed.ncbi.nlm.nih.gov/31615655/",Covalent Inhibitor,"158 nM, 69 nM",Kinase Assay,50 nM,FACS cell cycle analysis; Pulldown Western blot,IC 50,,,"THZ531R, THZ532"
CB-5083,3.7,3.7,3.0,No,https://www.chemicalprobes.org/cb-5083,VCP,ATPase,AAA+,2021-05-26,P55072,RDALZZCKQFLGJP-UHFFFAOYSA-N,Cc1cc2c(C(N)=O)cccc2n1-c1nc2c(c(NCc3ccccc3)n1)COCC2,No,No,CHEMBL3747513,400351,"www.doi.org/10.1021/acs.jmedchem.5b01346, https://pubmed.ncbi.nlm.nih.gov/26565666/",Inhibitor,11 nM,ATPase assay,"115â2000 nM, 150â800 nM","Cell Proliferation assay  (>300 tumor cell lines tested), IF assay on poly Ub accumulation (12 tumor cell lines tested)","IC50, EC50",Mouse,3 (IV)- 100 (PO) mg/Kg,cpd 7
Fasiglifam,3.5,3.5,2.0,No,https://www.chemicalprobes.org/fasiglifam,FFAR1,GPCR,Free fatty acid receptor,2021-01-12,O14842,BZCALJIHZVNMGJ-HSZRJFAPSA-N,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,No,No,CHEMBL1829174,725968,"www.doi.org/10.1021/ml1000855, www.doi.org/10.1124/jpet.111.183772, https://pubmed.ncbi.nlm.nih.gov/24900210/, https://pubmed.ncbi.nlm.nih.gov/21752941/",Agonist,"38 nM, 140 nM","GPR40 radioactive Receptor Binding Assay with human homolog, GPR40 radioactive Receptor Binding Assay with rat homolog",14 nM,FLIPR assay (Ca Efflux),EC50,Other,"1 IV, 3 PO mg/Kg Rat, 0.5 IV, 1 PO mg/Kg Dog",cpd 9b
DO264,3.5,3.5,2.0,No,https://www.chemicalprobes.org/do264,ABHD12,Lipid metabolism,Serine Esterase,2020-06-16,Q8N2K0,PIEQDBPBBQPLPL-UHFFFAOYSA-N,FC(F)(F)Oc1ccc(Oc2ccnc(N3CCC(NC(=S)Nc4cccnc4)CC3)c2Cl)c(Cl)c1,No,Yes,CHEMBL4444498,2913054,"www.doi.org/10.1038/s41589-018-0155-8, www.doi.org/10.1021/acs.jmedchem.8b01958, www.doi.org/10.1021/acschembio.0c00086, https://pubmed.ncbi.nlm.nih.gov/30420694/, https://pubmed.ncbi.nlm.nih.gov/30720278/, https://pubmed.ncbi.nlm.nih.gov/32195565",Reversible Competitive Inhibitor,11 nM,Inhibition of lyso-PS hydrolysis,26 nM,Gel-Based ABPP,IC50,Mouse,"30 mg/Kg, 60 mg/Kg",DO271
PIM-447,3.5,3.5,2.0,No,https://www.chemicalprobes.org/pim-447,"PIM1, PIM2, PIM3","Kinase, Kinase, Kinase","CAMK, CAMK, CAMK",2021-02-24,"P11309, Q9P1W9, Q86V86",VRQXRVAKPDCRCI-ZNMIVQPWSA-N,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,No,No,CHEMBL3651966,474134,"www.doi.org/10.1021/acs.jmedchem.5b01275, https://pubmed.ncbi.nlm.nih.gov/26505898/",Inhibitor,"0.006 nM, 0.018 nM, 0.009 nM","Kinase-Glo assay, with [ATP] at or below ATP Km for each isoform",170 nM,Antiproliferation activity assay,EC50,Other,30 or 100 mg/Kg,cpd 1
THPP-1,3.5,4.0,2.0,No,https://www.chemicalprobes.org/thpp-1,PDE10A,Epigenetic,Phosphodiesterase ,2020-05-26,Q9Y233,JBHLOPKIPKTRSU-UHFFFAOYSA-N,COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2,No,Yes,CHEMBL2204538,524719,"www.doi.org/10.1016/j.bmcl.2012.07.072, www.doi.org/10.1016/j.neuropharm.2012.06.013, www.doi.org/10.1007/s00213-016-4290-1, https://pubmed.ncbi.nlm.nih.gov/22892116/, https://pubmed.ncbi.nlm.nih.gov/22750078, https://pubmed.ncbi.nlm.nih.gov/27117142",Inhibitor,0.99 nM,Phosphodiesterase (PDE) activity was determined using an IMAPÂ® FP kit,49 nM,cAMP Gs dynamic kit,IC50,Other,1-10 mg/Kg,THPP-1-NC
NIK-SMI1,3.5,3.5,2.0,No,https://www.chemicalprobes.org/nik-smi1,MAP3K14,Kinase,STE,2020-10-27,Q99558,LQSHXYHWYGKAMX-FQEVSTJZSA-N,COc1cc(C(N)=O)nc(-c2cccc(C#C[C@]3(O)CCN(C)C3=O)c2)c1,No,No,CHEMBL4211840,1884403,"www.doi.org/10.1021/acs.jmedchem.8b00678, https://pubmed.ncbi.nlm.nih.gov/29940120/",Inhibitor,0.23 Â± 0.17 nM,NIK Ki biochemical assay,34 Â± 6 nM,NF-ÎºB reporter assay; nuclear translocation inhibition of RelB,IC50,Other,"5 mg/Kg, Reviewer suggests higher than 100-200 mg/Kg PO",
GSK2194069,3.5,2.5,2.0,No,https://www.chemicalprobes.org/gsk2194069,FASN,Lipid metabolism,Synthase ,2020-10-21,P49327,AQTPWCUIYUOEMG-INIZCTEOSA-N,O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(-c3ccc4occc4c3)cc2)C1,No,No,CHEMBL3646801,473103,"www.doi.org/10.1038/nchembio.1603, https://doi.org/10.1016/j.juro.2013.02.1903, https://pubmed.ncbi.nlm.nih.gov/25086508/",Inhibitor,"7.7 Â± 4.1 nM, 5 nM","Endpoint assay for thiols using a fluorescent maleimide, Stopped-flow experiments",15.5 Â± 9 nM,Decreased phosphatidylcholine levels in A549 cells; Measurement of cellular de novo fatty acid synthesis in gastric and non-small-cell lung.,EC50,Mouse,3 mg/Kg,
SS-208,3.5,2.5,2.0,No,https://www.chemicalprobes.org/ss-208,HDAC6,Epigenetic,HDAC,2021-02-18,Q9UBN7,JFGOILLZIAIYGA-UHFFFAOYSA-N,O=C(NCCc1cc(C(=O)NO)no1)c1ccc(Cl)c(Cl)c1,No,Yes,CHEMBL4469488,2965041,"www.doi.org/10.1021/acs.jmedchem.9b00946, https://pubmed.ncbi.nlm.nih.gov/31414801/",Inhibitor,12 nM,HDAC inhibition assay,500 nM,NanoBRET-target engagement assay,IC50,Mouse,25 mg/Kg,
BAY-707,3.5,4.0,2.0,No,https://www.chemicalprobes.org/bay-707,NUDT1,Epigenetic,Nudix Hydrolase,2020-05-24,P36639,RPMGXDCRCWWCRY-JTQLQIEISA-N,CCNC(=O)c1cc2c(N3CCOC[C@@H]3C)ccnc2[nH]1,No,No,CHEMBL4096813,1303476,"www.doi.org/10.1021/acschembio.7b00370, https://doi.org/10.1021/acs.jmedchem.7b01884, https://pubmed.ncbi.nlm.nih.gov/28679043/, https://pubmed.ncbi.nlm.nih.gov/29485874",Inhibitor,2.3 nM,MTH1 enzymatic assay,7.6 nM,Isothermal concentration response curves were used to determine cellular target engagement potency,EC50,Other,"25 mg/Kg, 250 mg/Kg",BAY-604
ULK-101,3.5,0.0,2.0,No,https://www.chemicalprobes.org/ulk-101,"ULK1, ULK2","Kinase, Kinase","Autophagy Activating Kinases, Autophagy Activating Kinases",2020-06-17,"O75385, Q8IYT8",PFZRXJIYAFANHP-IBGZPJMESA-N,O=C(N[C@@H](C1CC1)C(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(F)cc4)cnc23)cs1,No,No,CHEMBL4744680,2879307,"www.doi.org/10.1016/j.isci.2018.09.012, https://pubmed.ncbi.nlm.nih.gov/30292171/",Inhibitor,"8.3 nM, 30 nM",Kinase profiler (Eurofin),390 nM,Quantification OF pSer15-BECLIN 1,"EC 50, EC50",,,
Filgotinib,3.3,3.7,3.0,No,https://www.chemicalprobes.org/filgotinib,JAK1,Kinase,TK,2017-02-10,P23458,RIJLVEAXPNLDTC-UHFFFAOYSA-N,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,No,No,CHEMBL3301607,244857,"http://www.jimmunol.org/content/191/7/3568.long, http://pubs.acs.org/doi/abs/10.1021/jm501262q, https://www.ncbi.nlm.nih.gov/pubmed/?term=24006460, https://www.ncbi.nlm.nih.gov/pubmed/25369270",Inhibitor,"11  nM, 10 nM","KDs were measured by displacement of a fluorescent-derivative of ATP, In enzyme activity assays using recombinant enzymes",629 nM,"In whole blood assays, filgotinib inhibited IL-6-induced phosphorylation of STAT1 (JAK1-dependent activity) ~27-fold better than GM-CSF-induced phosphorylation of STAT5 (JAK2-specific activity), consistent with filgotinib showing selectivity for JAK1 in cells.",IC50,Rat,1 mg/kg (IV); 5 mg/kg (oral),
Talazoparib,3.3,3.7,3.0,No,https://www.chemicalprobes.org/talazoparib,"PARP1, PARP2","Other post-translational modification, Other post-translational modification","PARP, PARP",2016-07-29,"P09874, Q9UGN5",HWGQMRYQVZSGDQ-HZPDHXFCSA-N,Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,No,No,CHEMBL3137320,115543,"http://clincancerres.aacrjournals.org/content/19/18/5003.long, http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00990, https://pubchem.ncbi.nlm.nih.gov/compound/44819241, https://www.ncbi.nlm.nih.gov/pubmed/?term=28001384",Inhibitor,"1.2 nM, 0.57 nM, 0.29 nM, 1.1 nM, 0.85 nM, 4.1 nM","Biochemical assay, PARP1 enzyme inhibition assay, Biacore binding assay with PARP1, In vitro ribosylation assays, PARP1 (full length), In vitro ribosylation assays, PARP2 (full length)",2.5 nM,In LoVo cell PAR synthesis assay,EC 50,Mouse,1 mg/kg,
CPI-1612,3.3,3.0,3.0,No,https://www.chemicalprobes.org/cpi-1612,"EP300, CREBBP","Epigenetic, Epigenetic","Histone acetyl transferase, Histone acetyltransferase",2020-06-23,"Q09472, Q92793",SEDFZSHSBUXKAC-NIYFSFCBSA-N,C[C@H](CN[C@@H](C(=O)Nc1ccc(-c2cnn(C)c2)cn1)c1ccccc1)c1ccc(C#N)cc1,No,No,CHEMBL4641354,2897513,https://doi.org/10.1021/acsmedchemlett.0c00155,Inhibitor,"0.5 nM, 2.9 nM","scintillation proximity assays (SPA) of full length EP300, scintillation proximity assays (SPA) of full length CBP","14 nM, 7.9 nM","H3K18Ac MSD assay (H3K18 = histone 3 lysine 18, MSD = meso scale discovery), Cell Proliferation","EC 50, GI 50",Other,"1.0 mg/Kg IV, 5.0 mg/Kg PO (M), 0.5 mg/Kg IV, 1.0 mg/Kg PO (D), 1.0 mg/Kg IV, 5.0 mg/Kg PO (R)",Compound 16
CCT244747,3.3,3.0,3.0,No,https://www.chemicalprobes.org/cct244747,CHEK1,Kinase,CAMK,2016-09-09,O14757,IENLGMOXAQMNEH-CYBMUJFWSA-N,COc1cc(Nc2cnc(C#N)c(O[C@H](C)CN(C)C)n2)ncc1-c1cnn(C)c1,No,No,CHEMBL2203843,295716,"http://clincancerres.aacrjournals.org/content/18/20/5650.long, http://pubs.acs.org/doi/abs/10.1021/jm3012933, http://mct.aacrjournals.org/content/early/2016/08/22/1535-7163.MCT-15-0998.long, http://clincancerres.aacrjournals.org/content/18/20/5650.long, http://pubs.acs.org/doi/abs/10.1021/jm3012933, http://mct.aacrjournals.org/content/early/2016/08/22/1535-7163.MCT-15-0998.long",ATP-competitive inhibitor,7.7 nM,"Inhibition of recombinant full-length CHK1 kinase activity was measured in a microfluidic assay that monitored the separation of a fluorescently labelled, phosphorylated product peptide from the unphosphorylated substrate (5-FAM-KKKVSRSGLYRSPSMPENLNRPR-COOH).",29 nM,"CCT244747 was assessed in HT29 human colon cancer cells for the ability to abrogate a G2 checkpoint, cell-cycle arrest induced by the DNA-damaging agent etoposide. The number of cells reaching mitosis was quantified following treatment with etoposide or etoposide + CCT244747.",IC50,Mouse,25 - 150 mg/kg,Not available
AMG-837,3.3,3.3,3.0,No,https://www.chemicalprobes.org/amg-837,FFAR1,GPCR,Free fatty acid receptor,2021-01-21,O14842,ZOPNBMMVVZRSGH-NRFANRHFSA-N,CC#C[C@@H](CC(=O)O)c1ccc(OCc2cccc(-c3ccc(C(F)(F)F)cc3)c2)cc1,No,No,CHEMBL1829173,428434,"www.doi.org/10.1016/j.bmcl.2011.10.118, www.doi.org/10.1371/journal.pone.0046300, https://pubmed.ncbi.nlm.nih.gov/22217876/, https://pubmed.ncbi.nlm.nih.gov/23056280/",Partial agonist,,,"120 nM (Emax 29 %), 7.8 nM, 4.8 nM","Aequorin Ca2+ assay, Inositol phosphate (IP) accumulation assay, Radiolabelled displacement assay, insulin secretion (IS) assay (AM-1638)","EC50, IC50",Other,"0.8 (M), 0.5 (R) 0.5 (D) 0.5 (C) mg/Kg IV, 5 (M), 0.5 (R) 2 (D) 0.5 (C) mg/Kg PO",
NVP-AEW541,3.3,3.0,3.0,No,https://www.chemicalprobes.org/nvp-aew541,IGF1R,Kinase,TK,2015-12-10,P08069,AECDBHGVIIRMOI-UHFFFAOYSA-N,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCC2)C1,No,No,CHEMBL3188172,531916,"www.doi.org/10.1016/S1535-6108(04)00051-0, http://www.ncbi.nlm.nih.gov/pubmed/15050915",Inhibitor,150 nM,in vitro kinase assay on isolated kinase domain,86 nM,Inhibition of autophosphorylation; NVP-AEW541 also dose-dependently inhibited phosphorylation of IGF1R substrates in cells,IC50,Mouse,20-50 mg/kg,
Relacatib,3.3,3.3,3.0,No,https://www.chemicalprobes.org/relacatib,"CTSK, CTSL, CTSV","Protein metabolism, Protein metabolism, Protein metabolism","Protease, Protease, Protease",2020-10-27,"P43235, P07711, O60911",BWYBBMQLUKXECQ-GIVPXCGWSA-N,CC(C)C[C@H](NC(=O)c1cc2ccccc2o1)C(=O)N[C@H]1CC[C@@H](C)N(S(=O)(=O)c2ccccn2)CC1=O,No,No,CHEMBL203665,757903,"www.doi.org/10.1021/jm050915u, www.doi.org/10.1016/j.bone.2006.07.015, https://pubmed.ncbi.nlm.nih.gov/16509577/, https://pubmed.ncbi.nlm.nih.gov/16962401/",Inhibitor,"0.041 nM, 0.068 nM, 0.053 nM",Cathepsin K Proteolytic Catalytic Activity assay,22 nM; 45 nM; ~70 nM,"in vitro osteoclast resorption assay, 
osteoclast cathepsin activity inhibition, 
bone resorption inhibition",IC50,Other,"1-2 (IV), 2-4 (PO) mg/Kg, Reviewer Suggest 3-30 mg/Kg",
AC220,3.3,4.0,3.0,No,https://www.chemicalprobes.org/ac220,FLT3,Kinase,TK,2015-12-10,P36888,CVWXJKQAOSCOAB-UHFFFAOYSA-N,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,No,No,CHEMBL576982,819163,"www.doi.org/10.1182/blood-2009-05-222034, http://www.ncbi.nlm.nih.gov/pubmed/19654408",Inhibitor,1.6 nM,In vitro binding assay,4.2 nM,Inhibition of FLT3 autophosphorylation in MV4-11 and RS4;11 cells.,IC50,Mouse,10 mg/mL,
A-485,3.3,3.0,3.0,No,https://www.chemicalprobes.org/485,"EP300, CREBBP","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2020-05-20,"Q09472, Q92793",VRVJKILQRBSEAG-LFPIHBKWSA-N,CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O,No,No,CHEMBL4282264,790465,"www.doi.org/10.1038/nature24028, www.doi.org/10.1021/acs.biochem.7b01179, www.doi.org/10.1016/j.cell.2018.04.033, https://pubmed.ncbi.nlm.nih.gov/28953875, https://pubmed.ncbi.nlm.nih.gov/29244478, https://pubmed.ncbi.nlm.nih.gov/29804834",Inhibitor,"9.8 nM, 15 nM, 2.6 nM","TR-FRET, SPR, TR-FRET, SPR",73 nM,Inhibition of histone acetyl marks upon treatment with the compounds,EC50,Mouse,"50, 100, 200, 500 mg/kg",A-486
Rapamycin,3.3,3.0,3.0,No,https://www.chemicalprobes.org/rapamycin,MTOR,Kinase,Atypical,2015-12-10,P42345,QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,No,No,CHEMBL413,997103,"www.doi.org/10.1038/369756a0, www.doi.org/10.1074/jbc.274.7.4266, http://www.ncbi.nlm.nih.gov/pubmed/8008069, http://www.ncbi.nlm.nih.gov/pubmed/9933627",Inhibits mTOR (FRAP domain) as a complex with FKBP12,0.2 nM (FKBP1A),,0.1 nM,Inhibition of G1 progression in MG-63 cells,IC50,,,
PF3644022,3.3,2.3,3.0,No,https://www.chemicalprobes.org/pf3644022,MAPKAPK2,Kinase,CAMK,2015-12-10,P49137,CMWRPDHVGMHLSZ-GFCCVEGCSA-N,Cc1ccc(-c2ccc3c(ccc4sc5c(c43)NC[C@@H](C)NC5=O)n2)cn1,No,No,CHEMBL1231206,1825686,"http://jpet.aspetjournals.org/content/333/3/797.abstract, http://www.ncbi.nlm.nih.gov/pubmed/20237073",ATP-competitive inhbitor,"3 nM, 5.9 nM, 5.2 nM",,"200 nM, 159 nM","Inhibition of protein substrate phosphorylation., PF3644022 also inhibited TNFalpha production in human U937 or PBMCs",IC50,Rat,3 mg/kg,
EPZ-6438,3.3,2.3,3.0,No,https://www.chemicalprobes.org/epz-6438,EZH2,Epigenetic,Protein methyltransferase,2016-08-08,Q15910,NSQSAUGJQHDYNO-UHFFFAOYSA-N,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,No,No,CHEMBL3414621,873616,"http://www.pnas.org/content/110/19/7922.long?tab=related, http://www.ncbi.nlm.nih.gov/pubmed/?term=23620515",SAM competitive inhibitor,EZH2 2.5 nM,"PRC2-containing enzyme assay. The Ki was comparable for wild-type enzyme and for the following mutants: A677G, A687V, Y641F, Y641H, Y641N, and Y641S.",1.4-5.6 nM,Dose-dependent decrease in substrate (H3K27) methylation in multiple cell types and against multiple EZH2 mutants.,IC50,Mouse,125-500 mg/kg,
Lapatinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/lapatinib,"EGFR, ERBB2","Kinase, Kinase","RTK, RTK",2021-01-19,"P00533, P04626",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,No,No,CHEMBL554,810723,https://pubmed.ncbi.nlm.nih.gov/12467226/,Inhibitor,"10.2 nM, 9.8 nM",In vitro kinase assay using intracellular kinase domain,"170 nM, 80 nM","Autophosphorylation Inhibition (immunoprecipitation and WB), Cell growth inhibition",IC 50,Mouse,30-100 mg/Kg,
Golvatinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/golvatinib,"MET, KDR","Kinase, Kinase","TK, TK",2021-04-28,"P08581, P35968",UQRCJCNVNUFYDX-UHFFFAOYSA-N,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,No,No,CHEMBL3039525,918750,"www.doi.org/10.1111/j.1349-7006.2009.01343.x, https://www.ncbi.nlm.nih.gov/pubmed/?term=19832844",Inhibitor,,,"14 nM, 24 nM, 23 nM, 16 nM, 6.2 nM, 37 nM","MET Autophosphorylation Inhibition, Cell Proliferation assay (SNU-5, Hs746T, EBC-1, and MKN45 tumor cells), VEGF-induced phosphorylation assays","IC50, IC 50",Mouse,50-200 mg/Kg,
SR9238,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sr9238,"NR1H2, NR1H3","NHR, NHR","NR1 Subfamily, NR1 Subfamily",2020-07-16,"P55055, Q13133",HDZWHJYZJWLTAG-UHFFFAOYSA-N,CCOC(=O)c1ccc(CN(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)S(=O)(=O)c2c(C)cc(C)cc2C)o1,No,No,CHEMBL4284414,859517,"https://doi.org/10.1021/cb300541g, www.doi.org/10.1016/j.molmet.2015.01.009, www.doi.org/10.1021/acsptsci.8b00003, https://pubmed.ncbi.nlm.nih.gov/23237488/, https://pubmed.ncbi.nlm.nih.gov/25830098/, https://pubmed.ncbi.nlm.nih.gov/31696159/",Inverse Agonist,"214 nM, 43 nM",Co-Transfection Assay,,Co-transfected LXR responsive luciferase reporter assay,,Mouse,30 mg/Kg/Day,SR10389
Canertinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/canertinib,"EGFR, ERBB2","Kinase, Kinase","RTK, RTK",2021-01-18,"P00533, P04626",OMZCMEYTWSXEPZ-UHFFFAOYSA-N,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,No,Yes,CHEMBL31965,555762,"www.doi.org/10.1021/jm990482t, www.doi.org/10.1016/j.bbrc.2011.09.118, www.doi.org/10.1016/s0093-7754(01)90285-4, https://pubmed.ncbi.nlm.nih.gov/10753475/, https://pubmed.ncbi.nlm.nih.gov/21982771/, https://pubmed.ncbi.nlm.nih.gov/11706399",Covalent Inhibitor,1.5 nM EGFR,phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme,"7.4 nM, 9.0 nM",Autophosphorylation Assay,IC 50,Mouse,20-80 mg/kg,
Trametinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/trametinib,"MAP2K1, MAP2K2","Kinase, Kinase","STE, STE",2015-12-10,"Q02750, P36507",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,No,No,CHEMBL2103875,735652,"www.doi.org/10.1021/ml200004g, www.doi.org/10.3892/ijo.2011.1015, www.doi.org/10.1038/s41586-020-2760-4, www.doi.org/10.18632/oncotarget.747, https://pubmed.ncbi.nlm.nih.gov/24900312, https://pubmed.ncbi.nlm.nih.gov/23237773, https://pubmed.ncbi.nlm.nih.gov/32927473/, https://pubmed.ncbi.nlm.nih.gov/21523318/",Allosteric inhibitor,"0.92 nM, 1.8 nM",Raf-MEK-ERK cascade kinase assay,"9.8 nM ACHN; 0.57 nM HT-29, 0.57 nM, 9.8 nM","In HT-29 cells, trametinib dose-dependently inhibited substrate phosphorylation and autophosphorylation.","IC50, IC 50",Mouse,0.1-1 mg/Kg,
GNE-049,4.0,3.0,1.0,No,https://www.chemicalprobes.org/gne-049,"CREBBP, EP300","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2020-11-25,"Q92793, Q09472",LWXLECMNBTVASW-UHFFFAOYSA-N,CC(=O)N1CCc2c(c(N3CCCc4cc(-c5cnn(C)c5)c(C(F)F)cc43)nn2C2CCOCC2)C1,Yes,No,CHEMBL4076748,751163,"www.doi.org/10.1021/acs.jmedchem.7b00796, https://pubmed.ncbi.nlm.nih.gov/28892380/",Inhibitor,"1.1 nM, 1.3 nM",Time-Resolved Fluorescence Resonance Energy Transfer Assays,"12 nM, 13.8 nM","CBP BRET assay, Myc expression inhibition","IC 50, EC 50",Other,"1 mg/Kg IV, 5 mg/Kg PO",
Brigatinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/brigatinib,ALK,Kinase,RTK,2021-02-16,Q9UM73,AILRADAXUVEEIR-UHFFFAOYSA-N,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,No,Yes,CHEMBL3545311,829699,"www.doi.org/10.1021/acs.jmedchem.6b00306, www.doi.org/10.1158/1078-0432.CCR-16-0569, https://pubmed.ncbi.nlm.nih.gov/27144831/, https://pubmed.ncbi.nlm.nih.gov/27780853/",Inhibitor,0.6 nM WT; 0.6 nM C1156Y; 1.4 nM F1174L; 1.7 nM L1196M; 4.9 nM G1202R; 6.6 nM R1275Q,Kinase Assay @ 10 uM ATP,29 nM (ALK+); 3194 nM (ALK-); 14 nM EML4-ALK; 45 nM EML4-ALK (C1156Y); 55 nM EML4-ALK (F1174L); 41 nM EML4-ALK (L1196M); 194 nM EML4-ALK (G1202R),"Cell viability assay, CyQuant Cell Proliferation assay","IC50, GI50",Other,"3, 10 mg/Kg",
Rociletinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/rociletinib,EGFR,Kinase,RTK,2021-01-07,P00533,HUFOZJXAKZVRNJ-UHFFFAOYSA-N,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,No,Yes,CHEMBL3545308,829698,"www.doi.org/10.1158/2159-8290.CD-13-0314, www.doi.org/10.1158/1535-7163.MCT-13-0966, https://pubmed.ncbi.nlm.nih.gov/24065731/, https://pubmed.ncbi.nlm.nih.gov/24723450/",Covalent Inhibitor,21.5 nM L858R/T790M; 303.3 nM WT,Continuous OmniaÂ® Read Assay,62-187 nM,"Immunoblotting pEGFR and total EGFR, Cell proliferation assays",IC50,Mouse,3-100 mg/Kg,
GI254023X,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gi254023x,ADAM10,Other,ADAM family,2021-06-22,O14672,GHVMTHKJUAOZJP-CGTJXYLNSA-N,CNC(=O)[C@@H](NC(=O)[C@H](CCCc1ccccc1)[C@H](C)N(O)C=O)C(C)(C)C,No,Yes,CHEMBL1229516,1921859,"www.doi.org/10.2174/1386207053258488, www.doi.org/10.1182/blood-2002-12-3775, https://pubmed.ncbi.nlm.nih.gov/15777180/, https://pubmed.ncbi.nlm.nih.gov/12714508/",Inhibitor,5.3 nM,Enzyme inhibition assay using fluorogenic substrate,"1500 nM, 400 nM, 1800 nM","Ability to block shedding of cell-expressed IL6R, CX3CL1 and CXCL16 (ELISA) CX3CL1; 400 nM CXCL16; 1800 nM IL6R, Ability to block shedding of cell-expressed CXCL16, Ability to block shedding of cell-expressed IL6R",IC50,Other,100 mg/Kg,
PF470,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pf470,GRM5,GPCR,Metabatropic Glutamate Receptor,2021-03-05,P41594,RDLSKDOSNKLEAQ-UHFFFAOYSA-N,Cc1ccncc1-c1nn(C)c2nc(OCc3ccccn3)cnc12,No,No,CHEMBL3122212,1654535,"www.doi.org/10.1021/jm401622k, https://pubmed.ncbi.nlm.nih.gov/24392688/",Negative Allosteric Modulator,0.9 nM,Human mGluR5 Radioligand Binding Assay,2.5 nM,fluorimetric imaging plate reading (FLIPR) assay,IC50,Other,"1 (IV), 5-30 (PO) mg/Kg",compound 2
LYS006,0.0,0.0,0.0,No,https://www.chemicalprobes.org/lys006,LTA4H,Other,Hydrolase,2021-03-16,P09960,ZEGMEJVULDALSH-NSHDSACASA-N,N[C@@H](CC(=O)O)Cn1nnc(-c2ccc(Oc3ncc(Cl)cc3F)cc2)n1,No,No,CHEMBL4852381,3317107,"www.doi.org/10.1021/acs.jmedchem.0c01955, https://pubmed.ncbi.nlm.nih.gov/33592148/",Inhibitor,0.12 nM,LTA4H enzyme inhibition assay using Arg-AMC as substrate with <1 nM enzyme concentration,"3.7 nM, 53 nM","Human PBMC ionophore stimulated LTB4 release assay with 4 h compound preincubation (Eicosanoid Release assay). (IC90 27 nM), Whole Blood ionophore stimulated LTB4 release assay with 4 h compound preincubation (Eicosanoid Release assay). (148 nM IC90)",IC50,Other,"0.1, 1, 3 (IV) mg/Kg, 0.3, 3, 10 (PO) mg/Kg",cpd 10
GNE-9822,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gne-9822,ITK,Kinase,TK,2020-12-03,Q08881,XFYUTGIEFKGWND-NRFANRHFSA-N,CN(C)CC[C@@H](c1ccccc1)n1cc(NC(=O)c2n[nH]c3c2CCC(C)(C)C3)cn1,No,No,CHEMBL3298371,388599,"www.doi.org/10.1021/jm500550e, https://www.ncbi.nlm.nih.gov/pubmed/24918870",Inhibitor,0.7 nM,Biochemical Assay,55 nM,PLCÎ³ Cellular Assay,IC50,Other,"1 IV, 5-50 PO mg/Kg",
PF-4181366,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pf-4181366,PDE9A,Nucleic acid metabolism,Phosphodiesterase,2017-07-20,O76083,SNCRCEGCQVMUBS-DNVCBOLYSA-N,C[C@@H]1CN(Cc2ccc3nccnc3c2)C[C@H]1c1nc2c(cnn2C2CCCC2)c(=O)[nH]1,No,No,CHEMBL583914,427078,"http://pubs.acs.org/doi/abs/10.1021/jm9015334, https://www.ncbi.nlm.nih.gov/pubmed/?term=19919087",Inhibitor,1.8 nM,Enzymatic assay using recombinant proteins,,,,Rat,10 mg/kg,
AM-4668,0.0,0.0,0.0,No,https://www.chemicalprobes.org/am-4668,FFAR1,GPCR,Free fatty acid receptor,2021-01-21,O14842,BMLGZNVPWRUVNM-IBGZPJMESA-N,Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1COc1ccc([C@H](CC(=O)O)c2ccon2)cc1,No,No,CHEMBL3287574,612739,"www.doi.org/10.1021/ml400501x, https://www.ncbi.nlm.nih.gov/pubmed/24900872",Agonist,,,"36 nM, 3.6 nM","GPR40 aequorin assay, GPR40 IP3 assay",EC50,Other,"0.5 mg/Kg IP, 2 mg/Kg PO",
Roblitinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/roblitinib,FGFR4,Kinase,TK,2021-02-01,P22455,BHKDKKZMPODMIQ-UHFFFAOYSA-N,COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N,No,No,CHEMBL3908979,747084,"www.doi.org/10.1021/acs.jmedchem.0c01019, https://pubmed.ncbi.nlm.nih.gov/32930584/",Reversible-Covalent Inhibitor,"0.9 Â± 0.4 nM, 2.9 nM",Biochemical Assay,"4.3 Â± 2.5 nM, 12 Â± 6 nM","Autophosphorylation Inhibition assay, Cell Proliferation assay",IC50,Other,"1 IV, 3 PO mg/Kg (M), 0.5 IV, 3 PO mg/Kg (R), 0.1 IV, 0.3 PO mg/Kg (D)",
Ceritinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ceritinib,ALK,Kinase,RTK,2021-02-16,Q9UM73,VERWOWGGCGHDQE-UHFFFAOYSA-N,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,No,No,CHEMBL2403108,776071,"www.doi.org/10.1021/jm400402q, https://pubmed.ncbi.nlm.nih.gov/23742252/",Inhibitor,0.2 nM,Enzymatic Inhibition assay (LabChip mobility-shift assay),"26 nM, 22.8 nM","Cell Proliferation Assay, Bright-Glo luciferase assay",IC50,Other,"5 IV, 20 PO (M); 3 IV, 10 PO (R); 5 IV, 20 PO (D);	5 IV, 60 PO (C) mg/Kg",
GT949,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gt949,SLC1A2,Other,SLC Family,2021-03-29,P43004,ZVWPOIUAPXDLMB-UHFFFAOYSA-N,COc1ccc2[nH]c(=O)c(C(c3nnnn3CCc3ccccc3)N3CCN(C4CCCCC4)CC3)cc2c1,No,No,,3312904,,Noncompetitive Positive Allosteric Modulator,,,0.041 nM,EEAT2-mediated glutamate update assay,EC50,,,GT996
TUG-891,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tug-891,FFAR4,GPCR,Free fatty acid receptor,2017-07-21,Q5NUL3,LPGBXHWIQNZEJB-UHFFFAOYSA-N,Cc1ccc(-c2ccc(F)cc2COc2ccc(CCC(=O)O)cc2)cc1,No,No,CHEMBL2058533,1850605,"www.doi.org/10.1124/mol.113.087783, www.doi.org/10.1021/jm300215x, https://pubmed.ncbi.nlm.nih.gov/23979972, https://pubmed.ncbi.nlm.nih.gov/22519963/",Agonist,,,43.6 nM,"BRET Î²-Qrrestin 2 Interaction Assay, Calcium Assay, [35S]GTPÎ³S assay (17 nM for Mouse analog)",EC50,Mouse,,
MSC-4381,0.0,0.0,0.0,No,https://www.chemicalprobes.org/msc-4381,SLC16A3,Transporter,Monocarboxylate transporter,2021-11-19,O15427,FNBUZGRPJLEIMO-UHFFFAOYSA-N,CCOc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C#Cc2cnc(C(=O)O)cc2OC)c2ncccc12,No,No,CHEMBL4802043,3455497,,Inhibitor,77 nM,Fluorescence Cross Correlation Spectroscopy,1 nM,Lactate efflux inhibition assay,IC 50,,,
1G244,0.0,0.0,0.0,No,https://www.chemicalprobes.org/1g244,"DPP8, DPP9","Peptidase, Peptidase","Prolyl Peptidase, Prolyl Peptidase",2021-03-29,"Q6V1X1, Q86TI2",ZKIQFLSGMMYCGS-SANMLTNESA-N,N[C@@H](CC(=O)N1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1)C(=O)N1Cc2ccccc2C1,No,No,CHEMBL1814633,724876,"www.doi.org/10.1039/C5MD00454C, www.doi.org/10.1016/j.bcp.2009.03.032, www.doi.org/10.1038/nchembio.2229, https://pubmed.ncbi.nlm.nih.gov/19439267/, https://pubmed.ncbi.nlm.nih.gov/27820798/",Inhibitor,"14 nM, 0.9 nM DPP8, 53 nM, 4.2 nM","Enzymatic assay, Enzymatic Assay","2.7 uM, 320 nM","Cell viability (CellTiter-Glo) assay, DPP activity assay in lysate after exposure of intact cells to 1G244",IC50,Rat,"1, 10, 30 mg/Kg, 1.1 (IV), 2.2 (PO) mg/Kg",
Salvinorin-A,3.0,3.0,3.0,No,https://www.chemicalprobes.org/salvinorin,OPRK1,GPCR,Opioid receptor,2015-07-16,P41145,OBSYBRPAKCASQB-AGQYDFLVSA-N,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C,No,No,CHEMBL445332,338794,"www.doi.org/10.1073/pnas.182234399, http://www.ncbi.nlm.nih.gov/pubmed/12192085",Agonist,16 nM,,235 nM,"Agonism for guinea pig KOR. 
In 293 cells, Salvinorin A inhibited adenylate cyclase with EC50 = 1.05 nM.",EC50,,,
MAVATREP,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mavatrep,TRPV1,Ion Channel,,2021-11-06,Q8NER1,ORDHXXHTBUZRCN-NTEUORMPSA-N,CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1,No,No,CHEMBL2364618,382027,,Antagonist,,,"7 nM, 4.6 nM","blockade of capsaicin-induced Ca2+ flux (FLIPR), Human TRPV1 Binding Assay",IC 50,"Rat, Mouse, Dog, Monkey (Rheus)","10 mg/Kg, 2 mg/Kg",Cpd 28
Asciminib,4.0,4.0,3.0,No,https://www.chemicalprobes.org/asciminib,ABL1,Kinase,TK,2020-11-23,P00519,VOVZXURTCKPRDQ-CQSZACIVSA-N,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,No,No,CHEMBL4208229,403250,"www.doi.org/10.1038/nature21702, www.doi.org/10.1182/blood.V124.21.398.398, https://pubmed.ncbi.nlm.nih.gov/28329763/",Allosteric Inhibitor,0.5-0.8 nM,"ITC, conformational NMR assay",0.25 nM,Antiproliferative assay in Ba/F3 cells grown without IL-3,IC50,Other,"1 (M), 2(R), 1(D) mg/Kg IV, 30 (M), 30 (R), 15 (D) 30 mg/Kg PO",
AM-6226,3.0,3.0,2.0,No,https://www.chemicalprobes.org/am-6226,FFAR1,GPCR,Free fatty acid receptor,2021-03-26,O14842,CUBDGLIBZGKXKQ-ZBLYBZFDSA-N,CC[C@H](CC(=O)O)c1cccc(OCc2ccc(-c3cc(OC)ccc3F)c([C@@H]3CCCC3(C)C)c2)c1F,No,No,CHEMBL4205882,790301,"www.doi.org/10.1021/acsmedchemlett.8b00213, www.doi.org/10.1371/journal.pone.0046300, https://pubmed.ncbi.nlm.nih.gov/30034614/, https://pubmed.ncbi.nlm.nih.gov/23056280/",Full Agonist,,,"130 nM, 5.7 nM, 940 nM","Aequorin Calcium assay (Emax 105%), Inositol phosphate assay, Insulin secretion potentiation assay","EC50, IC50","Rat, Dog, Monkey (Cynomolgus)","0.5 mg/kg, 2 mg/Kg, 0.5 mg/Kg, 10 mg/Kg",
AM-5262,3.0,3.0,1.0,No,https://www.chemicalprobes.org/am-5262,FFAR1,GPCR,Free fatty acid receptor,2017-07-27,O14842,XPLWBHWPOUEOSJ-GSZYCOFVSA-N,COc1ccc(F)c(-c2ccc(COc3ccc4c(c3)[C@]3(CC4)C[C@H]3C(=O)O)cc2[C@@H]2CCCC2(C)C)c1,No,No,CHEMBL2385460,775938,https://www.ncbi.nlm.nih.gov/pubmed/24900707,Agonist,,,81 nM,GPR40 aqueorin assay (Emax 101%),EC50,"Rat, Monkey (Cynomolgus)","0.5 mg/Kg, 2 mg/Kg",
GSK256066,3.0,2.0,1.0,No,https://www.chemicalprobes.org/gsk256066,PDE4B,Nucleic acid metabolism,Phosphodiesterase,2021-02-15,Q07343,JFHROPTYMMSOLG-UHFFFAOYSA-N,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,No,No,CHEMBL570015,724624,,Inhibitor,0.079 nM,Scintillation Proximity Assay (SPA),"0.01 nM, 0.12 nM","Inhibition of LPS induced TNF-Î± production from isolated human peripheral blood mononuclear cells (PBMC) using IGEN technology, Inhibition of LPS induced TNF-Î± production from isolated human whole blood using IGEN technology",IC50,Rat,1 mg/Kg,cpd 3
KISS1-305,0.0,0.0,0.0,No,https://www.chemicalprobes.org/kiss1-305,KISS1R,GPCR,KISS 1 Receptor,2021-12-01,Q969F8,YSVWFFNZZGLLAI-XNTOLAJGSA-N,CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc1ccncc1)NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,No,Yes,CHEMBL3086284,1008841,,Agonist,"0.089 nM, 0.10 nM","Biological Activity of Nonapeptide Metastin human analogs, Biological Activity of Nonapeptide Metastin rat analogs",8.94 nM,Inhibition of CHO/h175 Cell Growth by Metastin and Metastin Analogs,IC50,Rat,30 nM/kg,KISS1-543
EML631,3.0,0.0,1.0,No,https://www.chemicalprobes.org/eml631,SPIN1,Transcription factor,Chromatin regulator,2020-06-17,Q9Y657,LPCWQWNRCGWRFC-UHFFFAOYSA-N,O=C(c1ccc(C(=O)N2CCC(CCN3CCCC3)CC2)c(Nc2ccc(OCN3CCCC3)cc2)c1)N1CCC(CCN2CCCC2)CC1,No,Yes,CHEMBL4476514,2956797,"www.doi.org/10.1038/nchembio.2377, https://pubmed.ncbi.nlm.nih.gov/28504676/",Inhibitor,3000 nM,ITC,,Cellular Thermal Shift Assay (CETSA),,,,
GW1100,4.0,3.0,1.0,No,https://www.chemicalprobes.org/gw1100,FFAR1,GPCR,Free fatty acid receptor,2021-01-22,O14842,PTPNCCWOTBBVJR-UHFFFAOYSA-N,CCOC(=O)c1ccc(-n2cc(Cc3cnc(OCC)nc3)c(=O)nc2SCc2ccc(F)cc2)cc1,No,No,CHEMBL4303679,714811,"www.doi.org/10.1038/sj.bjp.0706770, www.doi.org/10.1371/journal.pone.0081563, https://pubmed.ncbi.nlm.nih.gov/16702987, https://pubmed.ncbi.nlm.nih.gov/24349089/",Selective antagonist,,,1 uM,"intracellular Ca2+ release, GPR40 reporter assay, MIN6 insulin secretion assay",IC50,Mouse,10 ug/Mouse,
NVS-MALT1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/nvs-malt1,MALT1,Enzyme,Peptidase,2021-12-19,Q9UDY8,NVGROBHDOYRPAN-FPTDNZKUSA-N,CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12,No,No,CHEMBL4568735,3225199,,Allosteric Inhibitor,"2.4 nM, 18 nM","Human biochemical (TR-FRET) assay (high salt), Human biochemical (TR-FRET) assay (low salt)","2.4 nM, 200 nM, 130 nM","Jurkat IL-2 (IL2-RGA PMA + anti-CD28), IL-2 â PMA + anti-CD28 + 50% Human whole blood, IL-2 â PMA + anti-CD28 + 50% Rat whole blood",IC50,"Mouse, Rat, Dog","3 mg/Kg, 1 mg/Kg, 0.3 mg/Kg, 0.1 mg/Kg",NVS-MALT1-C
GSK-LSD1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsk-lsd1,KDM1A,Epigenetic,,2015-11-12,O60341,BASFYRLYJAZPPL-UONOGXRCSA-N,c1ccc([C@@H]2C[C@H]2NC2CCNCC2)cc1,No,No,CHEMBL4301645,68218,"http://www.sciencedirect.com/science/article/pii/S1535610815002123, http://www.ncbi.nlm.nih.gov/pubmed/26175415",Inhibitor,Kiapp 160 nM,"Kinetic characterization of the inhibition of LSD1 by GSK-LSD1 is consistent with a reversible binding step followed by time-dependent irreversible inactivation. (kinact = 0.13 Â± 0.01 minâ1, kinact/ KIapp = 0.81 Â± 5.95 Ã 10â2 minâ1 Î¼Mâ1)",0.1-10 nM,Cell Proliferation assay,EC50,Mouse,5 mg/kg,
Nidufexor,4.0,4.0,1.0,No,https://www.chemicalprobes.org/nidufexor,NR1H4,Transcription factor,Nuclear Receptor,2021-01-30,Q96RI1,JYTIXGYXBIBOMN-UHFFFAOYSA-N,Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(C(=O)O)cc2)c2c1-c1cc(Cl)ccc1OC2,No,No,CHEMBL4297626,672025,"www.doi.org/10.1021/acs.jmedchem.9b01621, https://pubmed.ncbi.nlm.nih.gov/31940200/",Partial Agonist,7 nM,FXR coactivator interaction assay (57% efficacy),32 nM,BSEP-luciferase reporter gene assay (50% efficacy),EC50,Other,"IV: 3 mg/Kg PO: 10 mg/kg (M) IV: 5 mg/kg / PO: 10 mg/kg (R), IV: 0.5 mg/kg / PO: 2 mg/kg (D)",
CCT251236,3.7,3.0,3.0,No,https://www.chemicalprobes.org/cct251236,PIR,Other,Cupin,2017-01-17,O00625,KLHOCHQJHXNKAS-UHFFFAOYSA-N,Cc1ccc(NC(=O)c2ccc3c(c2)OCCO3)cc1NC(=O)c1ccc2nc(OCCN3CCCC3)ccc2c1,No,No,CHEMBL4087666,858057,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01055, https://www.ncbi.nlm.nih.gov/pubmed/28004573",pirin ligand,44 nM,Surface Plasmon Resonance,19 nM,"In SK-OV-3 cells, CCT251236 inhibited 17-AAG-induced HSP72 expression (assayed by ELISA). This assay was designed as an HSF1 phenotypic screen.",IC50,Mouse,20 mg/kg,"N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamido)-2-methylphenyl)-2-(2-(pyrrolidin-1-yl)ethoxy)quinoline-6-carboxamide"
Onalespib,3.0,3.0,1.0,No,https://www.chemicalprobes.org/onalespib,"HSP90AA1, HSP90AB1","Other post-translational modification, Other post-translational modification","Chaperone, Chaperone",2020-12-02,"P07900, P08238",IFRGXKKQHBVPCQ-UHFFFAOYSA-N,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,No,No,CHEMBL1214827,266432,"www.doi.org/10.1021/jm100060b, www.doi.org/10.1111/j.1349-7006.2011.02191.x, https://pubmed.ncbi.nlm.nih.gov/20662534/, https://pubmed.ncbi.nlm.nih.gov/22181674/",Inhibitor,0.71 nM,ITC,30 nM,Expression Inhibition for the oncogenic client proteins Raf-1 and CDK4 (WB),IC50,Mouse,2-60 mg/Kg,
8RK64,0.0,0.0,0.0,No,https://www.chemicalprobes.org/8rk64,UCHL1,Enzyme,Peptidase,2022-01-14,P09936,KIWKRCCIHSGWQS-VIFPVBQESA-N,N#CN1CC[C@H](C(=O)Nc2nc3c(s2)CN(C(=O)CN=[N+]=[N-])CC3)C1,Yes,Yes,CHEMBL4802050,3550532,,Covalent Inhibitor,320 nM,"UCHL1 inhibition assay with Ub-Rho-morpholine as substrate
Kinetic profile: kinact = 0.01382 1/s; KI(app) = 164 ÂµM; kinact/KI = 84 * 1/(M*s)",,"ABPP assay: Full inhibition at a concentration of 3 Î¼M (1h, 37Â°C).",,Other,5 uM,JYQ88
SU6656,1.0,1.0,3.0,No,https://www.chemicalprobes.org/su6656,"SRC, YES1, LYN, FYN","Kinase, Kinase, Kinase, Kinase","TK, TK, TK, TK",2021-01-06,"P12931, P07947, P07948, P06241",LOGJQOUIVKBFGH-YBEGLDIGSA-N,CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2,Yes,No,CHEMBL605003,1716784,"www.doi.org/10.1128/mcb.20.23.9018-9027.2000, www.doi.org/10.3109/00207454.2013.879869, https://pubmed.ncbi.nlm.nih.gov/11074000/, https://pubmed.ncbi.nlm.nih.gov/24397498/",ATP Competitive Inhibitor,"280 nM, 20 nM, 130 nM, 170 nM",Biochemical Kinase Assay,"49-100%, 49-100 %","Inhibition PDGF-stimulated c-Myc induction, 
Inhibition of PDGF-stimulated NIH 3T3 cell DNA synthesis, Immunoblots",% in,Mouse,2-4 mg/Kg,
BAY-876,3.5,3.0,2.0,No,https://www.chemicalprobes.org/bay-876,SLC2A1,Transporter,Solute Carrier,2021-04-19,P11166,BKLJDIJJOOQUFG-UHFFFAOYSA-N,Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1,No,No,CHEMBL4448899,3144241,,Inhibitor,2 nM,Inhibition of glucose uptake measured by measuring ATP levels using CellTiter-Glo Luminescent Cell viability assay,3.2 nM,Glucose uptake assay in HeLa-MaTu cell line,IC50,"Rat, Dog","0.3 mg/Kg, 0.6 mg/Kg, 0.1 mg/Kg, 0.2 mg/Kg",BAY-588
Ammocidin-A,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ammocidin-a,ATP5F1B,Enzyme,,2022-01-21,P06576,QVIWDCUKIZPUBD-WLRWWHNQSA-N,COCCC[C@H]1O[C@@](O)([C@H](C)[C@@H]2C[C@H](OC)[C@H](O)/C=C(C)\C=C(C)/C=C(/C)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](C)/C=C(C)\C=C(OC)/C=C(/C)C(=O)O2)[C@H](OC)[C@@H](O)[C@]1(C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@@](C)(O)[C@H](O)[C@@H](C)O2)[C@@H](C)O1,No,No,,3550533,,Inhibitor,20nM,"Enzyme-coupled ATPase assay.
The assay buffer consisted of 60âmM Trisâacetate pH 7.8, 1âmM MgCl2, 2.5âmM phosphoenolpyruvate and 1âmM KCN. The working solution was prepared at 2Ã for a final concertation of 0.4âmM NADH; 3âUâmlâ1 of pyruvate kinaseâ+â4.5âUâmlâ1 lactate dehydrogenase (Sigma P0294);âÂ±â10âÎ¼M FCCP. Unless otherwise specified, ATP was added as a 4Ã solution at 200âÎ¼M. Absorbance was monitored at 340ânm using a SpectraMax Plus 384 plate reader (Molecular Devices) set at 25âÂ°C using Softmax Pro v.4.3 acquisition software. Fifty microliters of enzyme [purified yeast FoF1 ATP synthase] was added to 100âÎ¼l of working solution and monitored for 2âmin, 50âÎ¼l of ATP was then added for a final volume of 200âÎ¼l and absorbance was monitored over 10âmin.",1.7nM,"MTT viability assay. 

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay protocol was adapted from Deguire et al.19 Briefly, 100âÎ¼l of suspension cells at 100,000 cells mlâ1 were added to wells of a microtiter plate precoated with 0.5âÎ¼l of test compound at 200Ã in dimethylsulfoxide and incubated for 48â72 h (as noted). MTT reagent was dissolved in fresh media at 1âmg mlâ1 and 100âÎ¼l was added to each well to achieve a final concentration of 0.5âmg mlâ1 and incubated for 2 h at 37âÂ°C. Cells were centrifuged at 800g for 5âmin and decanted. MTT crystals were redissolved in 100âÎ¼l of dimethylsulfoxide, allowed to incubate for 5âmin at room temperature, and read at 560ânm using a SpectraMax plus 384 plate reader (Molecular Devices). Absorbance values were normalized by background subtraction (wells without cells) such that vehicle-treated cells had a viability of 1.0. Concentrationâresponse curves were fit using the DRC R package with a four-parameter log-logistic function. Statistical testing of differences between concentrationâresponse curves was carried out using the EDcomp function with default parameters for comparison of half maximal inhibitory concentration values and the paramcomp function for comparison of other parameters.",EC50,Mouse,100 mg/kg,
SR9243,3.0,2.5,2.0,No,https://www.chemicalprobes.org/sr9243,"NR1H2, NR1H3","NHR, NHR","NR1 Subfamily, NR1 Subfamily",2020-07-16,"P55055, Q13133",FYQFEJFTCLKXTQ-UHFFFAOYSA-N,Cc1cc(C)c(S(=O)(=O)N(CCc2cccc(Br)c2)Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C)c1,No,No,,2933236,"www.doi.org/10.1016/j.ccell.2015.05.007, www.doi.org/10.1038/s41419-019-1654-6, https://pubmed.ncbi.nlm.nih.gov/26120082/, https://pubmed.ncbi.nlm.nih.gov/31138790",Inverse Agonist,,,15 to 104 nM,consensus LXRE- and endogenous (FASN) promoter driven luciferase reporter-assays in various cancer cells,IC 50,Mouse,"30, 60 mg/Kg/day",
BAY1125976,3.7,3.7,3.0,No,https://www.chemicalprobes.org/bay1125976,"AKT2, AKT1","Kinase, Kinase","AGC, AGC",2020-08-10,"P31751, P31749",JBGYKRAZYDNCNV-UHFFFAOYSA-N,NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1,No,No,CHEMBL4751394,2860091,"www.doi.org/10.1002/ijc.30457, www.doi.org/10.3390/cancers11121987, https://pubmed.ncbi.nlm.nih.gov/27699769/, https://pubmed.ncbi.nlm.nih.gov/31835495/",Allosteric Inhibitor,"18/36 nM Hi/Lo ATP, 5.2/44 Hi/Lo ATP, 2.7 (active), 1.3 (inactive) nM","TRâFRETâbased in vitro kinase assays, SPR",0.9 nM (T308); 1.1 nM (S473),"Reduced the basal levels of AKT phosphorylation in KPLâ4 cells specific at T308 and S473, Block signalling pathway","IC 50, IC50",Mouse,10 - 50 mg/Kg,
BI-3812,3.0,0.0,3.0,No,https://www.chemicalprobes.org/bi-3812,BCL6,Transcription factor,Transcriptional Repressor,2021-01-20,P41182,XCGYXEVLQIIEJH-UHFFFAOYSA-N,CNC(=O)COc1cc2cc(Nc3nc(N4CCC(C(=O)N(C)C)CC4)ncc3Cl)cc(OC)c2n(C)c1=O,No,No,CHEMBL4755229,3313079,"www.doi.org/10.1016/j.celrep.2017.08.081, www.doi.org/10.1038/s41586-020-2925-1, https://pubmed.ncbi.nlm.nih.gov/28930682/, https://pubmed.ncbi.nlm.nih.gov/33208943/",PPI Inhibitor,â¤ 3 nM,BCL6::BCOR ULight TR-FRET assay.,40 nM,BCL6::NCOR LUMIER in cells,IC50,,,
TP-021,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tp-021,BCL6,Transcription factor,Transcriptional Repressor,2022-01-14,P41182,RRELDGDKULRRDM-UHFFFAOYSA-N,O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1,No,No,CHEMBL4075278,228286,,Inhibitor,100 nM,ELISA,720 nM,Cell-based mammalian two-hybrid assay (M2H),IC50,Mouse,"0.1 mg/kg IV, 1 mg/kg PO",TP-021n
BI 605906,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi605906,IKBKB,Kinase,Serine kinase,2022-01-26,O14920,IYHHRZBKXXKDDY-UHFFFAOYSA-N,CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12,No,No,CHEMBL4522930,3183744,"http://www.biochemj.org/content/434/1/93, http://www.ncbi.nlm.nih.gov/pubmed/21138416",Inhibitor,"280 nM, 49 nM","In vitro kinase assay at 0.100 mM ATP, Inhibition of IKKbeta","900 nM, 700 nM","Inhibition of phospho-IÎºBÎ± in HeLa cells, (Inhibition of expression of ICAM1 in HeLa cells",EC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","1 mg/Kg IV, 10 mg/Kg PO",BI-5026
BAY-3153,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-3153,CCR1,GPCR,Chemokine Receptor,2022-02-09,P32246,LZSPYTNDRPEZBK-OXYJHPMESA-N,CCOc1cc(N2C3COCC2CN(C(=O)[C@H]2C[C@H](O)CN2c2ccc(Cl)cc2)C3)ccc1Cl,No,No,CHEMBL4638406,3325783,,Antagonist,,,3 nM,CCR1 cellular Ca2+-flux assay,IC50,Rat,10 mg/Kg,BAY-173
BAY-179,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-179,NDUFS2,Enzyme,Dehydrogenase,2022-02-10,O75306,DYUTWRFEEOPXMN-UHFFFAOYSA-N,C1=CC2NC(CN3CCC(c4nc(-c5cc6ccccc6o5)cs4)CC3)=NC2N=C1,No,No,CHEMBL4538849,3196192,,Inhibitor,,,"79 nM, 33 nM","Proliferation assay with cellular ATP kit HTS, Proliferation assay with CellTiter-Glo ATP",IC50,Rat,"0.2 mg/Kg, 0.6 mg/Kg",BAY-070
GNE-2256,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gne-2256,IRAK4,Kinase,TKL,2022-02-10,Q9NWZ3,AUYCSWFYKYVCLD-HXUWFJFHSA-N,CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O,Yes,No,CHEMBL4475494,2905509,,Inhibitor,"1.4 Â±0.32 nM, 80 Â± 9.2 %","Biochemical Assay (FRET), Biochemical assay","190 Â± 79 nM, 3.3 nM, 290 nM","R848-induced IL-6 production in human whole blood, NanoBRET assay (IRAK4), IFNalpha human whole blood assay",IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)",1 mg/Kg IV and PO,GNE-6689
ABBV-744,3.3,3.3,3.0,No,https://www.chemicalprobes.org/abbv-744,"BRD2, BRD4, BRD3, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2020-04-29,"P25440, O60885, Q15059, Q58F21",OEDSFMUSNZDJFD-UHFFFAOYSA-N,CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1,No,No,CHEMBL4297454,711502,"www.doi.org/10.1038/s41586-020-1930-8, www.doi.org/10.1021/acs.jmedchem.0c00628, https://www.ncbi.nlm.nih.gov/pubmed/31969702, https://www.ncbi.nlm.nih.gov/pubmed/32324999",Inhibitor,"4.6 nM BD2, 1.6 nM BD2, 4.9 nM BD2, 1 nM","TR-FRET, SPR","11 nM (LNCaP); 9 nM (MDA-PCa-2B); 18 nM (MDV-R), 27.5","Cell proliferation assay, NanoBRET",IC50,Mouse,1 mg/kg,
BI-9627,3.0,4.0,2.0,No,https://www.chemicalprobes.org/bi-9627,SLC9A1,Transporter,Solute Carrier,2021-04-12,P19634,QMHRLXNEGYTSRV-UHFFFAOYSA-N,CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,No,No,CHEMBL2170610,1645687,,Antagonist,6 nM,pHi change assay: SLC9A1,"31 nM, 138 nM","Human platelet swelling inhibition (hPSA) assay, Rat PSA",EC50,"Rat, Dog","1 mg/Kg IV, 5 mg/Kg PO",BI 0054
GSK778,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsk778,"BRD2, BRD3, BRD4, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2022-02-10,"P25440, Q15059, O60885, Q58F21",ZORLJXWXFABTPZ-CTNGQTDRSA-N,COCc1nc2cnc3cc(-c4c(C)noc4C)c(OC[C@H]4CCNC4)cc3c2n1[C@H](C)c1ccccc1,No,No,CHEMBL4639128,2927349,,Inhibitor,"75 nM, 13 nM, 41 nM, 5 nM, 5.9 nM, 143 nM, 18 nM","TR-FRET assay (BRD2 BD1), BROMOScan (DiscoverX), TR-FRET assay (BRD3 BD1), TR-FRET assay (BRD4 BD1), TR-FRET assay (BRDT BD1)","50 nM, 100 nM","NanoBRET, Cell proliferation assay in AML cell line MV-4â11 with MLL-AF4 rearrangement",IC50,Mouse,10 mg/Kg,
A-1596586,0.0,0.0,0.0,No,https://www.chemicalprobes.org/a-1596586,CFTR,Ion Channel,Conductance Regulator ,2022-02-10,P13569,KDOQEEMQPHIANX-NFBKMPQASA-N,COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1,No,No,CHEMBL4093612,808891,,Corrector,,,"28 nM, 130 nM, 35 nM","HBE-TECC (Human Bronchial Epithelial- Trans-Epithelial Current Clamp) assay, CSE-HRP surface expression (Cell surface expression-horseradish peroxidase) assay, Plasma membrane-expressed enzyme acceptor protein (EA-MEM) assay",EC50,,,A-1596584
A-1211212,0.0,0.0,0.0,No,https://www.chemicalprobes.org/a-1211212,BCL2,Enzyme,Apoptosis Regulator,2022-02-09,P10415,CSBKUBOVPUXFLO-MAVVKCOWSA-N,CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,No,No,CHEMBL4228713,995003,,Inhibitor,1.4 nM,Time-resolved fluorescence energy transfer (TR-FRET),6 nM,"CellTiter-Glo assays (10 % HS, 48 hr) in BCL2 dependent RS4;11 cells (EC50 > 5000 nM in BCL2L1 dependent H146 cells (10 % HS, 48 hr) and EC50 > 1000 nM in MCL1 dependent AMO-1 cells (10 % HS, 24 hr))",EC50,Mouse,50 mg/Kg/day,A-1210227
A-192621,4.0,4.0,1.0,No,https://www.chemicalprobes.org/a-192621,EDNRB,GPCR,Endothelin Receptor,2022-02-08,P24530,LQEHCKYYIXQEBM-FUKIBTTHSA-N,CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1,No,No,CHEMBL332794,841256,,Antagonist,"8.8 nM, 4.5 nM","125I-labelled ET-1 saturation binding studies with EDNRB, Inhibition of 125I labeled ET-3 binding to EDNRB",0.8 nM,EDNRB- dependent phosphatidylinositol hydrolysis assay,IC50,"Rat, Dog, Monkey (Cynomolgus)","5 mg/Kg IV, 10 mg/Kg PO",A-1806262
BAY-474,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-474,MET,Kinase,TK,2022-01-31,P08581,QKVFMAAIXZONRN-UHFFFAOYSA-N,CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1,No,No,CHEMBL4593677,3247536,,Inhibitor,<1 nM,Biochemical MET assay,"2.9 nM, IC90 24 nM, IC90 56 nM","Mechanistic cellular assay (p-c-Met, MKN-45 cells), Cell proliferation Hs746T (gastric) IC90, Cell proliferation MKN-45 (gastric) IC90",IC50,"Mouse, Rat, Dog",10 mg/Kg BID,BAY-827
PF-05105679,4.0,3.0,1.0,No,https://www.chemicalprobes.org/pf-05105679,TRPM8,Ion Channel,Cation Channel,2022-01-21,Q7Z2W7,BXNMZRPTQFVRFA-QGZVFWFLSA-N,C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1,No,No,CHEMBL3577885,469191,,Antagonist,103 nM,Inhibition of binding to TRPM8,"103 Â± 29 nM, 13.8 Â± 2.2 nM","Inhibition of voltage-induced current in HEK-293 cells expressing human and guinea pig TRPM8 channels.  IC50 = 109 Â± 38.8 nM for guinea pigs., Voltage activation in HEK-293 cells at 12Â°C.",IC50,"Rat, Dog","2-10 mg/Kg, 20 mg/Kg",PF-05257137
TP-008,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tp-008,"ACVR1B, TGFBR1","Kinase, Kinase","TKL, TKL",2022-01-14,"P36896, P36897",LVEUPFUJRKZPEN-UHFFFAOYSA-N,Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21,No,No,CHEMBL4564126,3222830,,Inhibitor,"25 nM, 300 nM, 1000 nM, 120 nM","Lanthascreen, Radioactive kinase assay (Reaction Biology)","526 nM, 245 nM",Reporter gene assay,IC50,,,Al11
BAY-293,3.0,0.0,1.0,No,https://www.chemicalprobes.org/bay-293,SOS1,Enzyme,Nucleotide exchange factor,2022-01-14,Q07889,WEGLOYDTDILXDA-OAHLLOKOSA-N,CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1,No,No,CHEMBL4535474,2879016,,Inhibitor,21 nM,SOS1 interaction assay,< 1000 nM,"Inhibition of RAS-activation, pERK levels in K-562 cells",IC50,,,BAY-294
BAY-1797,4.0,4.0,1.0,No,https://www.chemicalprobes.org/bay-1797,P2RX4,Ion Channel,ATP Receptor,2022-01-14,Q99571,CSJYMAFXYMYNCK-UHFFFAOYSA-N,NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1,No,No,CHEMBL4521594,3180904,,Inhibitor,"211 nM, 108 nM","FLIPR assay: Human P2RX4 IC50 at 211 nM (HEK, Ca2+) 
Equipotent on human, rat (IC50 = 233 nM) and mouse (IC50 = 112 nM) P2RX4, FLIPR assay: Human P2RX4 1321N1 astrocytoma, Ca2+
Equipotent on human, rat (IC50 = 233 nM) and mouse (IC50 = 112 nM) P2RX4","274 nM, 320 nM","Ephys human P2RX4 IC50 = 274 nM (Qpatch, HEK cells), Patch-clamp experiments on human P2X4
 (QPatch, 1321N1 cells)
Efficacy in several in vitro and in vivo mechanistic models was demonstrated.",IC50,Rat,"1 mg/Kg, 2 mg/kg",BAY-207
ABT-546,3.0,3.0,1.0,No,https://www.chemicalprobes.org/abt-546,EDNRA,GPCR,Endothelin Receptor,2022-01-14,P25101,OAEWNSKRLBVVBV-QSEAXJEQSA-N,CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC,No,No,CHEMBL111612,755402,,Antagonist,0.46 nM,Enzymatic assay,"0.59 nM, 1.1 nM","Endothelin-1-evoked phosphatidylinositol hydrolysis in MMQ cells, Rat aortic ring contraction","IC50, EC50","Rat, Dog, Monkey (Cynomolgus)","5 mg/Kg, 10 mg/Kg",A-545
FB23-2,2.5,2.5,2.0,No,https://www.chemicalprobes.org/fb23-2,FTO,Epigenetic,RNA demethylase,2021-12-20,Q9C0B1,ILHNIWOZZKIBNW-UHFFFAOYSA-N,Cc1noc(C)c1-c1cc(Cl)c(Nc2ccccc2C(=O)NO)c(Cl)c1,No,Yes,CHEMBL4567838,3224326,,Inhibitor,2600 Â± 500 nM,HPLC assay of FTO demethylation of m6A RNA,"800-1500 nM, 5000 nM","anti-proliferation assay, increase of m6A abundance in transcriptomes assessed by dot blot or LC-MS","IC50, Activity",Rat,3 mg/kg,
MSD-M1PAM,0.0,0.0,0.0,No,https://www.chemicalprobes.org/msd-m1pam,CHRM1,GPCR,Acetylcholine Receptor,2021-12-19,P11229,RJTJRVASUFIDQM-UHFFFAOYSA-N,N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1,No,No,CHEMBL1800285,168214,,Positive allosteric modulator,,,IP = 136 nM,"Inflection Point (IP), Fold potentiation assay with CHONFAT cells expressing human mAChR1 receptor",,"Rat, Dog","2.5 mg/Kg, 1 mg/Kg, 1.5 mg/Kg",MSD-M1PAM-NC
BAY-899,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-899,LHCGR,GPCR,Hormone Receptor,2021-12-19,P22888,VKQBTIMLSDGNLG-QHCPKHFHSA-N,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1,No,No,CHEMBL4458424,3154025,,Allosteric Antagonist,,,185 nM,Human LH-R Antagonism (Frozen Cells Assay),IC50,Rat,"2 mg/Kg, 0.5 mg/Kg",BAY-897
SR-302,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sr-302,"DDR1, DDR2, MAPK11, MAPK14","Kinase, Kinase, Kinase, Kinase","CMGC, CMGC, CMGC, CMGC",2021-12-19,"Q08345, Q16832, Q15759, Q16539",WGMNFJAFXXXRLZ-GEVKEYJPSA-N,CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1,No,No,CHEMBL4591082,3244218,,Inhibitor,"53.3 nM, 0.75 nM, 45.1 nM, 6.2 nM","Enzyme kinetic assay from""Reaction Biology"" (ATP conc.: 100 ÂµM), Enzyme kinetic assay from""Reaction Biology"":  (ATP conc.: 5 ÂµM), Enzyme kinetic assay from""Reaction Biology"": DDR1: ATP conc.: 50 ÂµM, Enzyme kinetic assay from""Reaction Biology"": (ATP conc.: 2.5 ÂµM)","23 nM, 18 nM, 196 nM, 125 nM","NanoBRET assay (HEK293T cells, full-length protein)
Destabilizing effect on E-cadherin",IC50,,,SR-301
NAPHTHYRIDINONE,0.0,0.0,0.0,No,https://www.chemicalprobes.org/naphthyridinone,CNR1,GPCR,Cannabinoid Receptor,2021-12-19,P21554,VHSIAYLBCLUAFT-UHFFFAOYSA-N,CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12,No,No,CHEMBL204232,561495,,Inverse Agonist,7.5 nM,Radioligand Binding Assay (CNR1),4.9 nM,Functional activation assay in recombinant hCNR1 CHO cells,EC50,"Mouse, Rat, Dog, Monkey (Rheus)",10 mg/Kg,MRL-CB1-NC
BAY-7598,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-7598,MMP12,Enzyme,Metallopeptidase,2021-12-15,P39900,ZGBAPSHWPBXEKN-OPHFCASCSA-N,O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O,No,No,CHEMBL4585243,3234851,,Inhibitor,"0.085 nM, 0.004 nM","Biochemical assay, Biophysical assay (SPR biosensor-based assay)",,N/A extracellular function,,Mouse,"0.3 mg/Kg, 5 mg/Kg",BAY-694
BAY-069,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-069,"BCAT1, BCAT2","Enzyme, Enzyme","Amino acid transaminase, Amino acid transaminase",2021-12-15,"P54687, O15382",UNSHMXUHOHBLIQ-UHFFFAOYSA-N,Cc1ccccc1Oc1cc(-n2c(=O)cc(C(F)(F)F)[nH]c2=O)c2ccccc2c1Cl,No,No,CHEMBL4551635,3213584,,Inhibitor,"27 nM, 130 nM",Biochemical Assay,"358 nM, 874 nM","Cellular mechanistic assay â BCAA measurement: U-87-MG (high BCAT1 expression) cells, Cellular mechanistic assay â BCAA measurement in MDA-MB-231 (high BCAT2 expression) cells",IC50,"Rat, Mouse","0.3 mg/Kg, 0.6 mg/Kg, 25, 50, 100 mg/Kg",BAY-771
MSD-CYP11B2,0.0,0.0,0.0,No,https://www.chemicalprobes.org/msd-cyp11b2,CYP11B2,Enzyme,B,2021-12-14,P19099,OAMLIJKKGZLNHE-UHFFFAOYSA-N,CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1,No,No,CHEMBL3582478,1471596,,Inhibitor,,,2.3 nM,Assay using V79 cell lines stably expressing human CYP11B2 enzyme,IC50,"Rat, Monkey (Rheus)","1 mg/kg, 0.5 mg/Kg",MSD-CYP11B2-Negative-control
IPP/CNRS-A017,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ipp_cnrs_a017,DHODH,Enzyme,Class 2 Dihydroorotate dehydrogenase,2021-12-14,Q02127,JNAABFZPXJJMPX-UHFFFAOYSA-N,Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F,No,No,CHEMBL3589752,211902,,Inhibitor,25 nM,Activity assay,"2.5 nM, 50 nM","Measles Virus Inhibition Assay using HEK-293T cells infected with rMV2/Luc, Inhibition of T cell proliferation in Jurkat cells","EC50, IC50",,,IPP/CNRS-A019
T3-CLK,0.0,0.0,0.0,No,https://www.chemicalprobes.org/t3-clk,"CLK1, CLK2, CLK3, CLK4","Kinase, Kinase, Kinase, Kinase","CMGC, CMGC, CMGC, CMGC",2021-12-14,"P49759, P49760, P49761, Q9HAZ1",IEFFSHLHNYVSEF-UHFFFAOYSA-N,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5ccncc5)ccc4n3)cc2)CC1,No,No,CHEMBL4531334,2912953,,Inhibitor,"0.67 nM, 15 nM, 110 nM",In vitro kinase assay,"3.49 nM, 0.5 ÂµM, 16.6 nM, 1.98 nM","NanoBRET, Western of phospho-SR isoforms",IC50,,,T3-CLK-N
MK-7246,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mk-7246,PTGDR2,GPCR,Prostaglandin D2 receptor,2021-12-13,Q9Y5Y4,JTCAGRAKUAAYDY-OAHLLOKOSA-N,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,Yes,No,CHEMBL561132,165276,,Antagonist,2.5 nM,Prostanoid receptor binding assay (PTGDR2),"3 nM, 2.2 nM, 2.3 nM","cAMP Functional Assay, Functional Assay: Eosinophil Shape Change (whole blood), Functional Assay: Eosinophil CD11b (whole blood)",IC50,"Rat, Dog","5 mg/Kg PO, 1 mg/Kg IV",CRTH2-negative-control
MRK-560,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mrk-560,PSEN1,Enzyme,Gamma-Secretase complex,2021-12-01,P49768,WDZVWDXOIGQJIO-UHFFFAOYSA-N,O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,No,Yes,CHEMBL1091513,428751,,Inhibitor,0.65 nM,CHAPSO-solubilized SH-SY5Y neuroblastoma P2 cell membranes,0.5 nM,"AÎ²42 inhibition assay, AÎ²40 inhibition assay",IC50,Rat,"1 mg/kg IV, 5 mg/Kg PO",GSI-NC
BI-665915,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi665915,ALOX5AP,Membrane protein,Five-Lipoxygenase Activating Protein,2021-12-01,P20292,QGPXEIMWTKWHMH-DEOSSOPVSA-N,CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1,No,No,CHEMBL3417525,623542,,Inhibitor,1.7 nM,FLAP binding assay,45 nM,FLAP functional inhibition of human whole blood,IC50,"Rat, Dog, Monkey (Cynomolgus)","1 mg/kg IV, 10 mg/kg PO",BI 0153
PF-04418948,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pf-04418948,PTGER2,GPCR,Prostaglandin E Receptor 2,2021-12-01,P43116,LWJGMYMNSNVCEM-UHFFFAOYSA-N,COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1,No,No,CHEMBL3286797,356356,,Antagonist,5 nM,Inhibition of binding to PTGER2,KB = 5.4 nM,"Functional native assay: human myometrium 5.4 nM; Dog bronchiole 2.5 nM, mouse trachea 1.3 nM KB",,"Mouse, Rat","0.1 - 10 mg/Kg, 1 - 10 mg/Kg",PF-04475866
A-079,0.0,0.0,0.0,No,https://www.chemicalprobes.org/a-079,TRPA1,Ion Channel,"Transient receptor, TRPV subfamily",2021-12-01,O75762,HKROEBDHHKMNBZ-CHBKHGQFSA-N,CCC(=N\O)/C(C)=C/c1ccc(F)cc1,No,Yes,CHEMBL3697701,63385,,Antagonist,67 nM,FLIPR-based Ca2+ assay.,51 nM,A-967079 blocks AITC (100 Âµmol/L)-evoked currents in HEK-293F cells transiently overexpressing hTRPA1 (held at -60 mV),IC50,Rat,30 Î¼mol/kg,A-226
ABT-724,0.0,0.0,0.0,No,https://www.chemicalprobes.org/abt-724,DRD4,GPCR,Dopamine D4 receptors,2021-12-01,P21917,FRPJGTNLZNXQEX-UHFFFAOYSA-N,c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1,No,No,CHEMBL440687,1323829,,Agonist,46.8 - 63.6 nM,Radioligand-binding affinity for the dopamine receptor agonists using [3H]-A-369508 and membrane preparations expressing the human D4 variants (hDRD4.2: Ki=57.5 nM; hDRD4.4: Ki=63.6 nM; hDRD4.7: Ki= 46.8 nM),12.5 nM,Efficacy of 61% compared to Dopamine in cellular FLIPR assay,EC50,Rat,0.03 umol/Kg,A-769
MILVEXIAN,0.0,0.0,0.0,No,https://www.chemicalprobes.org/milvexian,F11,Enzyme,Peptidase S1 family,2021-11-22,P03951,FSWFYCYPTDLKON-CMJOXMDJSA-N,C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O,No,No,CHEMBL4112929,894483,,Inhibitor,0.11 nM,enzyme activity assay,500 nM EC1.5x,Human aPTT coagulation assay (aPTT - activated partial thromboplastin time). EC1.5x is the plasma concentration of FXIa inhibitor that increases the clotting time to 1.5 times baseline,,"Rat, Monkey (Cynomolgus), Other","0.52 (IV), 1.04 (PO) mg/Kg, 0.50 (IV), 1.50 (PO) mg/Kg",
Sivopixant,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sivopixant,P2RX3,GPCR,Purinoceptor,2021-11-22,P56373,SKZQFKBIJUXXCG-INIZCTEOSA-N,C[C@@H](Cn1c(=O)nc(Nc2ccc(Oc3ccccn3)cc2)n(Cc2ccc(Cl)cc2)c1=O)C(=O)O,No,No,,3455496,,Antagonist,,,"4.2 nM (human), 4.0 nM (rat)","Measurement of fluorescence intensity in C6BU-1 transfected cells expressing P2X3 and treated with ATP as agonist, Measurement of fluorescence intensity in C6BU-1 transfected cells expressing rat P2X3",IC50,Rat,"1 mg/kg, 3 mg/Kg",
BAY-091,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-091,PIP4K2A,Kinase,,2021-11-22,P48426,DVIVLYHDLNAXAT-OAQYLSRUSA-N,CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O,No,No,CHEMBL4802045,3318578,,Inhibitor,"1.3 nM, 2.6 nM, 8.5 nM, 16.4 nM","ADP-Glo 10 uM ATP (low ATP), ADP-Glo 250 uM ATP (high ATP), Quantification of produced PI(4,5)P2 (Homogeneous Time Resolved Fluorescence (HTRF)) at 10 ÂµM ATP, Quantification of produced PI(4,5)P2 (Homogeneous Time Resolved Fluorescence (HTRF)) at 2 mM ATP","8.5 nM, 16.4 nM","Quantification of produced PI(4,5)P2 (Homogeneous Time-Resolved Fluorescence (HTRF)) at 10 uM ATP (low ATP), Quantification of produced PI(4,5)P2 (Homogeneous Time-Resolved Fluorescence (HTRF)) at 2 mM ATP (high ATP)",IC50,,,BAY-0361
Vimseltinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/vimseltinib,CSF1R,Kinase,TK,2021-11-22,P07333,TVGAHWWPABTBCX-UHFFFAOYSA-N,Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1Oc1ccnc(-c2cnn(C)c2)c1,No,No,,3455498,,Inhibitor,4.2 nM @ 4 mM ATP,In vitro Kinase assay,"19 nM, 9.2 nM","Inhibition of CSF1-stimulated phosphorylation of CSF1R in the human THP1 mononuclear cell line; Inhibition of CSF1-stimulated phosphorylation of ERK downstream of CSF1R signaling in human whole blood IC50: 403 nM, Inhibition of osteoclast precursor differentiation stimulated by RANKL (measuring levels of tartrate-resistant acid phosphatase activity in the supernatant of assay wells)",IC50,Mouse,"10 mg/Kg, 3 mg/Kg, 1 mg/Kg",
Tomivosertib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tomivosertib,"MKNK1, MKNK2","Kinase, Kinase","CAMK, CAMK",2021-06-26,"Q9BUB5, Q9HBH9",HKTBYUWLRDZAJK-UHFFFAOYSA-N,Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,No,No,CHEMBL4073443,1682158,"www.doi.org/10.1021/acs.jmedchem.7b01795, https://pubmed.ncbi.nlm.nih.gov/29526098/",Inhibitor,"2.4 nM, 1 nM",ADP-Glo kinase assay,6 nM,peIF4E Signaling Cellular Assay,IC 50,Mouse,1 (IV)-10 (PO) mg/Kg,
SR-0813,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sr-0813,"MLLT1, MLLT3","Epigenetic, Epigenetic","YEATS, YEATS",2021-06-10,"Q03111, P42568",GPMTWAPXRJMXCC-UHFFFAOYSA-N,O=C(NC1CCC1)c1ccc2nc(-c3cccc(NS(=O)(=O)NCCN4CCCCC4)c3)cn2c1,No,No,,3313090,"www.doi.org/10.1021/acscentsci.0c01550, https://pubmed.ncbi.nlm.nih.gov/34079898/",Inhibitor,"25 nM, 30 nM, 311 nM","ENL-H3K27cr HTRF, SPR","205 nM, 76 nM",ENL and AL9 (YEATS)-HiBiT CETSA,EC 50,,,
MRIA9,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mria9,"SIK1, SIK2, SIK3","Kinase, Kinase, Kinase","CAMK, CAMK, CAMK",2022-02-17,"P57059, Q9H0K1, Q9Y2K2",KTACUAZSJJIUKD-QXONSOMPSA-N,CNc1cc2c(cn1)cc(-c1ccc(-c3ncccc3F)cc1Cl)c(=O)n2C[C@H]1OC[C@H](N)CO1,No,No,,3318719,,Inhibitor,"55 nM, 48 nM, 22 nM",Radiometric assay 33-PanQinase,"516 Â± 5 nM, 180 Â± 40 nM, 127 Â± 23 nM",NanoBRET,IC50,,,MR7
GSK046,4.0,3.0,1.0,No,https://www.chemicalprobes.org/gsk046,"BRD2, BRD3, BRD4, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic",Bromodomain,2022-02-11,"P25440, Q15059, O60885, Q58F21",FRBRZGLUFOZRGD-JVPBZIDWSA-N,CC(=O)Nc1c(F)cc(C(=O)N[C@H]2CC[C@H](O)CC2)cc1O[C@@H](C)c1ccccc1,No,No,CHEMBL4636881,2863034,,Inhibitor,"264 nM, 250 nM, 35 nM, 98 nM, 100 nM, 32 nM, 49 nM, 50 nM, 9 nM, 30 nM, 214 nM, 200 nM, 15 nM","TR-FRET assay (BRD2 BD2), BET mutant TR-FRET assay (BRD2 BD2), BRD2 BD2 Bromoscan (DiscoverX), TR-FRET assay (BRD3 BD2), BET mutant TR-FRET assay (BRD3 BD2), BRD3 BD2 Bromoscan (DiscoverX), TR-FRET assay (BRD4 BD2), BET mutant TR-FRET assay (BRD4 BD2), BRD4 BD2 Bromoscan (DiscoverX), SPR, TR-FRET assay (BRDT BD2), BET mutant TR-FRET assay (BRDT BD2), BRDT BD2 Bromoscan (DiscoverX)","315 nM, 31 nM","In vitro inhibition of MCP-1 in Lipopolysaccharide-stimulated human whole blood, LPS-PBMC assay (MCP-1)",IC50,"Rat, Dog","1 mg/Kg, 3 mg/Kg, 0.5 mg/Kg",
BI-639667,3.0,4.0,1.0,No,https://www.chemicalprobes.org/bi-639667,CCR1,GPCR,Chemokine Receptor,2022-02-01,P32246,PXQATVYJKMMHAU-UHFFFAOYSA-N,CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1,No,No,CHEMBL4456123,3151671,,Antagonist,"5.4 nM, 24 nM","CCR1 binding affinity Scintillation Proximity Assay binding, CCR1 molecular potency, IC50= 24nM (Ca2+ flux)","2.4 nM, 9 nM","CCR1 cellular potency, chemotaxis, Whole blood potency for CCR1 internalization",IC50,"Rat, Dog, Monkey (Cynomolgus)",,BI 9307
BAY-784,3.5,3.5,2.0,No,https://www.chemicalprobes.org/bay-784,GNRHR,GPCR,Hormone Receptor,2022-01-31,P30968,PZGSYNNVPNLHQG-SANMLTNESA-N,O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1,No,No,CHEMBL4537788,3194418,,Antagonist,27 nM,Tag Lite binding assay using human GnRHR,21 nM,Mechanistic assay measuring cellular IP1 (superagonist Buserelin stimulation at EC80),IC50,"Rat, Dog, Monkey (Cynomolgus)","0.5 mg/kg IV, 2.0, 10 and 30 mg/kg PO, 0.5 mg/kg IV, 2.0 mg/kg PO, 0.5 mg/kg IV, 2.0 and 20 mg/kg PO",BAY-786
BI-99179,4.0,4.0,2.0,No,https://www.chemicalprobes.org/bi-99179,FASN,Enzyme,Synthase,2022-01-31,P49327,YNFDIGJKJPNFFD-SJORKVTESA-N,CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1,No,No,CHEMBL1834184,171437,,Inhibitor,79 nM,Inhibition of FASN,"570 nM, 180 nM","Inhibition of [14C]acetate incorporation into mouse N-42 cells, Inhibition of [14C]acetate incorporation into human H1975 cells",IC50,Rat,4 mg/kg,BI 99990
BI-1942,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi-1942,CMA1,Enzyme,Peptidase,2022-02-20,P23946,PCJVXTDIDUMIRR-QGZVFWFLSA-N,CC[C@H](CC(=O)O)n1c(=O)c2ncccc2n(Cc2cn(C)c3cc(C)cc(C)c23)c1=O,No,No,CHEMBL3640116,473137,,Inhibitor,0.4 nM,Inhibition of recombinant human CMA1,198 nM,Angiotensin II formation by CMA1 in human plasma,IC50,,,
BI-653048,3.0,0.0,1.0,No,https://www.chemicalprobes.org/bi-653048,NR3C1,NHR,Subfamily 3,2022-01-31,P04150,AUIFRJWXYUNPPV-QFIPXVFZSA-N,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,No,No,CHEMBL3358954,625199,,Agonist,55 nM,Fluorescence polarization assay,23 nM,Fibroblast IL-6 assay (88% maximal efficiency@ 2ÂµM),IC50,,,BI 3047
BI-4394,4.0,4.0,1.0,No,https://www.chemicalprobes.org/bi4394,MMP13,Enzyme,Peptidase,2022-02-10,P45452,MMJPVSDTLGFIQW-UHFFFAOYSA-N,CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1,No,No,CHEMBL1939876,519764,,Inhibitor,1 nM,FRET assay,"31 nM, 11 nM","Collagen degradation assay: Inhibition of bovine nasal cartilage, Collagen degradation assay",IC50,Rat,"1 mg/Kg IV, 10 mg/Kg PO",BI 4395
MRL-SYKi,4.0,4.0,1.0,No,https://www.chemicalprobes.org/mrl-syki,SYK,Kinase,TK,2022-02-11,P43405,OYKPWSZSBLRRPL-HOYKHHGWSA-N,Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1,No,No,CHEMBL3685796,471230,,Inhibitor,0.9 nM,Human SYK enzyme assay,"38 nM, 287 nM","Human Mast Cell degranulation, Human Whole Blood Cys LT a-IgE",IC50,"Rat, Dog",1-30 mg/Kg,MRL-SYKi-NC
UCSF924,4.0,2.5,2.0,No,https://www.chemicalprobes.org/ucsf924,DRD4,GPCR,Dopamine receptor,2022-02-08,P21917,RPHDOVLXDYWDGF-UHFFFAOYSA-N,Cc1ccc2[nH]c(CNCCCOc3ccccc3)cc(=O)c2c1,No,No,,3550538,,Agonist,3.0 nM,Radioligand binding assay (DRD4),"0.2 nM, 4.2 nM","BRET-Gi dissociation assay, cAMP receptor assay",EC50,Mouse,10 mg/kg,UCSF924NC
WM-3835,3.0,1.5,2.0,No,https://www.chemicalprobes.org/wm-3835,KAT7,Epigenetic,Histone Acetyltransferase,2022-01-21,O95251,KVJFJJXCBRSCDY-UHFFFAOYSA-N,Cc1cc(-c2ccccc2)cc(C(=O)NNS(=O)(=O)c2cccc(O)c2)c1F,No,Yes,,2849398,,Inhibitor,"30 nM, 34 nM","Biochemical (acetyltransferase) assay, SPR",297 nM,Growth inhibition assays of the MLLâAF9 AML cell line Molm13 treated with WM-3835 at the doses indicated. Boxes represent minimum and maximum values. n = 11. Mean Â± s.e.m,IC50,Mouse,100 mg/Kg BID,WM-2474
BAY-678,2.0,2.0,1.0,No,https://www.chemicalprobes.org/bay-678,ELANE,Enzyme,Protease,2022-01-21,P08246,PGIVGIFOWOVINL-GOSISDBHSA-N,CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1,No,No,CHEMBL3617968,213469,,Inhibitor,"20 nM, 15 nM",Biochemical Neutrophil Elastase Assay,,"Extracellular protein, no evidence of intracellular activity",,Rat,0.3 mg/Kg,BAY-677
GSK789,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsk789,"BRD2, BRD3, BRD4, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2022-02-11,"P25440, Q15059, O60885, Q58F21",NDEORODKVUYMFQ-NHCUHLMSSA-N,Cc1cc2c(-c3ccco3)cnc(N[C@@H]3CCN(C)C[C@H]3C(=O)NC3CCCCC3)c2[nH]c1=O,No,No,CHEMBL4648362,2897507,,Inhibitor,"100 nM, 20 nM, 4 nM, 158 nM, 16 nM, 31 nM, 6.3 nM, 630 nM, 10 nM","BET mutant TR-FRET assay (BRD2 BD1), BRD2 BD1 Bromoscan (DiscoverX), BRD2 BD1 Chemoproteomics, BET mutant TR-FRET assay (BRD3 BD1), BRD3 BD1 Bromoscan (DiscoverX), BRD3 BD1 Chemoproteomics, BET mutant TR-FRET assay (BRD4 BD1), BRD4 BD1 Chemoproteomics, BET mutant TR-FRET assay (BRDT BD1), BRD4 BD1 Bromoscan (DiscoverX), BRDT BD1 Chemoproteomics","125 nM, 390 nM, 258 nM, 670 nM, 20 nM","Proliferation assay (MV-4â11 cells), Proliferation assay (HL60 cells), Proliferation assay (THP-1 cells), In vitro inhibition of MCP-1 in Lipopolysaccharide-stimulated human whole blood, LPS-PBMC assay (MCP-1)",IC50,,,GSK791
GSK973,3.5,3.5,2.0,No,https://www.chemicalprobes.org/gsk973,"BRD2, BRD3, BRD4, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2022-02-11,"P25440, Q15059, O60885, Q58F21",WZQLVEPIBAOOGF-RMMWZPCPSA-N,CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@H](CF)[C@H]2c1ccccc1,No,No,CHEMBL4637208,3319397,,Inhibitor,"32 nM, 5 nM, 16 nM, 3 nM, 2 nM, 34 nM","BET mutant TR-FRET assay (BRD2 BD2), BRD2 BD2 Bromoscan (DiscoverX), BET mutant TR-FRET assay (BRD3 BD2), BRD3 BD2 Bromoscan (DiscoverX), BET mutant TR-FRET assay (BRD4 BD2), BR43 BD2 Bromoscan (DiscoverX), BRD4 BD2 SPR, BET mutant TR-FRET assay (BRDT BD2), BRDT BD2 Bromoscan (DiscoverX)",50 nM,In vitro inhibition of MCP-1 in Lipopolysaccharide-stimulated human whole blood,IC50,"Rat, Dog","1 mg/Kg, 3 mg/Kg, 2 mg/Kg",GSK943
GSK620,4.0,4.0,2.0,No,https://www.chemicalprobes.org/gsk620,"BRD2, BRD3, BRD4, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2022-02-11,"P25440, Q15059, O60885, Q58F21",QZZCUOVXHPAQRQ-UHFFFAOYSA-N,CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2ccccc2)c1=O,No,No,CHEMBL4635134,2972672,,Inhibitor,"285 nM, 318 nM, 15 nM, 72 nM, 63 nM, 12 nM, 81 nM, 6 nM, 50 nM, 184 nM, 200 nM","TR-FRET assay (BRD2 BD2), BET mutant TR-FRET assay (BRD2 BD2), BRD2 BD2 Bromoscan (DiscoverX), TR-FRET assay (BRD3 BD2), BET mutant TR-FRET assay (BRD3 BD2), BRD3 BD2 Bromoscan (DiscoverX), TR-FRET assay (BRD4 BD2), BET mutant TR-FRET assay (BRD4 BD2), BRD4 BD2 Bromoscan (DiscoverX), BRD4 BD2 SPR, TR-FRET assay (BRDT BD2), BET mutant TR-FRET assay (BRDT BD2), BRDT BD2 Bromoscan (DiscoverX)","790 nM, 63 nM","In vitro inhibition of MCP-1 in Lipopolysaccharide-stimulated human whole blood, LPS-PBMC assay (MCP-1)",IC50,"Rat, Dog","1 mg/Kg, 3 mg/Kg, 0.5 mg/Kg, 1.0 mg/Kg",
BI 1950,4.0,3.0,2.0,No,https://www.chemicalprobes.org/bi-1950,ITGAL,Integrin,,2022-03-09,P20701,JZTTUZXIQIRVAB-FZEVHQGJSA-N,C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1,No,No,CHEMBL4530740,3189556,,Inhibitor,9 nM,ITGAL binding assay,"3 nM, 120 nM","Inhibits staphylococcal enterotoxin B-induced production of IL2 in human PBMC (peripheral blood mononuclear cell), Inhibits staphylococcal enterotoxin B-induced production of IL2 in human whole blood",IC50,Mouse,3 mg/Kg,BI 9446
MD-224,3.7,3.7,3.0,No,https://www.chemicalprobes.org/md-224,MDM2,Other post-translational modification,E3 ubiquitin ligase,2020-11-24,Q00987,ZLGNYFOIDAVMHY-MPKOGUQCSA-N,O=C1CCC(N2Cc3c(C#CCCCNC(=O)c4ccc(NC(=O)[C@@H]5NC6(CCCCC6)[C@@]6(C(=O)Nc7cc(Cl)ccc76)[C@H]5c5cccc(Cl)c5F)cc4)cccc3C2=O)C(=O)N1,No,No,,3312894,"www.doi.org/10.1021/acs.jmedchem.8b00909, https://pubmed.ncbi.nlm.nih.gov/30525597/",Degrader (PROTAC),"0.16 nM, 4.4 nM","Fluorescence Polarization-Based (FP-Based), Protein Binding Assay, Mi-1061 binding MDM2",1.5 nM,"cell growth inhibition assay, western blots assessing MDM2 degradation and p53 activation; Cell Growth Inhibition, Activity of MD-224 in a Panel of Human AML or ALL Cell Lines MOLM-13 7.3 nM, OL-14, 10.5 nM, SIG-M5 19.8 nM, ML-2 4.4 nM, OCL-AML-5 33.1 nM, mono-Man-6 >10 uM, KG-1 >10 uM. MD-224 is highly selective over leukemia cell lines with mutated p53.",IC50,Mouse,"25 mg/Kg IV once weekly, 10 mg/Kg 3 times weekly, 25 mg/Kg 5 days a week for 2 weeks, 50 mg/Kg every other day for 3 weeks",
BIIB021,3.5,3.0,2.0,No,https://www.chemicalprobes.org/biib021,"HSP90AA1, HSP90AB1","Other post-translational modification, Other post-translational modification","Chaperone, Chaperone",2020-12-01,"P07900, P08238",QULDDKSCVCJTPV-UHFFFAOYSA-N,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C,No,No,CHEMBL467399,1324570,"www.doi.org/10.1158/1535-7163.MCT-08-0758, www.doi.org/10.1158/1078-0432.CCR-09-0213, www.doi.org/10.1021/jm050752+, https://pubmed.ncbi.nlm.nih.gov/19372565/, https://pubmed.ncbi.nlm.nih.gov/19671844/, https://pubmed.ncbi.nlm.nih.gov/17488003/",Inhibitor,1.7 Â± 0.4 nM,fluorescence polarization competition assay,"38 Â± 10 nM (EC50); 60-310 nM (IC50), 38 Â± 10 nM (EC50)","HER-2 Degradation Assay, Western Blot, HER-2 Degradation Assay,  Western Blot","EC50, IC50",Mouse,"31, 62.5, 125 mg/Kg, 75, 150 mg/Kg, 100 mg/Kg",
RGFP966,3.0,3.0,6.0,No,https://www.chemicalprobes.org/rgfp966,HDAC3,Epigenetic,HDAC,2017-04-10,O15379,BLVQHYHDYFTPDV-VCABWLAWSA-N,Nc1cc(F)ccc1NC(=O)/C=C/c1cnn(C/C=C/c2ccccc2)c1,No,Yes,CHEMBL4078477,1881839,"http://www.sciencedirect.com/science/article/pii/S1074552109002427, http://www.pnas.org/content/110/7/2647.long, https://www.google.com/patents/WO2012016081A2?cl=en, https://www.ncbi.nlm.nih.gov/pubmed/19778726, https://www.ncbi.nlm.nih.gov/pubmed/23297220",Inhibitor,0.08 uM,Substrate-dependent biochemical assays (Reaction Biology). Extensive biochemical characterization has been published on a related compound 106 (Chem Biol. publication): HDAD3 Ki= 14 nM; IC50 with recombinant HDAC3=0.79 uM.,1.3 uM,General HDAC inhibition assay in HeLa cells.,IC50,Other,10 mg/mL,
AZD-7648,4.0,4.0,2.0,No,https://www.chemicalprobes.org/azd-7648,PRKDC,Kinase,PI3/PI4,2022-03-19,P78527,XISVSTPEXYIKJL-UHFFFAOYSA-N,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,No,No,CHEMBL4439259,2849455,,Inhibitor,0.63 nM,Measured by time-resolved fluorescence (TR-FRET) in a biochemical assay.,91 nM,Measuring inhibition of irradiation-induced DNA-PK autophosphorylation in A549 cells by ELISA.,IC50,"Rat, Dog","2 mg/Kg, 5 mg/Kg, 1 mg/Kg",
KI-696,3.3,3.5,5.0,No,https://www.chemicalprobes.org/ki-696,KEAP1,Other post-translational modification,Protein ubiquitination,2017-06-01,Q14145,ZDNGJXBUEQNFBQ-GCJKJVERSA-N,COc1cc([C@@H](CC(=O)O)c2ccc(C)c(CN3C[C@@H](C)Oc4ccccc4S3(=O)=O)c2)cc2nnn(C)c12,No,No,CHEMBL3819587,805747,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b00228, https://www.ncbi.nlm.nih.gov/pubmed/27031670",Inhibitor of KEAP1-NRF2 protein-protein interaction,1.3 nM,Isothermal Titration Calorimetry (ITC),12 nM,Beas2B cells treated with compound and NQO1 activity measured after 48 hrs using MTT. NQO1 is an NRF2-dependent gene.,EC50,Rat,35-50 Âµmol/kg,
ATABECESTAT,2.5,3.0,4.0,No,https://www.chemicalprobes.org/atabecestat,"BACE1, BACE2","Enzyme, Enzyme","Protease, Protease",2022-03-19,"P56817, Q9Y5Z0",VLLFGVHGKLDDLW-SFHVURJKSA-N,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1,No,No,CHEMBL3916243,1782304,,Inhibitor,9.8 nM,Biochemical homogeneous time-resolved fluorescence (HTRF)-based assay,1.1 nM,Cellular IC50 values were determined by measuring the levels of secreted AÎ²40 in human APP-transfected human neuroblastoma (SH-SY5Y) cells via an HTRF-based assay.,IC50,"Rat, Dog, Monkey (Cynomolgus)","0.3 mg /Kg, 1 mg/Kg, 0.3 mg/Kg",cpd 10
NI-57,3.0,2.3,6.0,No,https://www.chemicalprobes.org/ni-57,"BRPF1, BRD1, BRPF3","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2017-07-25,"P55201, O95696, Q9ULD4",UEMQPCYDWCSVCU-UHFFFAOYSA-N,COc1cc(C#N)ccc1S(=O)(=O)Nc1ccc2c(c1)cc(C)c(=O)n2C,No,No,CHEMBL3752151,1874277,"www.doi.org/10.1021/acs.jmedchem.7b00611, www.doi.org/10.1021/acschembio.7b00481, https://www.ncbi.nlm.nih.gov/pubmed/28714688, https://www.ncbi.nlm.nih.gov/pubmed/28849908",Antagonist,"31 nM, 110 nM, 410 nM",ITC,70 nM,"Cellular âon-targetâ activity for NI-57 was assessed in a BRPF1B-Histone3.3 nanoBRET assay which showed dose-dependent displacement of BRPF1B (but not BRPF1A) from Histone H3.3 with an estimated IC50 of 0.07 Â± 0.0034 uM. These results were verified in a FRAP assay where NI-57 displaced a triple BRD-BRPF1B-GFP fusion construct, as well as full length BRD1-GFP, which was demonstrated by significant reduction in recovery times in the presence of the inhibitor. Hence, the nanoBRET and FRAP experiments confirm NI-57 inhibit BRPF BRDs in the nucleus.",IC50,Mouse,"3 mg/kg (oral), 1 mg/kg (IV)",NI-198
DDD85646,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ddd85646,"NMT1, NMT2","Other post-translational modification, Other post-translational modification","Acyltransferase, Acyltransferase",2021-02-02,"P30419, O60551",XMBSZPZJLPTFMV-UHFFFAOYSA-N,Cc1nn(C)c(C)c1NS(=O)(=O)c1c(Cl)cc(-c2ccnc(N3CCNCC3)c2)cc1Cl,No,No,CHEMBL1230468,433471,"http://www.nature.com/nature/journal/v464/n7289/pdf/nature08893.pdf, http://pubs.acs.org/doi/pdf/10.1021/jm201091t, http://www.ncbi.nlm.nih.gov/pubmed/20360736, http://www.ncbi.nlm.nih.gov/pubmed/22148754",Inhibitor,"3 nM, 14 nM, 2 nM TbNMT, 3 nM HsNMT-1, 2 nM LmNMT, 3 nM TcNMT; ; 1 nM TbNMT, 14 nM HsNMT-1 KD","NMT enzyme assay
2 nM TbNMT, 2 nM LmNMT, 3 nM TcNMT;, SPR (1 nM TbNMT), NMT enzyme assay, SPR (KD)",2 nM Tb,trypanocidal activity in cultured T. brucei,EC 50,Mouse,"3 mg/Kg IV, 10 mg/Kg PO, up to 50 mg/Kg",
Apoptolidin,4.0,0.0,1.0,No,https://www.chemicalprobes.org/apoptolidin,ATP5F1B,Enzyme,,2022-01-21,P06576,WILMROCKORZEMQ-VJVIIGMYSA-N,COC[C@@H](C[C@H]1O[C@@](O)([C@H](O)[C@@H]2C[C@H](OC)[C@@H](O)CC/C=C(C)/C=C/[C@@H](O[C@@H]3O[C@@H](C)[C@H](OC)[C@@H](O)[C@@H]3O)[C@H](C)/C=C(C)/C=C(C)/C=C(\C)C(=O)O2)[C@H](C)[C@@H](O)[C@H]1C)OC1C[C@](C)(O)[C@@H](O[C@H]2C[C@@H](OC)[C@H](O)[C@@H](C)O2)[C@H](C)O1,No,No,CHEMBL266642,1005436,,Inhibitor,100 nM,"Enzyme-coupled ATPase assay. The assay buffer consisted of 60âmM Trisâacetate pH 7.8, 1âmM MgCl2, 2.5âmM phosphoenolpyruvate and 1âmM KCN. The working solution was prepared at 2Ã for a final concertation of 0.4âmM NADH; 3âUâmlâ1 of pyruvate kinaseâ+â4.5âUâmlâ1 lactate dehydrogenase (Sigma P0294);âÂ±â10âÎ¼M FCCP. Unless otherwise specified, ATP was added as a 4Ã solution at 200âÎ¼M. Absorbance was monitored at 340ânm using a SpectraMax Plus 384 plate reader (Molecular Devices) set at 25âÂ°C using Softmax Pro v.4.3 acquisition software. Fifty microliters of enzyme was added to 100âÎ¼l of working solution and monitored for 2âmin, 50âÎ¼l of ATP was then added for a final volume of 200âÎ¼l and absorbance was monitored over 10âmin.",5 nM,"MTT viability assay.. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay protocol was adapted from Deguire et al.19 Briefly, 100âÎ¼l of suspension cells at 100,000 cells mlâ1 were added to wells of a microtiter plate precoated with 0.5âÎ¼l of test compound at 200Ã in dimethylsulfoxide and incubated for 48â72 h (as noted). MTT reagent was dissolved in fresh media at 1âmg mlâ1 and 100âÎ¼l was added to each well to achieve a final concentration of 0.5âmg mlâ1 and incubated for 2 h at 37âÂ°C. Cells were centrifuged at 800g for 5âmin and decanted. MTT crystals were redissolved in 100âÎ¼l of dimethylsulfoxide, allowed to incubate for 5âmin at room temperature, and read at 560ânm using a SpectraMax plus 384 plate reader (Molecular Devices). Absorbance values were normalized by background subtraction (wells without cells) such that vehicle-treated cells had a viability of 1.0. Concentrationâresponse curves were fit using the DRC R package with a four-parameter log-logistic function. Statistical testing of differences between concentrationâresponse curves was carried out using the EDcomp function with default parameters for comparison of half maximal inhibitory concentration values and the paramcomp function for comparison of other parameters.",EC50,,,ISOAPOPTOLIDIN
ERD-308,4.0,0.0,1.0,No,https://www.chemicalprobes.org/erd-308,ESR1,NHR,Estrogen Receptor,2022-03-07,P03372,BQXUPNKLZNSUMC-YUQWMIPFSA-N,CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(-c2scnc2C)cc1)C(C)(C)C)CCOc1ccc(C(=O)c2c(-c3ccc(O)cc3)sc3cc(O)ccc23)cc1,No,No,CHEMBL4582373,3228219,,Degrader (PROTAC),,,"0.17 nM, >99%, 0.43 nM, >95%, 0.77 nM","Degradation of ER in MCF-7 cells after 4 h treatment, Degradation of ER in MCF-7 cells after 4 h treatment with Tmax < 3h, Degradation of ER in T47D cells after 4 h treatment, Degradation of ER in T47D cells after 4 h treatment with Tmax  about 3 h, Cell Proliferation assay in MCF-7 cells","DC50, Dmax, IC50",,,
AMG-18,3.3,3.0,5.0,No,https://www.chemicalprobes.org/amg-18,ERN1,Kinase,Other,2016-12-08,O75460,XMWUCMFVDXDRDE-NRFANRHFSA-N,Cc1ccc2c(NS(=O)(=O)c3ccccc3Cl)cccc2c1Oc1ncccc1-c1ccnc(N[C@H]2CCCNC2)n1,No,No,CHEMBL3356009,873758,"http://pubs.acs.org/doi/abs/10.1021/ml500315b, https://www.ncbi.nlm.nih.gov/pubmed/25589933",Allosteric inhibitor,13 nM,"IRE 1 biochemical fluorescence quenching kinase assay: 
A truncated human IRE1Î± WT protein, containing the catalytic part (AA 469-977), was expressed in insect cells. The purified protein (1.2 Î¼g/mL) was incubated with a fluorescently quenched IRE1Î± substrate (1.45 Î¼g/mL; 5â [6FAM] â GAG UCC GCA GCA CUC - [BHQ1] 3â) and a titration of inhibitor, starting at 50 Î¼M (final DMSO concentration = 1%), for 40 min at room temperature in assay buffer. Reactions were carried out in a final volume of 20 Î¼L in a 384 well PP plate (Greiner #784209). The reaction was stopped by addition of 15 Î¼L 100 mM Tris-HCl pH9 and the fluorescence intensity of the IRE1Î±-substrate was measured using a fluorescent plate reader (Ex 485 nm / Em 535 nm, Perkin Elmer Envision).",99 nM,XBP1 luciferase reporter assay (measures amount of XBP1 splicing in cells),IC50,,,
TX1-85-1,1.7,0.0,3.0,No,https://www.chemicalprobes.org/tx1-85-1,ERBB3,Protein kinase,RTK,2015-12-10,P21860,FYICDSWKKFSYOM-UHFFFAOYSA-N,C=CC(=O)Nc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1Oc1ccccc1,No,Yes,,2948442,"http://www.nature.com/nchembio/journal/v10/n12/abs/nchembio.1658.html, http://www.ncbi.nlm.nih.gov/pubmed/25326665",Covalent Inhibitor,23 nM,FRET-based LanthaScreen Eu methodology,10 uM,biotin-tagged version of the chemical probe labeled HER3 in cells,EC50,,,
JQEZ5,2.0,2.3,6.0,No,https://www.chemicalprobes.org/jqez5,EZH2,Epigenetic,Protein methyltransferase,2016-07-29,Q15910,LQTWDAYNGMMHLV-UHFFFAOYSA-N,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C)CC3)nc2)nc2c1cnn2C(C)C,No,No,CHEMBL4545488,2937942,"http://cancerdiscovery.aacrjournals.org/content/early/2016/06/16/2159-8290.CD-16-0164.long, http://www.ncbi.nlm.nih.gov/pubmed/?term=jqez5, http://www.ncbi.nlm.nih.gov/pubmed/?term=qi+j+and+sharpless",SAM competitive inhibitor,11 nM,"Radiometric Scintillation Proximity Assay (SPA), Biocore SPR (87 nM)",2.5 uM,"Antiproliferation against lung cancer cells, and western blot assessing H3K27Me3 level with compound treatment",IC50,Other,5 mg/kg or 75 mg/kg,JQEZ23
"(R,R)-59",3.3,0.0,3.0,No,https://www.chemicalprobes.org/r_r-59,SETDB1,Enzyme,methyltransferase,2021-12-20,Q15047,NBDJDKAXIGWAIM-XZOQPEGZSA-N,C=CCn1c(N[C@@H]2C[C@H](c3ccc(OCc4ccccc4)cc3)CN(C)C2)nc2cc[nH]c2c1=O,No,No,,3318350,,Inhibitor,"88 Â± 45 nM, 106 Â± 2 nM","ITC, SPR",2 Â°C,"CETSA (cellular Thermal Shift Assay) follwoed by Western blot analysis; (R,R)-59  (but not  (S,S)-59) at concentrations of >=5âÎ¼M  efficiently and dose-dependently stabilized SETDB1-TTD protein.",ÎTm,,,"(S,S)-59"
M5049,0.0,0.0,0.0,No,https://www.chemicalprobes.org/m5049,"TLR7, TLR8","Toll-Like Receptor, Toll-Like Receptor",,2022-03-19,"Q9NYK1, Q9NR97",BJXYHBKEQFQVES-NWDGAFQWSA-N,N#Cc1ccc(N2C[C@@H](C(F)(F)F)C[C@@H](N)C2)c2cccnc12,No,No,CHEMBL4802159,3319446,,Inhibitor,,,"11.1 nM, 68.3 nM, 24.1 nM, 620 nM","Inhibition in NF-ÎºB-luciferase reporter cells, AlphaLISA determination of IL-6",IC50,"Mouse, Rat, Dog",1 mg/Kg,
Glyburide,3.0,3.5,4.0,No,https://www.chemicalprobes.org/glyburide,"ABCC8, KCNJ11","Ion Channel, Ion Channel","Potassium channel, Potassium channel",2017-08-09,"Q09428, Q14654",ZNNLBTZKUZBEKO-UHFFFAOYSA-N,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,No,No,CHEMBL472,490179,"www.doi.org/10.1016/j.metabol.2012.07.010, www.doi.org/10.1016/s0026-0495(96)90297-8, www.doi.org/10.1016/0024-3205(93)90448-c, www.doi.org/10.1016/j.metabol.2012.07.010, https://www.ncbi.nlm.nih.gov/pubmed/2110566, https://www.ncbi.nlm.nih.gov/pubmed/2117388, https://www.ncbi.nlm.nih.gov/pubmed/6767639",Inhibitor,4.3 nM,Inhibition of human SUR1/Kir6.2 expressed in CHO cells. More data available in ChEMBL.,3 nM,"Stimulation of insulin secretion in rat INS-1E cells after 1 hr by alphaLISA assay in presence of 5 mM glucose (Bioorg. Med. Chem. Lett., (2014) 24:4:1031). In HIT (hamster beta cell line) cells, glyburide stimulates insulin secretion with ED50=0.4 nM.",EC50,Other,"0.4, 1, 10 mg/Kg",
AC-4-130,2.3,2.0,6.0,No,https://www.chemicalprobes.org/ac-4-130,STAT5B,Transcription factor,Signal transducer and transcription activator,2020-05-27,P51692,NMQUSJQZQWKQBL-UHFFFAOYSA-N,CC(C)(C)c1cc(CN(C(=O)CN(Cc2ccc(Cl)cc2)S(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccc(C(=O)O)cc2)cc(C(C)(C)C)c1,No,No,,3312900,"www.doi.org/10.1038/s41375-017-0005-9, www.doi.org/10.3390/cancers12041021, https://doi.org/10.1021/ml500165r, https://pubmed.ncbi.nlm.nih.gov/29472718/, https://pubmed.ncbi.nlm.nih.gov/32326377, https://pubmed.ncbi.nlm.nih.gov/25419444",SH2 Domain Specific Inhibitor,,"Thermal Shift Assay, 19F NMR",,,,Other,25 mg/Kg,
CPI-1205,3.0,2.7,6.0,No,https://www.chemicalprobes.org/cpi-1205,EZH2,Epigenetic,Protein methyltransferase,2017-07-06,Q15910,HPODOLXTMDHLLC-QGZVFWFLSA-N,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12,No,No,CHEMBL4297463,753681,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01315, https://www.ncbi.nlm.nih.gov/pubmed/27739677",SAM-competitive inhibitor,EZH2: 2 nM,Scintillation proximity assay,32 nM,"In HeLa cells, CPI-1205 inhibited H3K27me3 levels.",EC50,Other,"1 mg/kg (IV), 100 mg/kg (oral)",
KZR-504,3.7,3.3,6.0,No,https://www.chemicalprobes.org/kzr-504,PSMB9,Protein metabolism,Proteasome subunit,2017-06-21,P28065,QYDASSGXBXGRBS-CKJXQJPGSA-N,C[C@]1(C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CO)NC(=O)c2cccc(=O)[nH]2)CO1,No,Yes,CHEMBL4100295,318266,"http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00496, https://www.ncbi.nlm.nih.gov/pubmed/28435528",Covalent Inhibitor,51 nM,"In a MOLT-4 (human T cell leukemia) cellular lysate, a proteasome constitutive/immunoproteasome subunit ELISA (ProCISE) was employed for quantitative assessment of subunit-specific activity.",136 nM,"Utilizing MOLT-4 (human T cell leukemia) whole (live) cells, a proteasome constitutive/immunoproteasome subunit enzyme-linked immunosorbent (ProCISE) ELISA assay was employed for quantitative assessment of subunit-specific activity.",IC50,Other,1 mg/kg and 30 mg/kg,
Repaglinide,2.5,3.0,4.0,No,https://www.chemicalprobes.org/repaglinide,"ABCC8, KCNJ11","Ion Channel, Ion Channel","Potassium channel, Potassium channel",2017-08-09,"Q09428, Q14654",FAEKWTJYAYMJKF-QHCPKHFHSA-N,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,No,No,CHEMBL1272,494113,"https://doi.org/10.2337/diabetes.51.9.2789, https://doi.org/10.1016/j.bmcl.2004.07.059, https://doi.org/10.2337/diabetes.47.3.345, https://www.ncbi.nlm.nih.gov/pubmed/12196472, https://www.ncbi.nlm.nih.gov/pubmed/15380228, https://www.ncbi.nlm.nih.gov/pubmed/9519738",Inhibitor,106 nM,In vitro assays with membranes from COS-1 cells expressing SUR-1. A KD of 50 nM was derived from the IC50 value. These data have been replicated in comparable experiments with HEK293 extracts (KD=0.4 nM) and BetaTC3 cells (KD=6.4 nM) using [3H]-labeled repaglinide.,800 nM,"In HEK293 cells, repaglinide inhibited Kir6.2/SUR-1 currents in patch-clamp assay. In islets isolated from Wistar rats, Repaglinide induced insulin release (2.1 ng/islet/hour) at 5 mM glucose.",IC50,Rat,1 mg/kg,
BAY-6672,4.0,4.0,2.0,No,https://www.chemicalprobes.org/bay-6672,PTGFR,GPCR,Prostaglandin F Receptor,2021-03-01,P43088,YQOLEILXOBUDMU-KRWDZBQOSA-N,Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl,No,No,CHEMBL4643852,3312899,"www.doi.org/10.1021/acs.jmedchem.0c00834, https://pubmed.ncbi.nlm.nih.gov/32969660/",Antagonist,"22 nM, 16 nM",Panlabs binding assay,"11 nM, 12-18 nM, 52 nM","hFP-R cell-based assay, functional cell-based assays, cytokine production (KC / MCP-1) in 3T3 fibroblasts, functional tissue contraction assay, rat",IC50,Other,3-30 mg/Kg,BAY-403
ABD957,0.0,0.0,0.0,No,https://www.chemicalprobes.org/abd957,ABHD17B,Other post-translational modification,Depalmitoylase,2021-06-10,Q5VST6,ISNXAOFEMNFJCO-YUXAGFNASA-N,C[C@H]1CN(Cc2ccc(C(F)(F)F)cc2N2[C@H]3CC[C@@H]2CN(CC(=O)O)C3)CCN1C(=O)n1ccc(S(=O)(=O)N(C)C)n1,No,No,,3313084,"www.doi.org/10.1038/s41589-021-00785-8, https://pubmed.ncbi.nlm.nih.gov/33927411/",Covalent Inhibitor,210 nM ABHD17B,Gel-based activity-based protein profiling assay,29 nM,Dynamic palmitoylation assay,EC50,,,"ABD298, JJH254"
MT1,4.0,4.0,6.0,No,https://www.chemicalprobes.org/mt1,"BRD2, BRD4, BRD3, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain , Bromodomain , Bromodomain , Bromodomain ",2016-11-04,"P25440, O60885, Q15059, Q58F21",JNSLBXJNVHYNNW-CXNSMIOJSA-N,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCOCCOCCOCCOCCOCCOCCOCCNC(=O)C[C@@H]1N=C(c3ccc(Cl)cc3)c3c(sc(C)c3C)-n3c(C)nnc31)c1nnc(C)n1-2,No,No,,2960689,"http://www.nature.com/nchembio/journal/vaop/ncurrent/full/nchembio.2209.html, https://www.ncbi.nlm.nih.gov/pubmed/?term=27775715",Bivalent inhibitor,"16.7 nM, 3.09 nM, 1.32 nM","ITC, AlphaScreen","0.170 nM, 0.792 nM",ATPlite cellular viability assay,IC50,Mouse,50 mg/kg,
Englerin-A,2.0,1.0,4.0,No,https://www.chemicalprobes.org/englerin,"TRPC4, TRPC5","Ion Channel, Ion Channel","Transient receptor potential channels, Transient receptor potential channels",2017-01-31,"Q9UBN4, Q9UL62",GACOFEKSDCOVMV-RRYXBOBMSA-N,CC(C)[C@@]12C[C@@H](OC(=O)CO)[C@@](C)(O1)[C@@H]1CC[C@@H](C)[C@H]1[C@@H]2OC(=O)/C=C/c1ccccc1,No,Yes,CHEMBL2024567,453310,"http://onlinelibrary.wiley.com/doi/10.1002/anie.201411511/abstract, http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0127498, http://www.jbc.org/content/early/2016/11/14/jbc.M116.755678.long, https://www.ncbi.nlm.nih.gov/pubmed/25707820, https://www.ncbi.nlm.nih.gov/pubmed/26098886, https://www.ncbi.nlm.nih.gov/pubmed/27875305",Agonist,,,"11.2 nM, 7.6 nM","Measurements of the free intracellular calcium ion concentrations using the Fura-2-AM at an extracellular Ca2+ concentration of 1.5 mM in HEK293 cells conditionally expressing human TRPC4 or TRPC5. In A498 cells, which only express TRPC4, EC50=10 nM, and this activity was sensitive to the TRPC4 inhibitor, ML204.",EC 50,,,(+)-englerin A
BIIE0246,4.0,4.0,2.0,No,https://www.chemicalprobes.org/biie0246,NPY2R,GPCR,Neuropeptide Y receptor Y2,2021-03-12,P49146,RSJAXPUYVJKAAA-JPGJPTAESA-N,N=C(N)NCCC[C@H](NC(=O)CC1(CC(=O)N2CCN(C3c4ccccc4NC(=O)c4ccccc43)CC2)CCCC1)C(=O)NCCn1c(=O)n(-c2ccccc2)n(-c2ccccc2)c1=O,No,No,CHEMBL540989,999076,"www.doi.org/10.1038/sj.bjp.0703162, www.doi.org/10.1016/s0014-2999(99)00650-0, https://pubmed.ncbi.nlm.nih.gov/10725255/, https://pubmed.ncbi.nlm.nih.gov/10611450/",Antagonist,,,3.3 nM,Radioligand binding Assay,IC50,Other,3 mg/Kg,BIIE0212
WEHI-539,3.5,1.0,3.0,No,https://www.chemicalprobes.org/wehi-539,BCL2L1,Other,Apoptosis regulator,2017-06-22,Q07817,JKMWZKPAXZBYEH-JWHWKPFMSA-N,NCc1ccc(OCCCc2sc(-c3ccc4c(c3)/C(=N/Nc3nc5ccccc5s3)CCC4)nc2C(=O)O)cc1,No,Yes,CHEMBL3342187,841272,"https://www.nature.com/nchembio/journal/v9/n6/full/nchembio.1246.html, https://www.ncbi.nlm.nih.gov/pubmed/23603658",BH3 mimetic,1.4 nM,Direct binding assay by SPR,,"In mouse embryonic fibroblasts (MEFs), WEHI-539 induces apoptosis only in cells where MCL-1 is absent and not in cells where other BCL protein family members are absent. Restoration of MCL-1 expression renders MEFs resistant to WEHI-539. WEHI-539-induced apoptosis is dependent upon BAK but not BAX. In mouse and human platelets, WEHI-539 induces apoptosis.",,,,
GSK4027,3.8,2.3,8.0,No,https://www.chemicalprobes.org/gsk4027,"KAT2B, KAT2A","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2017-03-13,"Q92831, Q92830",VZAFGXCWAWRULT-UONOGXRCSA-N,CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccccc2)C1,No,No,CHEMBL4069412,1478189,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01566, https://www.ncbi.nlm.nih.gov/pubmed/28002667",Antagonist,"1.25 nM, 40 nM, 63 nM","BROMOscan, TR-FRET binding competition assay using truncated PCAF bromodomain and a fluorescently tagged bromodomain ligand., NanoBRET",60 nM,"NanoBRET assay, measuring displacement of NanoLuc-tagged full length PCAF from Halo-tagged histone H3.3 in HEK293 cells (Promega).",IC 50,,,GSK4028
FM-381,4.0,0.0,3.0,No,https://www.chemicalprobes.org/fm-381,JAK3,Kinase,TK,2017-04-24,P52333,GJMZWYLOARVASY-NTCAYCPXSA-N,CN(C)C(=O)/C(C#N)=C/c1ccc(-c2nc3cnc4[nH]ccc4c3n2C2CCCCC2)o1,Yes,Yes,CHEMBL4564280,2879306,"http://www.cell.com/cell-chemical-biology/abstract/S2451-9456(16)30386-5, https://www.ncbi.nlm.nih.gov/pubmed/27840070",Covalent Inhibitor,0.154 nM,Radiometric assay,100 nM,BRET assay in HeLa cells. FM-381 also inhibited IL-12-stimulated phosphorylation of STAT5 in human CD4+ T cells at 100 nM.,EC50,,,FM-479
AT1,4.0,2.0,4.0,No,https://www.chemicalprobes.org/at1,BRD4,Epigenetic,Bromodomain,2020-03-05,O60885,SQNZDYHMCMIGGV-TZPPCSJFSA-N,CC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(-c2scnc2C)cc1)C(C)(C)SCCCCCCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2c(sc(C)c2C)-n2c(C)nnc21,No,No,CHEMBL4455124,2960266,"http://dx.doi.org/10.1038/nchembio.2329, http://europepmc.org/abstract/MED/28288108",Degrader (PROTAC),"75 nM BD1, 45 nM BD2",Isothermal Titration Calorimetry ITC,100 nM,"Western blot  DC50 refers to the half-maximal degradation concentration.
AT2 (butyl), AT3 (PEG2), AT4 (poly-propyleneglycol-2), AT5 (mixed PEG-alkyl chain linker) and AT6 (PEG3) were all evaluated for their selectivity of intracellular degradation against BRD4 vs BRD2 vs BRD3.
AT1 has a linear hexyl chain linker",DC50,,,cis-AT1
VT103,3.0,3.0,6.0,No,https://www.chemicalprobes.org/vt103,TEAD1,Transcription factor,TEA domain,2021-05-26,P28347,LLCVDQHLYHBAHR-UHFFFAOYSA-N,CNS(=O)(=O)c1ccc(Nc2ccc(C(F)(F)F)cc2)c(-c2cn(C)cn2)c1,No,No,,3313087,"www.doi.org/10.1158/1535-7163.MCT-20-0717, https://pubmed.ncbi.nlm.nih.gov/33850002/",Inhibitor,8.3,Thermal Shift Assays (TSA),"1.02 Â± 0.09 nM, 1-21 nM","YAP reporter assay, Cell Proliferation assay","IC50, GI50",Mouse,10 mg/Kg,VT106
BATEFENTEROL,0.0,0.0,0.0,No,https://www.chemicalprobes.org/batefenterol,"CHRM2, CHRM3, ADRB2","GPCR, GPCR, GPCR","Muscarinic Receptor, Muscarinic Receptor, Adrenoceptor",2022-05-18,"P08172, P20309, P07550",URWYQGVSPQJGGB-DHUJRADRSA-N,COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,No,No,CHEMBL3039518,964366,,Antagonist,"1.4 nM, 1.3 nM, 3.7 nM",competition radioligand binding studies at human recombinant receptors,0.29 nM,Inhibition of oxotremorine-induced calcium mobilization in FLIPR,EC50,Rat,0.25 mg/Kg,
NVP-CRL-457,0.0,0.0,0.0,No,https://www.chemicalprobes.org/nvp-crl457,"PIK3CA, PIK3CB, PIK3CG","Kinase, Kinase, Kinase","PI3/PI4, PI3/PI4, PI3/PI4",2022-06-08,"P42336, P42338, P48736",WCPXAGKUVIPMIY-TZQLILQPSA-N,C[C@H]1OC(=O)C(c2cc(-c3cnc(N)nc3C(F)(F)F)nc(N3CCOCC3)n2)[C@H]1CO,No,No,,3622969,,Inhibitor,"12 nM, 8.3 nM",Biochemical PI3K assay,"42 nM, 65 nM, 26 nM",Cellular PI3K Assays in RAT1 Cells,IC50,"Mouse, Dog, Rat","3 mg/Kg IV, 10 mg/Kg PO, 0.1 mg/Kg IV, 0.3 mg/Kg PO, 1 mg/Kg IV, 3 mg/Kg PO",cpd 16
MK-4256,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mk-4256,SSTR3,GPCR,Somatostatin Receptor,2022-06-13,P32745,NTIFDLOQPKMIJK-AJTFRIOCSA-N,Cc1nc([C@]2(c3cnn(C)c3)N[C@@H](c3nc(-c4ccc(F)cc4)c[nH]3)Cc3c2[nH]c2ccccc32)no1,No,No,CHEMBL2204935,735548,,Antagonist,,,"0.66 nM, 0.95 nM, 83%","In Vitro SSTR assay in CHO transfected cells, functional cAMP antagonism assay, functional cAMP antagonism","IC50, % in","Mouse, Rat, Dog, Monkey (Rheus)","4 mg/Kg IV, 10 mg/Kg PO, 1 mg/Kg IV, 2 mg/Kg PO",
JJKK-048,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jjkk-048,MGLL,Enzyme,Lipase,2022-06-13,Q99685,CLSNATLUIXZPMV-UHFFFAOYSA-N,O=C(N1CCC(C(c2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)CC1)n1cncn1,No,No,CHEMBL3087181,462663,,Inhibitor,0.363 nM,"In competitive ABPP, JJKK-048 prevented TAMRA-fluorophosphonate (FP) labeling of the MAGL active site serine (S122).",~60%,Inhibitory activity of JJKK-048 in intact HEK293 cells transiently overexpressing human MAGL (hMAGL) 1h experiment.,Inhibition,Mouse,0.5-2 mg/Kg,
TH65,2.0,0.0,1.0,No,https://www.chemicalprobes.org/th65,HDAC10,Epigenetic,Histone Deacetylase,2022-06-08,Q969S8,MRHRACKJKBOJEI-UHFFFAOYSA-N,COc1ccc(C(=O)NO)cc1NC(=O)c1ccc(-c2ccccc2)cc1,No,Yes,CHEMBL3800394,1875008,,Inhibitor,"630 nM, 1250 nM","chemical proteomics, FRET",250 nM,"In-cell target engagement of TH65 by NanoBRET assays for HDAC10 and HDAC6 catalytic domainâ2. In this assay, the affinity of TH65 for HDAC10 was about 5-fold higher than that for HDAC6",EC50,,,
BAY-386,4.0,0.0,1.0,No,https://www.chemicalprobes.org/bay-386,F2R,GPCR,Trombin Receptor,2022-06-08,P25116,RNQODBQYMXYMCT-SJORKVTESA-N,O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1,No,No,CHEMBL4630644,3323196,,Antagonist,56 nM,Binding assay (platelet membranes),10 nM,Functional cellular assay (HEK-cells),IC50,Other,,BAY-448
TP-030-1,2.0,0.0,1.0,No,https://www.chemicalprobes.org/tp-030-1,RIPK1,Kinase,TKL,2022-06-08,Q13546,MAHFVAHPQSLLJF-IBGZPJMESA-N,CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21,No,No,CHEMBL4088216,316666,,Inhibitor,3.9 nM,Human RIPK1 in cell free assay,18 nM,HT29 necroptosis,IC50,,,TP-030n
APY0201,0.0,0.0,0.0,No,https://www.chemicalprobes.org/apy0201,PIKFYVE,Kinase,Serine Kinase,2022-06-16,Q9Y2I7,RFZQYGBLRIKROZ-PCLIKHOPSA-N,Cc1cccc(/C=N/Nc2cc(N3CCOCC3)n3nc(-c4ccncc4)cc3n2)c1,No,Yes,CHEMBL4303292,327159,,Inhibitor,5.4 nM,Cell-free functional assay of full-length PIKfyve kinase,"8.4 nM, 99 nM, 16 nM","Inhibition of IL-12p70 production, Inhibition of IL-12p40 production",IC50,Mouse,"3 mg/Kg, 10 mg/Kg, 30 mg/Kg",cpd 6
CCT251455,0.0,0.0,0.0,No,https://www.chemicalprobes.org/cct251455,TTK,Kinase,Ser/Thr Kinase,2022-06-15,P33981,BXKNUXDLZJPPBO-UHFFFAOYSA-N,Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1,No,No,CHEMBL3109945,723380,,Inhibitor,3 nM,Biochemical Assay,"43 nM, 160 nM","P-MPS1, Cell proliferation assay","IC50, GI50","Mouse, Rat",5 mg/Kg,
LENIOLISIB,4.0,3.0,2.0,No,https://www.chemicalprobes.org/leniolisib,PIK3CD,Kinase,PI3/PI4,2022-02-21,O00329,MWKYMZXCGYXLPL-ZDUSSCGKSA-N,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,No,No,CHEMBL3643413,473672,,Inhibitor,11 nM,Biochemical assay,56 nM,Inhibition of pAkt formation in Rat-1 cells,IC50,"Rat, Dog, Monkey (Cynomolgus)","1 mg/Kg, 3 mg/Kg, 30 mg/Kg, 0.1 mg/Kg, 0.3 mg/Kg",
JNJ-42396302,2.5,2.5,4.0,No,https://www.chemicalprobes.org/jnj-42396302,PDE10A,Enzyme,Phosphodiesterase,2022-06-08,Q9Y233,BPLVDYJDAVYLRQ-UHFFFAOYSA-N,COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1,No,No,CHEMBL2180408,1750473,,Inhibitor,"13 nM, 40 nM, 51 nM","SPA using human PDE10A and [3H]cAMP substrate, Inhibition of cAMP hydrolysis by isolated hPDE10A enzyme, Inhibition of cGMP hydrolysis by isolated hPDE10A enzyme",2.3 fold increase @ 1uM,Concentration-dependent increase in luciferase activity in PDE10A CRE-Luc transfected HEK293 cells: 2.3 fold increase at 1 Î¼M; 10 fold increase at 10 Î¼M; In wild type HEK293 cells no increase in luciferase activity was measured at these concentrations.,Activity,Rat,10 mg/Kg,JNJ-40573663
VinSpinIn,3.0,0.0,1.0,No,https://www.chemicalprobes.org/vinspinin,SPIN1,Transcription factor,Chromatin Regulator,2020-12-17,Q9Y657,XPEJZXWPKDAYFX-UHFFFAOYSA-N,CC1(C)C(N)=Nc2cc(OCCCN3Cc4ccc(OCCc5cn(CC(=O)N6CCC(CCN7CCCC7)CC6)nn5)cc4C3)c(OCC3CC3)cc21,No,No,CHEMBL4451634,2958551,"www.doi.org/10.1021/acs.jmedchem.9b00562, https://pubmed.ncbi.nlm.nih.gov/31550156/",Inhibitor,9.9 nM. (Kd); 33 nM (IC50),"AlphaScreen, SYPRO Orange thermal shift assay, ITC",270 nM,NanoBRET cellular target engagement assay,EC50,,,VinSpinInC
Tofacitinib,3.7,3.5,5.0,No,https://www.chemicalprobes.org/tofacitinib,"JAK1, JAK2, JAK3","Kinase, Kinase, Kinase","TK, TK, TK",2015-12-10,"P23458, O60674, P52333",UJLAWZDWDVHWOW-YPMHNXCESA-N,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,Yes,No,CHEMBL221959,1423145,"www.doi.org/10.1126/science.1087061, http://www.ncbi.nlm.nih.gov/pubmed/14593182",Inhibitor,"112 nM, 20 nM, 1 nM","Kinase assay, Kinase Assay, Kinase Asssay","11 nM, 324 nM","IL-2-induced JAK3 phosphorylation (IC90 160 nM), GM-CSF induced phosphorylation",IC50,,,
BAY1217389,3.0,3.0,4.0,No,https://www.chemicalprobes.org/bay1217389,TTK,Kinase,Ser/Thr Kinase,2021-02-05,P33981,WNEILUNVMHVMPH-UHFFFAOYSA-N,COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F,No,No,CHEMBL4456085,2937790,"www.doi.org/10.1158/1535-7163.MCT-15-0500, www.doi.org/10.1021/acs.jmedchem.9b02035, https://pubmed.ncbi.nlm.nih.gov/26832791/, https://pubmed.ncbi.nlm.nih.gov/32338514/",Inhibitor,0.7 nM  (10 uM ATP); 1 nM  (2 mM ATP),HTRF-based MPS1 assay with an ATP concentration of 2 mM,0.25 nM (S); 7.6 nM (H); 12 nM (K),"(S) SAC assay: inhibition of the spindle assembly checkpoint was assessed in a high content assay by p-histone H3 staining.  
(H) Inhibition Cell Proliferation Assay.  
(K) KNL1 Thr-875 phosphorylation assay.",IC50,Other,"0.5, 1, 2, 4, 8 mg/Kg",
MPS1-IN-1,2.7,2.0,4.0,No,https://www.chemicalprobes.org/mps1-in-1,TTK,Kinase,Ser/Thr Kinase,2015-12-10,P33981,NMJMRSQTDLRCRQ-UHFFFAOYSA-N,COc1cc(N2CCC(O)CC2)ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1,No,No,CHEMBL1235786,769427,"http://www.nature.com/nchembio/journal/v6/n5/full/nchembio.345.html, http://www.ncbi.nlm.nih.gov/pubmed/20383151",Inhibitor,27 nM,"Ambit KinomeScan 
In vitro kinase assay IC50 = 367 nM",650 nM,Phosphorylation of protein substrate,IC50,,,
Empesertib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/empesertib,TTK,Kinase,Ser/Thr Kinase,2021-02-05,P33981,NRJKIOCCERLIDG-GOSISDBHSA-N,COc1cc(S(C)(=O)=O)ccc1Nc1nc2ccc(-c3ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc3)cn2n1,No,No,CHEMBL4303241,813139,"www.doi.org/10.1158/1535-7163.MCT-15-0500, www.doi.org/10.1021/acs.jmedchem.9b02035, https://pubmed.ncbi.nlm.nih.gov/26832791/, https://pubmed.ncbi.nlm.nih.gov/32338514/",Inhibitor,1.7 nM,HTRF-based MPS1 assay with an ATP concentration of 2 mM,"53 nM, 260 nM","SAC assay: inhibition of the spindle assembly checkpoint was assessed in a high content assay by p-histone H3 staining., Inhibition Cell Proliferation Assay",IC50,Other,"0.5, 1, 2 mg/Kg",
XMD8-92,1.7,3.0,4.0,No,https://www.chemicalprobes.org/xmd8-92,MAPK7,Protein kinase,CMGC,2015-12-10,Q13164,QAPAJIZPZGWAND-UHFFFAOYSA-N,CCOc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,Yes,No,CHEMBL1673046,641963,"www.doi.org/10.1016/j.ccr.2010.08.008, http://www.ncbi.nlm.nih.gov/pubmed/20832753",ATP-competitive inhibitor,80 nM,ATP-binding displacement assay,1.5 uM,Kinativ assay,IC50,Other,2 mg/kg,
GSK8814,3.0,0.0,1.0,No,https://www.chemicalprobes.org/gsk8814,"ATAD2, ATAD2B","Epigenetic, Epigenetic","ATPase, ATPase",2021-03-28,"Q6PL18, Q9ULI0",YDPMMWAOCCOULO-JBRSBNLGSA-N,CO[C@H]1CNC[C@@H](OCC2CCC(F)(F)CC2)[C@@H]1Nc1ncc(-c2cncc(C)c2)c2cc(C)c(=O)[nH]c12,No,No,CHEMBL4206758,790313,,Inhibitor,"7.94 nM, 1.25 nM, 50.1 nM, 20 nM ATAD2B","ITC, BROMOscan, TR-FRET",2 uM,NanoBRET,IC 50,,,
ICI-199441,3.0,2.7,6.0,No,https://www.chemicalprobes.org/ici-199441,OPRK1,GPCR,Opioid receptors,2017-08-09,P41145,AEJOEPSMZCEYJN-HXUWFJFHSA-N,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1,No,No,CHEMBL38576,1689202,"www.doi.org/10.1016/0014-2999(88)90546-8, http://www.sciencedirect.com/science/article/pii/S0960894X05003057, http://www.sciencedirect.com/science/article/pii/S0960894X07014266, https://www.ncbi.nlm.nih.gov/pubmed/2850924, https://www.ncbi.nlm.nih.gov/pubmed/8893842, https://www.ncbi.nlm.nih.gov/pubmed/11086731",Agonist,0.04 nM,"[3H]-diprenorphine radioligand inhibitory binding assay [Bioorg. Med. Chem. Lett., (2005) 15:10:2647]. These numbers have been confirmed in multiple publications; additional assays and data are available in CHEMBL.",0.3 nM,"Agonist activity at human kappa opioid receptor transfected in CHO cells by [35S]GTP-gamma-S binding assay (Bioorg. Med. Chem. Lett., (2008) 18:12:3667). There are additional assay results in ChEMBL.",EC50,Other,10 mg/kg,
SB-612111,3.7,3.7,6.0,No,https://www.chemicalprobes.org/sb-612111,OPRL1,GPCR,Opioid receptor,2020-10-23,P41146,OHRDCQFCAWLDBP-SBUREZEXSA-N,Cc1cccc2c1CC[C@H](CN1CCC(c3c(Cl)cccc3Cl)CC1)C[C@@H]2O,No,No,CHEMBL559569,1912797,"www.doi.org/10.1124/jpet.103.055848, www.doi.org/10.1124/jpet.106.116764, www.doi.org/10.1124/jpet.106.116780, https://pubmed.ncbi.nlm.nih.gov/14593080/, https://pubmed.ncbi.nlm.nih.gov/17329552/, https://pubmed.ncbi.nlm.nih.gov/17329551/",NOP antagonist,0.33 Â± 0.03 nM,Competitive radioligand binding assays using membranes prepared from clonal cell lines,10.32 Â± 0.14,Antagonism of inhibition by nociceptin of forskolin-stimulated cAMP formation in whole CHOhNOP cells. CRE-luciferase-gene reporter assay.,pEC50,Other,1-10 mg/Kg,
CPI-637,2.3,0.0,3.0,No,https://www.chemicalprobes.org/cpi-637,"EP300, CREBBP","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2017-04-25,"Q09472, Q92793",BFTKDWYIRJGJCA-CYBMUJFWSA-N,C[C@@H]1CC(=O)Nc2cccc(-c3ccc4c(c3)c(-c3cnn(C)c3)nn4C)c2N1,No,No,CHEMBL3814752,220825,"http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00075, https://www.ncbi.nlm.nih.gov/pubmed/?term=27190605",Antagonist,"51 nM, 30 nM","TR-FRET assay, Isothermal calorimetry assay","300 nM, 600 nM","NanoBRET assay (Promega) in transfected HEK293 cells, MYC expression inhibition",EC 50,,,"enant-CPI-637: S)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one"
DS-1971a,3.7,3.0,6.0,No,https://www.chemicalprobes.org/ds-1971a,SCN9A,Ion Channel,Sodium Voltage-Gated Channel,2021-01-29,Q15858,OJKONCJPCULNOW-DYVFJYSZSA-N,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,No,No,CHEMBL4633566,2872291,"www.doi.org/10.1021/acs.jmedchem.0c00259, https://pubmed.ncbi.nlm.nih.gov/32392056/",Inhibitor,,,24.5 nM Human; 26.5 nM Mouse,"high-throughput electrophysiology system (IonWorks Quattro), whole-cell manual patch clamp method",IC50,Other,"1, 3, 10, 100 mg/Kg",
PI-3065,3.0,2.5,4.0,No,https://www.chemicalprobes.org/pi-3065,PIK3CD,Lipid kinase,Class I,2020-12-17,O00329,YDNOHCOYQVZOMC-UHFFFAOYSA-N,Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN(CC4CC4)CC3)cc2n1,No,No,CHEMBL4450504,3145795,"www.doi.org/10.1038/nature13444, https://pubmed.ncbi.nlm.nih.gov/24919154/",Inhibitor,1.5 nM; 15 nM,Enzymatic Activity,"36, 38 nM","anti-IgM Stimulation followed by FACS for CD69, Cell Proliferation Assay",IC50,Other,75 mg/Kg,
RU.521,2.5,0.0,2.0,No,https://www.chemicalprobes.org/ru521,CGAS,Other,cyclic GMP-AMP synthase,2020-11-05,Q8N884,VIQXILLOJLATEF-UHFFFAOYSA-N,Cc1nn(-c2nc3ccc(Cl)c(Cl)c3[nH]2)c(O)c1C1OC(=O)c2ccccc21,No,No,CHEMBL4567157,3186334,"www.doi.org/10.1038/s41467-017-00833-9, https://pubmed.ncbi.nlm.nih.gov/28963528/",Allosteric Inhibitor,"36.2 nM (KD), 110 nM (IC50)","ITC (KD), consumption of ATP and GTP, and the generation of cGAMP using an RF-MS",700 nM,Small-molecule inhibition of cGAS-dependent interferon induction by double-strand DNA in cellular luciferase reporter assay,IC50,,,
A-1210477,2.7,1.5,5.0,No,https://www.chemicalprobes.org/1210477,MCL1,Other,BCL2 family,2017-04-04,Q07820,XMVAWGSQPHFXKU-UHFFFAOYSA-N,Cc1nn(C)c(COc2ccc(N3CCN(S(=O)(=O)N(C)C)CC3)cc2)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)n(CCN3CCOCC3)c12,Yes,No,CHEMBL3417704,990301,"http://www.nature.com/cddis/journal/v6/n1/full/cddis2014561a.html, https://www.ncbi.nlm.nih.gov/pubmed/25590800",BH3 mimetic,0.454 nM,Time-resolved Flourescence resonance energy transfer (TR-FRET) binding assay,,"In H29 cells, A-1210477 competed with BIM for MCL1 binding in co-IP assays (tested at 10 uM) and increased MCL1 protein but not RNA expression. In a coupled co-IP-ELISA assay, A-1210477 dose-dependently decreased BIM co-IP with and IC50 in the low uM range and disrupted NOXA-MCL1 interaction in a mammalian yeast two hybrid assay (IC50 ~1 uM). In cellular fluorescence localization assays, A-1210477 redistributed BIM labeled with mCherry from the mitochondria to the cytosol.  In MCL1-dependent cells (H929 cells), A-1210477 induced apoptosis (IC50 <10 uM).",,,,
BAY-299,2.3,1.0,6.0,No,https://www.chemicalprobes.org/bay-299,"BRD1, TAF1, TAF1L","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2017-05-11,"O95696, P21675, Q8IZX4",OFWWWKWUCDUISA-UHFFFAOYSA-N,Cc1cc2c(cc1N1C(=O)c3cccc4c(CCCO)ccc(c34)C1=O)n(C)c(=O)n2C,No,No,CHEMBL4086276,484030,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b00306, https://www.ncbi.nlm.nih.gov/pubmed/28402630",Antagonist,"67 nM, 8 nM (BD2), 106 nM (BD2)",Time-resolved fluorescence resonance energy transfer (TR-FRET) assay,"575 nM H4, 825 nM H3.3, 970 nM H4, 1,400 nM H3.3",NanoBRET assay in HCT116 cells,IC 50,Rat,,BAY-364
T-26c,3.0,2.0,4.0,No,https://www.chemicalprobes.org/t-26c,MMP13,Protein metabolism,Metallopeptidase,2017-08-09,P45452,CDQRIIUMNLMHRH-UHFFFAOYSA-N,COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1,No,No,CHEMBL3337894,563683,http://www.ncbi.nlm.nih.gov/pubmed/25192810,Inhibitor,0.0069 nM,Inhibition of the human MMP13 catalytic domain,,"In nasal septum cartilage explants (bovine), T-26c inhibited cytokine-induced collagen degradation by MMPs (87.4% inhibition at 0.1 uM).",,Other,10 mg/kg (oral); 1 mg/kg (IV),"T-26f (5-((benzyl(methyl)amino)methyl)-N-(3-methoxybenzyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-2-carboxamide)"
GSK2334470,4.0,2.7,6.0,No,https://www.chemicalprobes.org/gsk2334470,PDPK1,Protein kinase,AGC,2015-12-10,O15530,QLPHOXTXAKOFMU-WBVHZDCISA-N,CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1,No,No,CHEMBL1765740,590098,"www.doi.org/10.1021/jm101527u, http://www.ncbi.nlm.nih.gov/pubmed/21341675",Type I Inhibitor,2.5 nM,,113 nM,Inhibition of phosphorylation of a protein substrate in PC3 cells,IC50,Other,100 mg/kg,
PDD00017273,3.3,1.0,4.0,No,https://www.chemicalprobes.org/pdd00017273,PARG,DNA replication & repair enzyme,Glycohydrolase,2016-10-18,Q86W56,IFWUBRBMMNTBRZ-UHFFFAOYSA-N,Cc1cc(Cn2c(=O)n(Cc3cnc(C)s3)c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc32)n(C)n1,No,No,CHEMBL4286938,671949,"http://pubs.acs.org/doi/abs/10.1021/acschembio.6b00609, https://www.ncbi.nlm.nih.gov/pubmed/27689388",PolyADP ribose (PAR) competitive inhibitor,26 nM,Biochemical PAR chain persistence assay,37 nM,Whole-cell PAR chain-persistence assay in HeLa cells after MMS challenge.,IC50,,,N-Methyl-PDD00017273
AM-1638,2.5,3.0,3.0,No,https://www.chemicalprobes.org/am-1638,FFAR1,GPCR,Free fatty acid receptor,2021-01-21,O14842,CHEANNSDVJOIBS-MHZLTWQESA-N,COc1ccc(F)c(-c2ccc(COc3cccc([C@@H](CC(=O)O)C4CC4)c3)cc2C2=CCCC2(C)C)c1,No,No,CHEMBL2152070,774862,"www.doi.org/10.1021/ml300133f, www.doi.org/10.1371/journal.pone.0046300, https://pubmed.ncbi.nlm.nih.gov/24900539/, https://pubmed.ncbi.nlm.nih.gov/23056280/",Full Agonist,,,160 nM; 710 nM in 100% human serum; 100 %,Aequorin Ca2+-flux assay,"EC50, Emax",Other,"1 mg/kg, iv; 5 mg/kg, po (M), 0.5 mg/kg, iv; 2 mg/kg, po (R), 0.5 mg/kg, iv; 2 mg/kg, po (C), up to 100 mg/Kg po",
BMX-IN-1,3.0,0.0,3.0,No,https://www.chemicalprobes.org/bmx-in-1,BMX,Protein kinase,TK,2015-12-10,P51813,SFMJNHNUOVADRW-UHFFFAOYSA-N,C=CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-c5ccc(NS(C)(=O)=O)cc5)cc4c32)ccc1C,No,Yes,CHEMBL4091991,787801,"http://pubs.acs.org/doi/abs/10.1021/cb4000629, http://www.ncbi.nlm.nih.gov/pubmed/23594111",covalent inhibitor,8 nM,Invitrogen SelectScreen Technology,25 nM,Inhibits the autophosphorylation of BIX.,IC50,,,
DDR1-IN-1,2.7,2.0,4.0,No,https://www.chemicalprobes.org/ddr1-in-1,DDR1,Protein kinase,TK,2015-12-10,Q08345,AOZPVMOOEJAZGK-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(Oc4ccc5c(c4)CC(=O)N5)c3)cc2C(F)(F)F)CC1,No,No,CHEMBL3421914,829470,"http://pubs.acs.org/doi/abs/10.1021/cb400430t, http://www.ncbi.nlm.nih.gov/pubmed/23899692",Inhibitor,105 nM,Lanthascreen,86 nM,Collagen-dependent autophosphorylation in U2OS cells,EC50,,,
A-1155463,3.0,2.7,6.0,No,https://www.chemicalprobes.org/1155463,BCL2L1,Other,Apoptosis regulator,2017-04-04,Q07817,SOYCFODXNRVBTI-UHFFFAOYSA-N,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1,No,No,CHEMBL3342332,922883,"http://pubs.acs.org/doi/abs/10.1021/ml5001867, https://www.ncbi.nlm.nih.gov/pubmed/25313317",BH3 mimetic,<0.01 nM,"Time-resolved, flourecence resonance energy transfer (TR-FRET) assays",8 nm,"In Mcl1-/- mouse embryonic fibroblasts, A-1155463 inhibited cell proliferation. In H146 cells, A-1155463 inhibited BCLXL-dependent proliferation (EC50=65 nM).",EC50,Other,5 mg/kg,
UNC3866,2.7,0.0,3.0,No,https://www.chemicalprobes.org/unc3866,"CBX7, CBX4","Epigenetic, Epigenetic","Methyl-lysine reader, Methyl-lysine reader",2016-09-09,"O95931, O00257",UMRRDXVUROEIKJ-JCXBGQGISA-N,CCN(CC)CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc(C(C)(C)C)cc1)C(=O)N[C@@H](CO)C(=O)OC,No,No,CHEMBL3939958,979628,"http://www.nature.com/nchembio/journal/v12/n3/full/nchembio.2007.html, http://www.ncbi.nlm.nih.gov/pubmed/26807715",Antagonist,"97 nM, 94 nM",Isothermal titration calorimetry (ITC),7.6 uM,"Consistent with inhibition of PRC1 chromodomains (Bernard, D. et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a//Arf locus. Oncogene 24, 5543-51 (2005)), UNC3866 inhibits PC3-cell proliferation in a dose-dependent manner and induces senescence after exposure for 6 days while a negative control, UNC4219, has no affect.",IC 50,,,UNC4219
UNC2025,3.0,3.0,6.0,No,https://www.chemicalprobes.org/unc2025,"FLT3, MERTK","Kinase, Kinase","TK, TK",2017-04-06,"P36888, Q12866",MJSHVHLADKXCML-RQNOJGIXSA-N,CCCCNc1ncc2c(-c3ccc(CN4CCN(C)CC4)cc3)cn([C@H]3CC[C@H](O)CC3)c2n1,No,No,CHEMBL3326006,617626,"http://pubs.acs.org/doi/abs/10.1021/jm500749d, https://www.ncbi.nlm.nih.gov/pubmed/?term=25068800",ATP-competitive inhibitor,"0.8 nM, 0.74 nM",Microcapillary assay (Carna Biosciences),"14 nM, 2.7 nM","In Molm-14 cells, UNC2025 dose-dependently inhibited phosphorylation of FLT3 (IC50=14 nM)., In EGF-induced 32D cells expressing EGFR-MER fusion protein, UNC2025 dose-dependently inhibited MER activity and was selective for MER over other TAM family kinases (see off target activity).",IC 50,Mouse,3 mg/mL,Compound 20 from J Med Chem paper
Venetoclax,4.0,4.0,6.0,No,https://www.chemicalprobes.org/venetoclax,BCL2,Other,Protein Phosphatase,2017-03-07,P10415,LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,No,No,CHEMBL3137309,990201,"http://www.nature.com/nm/journal/v19/n2/full/nm.3048.html, http://www.ncbi.nlm.nih.gov/pubmed/23291630",BH3 mimetic,<0.010 nM,Time-resolved FRET competition binding assay,4 nM,"In mouse FL5.12 cells that depend on BCL2 for survival in the absence of IL-3, venetoclax led to cell death. In comparable cells dependent upon BCL-XL, venetoclax had an EC50=261 nM. In ALL cells, venetoclax had an EC50 (cell death) in BCL2-dependent cells (RS4;11)=8 nM and in BCL-XL-dependent cells (H146)=4,260 nM. In a mammalian cell 2-hybrid assay, venetoclax disrupted BCL2-BIM complex (EC50=3 nM) but BCL-XL-BIM complex (EC50=2.2 uM). Venetoclax had no impact on Bak/Bax double knockout mouse embryonic fibroblasts.",EC50,Other,12.5 mg/kg,
RG7112,3.0,3.5,4.0,No,https://www.chemicalprobes.org/rg7112,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,QBGKPEROWUKSBK-QPPIDDCLSA-N,CCOc1cc(C(C)(C)C)ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@@](C)(c2ccc(Cl)cc2)N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1,No,No,CHEMBL2386346,942550,"http://pubs.acs.org/doi/abs/10.1021/ml4000657, http://clincancerres.aacrjournals.org/content/22/5/1185.long, http://cancerres.aacrjournals.org/content/73/8/2587.full-text.pdf, https://www.ncbi.nlm.nih.gov/pubmed/24900694, https://www.ncbi.nlm.nih.gov/pubmed/26482041, https://www.ncbi.nlm.nih.gov/pubmed/23400593",Antagonist,0.018 uM,Homogenous time-resolved fluoresence (HTRF) assay with N-terminal domain from MDM2 and a peptide from the p53 binding site.,0.4 uM,"MTT assay, also comparing selectivity of the compound for p53 wild-type (HCT-116, SJSA-1 and RKO cells) and p53 mutant (MDA-MB-435 and SW480) cells: 33.4-fold selective for the wild-type cells. In a broader panels of cells (7 mutant and 15 wild type lines), the compound was ~14-fold selective for wild-type cell lines.",IC50,Other,50 mg/kg,
BAY-549,3.0,3.0,6.0,No,https://www.chemicalprobes.org/bay-549,"ROCK1, ROCK2","Kinase, Kinase","AGC, AGC",2020-06-06,"Q13464, O75116",NRSGWEVTVGZDFC-UHFFFAOYSA-N,Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12,Yes,No,CHEMBL1971943,103049,"www.doi.org/10.1038/sj.bjp.0707484, https://doi.org/10.1002/cmdc.200800211, https://pubmed.ncbi.nlm.nih.gov/17934515/, https://pubmed.ncbi.nlm.nih.gov/18973168/",Inhibitor,"0.6 nM, 3.7 nM, 1.2 nM, 4.8 nM","biochemical ROCK assay, Functional inhibition: IC50 (pMBS, human)",65 nM,mechanistic tissue assay (arteria saphena rabbit),IC50,Other,"1 mg/Kg, 3 mg/Kg, 10 mg/Kg, 0.1-0.3 mg/Kg IV",BAY-4900
MCC950,3.0,3.0,4.0,No,https://www.chemicalprobes.org/mcc950,NLRP3,Other,"NACHT, LRR and PYD domains-containing Protein",2020-07-10,Q96P20,HUUSXLKCTQDPGL-UHFFFAOYSA-N,CC(C)(O)c1coc(S(=O)(=O)NC(=O)Nc2c3c(cc4c2CCC4)CCC3)c1,No,No,CHEMBL3183703,116400,"www.doi.org/10.1021/acsmedchemlett.6b00198, www.doi.org/10.1038/nm.3806, www.doi.org/10.1038/s41589-019-0278-6, www.doi.org/10.1038/s41589-019-0277-7, https://pubmed.ncbi.nlm.nih.gov/27994733/, https://pubmed.ncbi.nlm.nih.gov/25686105/, https://pubmed.ncbi.nlm.nih.gov/31086329/, https://pubmed.ncbi.nlm.nih.gov/31086327/",Inhibitor,224 nM,SPR,7.5 nM BMDM; 8.1 nM HMDM,"Inhibition of IL-1Î² secretion followed by Western Blot, ELISA and LDH assay",IC50,Other,"3 mg/Kg (IV), 20 mg/Kg (PO)",
AB680,3.7,3.7,6.0,No,https://www.chemicalprobes.org/ab680,NT5E,Other,Membrane Protein,2020-07-09,P21589,MFYLCAMJNGIULC-KCVUFLITSA-N,C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]1O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]1O)c1ccccc1F,No,Yes,CHEMBL4471306,2920849,"www.doi.org/10.1021/acs.jmedchem.0c00525, www.doi.org/10.1021/acs.biochem.9b00448, https://pubmed.ncbi.nlm.nih.gov/32614585/, https://pubmed.ncbi.nlm.nih.gov/31334635/",Reversible Competitive Inhibitor,"5 pM, 43 pM","AMP-Glo assay, Enzymatic reaction",8 pM hCD8+ T; 11 pM hPBMC,Enzymatic Assay,IC50,Other,"0.5 mg/Kg, 16 mg/Kg, 25 mg/Kg",
PF-477736,3.7,3.7,6.0,No,https://www.chemicalprobes.org/pf-477736,CHEK1,Protein kinase,CAMK,2015-12-10,O14757,NDEXUOWTGYUVGA-LJQANCHMSA-N,Cn1cc(-c2[nH]c3cc(NC(=O)[C@H](N)C4CCCCC4)cc4c(=O)[nH]ncc2c34)cn1,No,No,CHEMBL3990456,467169,"http://mct.aacrjournals.org/content/7/8/2394.long, https://www.ncbi.nlm.nih.gov/pubmed/18723486",ATP-competitive inhbitor,0.49 nM,In vitro kinase assay with the catalytic domain of CHEK1,45 nM,"Abrogation of G2 checkpoint induced by DNA damage (detected by pSer10 H3 in a dot blot assay) in CA46 cells. In HeLa cells, EC50 = 38 nM; in HT29 cells, 42 nM.",EC50,Other,"4, 20, and 40 mg/kg (4 mg/kg)",
RP-6306,0.0,0.0,0.0,No,https://www.chemicalprobes.org/rp-6306,PKMYT1,Kinase,Ser/Thr kinase,2022-07-28,Q99640,ARBRHWRTXPWZGN-UHFFFAOYSA-N,Cc1cc2c(C(N)=O)c(N)n(-c3c(C)ccc(O)c3C)c2nc1C,No,No,,3872897,,Inhibitor,< 10 nM,ADP-GLO assay,"14 nM, 2 nM","Cell-based activity assay monitoring phosphorylation of CDK1 (Thr14), AlphaLISA., NanoBRET",IC50,Rat,"1 mg/Kg IV, 2.5 or 5 mg/Kg PO",Cpd 4
SecinH3,0.0,0.0,0.0,No,https://www.chemicalprobes.org/secinh3,"CYTH1, CYTH3, CYTH2","Cytohesin, Cytohesin, Cytohesin",,2022-07-22,"Q15438, O43739, Q99418",QPGYAMIHXLCFTJ-UHFFFAOYSA-N,COc1nc(-c2ccc3c(c2)OCO3)n(-c2ccc(NC(=O)CSc3ccccc3)cc2)n1,No,No,CHEMBL1731533,519536,,Inhibitor,"200 nM, 239 nM, 250 nM",Aptamer displacement screening assay by fluorescence polarization,2200 nM,Insulin-dependent transcriptional repression of IGFBP1,IC50,,,D5
ACBI1,4.0,0.0,2.0,No,https://www.chemicalprobes.org/acbi1,"SMARCA2, SMARCA4, PBRM1","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2021-11-04,"P51531, P51532, Q86U86",IVARZBJJMMUJHI-SQKKEFIPSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)c(OCCOc2ccc(CN3CCN(c4cc(-c5ccccc5O)nnc4N)CC3)cc2)c1,No,Yes,CHEMBL4748407,3312896,"www.doi.org/10.1038/s41589-019-0294-6, https://pubmed.ncbi.nlm.nih.gov/31178587/",Degrader (PROTAC),770 nM Binary; 26 nM Ternary; 450 nM Binary (Ki); 16 nM Ternary (Ki),"Fluorescence Polarization competition assays, TR-FRET assay, SPR","6 nM, 11 nM, 32 nM",Protein Degradation,DC 50,,,cis-ACBI1
DT2216,3.7,3.7,6.0,No,https://www.chemicalprobes.org/dt2216,BCL2L1,Other,Apoptosis Regulator,2020-12-03,Q07817,PXVFFBGSTYQHRO-REQIQPEASA-N,Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCC(=O)N2CCN(CC[C@H](CSc3ccccc3)Nc3ccc(S(=O)(=O)NC(=O)c4ccc(N5CCN(CC6=C(c7ccc(Cl)cc7)CCC(C)(C)C6)CC5)cc4)cc3S(=O)(=O)C(F)(F)F)CC2)C(C)(C)C)cc1,No,Yes,CHEMBL4745523,3313532,"www.doi.org/10.1038/s41591-019-0668-z, https://pubmed.ncbi.nlm.nih.gov/31792461/",Degrader (PROTAC),12.8 nM BCL-XL; 1.8 nM BCL-2; 300.9 nM BCL-W,"AlphaScreen, AlphaLITE",63 nM (DC50); 90.8% (Dmax); 52 nM (EC50),"HiBIT assay, immunoprecipitation of HA-ubiquitin and FLAG-BCL","DC50, Dmax, EC50",Other,7.5-15 mg/Kg,DT2216NC
CRBN-6-5-5-VHL,3.3,2.0,4.0,No,https://www.chemicalprobes.org/crbn-6-5-5-vhl,CRBN,Other post-translational modification,E3 Ligase,2020-12-17,Q96SW2,LIMCHOLAKDUZDS-XARBDFOFSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCOCCCCCOCCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)C(C)(C)C)cc1,No,Yes,CHEMBL4455580,3151460,"www.doi.org/10.1039/C8CC09541H, https://pubmed.ncbi.nlm.nih.gov/30672516/",Degrader (PROTAC),,,1.5 nM,"Western blot, CellTiter-GloÂ® Luminescent Cell Viability Assay",DC50,,,"(-)CRBN-6-5-5-VHL, (*)CRBN-6-5-5-VHL, CRBN-6-5-5-VHL(-), (-)CRBN-6-5-5-VHL(-)"
TBK1 PROTAC 3i,3.0,0.0,3.0,No,https://www.chemicalprobes.org/tbk1-protac-3i,TBK1,Protein kinase,Ser/Thr Protein Kinase,2020-11-12,Q9UHD2,QMGHHBHPDDAGGO-IIWOMYBWSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCCOCCCCOCCCOc2ccc(Nc3ncc(Br)c(NCCCN(C)C(=O)C4CCC4)n3)cc2)C(C)(C)C)cc1,No,No,CHEMBL4227907,1040148,"www.doi.org/10.1021/acs.jmedchem.7b00635, https://pubmed.ncbi.nlm.nih.gov/28692295/",Degrader (PROTAC),4.6 nM,"Kd determined at DiscoverX, VHL Binding Assay Based on Fluorescence Polarization",12 nM; 96 %,,"DC50, Dmax",,,TBK1 control PROTAC 4
dTRIM24,3.0,0.0,2.0,No,https://www.chemicalprobes.org/dtrim24,TRIM24,Epigenetic,Tripartite Motif Family,2020-11-13,O15164,QUQTXFIMYFMULC-OGOZKGDESA-N,CCCOc1cccc(Oc2cc3c(cc2NS(=O)(=O)c2cccc(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCc4ccc(-c5scnc5C)cc4)C(C)(C)C)c2)n(C)c(=O)n3C)c1,No,No,,3314073,"www.doi.org/10.1038/s41589-018-0010-y, https://pubmed.ncbi.nlm.nih.gov/29507391/",Degrader (PROTAC),338 nM,TRIM24 ligand-displacement assay,72-76 %,"Immunoblotting, Antiproliferative effect of selective TRIM24 degradation, detection of genome-wide TRIM24-chromatin association",Dmax,,,eTRIM24
MG-277,3.0,0.0,1.0,No,https://www.chemicalprobes.org/mg-277,GSPT1,Other,Translation Termination Factor,2020-11-24,P15170,BANRYGZZIMCKNA-OYGJEQPESA-N,O=C1CCC(N2Cc3c(CCCCCNC(=O)[C@@H]4NC5(CCCCC5)[C@@]5(C(=O)Nc6cc(Cl)ccc65)[C@H]4c4cccc(Cl)c4F)cccc3C2=O)C(=O)N1,No,No,CHEMBL4449512,3145062,"www.doi.org/10.1021/acs.jmedchem.9b00846, https://pubmed.ncbi.nlm.nih.gov/31560543/",Molecular Glue Degrader,67.5 nM,FP competitive binding assay,"1.3 (R), 24.6 (MO), 7.9 (MV) nM","Proteomic Analysis/Protein Profiling, Cell Growth inhibition (cell lines used: RSA;11 (R), MOLM-13 (MO) MV411 (MV))",DC50,,,
ARD-266,3.0,0.0,1.0,No,https://www.chemicalprobes.org/ard-266,AR,Transcription factor,Nuclear Hormone Receptor,2020-11-30,P10275,RTNONCBKGZNCJS-LJLQSONVSA-N,Cc1cc([C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC(=O)N2CCC(C#Cc3ccc(C(=O)N[C@H]4C(C)(C)[C@H](Oc5ccc(C#N)c(Cl)c5)C4(C)C)cc3)CC2)c2ccccc2)C(C)C)on1,No,No,CHEMBL4525203,3143012,"www.doi.org/10.1021/acs.jmedchem.9b01393, https://pubmed.ncbi.nlm.nih.gov/31804827/",Degrader (PROTAC),,,"0.53 nM LNCaP, 0.97 nM VCaP, 0.15 nM 22Rv1 (DC50); 90% 10 nM, >95% 100 nM, >99% 1000 nM; 2 nM LNCaP,  6 nM VCaP (IC50)","Western Blotting, Cell viability determined by WST-8 assay.","DC50, Dmax, IC50",,,
CP-10,3.0,0.0,2.0,No,https://www.chemicalprobes.org/cp-10,CDK6,Kinase,CMGC,2020-12-01,Q00534,PACRWHUPEPCFHX-UHFFFAOYSA-N,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(Cc5cn(CCOCCNc6cccc7c6C(=O)N(C6CCC(=O)NC6=O)C7=O)nn5)CC4)cn3)nc2n(C2CCCC2)c1=O,No,Yes,CHEMBL4553408,3213557,"www.doi.org/10.1021/acs.jmedchem.9b00871, https://pubmed.ncbi.nlm.nih.gov/31330105/",Degrader (PROTAC),,,"2.1 nM (DC50); 10 nM MM.aS, 8 nM Mino; 72% @ 10 nM, 89% @ 100 nM","western blot, proliferation assay in correlation with protein degradation","DC50, IC50, Dmax",,,CP-23
IR-2,3.0,0.0,2.0,No,https://www.chemicalprobes.org/ir-2,BTK,Kinase,TK,2022-02-25,Q06187,ZJJZBBBSQKVNHL-BYBNZYMESA-N,Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2[C@@H]1CCCN(C(=O)/C=C/CCCCOCCOCCOCCOCCOc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)C1,No,Yes,,3314137,,Degrader (PROTAC),14 nM,Inhibition of BTK,"1.9 nM, 88%",Degradation of BTK in Mino cells after 24 h treatment,"DC50, Dmax",,,
UNC6852,3.0,0.0,2.0,No,https://www.chemicalprobes.org/unc6852,"EED, EZH2, SUZ12","Epigenetic, Epigenetic, Epigenetic",,2022-03-08,"O75530, Q15910, Q15022",PPNNFXIBKLCMTI-WXEAQWFJSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCNC(=O)c2ccc(-c3cnc(NCc4ccco4)n4cnnc34)cc2)C(C)(C)C)cc1,No,No,CHEMBL4749741,3313753,,Degrader (PROTAC),247 nM,IC50 of EED was tested by the TR-FRET assay,"790 nM, 610 nM, 3400 nM, 92%, 94%, 10 ÂµM, 300 nM, 670 nM, 64%, 96%, 590 nM, 22%, 82%","Degradation of EED in HeLa cells after 24 h treatment, Degradation of EED in DB cells after 24 h treatment, Inhibit the proliferation of DB cells, Western blot assessing H3K27me3 levels, Degradation of EZH2 in HeLa/DB cells after 24 h treatment, Degradation of EZH2 in DB cells after 24 h treatment, Degradation of EZH2 in HeLa cells after 24 h treatment, Degradation of SUZ12 in DB cells after 24 h treatment, Degradation of SUZ12 in HeLa cells after 24 h treatment","EC50, DC50, Dmax, Activity",,,UNC7043
MZP-54,2.5,0.0,2.0,No,https://www.chemicalprobes.org/mzp-54,"BRD2, BRD3, BRD4","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2020-11-25,"P25440, Q15059, O60885",FYSWLIFIYIVHPI-DDWISSAJSA-N,CC(=O)N1c2ccc(-c3ccc(C(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@H](O)C[C@H]4C(=O)NCc4ccc(-c5scnc5C)cc4)C(C)(C)C)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C,No,No,CHEMBL4229193,1040176,"www.doi.org/10.1021/acs.jmedchem.6b01912, https://pubmed.ncbi.nlm.nih.gov/28595007/",Degrader (PROTAC),4Â±2 nM,ITC with BRD4-BD2,"42 %, 50 nM, 49 nM, 91%, 8-25 nM, 98-85%, 269 nM","Protein degradation quantified by WB, Cell Proliferation Assay","Dmax, DC 50, EC 50",,,
PROTAC-AR-Degrader-4,1.0,0.0,1.0,No,https://www.chemicalprobes.org/protac-ar-degrader-4,AR,NHR,Dihydrotestosterone receptor,2021-06-10,P10275,YNDJPWSVYYRNTJ-MEXKHVBFSA-N,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)NCCOCCOCCOCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,No,Yes,CHEMBL2151741,972138,"www.doi.org/10.1016/j.bmc.2011.09.041, https://pubmed.ncbi.nlm.nih.gov/22014751/",Degrader (PROTAC),,,,,,,,
A1874,0.0,0.0,0.0,No,https://www.chemicalprobes.org/a1874,BRD4,Epigenetic,Bromodomain,2022-03-08,O60885,IPNTVOAQOGRLQB-JJMBTQCASA-N,COc1cc(C(=O)NCCOCCOCCOCCNC(=O)C[C@@H]2N=C(c3ccc(Cl)cc3)c3c(sc(C)c3C)-n3c(C)nnc32)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,No,No,CHEMBL4466284,3161206,,Degrader (PROTAC),,,"32 nM, 86.3 nM, 98%","Degradation of BRD4 in HCT116 cells after 24 h treatment, Inhibit viability of HCT116 cells","DC50, IC50, Dmax",,,
MS4078,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ms4078,ALK,Kinase,TK,2022-03-08,Q9UM73,AYMGZLUKTNXEMY-UHFFFAOYSA-N,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CC(=O)NCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,No,Yes,CHEMBL4161454,996893,,Degrader (PROTAC),19 nM,Competitive binding assay using DNA tag labeled ALK,"11 nM, 90%, 59 nM, 60 nM","Degradation of NPM-ALK/EML4-ALK in SU-DHL-1 cells after 16 h treatment, Degradation of NPM-ALK/EML4-ALK in NCI-H2228 cells after 16 h treatment, Assay Description: Degradation of NPM-ALK/EML4-ALK in NCI-H2228 cells after 16 h treatment., p-STAT (Western Blot) after 8h","DC50, Dmax, Activity",Mouse,50 mg/Kg,
DAPORINAD,0.0,0.0,0.0,No,https://www.chemicalprobes.org/daporinad,NAMPT,Enzyme,Nicotinamide phosphoribosyltransferase,2022-07-04,P43490,KPBNHDGDUADAGP-VAWYXSNFSA-N,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,No,Yes,CHEMBL566757,174287,,Inhibitor,0.3 nM,Competitive binding assay using K-562 cell extracts ; non-competitive inhibition,"1-3 nM, 1.6 nM, 7.4 nM","Cell growth inhibition (WST-1 assay, SRB assay), WST-1 assay, WST-1 Assay",IC50,Mouse,"5 mg/Kg, 10 mg/Kg, 30 mg/Kg",
L-745870,3.0,2.5,3.0,No,https://www.chemicalprobes.org/l-745870,DRD4,GPCR,Dopamine receptor,2022-07-04,P21917,OGJGQVFWEPNYSB-UHFFFAOYSA-N,Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1,Yes,No,CHEMBL267014,1402318,,Antagonist,,,0.43 nM,[3H]Spiperone binding assay.,Ki,Rat,"3 mg/Kg, 1 mg/Kg",
NMS-P715,2.0,2.0,1.0,No,https://www.chemicalprobes.org/nms-p715,TTK,Kinase,Ser/Thr Kinase,2022-06-15,P33981,JFOAJUGFHDCBJJ-UHFFFAOYSA-N,CCc1cccc(CC)c1NC(=O)c1nn(C)c2c1CCc1cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC(F)(F)F)nc1-2,No,No,CHEMBL1236095,941114,,Inhibitor,7 nM,Biochemical assay,"160 nM, 180 nM, 32 nM","MSD (Meso Scale Discovery) Assay for TTK Autophosphorylation, Cell proliferation assays, Mitotic checkpoint override","IC50, GI50",Mouse,10 mg/Kg,
SAR405,4.0,0.0,1.0,No,https://www.chemicalprobes.org/sar405,PIK3C3,Kinase,PI3/PI4 Kinase,2022-07-11,Q8NEB9,SPDQRCUBFSRAFI-DOMZBBRYSA-N,C[C@@H]1COCCN1c1cc(=O)n2c(n1)N(Cc1cncc(Cl)c1)[C@H](C(F)(F)F)CC2,No,No,CHEMBL3622372,302035,,Inhibitor,"1 nM, 1.5 nM","Phosphorylation of a PtdIns substrate by human recombinant Vps34 enzyme, Surface Plasmon Resonance (SPR) technology using immobilized human Vps34 protein; koff, of 3.03 Â± 0.55 10â3 sâ1, corresponding to a residence half-life, t1/2, of 3.8 min",27 nM,PtdIns3P relocalisation assay GFP-FYVEâtransfected HeLa cell line,IC50,,,
AGI-5198,2.0,2.5,3.0,No,https://www.chemicalprobes.org/agi-5198,IDH1,Enzyme,Dehydrogenase,2015-11-10,O75874,FNYGWXSATBUBER-UHFFFAOYSA-N,Cc1ccccc1C(C(=O)NC1CCCCC1)N(C(=O)Cn1ccnc1C)c1cccc(F)c1,No,No,CHEMBL2180727,596719,"www.doi.org/10.1126/science.1236062, http://www.ncbi.nlm.nih.gov/pubmed/23558169",Inhibitor,70 nM R132H,NADPH consumption,,"In TS603, TS676, and TS516 glioma cells, AGI-5198 showed a dose-dependent impact on R-2HG formation",,Mouse,"150 mg/kg, 450 mg/kg",
ARS-1620,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ars-1620,KRAS,Enzyme,GTPase,2020-06-11,P01116,ZRPZPNYZFSJUPA-UHFFFAOYSA-N,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,No,Yes,CHEMBL4214264,320348,"www.doi.org/10.1016/j.cell.2018.01.006, www.doi.org/10.1158/1078-0432.CCR-19-3523, www.doi.org/10.1038/s41467-020-16309-2, https://pubmed.ncbi.nlm.nih.gov/29373830, https://pubmed.ncbi.nlm.nih.gov/31776128, https://pubmed.ncbi.nlm.nih.gov/32499547",Covalent Inhibitor,"1,100 Â± 200 Mâ1 sâ1",kobs/[I] determined by Biochemical Binding Assay,120 nM,Inhibition of RAS signalling,IC 50,Mouse,"50 mg/Kg, 200 mg/Kg",R-atropisomer
AK120413,3.0,3.0,1.0,No,https://www.chemicalprobes.org/ak120413,BRS3,GPCR,Bombesin receptor,2022-08-03,P32247,WVAKRQOMAINQPU-UHFFFAOYSA-N,CCC(C)(C)Cc1c[nH]c(CCc2ccc(-c3ccccn3)cc2)n1,No,No,CHEMBL1091720,1613413,,Agonist,18.3 nM,"A competitive binding assay using radioligand and NFAT-CHO cell membranes.  
IC50 = 6.9 and 2.4 nM for mouse and rat homologs",47 nM,"Aequorin bioluminescence assay
Emax 99%",EC50,"Mouse, Rat","2 mg/Kg, 10 mg/Kg, 1 mg/Kg, 4 mg/Kg",
GW3965,3.0,3.7,3.0,No,https://www.chemicalprobes.org/gw3965,"NR1H2, NR1H3","NHR, NHR","NR1 Subfamily, NR1 Subfamily",2017-07-18,"P55055, Q13133",NAXSRXHZFIBFMI-UHFFFAOYSA-N,O=C(O)Cc1cccc(OCCCN(Cc2cccc(C(F)(F)F)c2Cl)CC(c2ccccc2)c2ccccc2)c1,No,No,CHEMBL59030,838143,"http://pubs.acs.org/doi/abs/10.1021/jm0255116, https://www.ncbi.nlm.nih.gov/pubmed/11985463",Agonist,125 nM,LXRalpha/SRC1 LiSA.,"190 nM, 30 nM",,EC 50,Mouse,10 mg/kg,
GNE-2861,2.7,0.0,3.0,No,https://www.chemicalprobes.org/gne-2861,"PAK4, PAK5, PAK6","Protein kinase, Protein kinase, Protein kinase","STE, STE, STE",2017-05-30,"O96013, Q9P286, Q9NQU5",RZXMIHOUHYSGJO-UHFFFAOYSA-N,COCCNc1nc2ccc(C#CC3(O)CCCCC3)cc2n1-c1ccnc(N)n1,No,No,CHEMBL3128042,312564,"http://pubs.acs.org/doi/abs/10.1021/jm401768t, https://www.ncbi.nlm.nih.gov/pubmed/24432870",Inhibitor,PAK4: 3.3 nM,"Activity of human recombinant PAK4 (KD, kinase domain) protein assessed through measuring the phosphorylation of a FRET peptide substrate.",10 uM,Cell viability in MDA-MB-436 and MCF10A PIK3CA (H1047R) cells. GNE-2861 dose-dependently inhibited cell migration in wound healing assays with the same cells (Essen Bioscience Incucyte platform).,EC50,,,
A-395,3.7,3.0,3.0,No,https://www.chemicalprobes.org/395,EED,Epigenetic,Polycomb family,2017-01-31,O75530,REVJNSVNICWODC-KIDMSAQOSA-N,CN(C)[C@H]1CN(C2CCc3cccc(F)c32)C[C@@H]1c1ccc(N2CCN(S(C)(=O)=O)CC2)cc1,Yes,No,CHEMBL4104741,609832,"www.doi.org/10.1038/nchembio.2306, https://www.ncbi.nlm.nih.gov/pubmed/28135237",Protein-Protein Interaction Antagonist,0.4 nM,"TR-FRET 
Compounds were tested in a modified LanthaScreen competition assay in which the in vitro potency of compounds (Ki) was measured through the disruption of a TR-FRET donor-acceptor complex of terbium-labeled anti-GST antibody and a custom synthesized Oregon green (488) labeled probe using a potent, pyrrolidine-based inhibitor. By SPR, the KD=1.5 nM, and A-395 inhibits PRC complex in vitro with a IC50=18 nM.","90 nM (H3K27me3), 390 nM (H3K27me1/2)","Cell (lymphoma and multiple myeloma) proliferation assays were conducted with the CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation). Specifically, 1,000 cells were seeded in each well of 96-well cell culture plates and treated with various compounds or DMSO control for 10 d before the cell proliferation assay. A-395 antagonist resulted in data similar to the EZH2 SAM-competitive inhibitors.",IC50,Mouse,300 mg/kg (with extended release vehicle),A-395N
VH298,3.7,0.0,3.0,No,https://www.chemicalprobes.org/vh298,VHL,Other post-translational modification,E3 ubiquitin ligase,2016-11-15,P40337,NDVQUNZCNAMROD-RZUBCFFCSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(C#N)CC2)C(C)(C)C)cc1,No,No,CHEMBL4225537,752635,"http://dx.doi.org/10.1038/ncomms13312, https://www.ncbi.nlm.nih.gov/pubmed/27811928",Protein-protein interaction inhibitor,"90 nM, 80 nM","Isothermal calorimetry assays, VH298 bounding VBC.
SPR, VH298 had a Kon = 6.47 X 10^5/M*sec and a Koff = 0.065/sec., Fluorescence polarization assays using a HIF-1alpha peptide, VH298 bounding VBC",,"In HeLa cells, VH298 led to the concentration-dependent accumulation of HIF-1alpha (hydroxylated form) and HIF-2alpha.",Not done,,,cisVH298
SAFit2,0.0,0.0,0.0,No,https://www.chemicalprobes.org/safit2,FKBP5,Enzyme,Prolyl isomerase,2022-09-20,Q13451,ZDBWLRLGUBSLPG-FDHYQTMZSA-N,COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@H](c2cc(OC)c(OC)c(OC)c2)C2CCCCC2)c2cccc(OCCN3CCOCC3)c2)cc1OC,No,No,CHEMBL3623630,982146,,Antagonist,6 Â± 2 nM,competitive fluorescence polarization (FP) assay,"195.5 Â± 14 nM, IC50 = 493 Â± 101 nM","NanoBRET assay (FKBP12-NLuc): FKBP5, NanoBRET assay (FKBP51-NLuc): FKBP5",IC50,Mouse,10 mg/Kg,ddSAFit2
JH-IX-179,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jh-ix-179,FLT3,Kinase,TK,2022-06-08,P36888,JRJKATLTRNXYCE-UHFFFAOYSA-N,CN(C)CCCn1cc(-c2ccc3c(c2)-c2[nH]c4cc(-c5cn[nH]c5)ccc4c2C3=O)cn1,No,No,CHEMBL3815054,543527,,Inhibitor,,,"4.28 nM, 10.22 nM, 2 nM, 11 nM","Ba/F3-D835Y (-IL-3) cells, Ba/F3-FLT3-ITD (-IL-3) cells, Cell proliferation assay",IC50,,,
Cortistatin-A,1.7,1.5,3.0,No,https://www.chemicalprobes.org/cortistatin,"CDK19, CDK8","Kinase, Kinase","CMGC, CMGC",2016-09-09,"Q9BWU1, P49336",KSGZCKSNTAJOJS-DZBMUNJRSA-N,CN(C)[C@H]1C[C@@]23CC[C@@]4(O2)C(=CC[C@]2(C)[C@@H](c5ccc6ccncc6c5)CC[C@@H]42)C=C3[C@@H](O)[C@@H]1O,No,No,CHEMBL4080906,668427,"http://www.nature.com/nature/journal/v526/n7572/full/nature14904.html, http://www.ncbi.nlm.nih.gov/pubmed/26416749",Inhibitor,"100 nM, 0.195 nM, 12 nM, 10 nM","immunoblot showing capture of native  CDK19 from MOLM-14 lysates, Probe displacement assay. CDK8âCCNC (0.62 nM) was preincubated with a reporter probe at a concentration equal to its binding affinity (Kd). After transfer of serially diluted cortistatin A, probe displacement was monitored for 60 min. Kd values were calculated using the ChengâPrusoff equation from the IC50 values obtained from the percentage displacement values at the last time point measured., kinase activity inhibition, immunoblot showing capture of native  CDK8 from MOLM-14 lysates",25-100 nM,Interferon-gamma-stimulated phosphorylation of STAT1-s727.,IC 50,Mouse,"1 mg/kg (PK study), 0.16 mg/kg once-daily (efficacy study)",
CPI-360,4.0,2.3,3.0,No,https://www.chemicalprobes.org/cpi-360,EZH2,Epigenetic,Protein methyltransferase,2016-08-08,Q15910,PFPSFENQCNMITC-MRXNPFEDSA-N,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12,No,No,CHEMBL3605456,468943,"http://www.sciencedirect.com/science/article/pii/S1074552114003421, http://www.ncbi.nlm.nih.gov/pubmed/?term=25457180",SAM competitive inhibitor,"0.07 nM, 2.5 nM","PRC2 enzyme inhibition assay using EZH2 wild-type, PRC2 enzyme inhibition assay using EZH2 Y641N",56 nM,"ELISA-based detection of protein substrate (H3K27) methylation, CETSA, and NanoBRET assay.",EC50,,,
BIX-01294,1.7,1.5,3.0,No,https://www.chemicalprobes.org/bix-01294,EHMT2,Epigenetic,Protein methyltransferase,2016-08-08,Q96KQ7,OSXFATOLZGZLSK-UHFFFAOYSA-N,COc1cc2nc(N3CCCN(C)CC3)nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC,No,No,CHEMBL569864,685872,"http://www.cell.com/molecular-cell/abstract/S1097-2765(07)00040-8?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1097276507000408%3Fshowall%3Dtrue, http://www.ncbi.nlm.nih.gov/pubmed/?term=17289593",Uncompetitive SAM inhibitor,2.7 uM,"Dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). 
In MS-based histone methyltransferase activity assay, IC50 = 1.7 uM.",,"No dose-dependent experiments were reported. In mouse ES cells and MEFs, BIX-01294 inhibited H3K9 methylation. In mouse ES cells, BIX-01294 decreased the H2K9me2 mark at Ehmt2 target genes: mage-a2, Bmi1, Serac1.",,,,
EPZ004777,4.0,1.0,3.0,No,https://www.chemicalprobes.org/epz004777,DOT1L,Epigenetic,Protein methyltransferase,2016-08-08,Q8TEK3,WXRGFPHDRFQODR-ICLZECGLSA-N,CC(C)N(CCCNC(=O)Nc1ccc(C(C)(C)C)cc1)C[C@H]1O[C@@H](n2ccc3c(N)ncnc32)[C@H](O)[C@@H]1O,No,No,CHEMBL2169919,856426,"http://www.cell.com/cancer-cell/abstract/S1535-6108(11)00227-3, http://www.ncbi.nlm.nih.gov/pubmed/?term=21741596",SAM competitive inhibitor,0.4 nM,DOT1L enzyme activity assay with PRC2,700 nM,"A dose-dependent decrease in the expression of HOXA9 and MEIS1 transcripts.
In MOLM-13, MLL-AF9, MV4-11, MLL-AF4, and Jurkat cells, EPZ004777 dose-dependently decreased DOT1L substrate methylation (H3K79) over 4-5 days as assessed by immunoblot.",IC50,Mouse,50 mg/mL continuous infusion,
E7449,3.0,3.0,3.0,No,https://www.chemicalprobes.org/e7449,"PARP1, PARP2, TNKS, TNKS2","Other post-translational modification, Other post-translational modification, Other post-translational modification, Other post-translational modification","PARP, PARP, PARP, PARP",2016-07-29,"P09874, Q9UGN5, O95271, Q9H2K2",JLFSBHQQXIAQEC-UHFFFAOYSA-N,O=c1[nH]nc2[nH]c(CN3Cc4ccccc4C3)nc3cccc1c32,No,No,CHEMBL3644587,1572017,"http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5846&pubmed-linkout=1, http://www.ncbi.nlm.nih.gov/pubmed/26513298",Inhibitor,"1.0 nM, 1.2 nM, 115 nM",Trevigen ELISA assay,,"DT40 cells lacking PARP proteins or other DNA repair proteins are resistant to E7449. 
In SW480 cells, E7449 dose-dependently stabilized axin2, TNKS, and TNKS2, and decreased beta-catenin activation.",,Mouse,30-100 mg/kg,
Defactinib,2.0,2.0,1.0,No,https://www.chemicalprobes.org/defactinib,"PTK2, PTK2B","Kinase, Kinase","TK, TK",2022-03-16,"Q05397, Q14289",FWLMVFUGMHIOAA-UHFFFAOYSA-N,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,No,No,CHEMBL3137331,652417,,Inhibitor,0.2 nM,Binding versus recombinant human enzyme kinase domain,3 nM,Inhibits PTK2 phosphorylation in A431 cells,IC50,"Rat, Dog",12.5-50 mg/Kg,PF-00911705
TL13-112,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tl13-112,ALK,Kinase,RTK,2020-11-12,Q9UM73,XIRQUXILNXIWDI-UHFFFAOYSA-N,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CCOCCOCCNC(=O)CNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1,No,Yes,CHEMBL4213986,1036881,"www.doi.org/10.1021/acs.jmedchem.7b01655, https://pubmed.ncbi.nlm.nih.gov/29660984/",Degrader (PROTAC),0.6 nM,ALK LANCE Activity Assay at ATP Km (18ÂµM),10 nM (H3122); 40 nM (K-299); 50 nM (Kelly),Immunoblots of dose titrated cell lysates TNT LC-MS,DC50 @ 16h,,,TL13-110
MZ1,3.5,0.0,4.0,No,https://www.chemicalprobes.org/mz1,"BRD4, BRD3, BRD2","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2016-11-18,"O60885, Q15059, P25440",PTAMRJLIOCHJMQ-PYNGZGNASA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOCCNC(=O)C[C@@H]2N=C(c3ccc(Cl)cc3)c3c(sc(C)c3C)-n3c(C)nnc32)C(C)(C)C)cc1,No,No,CHEMBL4226570,1034345,"http://pubs.acs.org/doi/abs/10.1021/acschembio.5b00216, https://www.ncbi.nlm.nih.gov/pubmed/26035625",Degrader (PROTAC),"39 nM (BD1), 15 nM (BD2), 21nM (BD1), 13 nM2 (BD2), 62 nM (BD1), 60 nM (BD2)","Isothermal calorimetry, ITC in BRD3 BD1/2, ITC in BRD2 BD1/2","5 nM, 98/100%, 100 nM, 50 nM, 100%, 40 nM, 98%","In HeLa cells, MZ1 led to time and concentration-dependent degradation of BRD4. BRD4 was preferentially degraded over BRD2 and BRD3, especially at low concentrations (0.1-1 uM).
In U2OS cells, MZ1 led to the degradation of a BRD4-GFP reporter., Degradation of BRD4 short/long in HeLa cells after 24 h treatment, Degradation of BRD3 in HeLa cells after 24 h treatment, Inhibit proliferation of MV4;11 cells, Degradation of BRD2 in HeLa cells after 24 h treatment","DC50, Dmax, EC50","Rat, Mouse",5 mg/Kg,cisMZ1
DANAVOREXTON,4.0,3.5,2.0,No,https://www.chemicalprobes.org/danavorexton,HCRTR2,GPCR,Orexin 2 receptor,2022-03-19,O43614,UXZAJSZFFARTEI-YRPNKDGESA-N,COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@@H](c2ccccc2)CC1,No,No,CHEMBL4650341,3053852,,Agonist,48 nM,Binding assay using [3H]T-516 (TAK-925 Analog) bound to the membrane fractions of hOX2R-transfected Expi293F cells with a single saturable high-affinity binding site.,"5.5 nM, 15 nM","Measuring TAK-925-induced calcium mobilization in hOX2R/CHO-K1 cells (calcium mobilization assays), Effects of TAK-925 on IP1 production in hOX2R/CHO-EA cells.",EC50,Mouse,3 mg/Kg,
Ibrutinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ibrutinib,BTK,Kinase,TK,2021-06-10,Q06187,XYFPWWZEPKGCCK-GOSISDBHSA-N,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,No,Yes,CHEMBL1873475,503835,"http://www.pnas.org/content/107/29/13075.long, https://www.ncbi.nlm.nih.gov/pubmed/20615965",Covalent Inhibitor,0.5 nM,IC50s were measured using 33P filtration binding assay,"11 nM, 29 nM, 13 nM","inhibits autophosphorylation of Btk, inhibition of phosphorylation of Btk's physiological substrate PLCÎ³, inhibition of phosphorylation of downstream kinase ERK",IC50,Mouse,"3.31 mg/Kg, 14.2 mg/Kg",
GNF-5,3.7,3.3,3.0,No,https://www.chemicalprobes.org/gnf-5,ABL1,Protein kinase,TK,2015-12-10,P00519,IIQUYGWWHIHOCF-UHFFFAOYSA-N,O=C(NCCO)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1,No,No,CHEMBL1257423,270147,"www.doi.org/10.1038/nature08675, http://www.ncbi.nlm.nih.gov/pubmed/20072125",Allosteric inhibitor,0.22 nM,pyruvate kinase-lactate dehydrogenase based ABL kinase assay,0.22 uM,Inhibition of auto-phosphorylation in Ba/F3 cells,IC50,Other,20 mg/kg,
VX-745,4.0,3.7,3.0,No,https://www.chemicalprobes.org/vx-745,MAPK14,Protein kinase,CMGC,2015-12-10,Q16539,VEPKQEUBKLEPRA-UHFFFAOYSA-N,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,No,No,CHEMBL119385,1891880,"http://www.nature.com/nbt/journal/v26/n1/full/nbt1358.html, http://pubs.acs.org/doi/abs/10.1021/ml2001455, http://www.ncbi.nlm.nih.gov/pubmed/18183025, http://www.ncbi.nlm.nih.gov/pubmed/24900264",ATP-competitive inhibitor,2.8 nM,"KD was determined in a kinase binding assay. 
The IC50 (0.009 uM) was determined using a spectrophotometric coupled-enzyme assay.",,,,Other,40 mg/kg (43 mg/kg),
CP-724714,4.0,4.0,3.0,No,https://www.chemicalprobes.org/cp-724714,ERBB2,Kinase,RTK,2015-12-10,P04626,LLVZBTWPGQVVLW-SNAWJCMRSA-N,COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,No,No,CHEMBL483321,626411,"http://cancerres.aacrjournals.org/content/67/20/9887.long, http://www.ncbi.nlm.nih.gov/pubmed/17942920",Inhibitor,3 nM,In vitro kinase assay with intracellular domain,32 nM,Protein substrate phosphorylation in transfected NIH 3T3 cells,IC50,Mouse,2.5 mg/kg,
CH5424802,4.0,4.0,3.0,No,https://www.chemicalprobes.org/ch5424802,ALK,Kinase,RTK,2015-12-10,Q9UM73,KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,No,No,CHEMBL1738797,696603,"http://www.sciencedirect.com/science/article/pii/S1535610811001486, http://www.ncbi.nlm.nih.gov/pubmed/21575866",ATP-competitive inhibitor,"0.83 nM, 1.9 nM, 2.4 nM","fluorescence polarization, In vitro kinase assay, Ambit",,"In cells, CH5424802 dose-dependently inhibited ALK and ALK L1196M autophosphorylation and protein substrate phosphorylation.",,Mouse,6 mg/kg,
JNK-IN-8,3.3,2.0,3.0,No,https://www.chemicalprobes.org/jnk-in-8,"MAPK8, MAPK9, MAPK10","Kinase, Kinase, Kinase","CMGC, CMGC, CMGC",2015-12-10,"P45983, P45984, P53779",GJFCSAPFHAXMSF-UXBLZVDNSA-N,Cc1cc(NC(=O)c2cccc(NC(=O)/C=C/CN(C)C)c2)ccc1Nc1nccc(-c2cccnc2)n1,No,Yes,CHEMBL2216824,774340,"www.doi.org/10.1016/j.chembiol.2011.11.010, http://www.ncbi.nlm.nih.gov/pubmed/22284361",Covalent Inhibitor,"14.7 nM, 18.7 nM, 1 nM",In vitro kinase assay,"338 nM, 486 nM","In A375 cells, JNK-IN-8 inhibited phosphorylation of protein substrates, In HeLa cells, JNK-IN-8 inhibited phosphorylation of protein substrates",IC 50,,,
SGX-523,3.7,3.7,3.0,No,https://www.chemicalprobes.org/sgx-523,MET,Kinase,TK,2015-12-10,P08581,BCZUAADEACICHN-UHFFFAOYSA-N,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,No,No,CHEMBL1236107,1723579,"www.doi.org/1158/1535-7163.MCT-09-0477, http://www.ncbi.nlm.nih.gov/pubmed/19934279",ATP-competitive inhibitor,2.7 nM,In vitro kinase assay IC50 = 4 nM,12 nM,"SGX-523 inhibited MET autophosphorylation; IC50 = 0.04 uM in GTL16 cells.
SGX-523 dose-dependently inhibited phosphorylation of MET substrates.",IC50,,,
BIX-02188,3.0,4.0,3.0,No,https://www.chemicalprobes.org/bix-02188,MAP2K5,Protein kinase,STE,2015-12-10,Q13163,FSZPIAXLCCQFCM-FCQUAONHSA-N,CN(C)Cc1cccc(N/C(=C2\C(=O)Nc3cc(C(N)=O)ccc32)c2ccccc2)c1,No,Yes,CHEMBL4303171,326840,"www.doi.org/10.1016/j.bbrc.2008.09.087, http://www.ncbi.nlm.nih.gov/pubmed/18834865",Inhibitor,4.3 nM,,,"In HeLa cells, BIX-02188 dose-dependently inhibited protein substrate phosphorylation",,,,
LLY-507,2.0,0.0,3.0,No,https://www.chemicalprobes.org/lly-507,SMYD2,Epigenetic,Protein methyltransferase,2015-10-02,Q9NRG4,PNYRDVBFYVDJJI-UHFFFAOYSA-N,Cc1cn(CCN2CCN(c3ccccc3-c3cc(C#N)cc(C(=O)NCCCN4CCCC4)c3)CC2)c2ccccc12,No,No,CHEMBL3414623,891142,"www.doi.org/10.1074/jbc.M114.626861, http://www.ncbi.nlm.nih.gov/pubmed/25825497",Inhibitor,15 nM,Scintillation proximity assay,0.6 uM,Protein substrate methylation assay in SMYD2-overexpressing U2OS cells with substrate methylation detected by ELISA.,IC50,,,SGC705
I-BET151,2.7,4.0,3.0,No,https://www.chemicalprobes.org/i-bet151,"BRD4, BRD2, BRD3","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2015-07-16,"O60885, P25440, Q15059",VUVUVNZRUGEAHB-CYBMUJFWSA-N,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,No,No,CHEMBL2017291,375924,"www.doi.org/10.1038/nature10509, http://www.ncbi.nlm.nih.gov/pubmed/21964340",Antagonist,"790 nM, 100 nM, 500 nM, 20 nM, 250 nM","IC50 was measured in ligand-displacement assay, SPR, IC50 was measured in ligand-displacement assays, IC50 were measured in ligand-displacement assay","160 nM, 1260 nM",Inhibition of IL-6 production in PBMCs or whole blood (IC50 = 1.26 uM).,IC 50,Mouse,3 mg/mL,
ADL-5747,3.0,3.0,1.0,No,https://www.chemicalprobes.org/adl-5747,OPRD1,GPCR,Opioid Receptor,2022-08-03,P41143,ALGHKWSXJUQNJJ-UHFFFAOYSA-N,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1,No,No,CHEMBL561339,165588,,Agonist,,,"2.7 nM, 94 nM","Radioligand binding assay, Receptor-Mediated [35S]GTPÎ³S Binding","Ki, EC50","Rat, Dog","2.5 mg/Kg, 10 mg/Kg, 1.0 mg/Kg, 3.0 mg/Kg",
UCSF7447,3.5,3.0,2.0,No,https://www.chemicalprobes.org/ucsf7447,MTNR1A,GPCR,Melatonin Receptor,2020-05-29,P48039,QPTCYEYTAWEZNT-UHFFFAOYSA-N,Clc1ccc(CNc2cccc(-c3ncn[nH]3)c2)c(Br)c1,No,No,,2962188,"www.doi.org/10.1038/s41586-020-2027-0, https://www.ncbi.nlm.nih.gov/pubmed/32040955",Inverse Agonist,7.5 nM,Radioligand Binding,41 nM,Glo cAMP assay,EC50,Mouse,30 ug,ZINC37781618
JH-XI-10-02,2.0,0.0,1.0,No,https://www.chemicalprobes.org/jh-xi-10-02,CDK8,Kinase,CMGC,2022-02-21,P49336,JECHBTRAPARMGI-KMIZWFMDSA-N,CN(C(=O)CCOCCOCCOCCOCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)[C@H]1CC[C@@]2(C)C(CC[C@@H]3C2CC[C@]2(C)[C@@H](c4ccc5ccncc5c4)CC[C@@H]32)C1,No,Yes,,3314133,,Degrader (PROTAC),159 nM,Biochemical assay,1 ÂµM,Inhibition of CDK8,Activity,,,
TENAPANOR,0.0,4.0,1.0,No,https://www.chemicalprobes.org/tenapanor,SLC9A3,Transporter,,2022-05-31,P48764,DNHPDWGIXIMXSA-CXNSMIOJSA-N,CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1,No,No,CHEMBL3304485,1040919,,Inhibitor,,,0.5 nM,Cell-based rat/human NHE3 inhibition assay in Opossum kidney (OK) cells,IC50,"Rat, Mouse","1-30 mg/Kg, 1-10 mg/Kg",
TH1760,3.7,2.0,3.0,No,https://www.chemicalprobes.org/th1760,NUDT15,Epigenetic,Nudix Hydrolase,2020-11-16,Q9NV35,HNCVDRFFJZJQRW-UHFFFAOYSA-N,O=C(c1ccc2[nH]ccc2c1)N1CCN(S(=O)(=O)c2ccc3[nH]c(=O)oc3c2)CC1,No,No,,2863040,"www.doi.org/10.1038/s41589-020-0592-z, https://pubmed.ncbi.nlm.nih.gov/32690945/",Inhibitor,"25 nM, 57 nM","MG (Malachite Green) assay dGDP, MG (Malachite Green) assay 6-thio-dGTP",+7 ÂºC,"CETSA/Western Blot, DARTS assay",ÎTm,,,
DANUSERTIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/danusertib,"AURKA, AURKB, AURKC","Kinase, Kinase, Kinase","Ser/Thr Kinase, Ser/Thr Kinase, Ser/Thr Kinase",2022-06-08,"O14965, Q96GD4, Q9UQB9",XKFTZKGMDDZMJI-HSZRJFAPSA-N,CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,No,No,CHEMBL402548,624473,,Inhibitor,"2.5 nM, 13 nM, 79 nM, 61 nM",Biochemical Assay,28-140 nM,Proliferation assay,IC50,Mouse,10 mg/Kg,
ULIXERTINIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ulixertinib,"MAPK1, MAPK3","Kinase, Kinase","CMGC, CMGC",2022-06-08,"P28482, P27361",KSERXGMCDHOLSS-LJQANCHMSA-N,CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1,No,No,CHEMBL3590106,211897,,Inhibitor,Km 0.3 nM,"ERK2 biochemical assay, ERK1 biochemical assay","140 nM (pRSK), 180 nM","Mechanism of action (MOA) assay was measured by the levels of phosphorylated ERK2 (pERK) and of the phosphorylation of the downstream kinase RSK (pRSK) in an A375 melanoma cell line containing a b-RAFV600E mutation., Cell Proliferation assay 1","IC50, EC50",Mouse,"1 mg/Kg, 10 mg/Kg",
SELGANTOLIMOD,4.0,4.0,2.0,No,https://www.chemicalprobes.org/selgantolimod,TLR8,GPCR,Toll-like receptor,2022-10-07,Q9NR97,HTCJUBZBSJQWBW-CQSZACIVSA-N,CCCC[C@](C)(CO)Nc1nc(N)nc2cc(F)cnc12,No,No,CHEMBL4594258,3238048,,Agonist,,,"220 nM, MEC 49 nM","High Throughput Cryopreserved PBMC Assay: quantification of the levels of IL-12p40 (TLR8 cytokine) and IFN-Î± (TLR7 cytokine) in the supernatant of human PBMCs., Reporter assay. The minimum effective concentration (MEC) of (R)-7 that resulted in a 3-fold increase above background was 49 nM for human TLR8. The MEC for human TLR7 was 5197 nM, further supporting a mechanism of selective engagement of (R)-7 on human TLR8 over human TLR7.",EC50,"Rat, Dog, Monkey (Cynomolgus), Other","1 mg/Kg, 5 mg/Kg, 0.25 mg/Kg, 0.5 mg/Kg, 0.1 mg/Kg, 3 mg/Kg, 3 mg/kg once weekly for 8 weeks",
Talnetant,0.0,0.0,0.0,No,https://www.chemicalprobes.org/talnetant,TACR3,GPCR,NK-3 Receptor,2022-10-20,P29371,BIAVGWDGIJKWRM-FQEVSTJZSA-N,CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,No,No,CHEMBL10188,141783,,Antagonist,"1 nM, 1.6 Â± 0.53 nM","Inhibition of [3H]-senktide binding on hNK-3r-CHO cell membranes, Senktide-induced contraction in isolated rabbit iris sphincter muscle",16.6 Â± 1.6 nM,Ca++ mobilization assay,IC50,"Rat, Dog","6.9âÂ±â0.1 mg/Kg, 0.93âÂ±â0.02 mg/Kg, 8.0âÂ±â0.0 mg/Kg, 4.2âÂ±â0.2",SB-223411
BO-264,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bo-264,TACC3,Motor Spindle Protein ,,2022-03-19,Q9Y6A5,WRCGBYNVBFVRTN-UHFFFAOYSA-N,COc1ccc(-c2cc(/N=c3\ccnc(N4CCOCC4)[nH]3)on2)cc1,No,No,,3445205,,Inhibitor,1.5 nM,ITC,"190 nM, 130 nM, 1 Î¼mol/L","Cell viability was measured by SRB assay, Cellular Thermal Shift Assay","IC50, Activity",Mouse,25 mg/Kg,
BI-6901,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi-6901,CCR10,GPCR,Chemokine receptor,2022-05-23,P46092,BRJXJOWXAFLRTE-OAQYLSRUSA-N,CC1CCN(C(=O)[C@@H](CCn2cccc2C#N)NS(=O)(=O)c2cccc3[nH]ccc23)CC1,No,No,,3872899,,Antagonist,,,1 nM,BI-6901 inhibits the CCL27 dependent Ca2+ flux in CHO-K cells stably transfected with human CCR10 and aequorin with a pIC50 of 9.0,IC50,Mouse,100 mg/Kg,BI-6902
PF-03882845,4.0,3.0,1.0,No,https://www.chemicalprobes.org/pf-03882845,NR3C2,NHR,Mineralocorticoid receptor ,2022-05-24,P08235,XNULRSOGWPFPBL-REWPJTCUSA-N,N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl,No,No,CHEMBL1215331,263441,,Antagonist,"0.755 nM, 2.7 nM","serum-free functional reporter assay utilizing the human MR ligand-binding domain, Radioligand binding assay",9.2 nM,MR Luciferase Reporter Antagonist Assay using a Gal4-MRLBD construct and a luciferase reporter under Gal4 control,IC50,Rat,2 mg/Kg,"3S,3aS-27c"
Sotuletinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sotuletinib,CSF1R,Kinase,TK,2022-09-23,P07333,ADZBMFGQQWPHMJ-RHSMWYFYSA-N,CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1,No,No,CHEMBL4227505,139722,,Inhibitor,1 nM,Biochemical assay,67 nM,"Inhibition of CSF-1âdependent proliferation, Western blot of CSF-1R phosphorylation (Y721)","EC50, Activity",Mouse,200 mg/Kg,
RUSKI-201,2.7,0.0,3.0,No,https://www.chemicalprobes.org/ruski-201,HHAT,Other post-translational modification,O-acyltransferase,2020-07-07,Q5VTY9,KYOIGHSNTIJBPW-UHFFFAOYSA-N,CCC(C)CNCC(=O)N1CCc2sccc2C1c1cccc(C)n1,No,No,CHEMBL4284857,1687445,"https://www.ncbi.nlm.nih.gov/pubmed/27779865, https://www.ncbi.nlm.nih.gov/pubmed/27077078",Inhibitor,IC50,Click-ELISA assay using alkyne-tagged palmitoyl CoA substrate,0.73 uM,"In SILAC based proteomic experiment, RUSKI-201 selectively inhibited Hh ligand palmitoylation. In alkyne-tagged palmitic acid (YnPal) experiments, RUSKI-201 inhibited Shh tagging with TC50=0.87 uM.",IC50,,,
OL-135,3.0,0.0,1.0,No,https://www.chemicalprobes.org/ol-135,"FAAH2, FAAH","Enzyme, Enzyme","Amidase, Amidase",2022-08-03,"Q6GMR7, O00519",ILOIOIGZFHGSMS-UHFFFAOYSA-N,O=C(CCCCCCc1ccccc1)c1ncc(-c2ccccn2)o1,No,No,CHEMBL177577,1591631,,Inhibitor,"4.7 nM, 13.4 nM, 206 nM","Competitive radioligand displacement, Competitive ABPP assay, Radiolabelled oleamide substrate assay",450 nM,FAAH inhibition was determined through quantitation of 1- 3H-ethanolamine by scintillation counting,EC50,Mouse,10 mg/Kg,
GSK8612,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsk8612,TBK1,Kinase,Ser/Thr kinase,2022-06-08,Q9UHD2,FFPHMUIGESPOTK-UHFFFAOYSA-N,Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1,No,No,CHEMBL4446892,3141075,,Inhibitor,10 nM,Chemoproteomic determination using Kinobeads,"1000 nM, 800 nM, 500 nM","IRF3 phosphorylation inhibition (western blot), inhibition of IFNÎ± secretion in human PBMC followed by FACS-based Cytometric Bead Array (CBA) assay., Inhibition of the secretion of IFNÎ² from THP-1 cGAMP stimulated cells",IC50,,,
PEXIDARTINIB,3.0,3.0,1.0,No,https://www.chemicalprobes.org/pexidartinib,CSF1R,Kinase,TK,2022-10-05,P07333,JGWRKYUXBBNENE-UHFFFAOYSA-N,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,Yes,No,CHEMBL3813873,220962,,Inhibitor,13 nM,Enzymatic assay with 100Î¼M ATP,8.5 nM,"BCR-CSF1R fusion-dependent proliferation of Ba/F3 cells. 
IC50 >10 uM for IL3 dependent proliferation of BCRCSF1R fusion Ba/F3 cells (control).",IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","1 mg/Kg, 5 mg/Kg, 50 mg/Kg, 30 mg/Kg, 160 mg/Kg",
HPK1-IN-3,0.0,0.0,0.0,No,https://www.chemicalprobes.org/hpk1-in-3,MAP4K1,Kinase,STE,2022-10-05,Q92918,RZLXOEIALAVGKH-UHFFFAOYSA-N,COc1cc2c(cc1Nc1ncc(C(N)=O)c(Nc3c(F)cccc3C(F)(F)F)n1)CN(C)CC2,No,No,CHEMBL4878586,3319832,,Inhibitor,0.25 nM,HPK1 Biochemical Assay (TR-FRET),"453 nM, 108 nM","Human pSLP-76 Enzyme-Linked Immunosorbent Assay (ELISA), Human IL-2 assay","IC50, EC50","Mouse, Rat","1 mg/Kg IV, 5 mg/Kg PO",
ML252,2.0,2.0,2.0,No,https://www.chemicalprobes.org/ml252,KCNQ2,Ion Channel,Potassium Channel,2022-06-08,O43526,FROGGFONBYACJB-KRWDZBQOSA-N,CC[C@H](C(=O)Nc1ccccc1N1CCCC1)c1ccccc1,No,No,CHEMBL2164048,1447040,,Inhibitor,,,70 nM,Automated electrophysiology assay (Patch Clamp assay),IC50,Rat,10 mg/Kg,
RBN-2397,4.0,4.0,1.0,No,https://www.chemicalprobes.org/rbn-2397,TIPARP,Other post-translational modification,PARP,2022-10-05,Q7Z3E1,UQZCQKXJAXKZQH-LBPRGKRZSA-N,C[C@@H](COCCC(=O)N1CCN(c2ncc(C(F)(F)F)cn2)CC1)Nc1cn[nH]c(=O)c1C(F)(F)F,No,No,CHEMBL5095043,3319306,,Inhibitor,"<3 nM, 0.22 nM","Probe displacement assay, SPR  (ka = 1.65 Ã 105 (1/Ms), kd = 3.56 Ã 10-5 (1/s) and t1/2 = 325 min)","1 nM, 2 nM, 100 nM","NanoBRET, MARylation Inhibition, STAT1 phosphorylation","IC50, Activity",Mouse,"3, 10, 30, 300 mg/Kg",RBN250036
AVACOPAN,4.0,4.0,2.0,No,https://www.chemicalprobes.org/avacopan,C5AR1,GPCR,Complement peptide receptor,2022-10-07,P21730,PUKBOVABABRILL-YZNIXAGQSA-N,Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F,No,No,CHEMBL3989871,866320,,Antagonist,,,"0.1 nM, 0.2 nM","Displacement of [125I]-C5a binding to C5aR on a human myeloid cell line, Inhibition of C5a-mediated chemotaxis, Calcium mobilization assay",IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","0.5 mg/Kg, 2 mg/Kg, 30 mg/Kg, 100 mg/Kg",
BERZOSERTIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/berzosertib,ATR,Kinase,PI3/PI4,2022-06-08,Q13535,JZCWLJDSIRUGIN-UHFFFAOYSA-N,CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,No,No,CHEMBL3989870,527711,,Inhibitor,0.2 nM,radiometric assay,19 nM,Immunoblot for Chk1 phosphorylation (Ser 345) in cell lysates,IC50,Mouse,60 mg/Kg,
RILZABRUTINIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/rilzabrutinib,BTK,Kinase,Tyrosin Kinase,2022-06-08,Q06187,LCFFREMLXLZNHE-GBOLQPHISA-N,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,No,Yes,CHEMBL3702854,943370,,Covalent Inhibitor,"1.3 nM, 84%","Biochemical assay using the Caliper electrophoresis method, Biochemical occupancy was determined at room temperature by a FRET-based fluorescence competition assay where 1.5 Î¼M compound was preincubated with BTK for 15 min","123 nM, 60%","Human whole blood (HWB) IC50 was evaluated by inhibition of CD69 surface expression following anti-IgM stimulation from at least two measurements unless noted, Cellular occupancy was determined at 37 Â°C using an ALPHAlisa-based occupancy assay in Ramos cells",IC50,Rat,"2 mg/Kg IV, 20 mg/Kg PO",cpd 17
T863,3.0,3.0,1.0,No,https://www.chemicalprobes.org/t863,DGAT1,Enzyme,Acyltransferase,2022-06-08,O75907,FUIYMYNYUHVDPT-HDJSIYSDSA-N,CC1(C)Oc2ncnc(N)c2N=C1c1ccc([C@H]2CC[C@H](CC(=O)O)CC2)cc1,No,No,CHEMBL473967,161110,,Inhibitor,15 nM,Biochemical assay,4 nM,Inhibition of triacylglycerol synthesis in human HuTu 80 cells,IC50,"Rat, Dog",1-3 mg/Kg,
Eleutherobin,3.0,0.0,3.0,No,https://www.chemicalprobes.org/eleutherobin,TUBB,Enzyme,GTPase,2017-07-17,P07437,XOPYFXBZMVTEJF-PDACKIITSA-N,CO[C@]12C=C[C@](C)(O1)[C@@H](OC(=O)/C=C/c1cn(C)cn1)C[C@H]1C(C)=CC[C@H](C(C)C)[C@H]1/C=C\2CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O,No,Yes,CHEMBL504387,924789,"http://cancerres.aacrjournals.org/content/58/6/1111.long, http://www.pnas.org/content/96/8/4256.long, http://pubs.acs.org.libproxy.lib.unc.edu/doi/abs/10.1021/bi983023n, https://link.springer.com/article/10.1007%2Fs002800050957, www.doi.org/10.1021/ja9717828, https://www.ncbi.nlm.nih.gov/pubmed/9515790, https://www.ncbi.nlm.nih.gov/pubmed/10200249, https://www.ncbi.nlm.nih.gov/pubmed/10220336, https://www.ncbi.nlm.nih.gov/pubmed/10412947",Inhibitor,6500 nM,"In vitro calf brain tubulin polymerization assays,",2000 nM,Displacement of 3H-taxol,EC50,,,
IMARADENANT,4.0,4.0,1.0,No,https://www.chemicalprobes.org/imaradenant,ADORA2A,GPCR,,2022-10-05,P29274,NCWQLHHDGDXIJN-UHFFFAOYSA-N,Cc1cc(-c2nnc(N)nc2-c2ccc(F)cc2)cc(Cl)n1,No,Yes,CHEMBL4594442,2964977,,Antagonist,,,"0.79 nM @ 0.1 uM Adenosine, 53 nM, 1.7 nM","Inhibition of adenosine-mediated cAMP accumulation in human A2AR-expressing cells, T Cell IFNÎ³ Secretion assay with 0.1 uM NECA inhibition, Radioligand assay","IC50, EC50, Ki",Mouse,50 mg/Kg BID,
OTS964,3.0,0.0,1.0,No,https://www.chemicalprobes.org/ots964,CDK11A,Kinase,CMGC,2022-09-21,Q9UQ88,WGYWHJPQFQGLOQ-UHFFFAOYSA-N,CC(CN(C)C)c1ccc(-c2c(O)ccc3[nH]c(=O)c4sccc4c23)cc1,No,No,CHEMBL3672267,1869623,,Inhibitor,10 nM,In Vitro Kinase Assay assessing phosphorylation of Ser2 and Ser5 of RNAPII CTD,"102 nM, 30-100 nM, 9.1 nM","NanoBRET with CFK11 + cyclin L2, RNAPII-CTD phosphorylation at Tyr1, Ser2, Thr4, Ser5 and Ser7 after 2âh to 4âh., Sulforhodamine B growth assays in WT HCT116 cells treated with increasing concentrations of OTS964.",IC50,,,
THIQ,4.0,3.0,1.0,No,https://www.chemicalprobes.org/thiq,MC4R,GPCR,Melanocortin Receptor,2022-07-01,P32245,HLCHESOMJVGDSJ-LOYHVIPDSA-N,O=C(N[C@H](Cc1ccc(Cl)cc1)C(=O)N1CCC(Cn2cncn2)(C2CCCCC2)CC1)[C@H]1Cc2ccccc2CN1,No,No,CHEMBL339053,862913,,Agonist,,,"1.2 nM, 2.1 nM","Displacement of [125I]-NDP-R-MSH from human receptors expressed in CHO cells., Concentration of compound at 50% maximum cAMP accumulation.  97 % Percentage of cAMP accumulation at 10 ÂµM compound relative to R-MSH.","IC50, EC50","Rat, Dog","1 mg/Kg IV, 10 mg/Kg PO, 0.2 mg/Kg IV, 0.5 mg/Kg PO",
iHAP1,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ihap1,,,,2022-09-21,,CSWHYHPUEDNIQY-UHFFFAOYSA-N,COc1ccc(C(=O)N2c3ccccc3Sc3ccc(Cl)cc32)cc1,No,No,CHEMBL1801816,1610895,,,,,,,,,,
Talabostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/talabostat,,,,2021-03-29,,PHCFSFBQEROREL-BQBZGAKWSA-N,CC[C@H](N)C(=O)N1CCC[C@H]1B(O)O,No,Yes,CHEMBL66032,27596,,,,,,,,,,
DT-061,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/dt-061,,,,2022-09-21,,WGKGADVPRVLHHZ-ZHRMCQFGSA-N,O=S(=O)(N[C@@H]1CCC[C@H](N2c3ccccc3Oc3ccccc32)[C@H]1O)c1ccc(OC(F)(F)F)cc1,No,No,CHEMBL4450419,2912974,,,,,,,,,,
GF109203X,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/gf109203x,,,,2017-07-20,,QMGUOJYZJKLOLH-UHFFFAOYSA-N,CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21,No,Yes,CHEMBL7463,321917,,,,,,,,,,
SPH3127,4.0,4.0,2.0,No,https://www.chemicalprobes.org/sph3127,REN,Enzyme,Angiotensinogenase,2022-10-21,P00797,GRTDDIZIUSADLD-CRAIPNDOSA-N,COC(=O)NCCCn1nc([C@@H](C)N(C(=O)[C@H]2CNCCO2)C2CC2)c2ccc(C)nc21,No,No,CHEMBL4110551,485193,,Inhibitor,0.4 nM,Recombinant Human Renin Inhibition Assay (Fluorescence Resonance Energy Transfer [FRET]),0.45 nM,Plasma Renin Activity Assay (competitive radioimmunoassay),IC50,"Rat, Monkey (Cynomolgus)",3 mg/Kg,cpd 10
ML277,3.0,0.0,1.0,No,https://www.chemicalprobes.org/ml277,KCNQ1,Ion Channel,Potassium Channel,2022-11-21,P51787,OXQNLLVUVDAEHC-OAQYLSRUSA-N,COc1ccc(-c2csc(NC(=O)[C@H]3CCCCN3S(=O)(=O)c3ccc(C)cc3)n2)cc1,No,No,CHEMBL2070953,454716,,Activator,,,"260 nM, 265.9 % MAx","Electrophysiological assay using the population patch clamp mode on the IonWorks Quattroâ¢., Percent increase in KCNQ1 currents recorded at +40 mV at saturating compound concentrations in dose-response experiments for each compound","EC50, Activity",Other,,
GW7647,3.0,3.0,2.0,No,https://www.chemicalprobes.org/gw7647,PPARA,Nuclear Hormone Receptor,Nuclear receptor 1C1,2022-11-07,Q07869,PKNYXWMTHFMHKD-UHFFFAOYSA-N,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(=O)O,No,No,CHEMBL21241,614275,,Agonist,"6 nM, 51.8 nM","Activity on the human PPAR subtypes in vitro, PPARA activation TR-FRET","inhibition of proliferation, 600 nM","Lipid transport processes enrichment, hSMCs proliferation in normal growth medium (GM) after G0/G1-phase synchronization with increased proportion of hSMCs in the G0/G1 and decreased proportion in S phases, respectively., increase of p16 mRNA and protein levels","INH, Activity","Rat, Other",3 mg/Kg BID,
SEW-2871,2.5,1.0,2.0,No,https://www.chemicalprobes.org/sew-2871,S1PR1,GPCR,Sphingosine receptor,2022-11-07,P21453,OYMNPJXKQVTQTR-UHFFFAOYSA-N,FC(F)(F)c1cccc(-c2noc(-c3cc(-c4ccccc4)c(C(F)(F)F)s3)n2)c1,No,No,CHEMBL224720,242363,,Agonist,13 Â± 8.58 nm,GTPÎ³S binding assays measured in CHO cell membranes expressing stably transfected hS1P1 receptor,"dose dependent increase (600 nM to 600ÂµM), 13.8x, 5.8x","Calcium flux assay on murine variant, pAkt and pERK1 levels after treatment with SEW2871","EC50, Activity",Mouse,10 mg/Kg,
HAMI3379,2.5,0.0,2.0,No,https://www.chemicalprobes.org/hami3379,CYSLTR2,GPCR,Cysteinyl leukotriene receptor,2022-11-07,Q9NS75,HRJWSEPIRZRGCL-UHFFFAOYSA-N,O=C(O)c1ccc(OCCCc2ccc(OCCCCOC3CCCCC3)cc2)c(C(=O)NC2CCCC(C(=O)O)C2)c1,No,No,CHEMBL3342944,882128,,Antagonist,37.9 Â± 14.7 nM,Radioligand displacement of [3H]-LTD4 bound to the CysLT2 in lysates of CHO cells stably expressing the human CysLT2,"3.8-4.4 nM, 10 nM to 1 ÂµM","inhibition of 10 nM LTD4- and LTC4-induced (â¼EC80â90) intracellular calcium release in the CysLT2 receptor cell line, HAMI3379 concentration-dependently antagonized the LTC4-induced perfusion pressure increase and the negative effects of LTC4 on contractility","IC50, INH",,,
TRAM-34,3.5,0.0,2.0,No,https://www.chemicalprobes.org/tram-34,KCNN4,Ion Channel,Potassium channel,2022-11-03,O15554,KBFUQFVFYYBHBT-UHFFFAOYSA-N,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1,No,No,CHEMBL498270,1605420,,Inhibitor,,,"20 nM, 295-910 nM, 22 nM","Blocked current in whole Cells (patch-clamp assay), TRAM-34 suppresses reactivation of lymphocytes by anti-CD3 Ab or with a combination of the PKC-activator PMA and calcium-ionophore ionomycin, Patch clamp assay","Kd, EC50",,,
BMS-820132,2.0,4.0,1.0,No,https://www.chemicalprobes.org/bms-820132,GCK,Kinase,Hexokinase,2022-08-03,P35557,OYUDYQMFVRHPIY-UHFFFAOYSA-N,CCOP(=O)(Cn1ccc(NC(=O)c2cc(Oc3cnc(C(=O)N4CCC4)cn3)cc(OC(C)C)c2)n1)OCC,No,Yes,CHEMBL5072532,3622973,,Partial Activator,29 nM; max activation 143%,Enzymatic GK activation assay using purified recombinant human islet GK,,,,"Mouse, Rat, Dog, Monkey (Cynomolgus)","2.5 mg/Kg, 5 mg/Kg, 3 mg/Kg",
ICENTICAFTOR,4.0,4.0,2.0,No,https://www.chemicalprobes.org/icenticaftor,CFTR,Structural protein,ABCC,2022-10-21,P13569,USHQRIKZLHNPQR-JTQLQIEISA-N,COc1nc(C(=O)NC[C@](C)(O)C(F)(F)F)c(N)cc1C(F)(F)F,No,No,CHEMBL4650318,2975052,,Modulator,,,"79 nM, 47 nM, 39 nM","CFTR Membrane Potential Assay
F508del EC50 79 Â± 52 nM (92%), 	
G551D EC50 497 Â± 198 nM (40%)	
WT EC50 113 Â± 45 nM (79%), CFTR Ion Works Quattro Assay 96% efficacy, CFTR Ion Transport Assays with Primary HBEC
F508del EC50 39 Â± 22 nM (84%)
WT EC50 72 Â± 45 nM (87%)",EC50,"Rat, Dog, Monkey (Cynomolgus)","1 mg/Kg IV, 3 mg/Kg PO, 0.46 mg/kg IV, 3 mg/kg PO, 0.1 mg/Kg IV, 10 mg/Kg PO",
SC-560,4.0,3.0,1.0,No,https://www.chemicalprobes.org/sc-560,PTGS1,Enzyme,Synthase,2022-07-12,P23219,PQUGCKBLVKJMNT-UHFFFAOYSA-N,COc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc(Cl)cc2)cc1,No,No,CHEMBL26915,1483595,,Inhibitor,9 nM,Biochemical assay using recombinant COX-1 and arachidonic acid,,,,Rat,10 mg/Kg,CELECOXIB
Ricolinostat,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ricolinostat,,,,2023-01-12,,QGZYDVAGYRLSKP-UHFFFAOYSA-N,O/N=C(\O)CCCCCC/N=C(\O)c1cnc(N(c2ccccc2)c2ccccc2)nc1,No,Yes,,3450665,,,,,,,,,,
STK16-IN-1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/stk16-in-1,STK16,Kinase,Ser/Thr Kinase,2023-01-24,O75716,WQNRDXHKVSKUPI-UHFFFAOYSA-N,Cc1cc(-n2c(=O)ccc3c[nH]c4nccc-4c32)ccc1F,No,No,CHEMBL4552060,3212927,,Inhibitor,"295 nM, 910 nM, 1200 nM","Invitrogen SelectScreen Biochemical assay, IP kinase assay monitoring phosphorylation of T37/46 of 4EBP1, IP kinase assay of STK16-IN-1 with DRG1 as a substrate (detection of the general threonine phosphorylation).","1200 nM, 10ÂµM, 10 ÂµM","IP kinase assay of STK16-IN-1 with DRG1 as a substrate (detection of the general threonine phosphorylation)., in STK16 kinase knock-down cells, STK16-IN-1âs efficacy to reduce cell numbers and G2/M cell cycle arrest was significantly decreased;, Rescues of sensitivity to STK16-IN-1 of an inhibitor-resistant mutant (STK16 F100C), resulting in G2/M-phase cell cycle arrest","IC50, Activity",,,
LLY-283,4.0,4.0,1.0,No,https://www.chemicalprobes.org/lly-283,PRMT5,Epigenetic,Methyltransferase,2022-12-20,O14744,WWOOWAHTEXIWBO-QFRSUPTLSA-N,Nc1ncnc2c1ccn2[C@@H]1O[C@H]([C@H](O)c2ccccc2)[C@@H](O)[C@H]1O,Yes,No,CHEMBL4168754,1684099,,Inhibitor,"22 Â± 3 nM, 6 Â± 2 nM","Radioactivity-based assay assessing methylation of an H4R3 derived peptide substrate, Surface Plasmon Resonance (SPR","25 Â± 1 nM, 37 Â± 3 nM, 46 Â± 5 nM","SmBBâ²-Rme2s levels change determined by Western blot after 3 days of compound treatment, splicing of MDM4 in qPCR assay, Cell titer Glo assay","IC50, EC50",Mouse,10 mg/Kg,CANSAR1684258
IBERDOMIDE,0.0,0.0,0.0,No,https://www.chemicalprobes.org/iberdomide,"CRBN, IKZF1, IKZF3","Post-translational , Transcription factor, Transcription factor","E3 Ligase, Zinc finger, Zinc Finger",2023-01-17,"Q96SW2, Q13422, Q9UKT9",IXZOHGPZAQLIBH-NRFANRHFSA-N,O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,No,No,CHEMBL3989927,536706,,"Modulator, Molecular glue, Molecular Glue",60 nM,TR-FRET cereblon binding assay,"10 nM, 1 nM, 1.8 nM, 2.4, 0.5 nM, <1 nM","Inhibition of anti-dsDNA and anti-phospholipid IgM autoantibody production, Cell-Based Chemiluminescent Substrate Degradation Assays, Protein level measured by microcapillary electrophoresis western blotting, IKZF1 HiBiT assay, Protein level measured by microcapillary electrophoresis western blotting1","IC50, EC50, DC50",,,
BI-1347,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi-1347,"CDK8, CDK19","Kinase, Kinase","CMGC, CMGC",2023-01-26,"P49336, Q9BWU1",WULUGQONDYDNKY-UHFFFAOYSA-N,CN(C)C(=O)Cn1cc(-c2ccc(-c3cncc4ccccc34)cc2)cn1,No,No,CHEMBL4455382,2843074,,Inhibitor,"0.77 nM, 1.7 nM","Biochemical assay, Selectivity assay, Invitrogen","5 nM, 3 nM, 10 nM","tau aggregation assay in cell, Inhibition of pSTAT S727, Secretion of Perforin","EC50, IC50","Mouse, Rat","1 mg/Kg IV, 10 mg/Kg PO, 3 mg/Kg IV, 10 mg/Kg PO",BI-1374
ML154,3.0,0.0,1.0,No,https://www.chemicalprobes.org/ml154,NPSR1,GPCR,Neuropeptide S Receptor,2022-11-15,Q6W5P4,CJAQCMBWGUOBIX-ZUQRMPMESA-M,Cc1c(P(=S)(c2ccccc2)c2ccccc2)n2ccccc2[n+]1C/C=C/c1ccccc1.[Br-],No,Yes,CHEMBL1474387,584508,,Antagonist,,,"22.1 nM, 36.5 nM, 9.3 nM, 5.0 nM","NPS-induced cAMP response, NPS-induced calcium response, NPS-induced ERK phosphorylation inhibition, Radioligand displacement of  125I-NPS",IC50,,,
HG-10-102-01,4.0,3.0,1.0,No,https://www.chemicalprobes.org/hg-10-102-01,LRRK2,Kinase,TKL,2022-11-09,Q5S007,YEVOZZZLKJKCCD-UHFFFAOYSA-N,CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl,No,No,CHEMBL2170016,1750413,,Inhibitor,"20.3 nM, 3.2 nM, 153.7 nM, 95.9 nM","Biochemical inhibition of WT GST-LRRK2 in the presence of 100 Î¼M ATP., Biochemical inhibition of G2019S GST-LRRK2 in the presence of 100 Î¼M ATP., Biochemical inhibition of A2016T GST-LRRK2 in the presence of 100 Î¼M ATP., Biochemical inhibition of G2019S-A2016T GST-LRRK2 in the presence of 100 Î¼M ATP.","1 ÂµM for wild-type LRRK2; 0.3 Î¼M for LRRK2[G2019S]; 1â3 Î¼M in the drug-resistant LRRK2[A2016T + G2019S] and LRRK2[A2016T] mutants, 0.3 ÂµM","Determination of phosphorylation of Ser910 and Ser935, dephosphorylation of endogenous LRRK2 at Ser910 and Ser935",INH,Mouse,"10 mg/kg, 1 mg/Kg, 3, 10, 30, 50, and 100 mg/kg",
ML075,3.0,3.0,1.0,No,https://www.chemicalprobes.org/ml075,NPY2R,GPCR,Neuropeptide Y receptor,2022-11-24,P49146,PMEQBGAGFZDWQX-UHFFFAOYSA-N,CCOc1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,No,Yes,CHEMBL1543306,442977,,Antagonist,,,"199 nM, Ki : 1.55 nM","Y2R cAMP biosensor assay, 125I-PYY displacement with Y2R-expressing cells","IC50, Ki",Rat,10 mg/Kg,
AZD3965,3.0,3.0,1.0,No,https://www.chemicalprobes.org/azd3965,SLC16A1,Transporter,Solute carrier,2023-01-26,P53985,PRNXOFBDXNTIFG-FQEVSTJZSA-N,Cc1[nH]nc(C(F)(F)F)c1Cc1sc2c(c1C(=O)N1C[C@](C)(O)CO1)c(=O)n(C)c(=O)n2C(C)C,No,No,CHEMBL3335793,619815,,Inhibitor,"1.6 nM, 3.2 nM","Scintillation proximity assay on cell membranes, AZD3965 binding affinity to yeast membranes expressing recombinant human MCT1 by displacement of [3H]-MCT1","5.12 nM, 12.35 nM","Inhibition of lactate transport in cells, Cell proliferation assay","IC50, GI50",Mouse,"10 mg/Kg, 100 mg/Kg",
UNC1215,4.0,3.0,3.0,No,https://www.chemicalprobes.org/unc1215,L3MBTL3,Epigenetic,Malignant brain tumor Reader,2015-10-02,Q96JM7,PQOOIERVZAXHBP-UHFFFAOYSA-N,O=C(c1ccc(C(=O)N2CCC(N3CCCC3)CC2)c(Nc2ccccc2)c1)N1CCC(N2CCCC2)CC1,No,No,CHEMBL2426364,878173,"www.doi.org/10.1038/nchembio.1157, http://www.ncbi.nlm.nih.gov/pubmed/23292653",Inhibitor,"120 nM, 40 nM","ITC, Alpha screen methylated histone peptide competition assay",50-100 nM,FRAP assay,EC50,,,UNC1079
CP-673451,2.3,2.5,3.0,No,https://www.chemicalprobes.org/cp-673451,PDGFRB,Protein kinase,TK,2015-12-10,P09619,DEEOXSOLTLIWMG-UHFFFAOYSA-N,COCCOc1ccc2c(c1)ncn2-c1ccc2cccc(N3CCC(N)CC3)c2n1,No,No,CHEMBL4303508,327322,"http://cancerres.aacrjournals.org/content/65/3/957.long, http://www.ncbi.nlm.nih.gov/pubmed/15705896",ATP-competitive inhibitor,1 nM,"PDGFRalpha IC50 = 10 nM, enzyme assays with GST-tagged intracellular domains",1 nM,PDGFRalpha IC50 = 14 nM in autophosphorylation and protein substrate phosphorylation assays,IC50,Other,10-100 mg/kg,
MIV-6R,2.3,2.0,3.0,No,https://www.chemicalprobes.org/miv-6r,KMT2A,Epigenetic,Protein methyltransferase,2016-08-08,Q03164,AUWUGRCKTQSGJY-HHHXNRCGSA-N,N#Cc1ccc(OCCCN2CCC([C@@](N)(c3ccccc3)C3CCCC3)CC2)cc1,No,No,CHEMBL3126198,385619,"http://pubs.acs.org/doi/abs/10.1021/jm401868d, http://www.ncbi.nlm.nih.gov/pubmed/?term=24472025",Menin-MLL PPI inhibitor,85 nM,ITC. IC50 data were also reported (56 nM).,1.1 uM,"In MLL-AF9 transformed BMCs, MIV-6 inhibited cell proliferation. Comparable data were obtained in human leukemia cell lines (MV4;11, MOLM-13). 
In HEK293 cells, MIV-6 disrupted menin-MLL-AF9 interaction as assayed by co-immunoprecipitation (no quantification). 
MIV-6 also decreased expression of gene downstream of MLL (HOXA9 and MEIS1).",GI50,,,MIC-nc
CCT251545,4.0,3.3,3.0,No,https://www.chemicalprobes.org/cct251545,"CDK19, CDK8","Kinase, Kinase","CMGC, CMGC",2017-01-13,"Q9BWU1, P49336",LBFYQISQYCGDDW-UHFFFAOYSA-N,Cn1cc(-c2ccc(-c3cncc(Cl)c3N3CCC4(CCNC4=O)CC3)cc2)cn1,No,No,CHEMBL3408213,367223,"http://www.nature.com/nchembio/journal/v11/n12/full/nchembio.1952.html, http://pubs.acs.org/doi/abs/10.1021/jm501436m, http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01685, https://www.ncbi.nlm.nih.gov/pubmed/26502155, https://www.ncbi.nlm.nih.gov/pubmed/25680029, https://www.ncbi.nlm.nih.gov/pubmed/26796641",ATP-competitive inhibitor,"6 nM, 5 nM","Reporter Displacement Assay for CDK8 and CDK19 provided by Proteros Biostructures GmbH. The assay is based upon the competitive displacement of a reporter probe designed to selectively target the ATP binding site of CDK8 or CDK19 with a fast binding kinetic signature. Binding of the probe to its target results in the emission of an optical signal. Competitive displacement of the probe by the corresponding compounds results in a loss of the optical signal that can be quantified with increasing compound concentrations. Methods Enzymol. 493, 299â320 (2011)","5 nM, 23 nM","Cell-based potency was assessed in 7dF3 cells harbouring a WNT-dependent luciferase reporter (7dF3 is a variant of HEK293 cells containing both estrogen receptor-DSH and 
TCF-luciferase-IRES-GFP constructs). Cell-based potency was also assessed in LS174T cells bearing a WNT-dependent luciferase reporter.",IC 50,Other,"0.2 mg/kg (IV), 0.5 mg/kg (PO)","Compound 7 and 9 (Nat. Chem. Biol. 2015, 11, 973-980)"
BAY-1816032,4.0,4.0,2.0,No,https://www.chemicalprobes.org/bay-1816032,BUB1,Kinase,Ser/Thr Protein Kinase,2020-07-20,O43683,QVOGVAVHOLLLAZ-UHFFFAOYSA-N,COc1cnccc1Nc1nc(-c2nn(Cc3c(F)cc(OCCO)cc3F)c3ccccc23)ncc1OC,No,No,CHEMBL5084426,2933081,"www.doi.org/10.1158/1078-0432.CCR-18-0628, https://pubmed.ncbi.nlm.nih.gov/30429199/",Inhibitor,"6.1 nM @ 10 uM ATP, 2.1 nM, 1 nM","Biochemical TR-FRET assay, SPR, ePCA binding competition",20 nM,Inhibition of histone H2A-Thr120 phosphorylation and of histone H3-Ser10 phosphorylation assay,IC50,Mouse,0.5 mg/Kg (d),
SJF1528,3.5,0.0,2.0,No,https://www.chemicalprobes.org/sjf1528,"EGFR, ERBB2","Kinase, Kinase","RTK, RTK",2021-01-15,"P00533, P04626",ZSCOIFSUFMYZEZ-YSWDPXALSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)cc2)C(C)(C)C)cc1,No,No,,3313082,"www.doi.org/10.1016/j.chembiol.2017.09.009, https://pubmed.ncbi.nlm.nih.gov/29129716/",Degrader (PROTAC),,,"39.2 nM, 97.6 %, 736.2 nM, 68.8 %","Immunoblots, Immunoblots, Cell proliferation assay, suppression of downstream signalling.","DC 50, Dmax",,,
JNJ-39758979,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jnj-39758979,HRH4,GPCR,Histamine Receptor,2022-09-20,Q9H3N8,COOGVHJHSCBOQT-MRVPVSSYSA-N,CC(C)c1cc(N2CC[C@@H](N)C2)nc(N)n1,No,No,CHEMBL3236549,90095,,Antagonist,12.5 nM,Binding assay with membranes from cells transfected with the receptor,pA2 = 7.9,Cell-Based cAMP Assay,,"Rat, Mouse, Dog","2 mg/Kg, 10 mg/Kg, 5 mg/Kg",JNJ-39668551
SGC-AAK1-1,2.0,0.0,1.0,No,https://www.chemicalprobes.org/sgc-aak1-1,"AAK1, BMP2K","Kinase, Kinase","Ser/Thr kinase, Ser/Thr kinase",2022-11-21,"Q2M2I8, Q9NSY1",UCBIQZUJJSVQHL-UHFFFAOYSA-N,CCN(CC)S(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1,No,No,CHEMBL4452939,3148788,,Inhibitor,"9.1 nM, 17 nM",TR-FRET binding assays,"770 nM, 2800 nM",Nanobret,IC50,,,CANSAR3153834
ITI-214,3.0,3.7,3.0,No,https://www.chemicalprobes.org/iti-214,"PDE1A, PDE1B, PDE1C","Enzyme, Enzyme, Enzyme","Phosphodiesterase, Phosphodiesterase, Phosphodiesterase",2022-06-08,"P54750, Q01064, Q14123",BBIPVJCGIASXJB-PKTZIBPZSA-N,CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,No,No,CHEMBL3769414,783181,,Inhibitor,"0.058 nM, 0.38 nM, 0.035 nM",Enzymatic assay with fluorescent-labeled cAMP,,,,"Rat, Mouse","1 mg/Kg, 9.75 mg/Kg, 10 mg/Kg",
BI01383298,3.5,0.0,2.0,No,https://www.chemicalprobes.org/bi01383298,SLC13A5,Transporter,Solute transporter,2023-01-24,Q86YT5,VUOYAALVGSMUHC-UHFFFAOYSA-N,O=C(NCc1ccc(F)cc1)C1CCN(S(=O)(=O)c2cc(Cl)cc(Cl)c2)CC1,No,No,CHEMBL4757114,3570159,,Inhibitor,> 10 K @ 10 uM,Thermo Stabilisation Assay,"56 nM, 24 nM","Citrate uptake inhibition, Citrate uptake inhibition; maximum inhibition achieved after 30 min with 10ÂµM pre-incubation of inhibitor",IC50,,,BI01372674
A-446,3.0,3.0,2.0,No,https://www.chemicalprobes.org/a-446,GLS,Enzyme,Glutaminase,2022-03-25,O94925,DLNFTRSEHUWEGO-HUUCEWRRSA-N,O=C(Cc1ccccc1)Nc1nnc(N2C[C@H]3C[C@@H]2CN3c2cccnn2)s1,No,No,CHEMBL4802038,3550552,,Inhibitor,31 nM,GAC (GLS) Enzyme activity assay,11 nM,CTG assay in A549 cells,IC50,Mouse,50-200 mg/Kg BID,CANSAR3550553
ACY-738,3.0,2.7,3.0,No,https://www.chemicalprobes.org/acy-738,HDAC6,Epigenetic,HDAC,2017-04-10,Q9UBN7,LIIWIMDSZVNYHY-UHFFFAOYSA-N,O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1,No,Yes,CHEMBL3655950,1227519,"http://www.nature.com/npp/journal/v39/n2/full/npp2013207a.html, https://www.ncbi.nlm.nih.gov/pubmed/23954848",Inhibitor,1.7 nM,Enzyme assay with recombinant enzyme,,"In RN46A-B12 cells, ACY-738 (2.5 uM) increased acetylation of alpha-tubulin at K40 as detected by western blot.",,Other,5 mg/kg,CANSAR1573319
GSK2656157,4.0,4.0,2.0,No,https://www.chemicalprobes.org/gsk2656157,EIF2AK3,Kinase,Ser/Thr Kinase,2022-10-14,Q9NZJ5,PRWSIEBRGXYXAJ-UHFFFAOYSA-N,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,No,No,CHEMBL2441340,384279,,Inhibitor,0.8 nM,Phosphorylation of human eIF2Î±,"10-30 nM, 30 nM","Inhibition of PERK activation as well as decrease in the downstream substrates, phospho-eIF2Î±, ATF4, and CHOP measured via Western Blot, PERK autophosphorylation",IC50,"Mouse, Rat, Dog","2 mg/Kg, 13.4 mg/Kg, 2.2 mg/Kg, 4.3 mg/Kg, 2.9 mg/Kg, 5.2 mg/Kg",CANSAR203754
Homer,3.5,0.0,2.0,No,https://www.chemicalprobes.org/homer,WDR5,WD40 Repeat,,2022-03-22,P61964,OFNZESNEBSQKSE-BQGOKDIQSA-N,Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCNC(=O)c2ccc(-c3ccc(N4CCN(C)CC4)c(NC(=O)c4c[nH]c(=O)cc4C(F)(F)F)c3)cc2)C(C)(C)C)cc1,No,No,,3550549,,Degrader (PROTAC),18 nM,ITC,"53 nM, DCmax: 58% at 1 ÂµM","WDR5 degradation in a catalytic manner with a DCmax of 58%, HiBiT assay from Homer and both negative controls show that only Homer degrades WDR5 in MV4-11 cells after 24 h. Western Blots validate HiBiT data and show degradation of WDR5 by Homer treatment in MV4-11 cells after 24 h.","DC50, Dmax",,,"CANSAR3550550, CANSAR3550551"
HSL-IN-1,2.0,2.0,1.0,No,https://www.chemicalprobes.org/hsl-in-1,LIPE,Enzyme,Lipase,2022-10-05,Q05469,PDMXSCCBEBCTGX-UHFFFAOYSA-N,O=C(Nc1ccc(Cl)cc1B(O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2)nc1,No,Yes,CHEMBL4063082,316006,,Inhibitor,2 nM,In vitro colorimetric HSL assay using human HSL fractions and p-nitrophenyl butyrate (PNPB) as a substrate.,,,,Rat,3 mg/Kg,CANSAR668256
JNJ-54119936,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jnj-54119936,RORC,NHR,Orphan Receptor,2022-03-25,P51449,QBIGUDRHHJTXKG-UUWRZZSWSA-N,COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1,No,No,CHEMBL4802042,3550546,,Inverse Agonist,5.3 nM,Binding to RORC ligand-binding domain (ThermoFluor Binding Assay),"332 nM, 30 nM","Human whole blood assay, One-hybrid LBD",IC50,"Mouse, Rat","3, 10, 30, 100 mg/kg BID or 60 mg/kg QD, 1 mg/kg, 5 mg/kg",CANSAR3452631
JNJ-65355394,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jnj-65355394,OGA,Enzyme,Hydrolase,2022-06-08,O60502,CYFBRQHYEQKYHH-MRXNPFEDSA-N,CC(=O)Nc1ncc(CN2CCC[C@H](Cc3cc(C)nc(C)c3)C2)s1,No,No,CHEMBL4802039,3597778,,Inhibitor,"1.3 nM, 0.035 nM","Fluorescence-based enzymatic assay., Time dependent inhibition: t = 0 (Ki = 1.1 nM); t = 15 min (Ki = 0.035 nM). Kinetic profile: kinact = 0.0036 1/min; kinact/Ki = 3.27 1/(ÂµM*s).",3.9 nM,Cell-based OGA assay,IC50,Mouse,100 mg/Kg,CANSAR3597779
L-365260,3.0,3.0,1.0,No,https://www.chemicalprobes.org/l-365260,CCKBR,GPCR,Cholecystokinin Receptor,2022-06-15,P32239,KDFQABSFVYLGPM-QFIPXVFZSA-N,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(C)C2=O)c1,No,No,CHEMBL9387,233191,,Antagonist,2 nM,[125I] CCK binding in guinea pig gastric glands and brain cortex,2 nM,Radioligand binding assay,IC50,"Rat, Dog, Monkey (Rheus)","5 mg/Kg, 50 mg/Kg",CANSAR236284
NVS-BPTF-1,3.0,0.0,2.0,No,https://www.chemicalprobes.org/nvs-bptf-1,BPTF,Epigenetic,Bromodomain,2022-03-22,Q12830,JYTISQGEFSHUIR-UHFFFAOYSA-N,Cc1c(Nc2ccc(S(=O)(=O)N3CCN(C)CC3)cc2F)nc2ccc(-c3cnn(C4CC4)c3)cn2c1=O,No,No,CHEMBL4780673,3550557,,Inhibitor,"3 nM, 71 nM, 56 nM","BROMOscan, BLI assay, Alphascreen",16 nM,NanoBRET assay based on a bespoke tracer (5961) was developed to measure the binding,IC50,,,CANSAR3550558
PF-06471553,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pf-06471553,MOGAT3,Enzyme,Acyltransferase,2022-07-08,Q86VF5,GRXCLNMCJWKTAT-UHFFFAOYSA-N,COc1cccc(CC(=O)N2Cc3ccc(S(=O)(=O)Nc4cnn(C5CCC5)n4)cc3C2)c1,No,No,CHEMBL3613709,536599,,Inhibitor,92 nM,Biochemical quantification of radioactive product assessing its DGAT activity.,205 nM,Incorporation of [14C]-glycerol into TAG in presence of DGAT inhibitors,IC50,Mouse,"1 mg/Kg, 5 mg/kg",CANSAR389394
PFI-653,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pfi-653,VNN1,Vanin ,Biotinidase,2022-03-25,O95497,VGRLXWFIXGZRMS-UHFFFAOYSA-N,O=C(c1cnc(NCc2cnccn2)nc1)N1CCC2(CCOCC2)C1,No,No,CHEMBL4802040,3511561,,Inhibitor,6.85 nM,Human recombinant VNN1 assay with 25 pM VNN1,9.0 nM,Human plasma VNN1 assay with 8 nM VNN1,IC50,Rat,"2 mg/kg IV, 10 mg/kg PO",CANSAR3511558
PFI-7,3.0,0.0,2.0,No,https://www.chemicalprobes.org/pfi-7,GID4,E3 Ligase,,2022-03-25,Q8IVV7,HLHNFJNSQZZUNW-MAEOIBBWSA-N,O=C(CNCc1cc2ccccc2[nH]1)N[C@H]1CC[C@@H](c2nc3ccccc3[nH]2)CC1,No,No,,3550544,,Inhibitor,"80 nM, 4.1 ÂµM Kdisp","SPR, FP assay",600 nM,NanoBRET assay: interaction was between NanoLucÂ® tagged degrons and full-length GID4.â,EC50,,,CANSAR3550545
SAREDUTANT,0.0,0.0,0.0,No,https://www.chemicalprobes.org/saredutant,TACR2,GPCR,Tachykinin receptor,2022-08-03,P21452,PGKXDIMONUAMFR-AREMUKBSSA-N,CC(=O)NC1(c2ccccc2)CCN(CC[C@H](CN(C)C(=O)c2ccccc2)c2ccc(Cl)c(Cl)c2)CC1,No,No,CHEMBL308148,759847,,Antagonist,,,0.51 nM,Competitive radioligand assay,Ki,Guinea Pig,,CANSAR3550576
TNO155,3.0,3.0,1.0,No,https://www.chemicalprobes.org/tno155,PTPN11,Enzyme,Protein-tyrosine phosphatase,2022-10-05,Q06124,UCJZOKGUEJUNIO-IINYFYTJSA-N,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N,No,No,CHEMBL4650521,3315041,,Inhibitor,11 nM,Biochemical DiFMUP Assay,"11 nM, 100 nM","Determination of p-ERK in cell (AlphaScreen SureFire), Cell proliferation assay",IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","1 mg/Kg, 5 mg/Kg, 0.2 mg/Kg, 0.3 mg/Kg",CANSAR3148275
TP-040,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tp-040,OGA,Enzyme,Hydrolase,2022-03-25,O60502,PWKAYICUBVNJAZ-UHFFFAOYSA-N,CC1CCN(c2ccnc(NCc3cn(C)cn3)n2)CC1,No,No,CHEMBL4778870,3550547,,Inhibitor,46 nM,Human OGA enzymatic assay,450 nM,Glycosylation in-cell western assay,EC50,Mouse,30 mg/Kg,CANSAR3550548
VU0364739,3.5,3.0,2.0,No,https://www.chemicalprobes.org/vu0364739,PLD2,Enzyme,Phospholipase,2022-08-03,O14939,MSTXJJGAXXJCBY-UHFFFAOYSA-N,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc2ccccc2c1,No,No,CHEMBL1254577,520081,,Inhibitor,100 nM,Biochemical assay using purified PLD2,"95%, 20 nM","Cell proliferation assay WST-1, Endogenous Cellular Phospholipase D Activity Assay using deuterated 1-butanol incorporation.","Inhibition, IC50",Rat,"1 mg/Kg, 10 mg/Kg",CANSAR260217
LNS8801,0.0,0.0,0.0,No,https://www.chemicalprobes.org/lns8801,GPER1,GPCR,,2023-02-13,Q99527,VHSVKVWHYFBIFJ-HKZYLEAXSA-N,CC(=O)c1ccc2c(c1)[C@@H]1C=CC[C@@H]1[C@H](c1cc3c(cc1Br)OCO3)N2,Yes,No,CHEMBL569766,1714743,,Agonist,,,"2 nM, 11 nM, 10 nM","Mobilization of intracellular calcium, Displacement of E2-Alexa633 from GFP-tagged GPR30 expressed in COS7 cells by FACS, Activation of PI3K, resulting in the nuclear accumulation of PIP3 (fluorescence imaging)","EC50, Ki, Activity",,,
NVS-CECR2-1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/nvs-cecr2-1,CECR2,Epigenetic,Bromodomain,2023-02-13,Q9BXF3,XVECNLUKQDKOST-UHFFFAOYSA-N,CCCS(=O)(=O)c1nc(-c2ccc3c(ccn3C3CC(C)(C)NC(C)(C)C3)c2)c/c(=N\C2CC2)[nH]1,No,No,,3449864,,Inhibitor,"80 nM, 47 nM, 12.52 Â°C","ITC, AlphaScreen, Thermal shift","255 nM, 100 nM","NanoBRET - Dose-dependent displacement of CECR2 from histone H3.3 following treatment with NVS-CECR2-1., FRAP assay measuring half-times of fluorescence recovery (t1/2) after photo bleaching measured for CECR2 after treatment with NVS-CECR2-1 at different concentrations with or without SAHA.","IC50, Activity",,,NVS-CECR2-C
FIIN-1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/fiin-1,"FGFR1, FGFR2, FGFR3, FGFR4","Kinase, Kinase, Kinase, Kinase","Tyrosine kinase, Tyrosine Kinase, Tyrosine Kinase, Tyrosine Kinase",2023-02-13,"P11362, P21802, P22607, P22455",DNVFTXQYIYFQBW-UHFFFAOYSA-N,C=CC(=O)Nc1cccc(CN2C(=O)N(c3c(Cl)c(OC)cc(OC)c3Cl)Cc3cnc(NCCCCN(CC)CC)nc32)c1,No,Yes,CHEMBL2216830,906703,,Inhibitor,"2.8 nM, 9.2 nM, 6.9 nM, 6.2, 5.4 nM, 11.9 nM, 120 nM, 189 nM","Biochemical Assay, Zâ²-lyte assay","14 nM, 4 ÂµM, 10 nM","proliferation inhibition of FGFR1-transformed Ba/F3 cells, Western blot assessing autophosphorylation of FGFR1 in cells with an inducible FGFR1 (iFGFR1) system where oligomerization and activation of FGFR1 are induced upon the treatment of a small molecule AP20187.
Irreversibility shown by wash-out experiments in same system and looking at ERK1/2 phosphorylation, proliferation inhibition of FGFRÂ 3-transformed Ba/F3 cells","EC50, INH",,,FRIN-1
GSK2830371,4.0,3.0,1.0,No,https://www.chemicalprobes.org/gsk2830371,PPM1D,Enzyme,Phosphatase,2023-01-24,O15297,IVDUVEGCMXCMSO-FQEVSTJZSA-N,Cc1ncc(Cl)cc1NCc1ccc(C(=O)N[C@@H](CC2CCCC2)C(=O)NC2CC2)s1,No,No,CHEMBL3613749,392882,,Inhibitor,6 nM,FDP hydrolysis assay,"13 nM, 100 -1000 nM","dephpsphorylation of phospho-p38 MAPK, Western Blot for Wip1 substrates including p53 (S15), Chk2 (T68), H2AX (S139) and ATM (S1981), using phospho-siteâspecific antibodies","IC50, INH",Mouse,150 mg/Kg,
BI-9321,4.0,0.0,1.0,No,https://www.chemicalprobes.org/bi-9321,NSD3,Epigenetic,Methyltransferase,2023-01-23,Q9BZ95,WOAOENGFAAUUGT-UHFFFAOYSA-N,Cc1cc(CN)cc(C)c1-c1ncn(C)c1-c1ccnc2cc(F)ccc12,No,No,CHEMBL4778517,2842990,,Antagonist,"166âÂ±â3ânM, 445âÂ±â8ânM, 5.5âÂ°C, 203 nM","SPR, ITC, DSF, TR-FRET assay","1400 Â± 500nM, 1200 Â± 60 nM, 1000 nM","BRET, NanoBRET (protein-protein interaction disruption between C-terminally NanoLuc tagged NSD3-PWWP1 with C-terminally HaloTag Fusion tagged histone H3 in a dose-dependent manner), FRAP assay","IC50, INH",,,BI-9466
Baricitinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/baricitinib,"JAK1, JAK2","Kinase, Kinase","TK, TK",2021-02-16,"P23458, O60674",XUZMWHLSFXCVMG-UHFFFAOYSA-N,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,No,No,CHEMBL2105759,1750990,"www.doi.org/10.4049/jimmunol.0902819, www.doi.org/10.1016/j.str.2015.12.015, https://pubmed.ncbi.nlm.nih.gov/20363976/, https://pubmed.ncbi.nlm.nih.gov/26853940/",Inhibitor,"5.9 nM, 5.7 nM",Biochemical Assay (TR-FRET),"44 nM, 128 nM, 20 nM, 40 nM","Inhibition of IL-6âinduced phosphorylation of STAT3 in cell, Inhibition of IL-6âinduced phosphorylation of STAT3 in Whole Blood, Inhibition pSTAT3 stimulated by IL-23, Chemokine MCP-1 production",IC 50,Other,"1, 3, 10 mg/Kg","INCB027753, INCB029843"
LY2090314,2.0,1.0,1.0,No,https://www.chemicalprobes.org/ly2090314,"GSK3A, GSK3B","Kinase, Kinase","CMGC, CMGC",2023-01-24,"P49840, P49841",HRJWTAWVFDCTGO-UHFFFAOYSA-N,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,No,Yes,CHEMBL362558,760641,,Inhibitor,"1.5 nM, 1.1âÂ±â0.3",Biochemical assay,0.7âÂ±â0.26 nM,Phospho-Tau assay,IC50,"Rat, Dog",5 mg/Kg,
CK156,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ck156,STK17A,Kinase,CAMK,2022-03-25,Q9UEE5,YCFFONJEHNSECY-UHFFFAOYSA-N,CC(C)(C)NC(=O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1,No,No,,3550542,,Inhibitor,"49 nM, 21 nM","Radiometric assay (33PanQinase), ITC",181 nM,NanoBRET,IC50,,,CANSAR3550543
NMS-873,2.0,0.0,2.0,No,https://www.chemicalprobes.org/nms-873,VCP,ATPase,AAA+,2021-06-10,P55072,UJGTUKMAJVCBIS-UHFFFAOYSA-N,Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(S(C)(=O)=O)cc1,No,No,CHEMBL2311578,700581,"www.doi.org/10.1038/nchembio.1313, https://pubmed.ncbi.nlm.nih.gov/23892893/",Allosteric Inhibitor,30 nM low ATP; 20 nM high ATP; 20 nM C522T,ATPase Assay,"400 nM, 700 nM","antiproliferative activity assay, Antiproliferative assay",IC50,,,
CX-4945,3.5,3.0,2.0,No,https://www.chemicalprobes.org/cx-4945,CSNK2A1,Kinase,CMGC,2015-12-10,P68400,MUOKSQABCJCOPU-UHFFFAOYSA-N,O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,No,No,CHEMBL1230165,1618107,"http://cancerres.aacrjournals.org/content/70/24/10288.long, http://www.nature.com/leu/journal/v28/n1/full/leu2013232a.html, http://cancerres.aacrjournals.org/content/70/24/10288.long, http://www.ncbi.nlm.nih.gov/pubmed/21159648, https://www.ncbi.nlm.nih.gov/pubmed/?term=21755459",ATP-competitive inhbitor,"0.38 nM, 1 nM","Binding assessed in Millipore Kinase Profiler assay, In vitro kinase assay",,"CX-4945 dose-dependently inhibited substrate phosphorylation in BT-474, BxPC-C and HUVEC cells. CX-4945 inhibited phosphorylation of AKT at S129.",,Mouse,75 mg/mL,
DEUCRAVACITINIB,4.0,3.5,2.0,No,https://www.chemicalprobes.org/deucravacitinib,TYK2,Kinase,Tyrosine Kinase,2023-01-25,P29597,BZZKEPGENYLQSC-FIBGUPNXSA-N,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,No,No,CHEMBL4435170,3129874,,Inhibitor,"0.2 nM, 0.02 nM","homogeneous time-resolved fluorescence (HTRF) binding assays measuring the displacement of a probe compound, Morrison titration by varying the concentration of the fluorescent probe in the TYK2 JH2 assay","2 nM, 9 nM, 13 nM","Measuring STAT5 phosphorylation in CD3+ T-cells as end point, Measuring STAT3 phosphorylation in CD161+ CD3+ T-cells, STAT5 phosphorylation in CD3+ T-cells as end point",IC50,"Mouse, Dog, Monkey (Cynomolgus)","1 mg/Kg, 10 mg/Kg, 2 mg/Kg",
GSK591,3.3,4.0,3.0,No,https://www.chemicalprobes.org/gsk591,PRMT5,Epigenetic,Protein methyltransferase,2016-01-25,O14744,TWKYXZSXXXKKJU-FQEVSTJZSA-N,O=C(NC[C@H](O)CN1CCc2ccccc2C1)c1ccnc(NC2CCC2)c1,No,No,CHEMBL4542380,2849142,"http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00380, https://www.ncbi.nlm.nih.gov/pubmed/?term=26985292","protein substrate competitive inhibitor, SAM uncompetitive inhibitor",4 nM,Homogeneous time-resolved fluorescence (HTRF) assay under balanced conditions to monitor the monomethylation of H4R3 on a histone H4 peptide by PRMT5:MEP50.,3 nM,In-cell western assay following inhibition of symmetric dimethylation of arginine-containing substrates in Z-138 cells over 4 days.,IC50,,,
OTSSP167,1.5,2.0,2.0,No,https://www.chemicalprobes.org/otssp167,MELK,Protein kinase,CAMK,2015-12-10,Q14680,DKZYXHCYPUVGAF-JCNLHEQBSA-N,CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1,No,No,CHEMBL3688339,537794,"www.doi.org/10.18632/oncotarget.790, https://pubmed.ncbi.nlm.nih.gov/23283305/","Inhibitor, ATP competitive",0.41 nM,In vitro kinase assay using recombinant proteins,"6.7, 4.3, 2.3, 6.0 and 97 nM",,IC50,Other,1-20 mg/Kg,Cpd1
Adavosertib,3.0,3.0,3.0,No,https://www.chemicalprobes.org/adavosertib,WEE1,Protein kinase,Ser/Thr Protein Kinase,2020-10-26,P30291,BKWJAKQVGHWELA-UHFFFAOYSA-N,C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,Yes,No,CHEMBL1976040,732889,"www.doi.org/10.1158/1535-7163.MCT-09-0463, https://pubmed.ncbi.nlm.nih.gov/19887545/","Inhibitor, ATP competitive",5.2 nM,Radioactive in vitro Kinase assay,49 nM (alone); 85 nM (in combination,p-CDC2 and pHH3 Assays (calorimetric ELISA),EC50,Other,"5, 10, or 20 mg/kg, Reviewer suggest: 20 and 30 mg/Kg",
Pevonedistat,3.0,3.0,3.0,No,https://www.chemicalprobes.org/pevonedistat,UBA3,Other post-translational modification,Ubiquitin-conjugating enzyme,2017-06-06,Q8TBC4,MPUQHZXIXSTTDU-QXGSTGNESA-N,NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,No,No,CHEMBL1231160,353731,"http://www.sciencedirect.com/science/article/pii/S1097276509009551, https://www.nature.com/nature/journal/v458/n7239/full/nature07884.html, http://www.ncbi.nlm.nih.gov/pubmed/20129059, https://www.ncbi.nlm.nih.gov/pubmed/19360080","Antagonist, Pevonedistat-NEDD8 covalent adduct inhibits NAE",0.004 uM,"Purified enzyme assay, monitoring the formation of E2-UBL thioester reaction products.",<0.1 uM,"In HCT-116 cells, pevonedistat dose-dependently decreased Ubcl2-NEDD8 thioester formation and NEDD8-cullin conjugates; it increased CRL substrates (e.g., CDT1, p27, NRF2).",IC50,Other,10-60 mg/kg,
eCF506,3.0,3.0,4.0,No,https://www.chemicalprobes.org/ecf506,SRC,Protein kinase,TK,2017-02-23,P12931,GMPQGWXPDRNCBL-UHFFFAOYSA-N,COc1cc(-c2nn(CCN3CCC(N(C)C)CC3)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C,No,No,CHEMBL3824089,746858,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b00065, https://www.ncbi.nlm.nih.gov/pubmed/?term=27115835","ATP-competitive, Type I kinase inhibitor",0.5 nM,"Radioisotope-based assay ([Î³-33P] ATP) consisting of measuring 33P incorporation on the substrate (poly [Glu, Tyr] 4:1) relative to DMSO. IC50 values were calculated from the corresponding 8-point half-log dose response curves.",EC50 (MDA-MB-231)= 9 nM; EC50 (MCF7)= 70 nM,Antiproliferative assays. The antiproliferative properties of eCF506 were tested against breast cancer MCF7 (ER+) and MDA-MB-231 (triple negative breast cancer) cells. Cell viability was measured using the PrestoBlue(R) reagent and analysed by spectrofluorometry. EC50 values were calculated using a 10-point half-log dose. response study (0.3-1000 nM).,EC50,Other,10 mg/kg,Derivative 12r
G749,2.0,2.0,3.0,No,https://www.chemicalprobes.org/g749,FLT3,Protein kinase,TK,2020-11-27,P36888,SXWMIXPJPNCXQQ-UHFFFAOYSA-N,CN1CCC(Nc2nc(Nc3ccc(Oc4ccccc4)cc3)c3c(=O)[nH]cc(Br)c3n2)CC1,No,No,CHEMBL4544478,3128514,"http://www.bloodjournal.org/content/123/14/2209.long?sso-checked=true, https://www.ncbi.nlm.nih.gov/pubmed/?term=24532805","Inhibitor, ATP Competitive","0.4 nM FLT3-WT, 0.6 nM FLT3-D835Y",TR-FRET Kinase Assay,WT 6.1 Â± 0.4 nM; ITD 11.8 Â± 3.7 nM; ITD/N676D 21.4 Â± 1.1 nM; ITD/F691L	 38.1 Â± 6.6 nM; D835Y/N676D 2.1 Â± 0.7 nM; D835Y 3.1 Â± 0.5 nM,"Cell viability by an ATPLite assay, Western Blot (autophosphorylation, p-ERK, p-AKT) and ELISA assay",IC50,Other,30 mg/Kg,
Gandotinib,3.0,3.0,3.0,No,https://www.chemicalprobes.org/gandotinib,JAK2,Protein kinase,TK,2021-02-17,O60674,SQSZANZGUXWJEA-UHFFFAOYSA-N,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1,No,No,CHEMBL2107823,524939,"www.doi.org/10.1038/bcj.2013.6, https://www.ncbi.nlm.nih.gov/pubmed/?term=23584399","Inhibitor, ATP-Competitive, Mutant Specific",2.52 nM JAK2; 19.8 nM JAK1; 48.0 nM JAK3; 0.203 nM JAK2 WT; 0.246 nM JAK2 V617F,JAK LanthaScreen Kinase assay,45 nM (T); 942 nM (N); 191 nM (A); 20 nM (S) Mutant; 55 nM (P) Mutant,"Cellomics detection assay (TF-1 JAK2 cell-based assay (T), NK-92 JAK3/JAK1 heterodimer cell-based assay (N)), TEL-JAK cell-based AlphaScreen assays (A), pSTAT5 AlphaScreen assay (S), Cell proliferation assay (P)",IC50,Other,"30, 60, 100 mg/Kg",
GDC-0834,3.0,3.0,3.0,No,https://www.chemicalprobes.org/gdc-0834,BTK,Protein kinase,TK,2020-11-17,Q06187,CDOOFZZILLRUQH-GDLZYMKVSA-N,Cc1c(NC(=O)c2cc3c(s2)CCCC3)cccc1-c1cn(C)c(=O)c(Nc2ccc([C@@H]3C(=O)N(C)CCN3C)cc2)n1,No,No,CHEMBL2057915,887849,"www.doi.org/10.1016/j.bmcl.2015.01.032, www.doi.org/10.1124/jpet.111.181545, www.doi.org/10.1124/dmd.114.061804, https://www.ncbi.nlm.nih.gov/pubmed/?term=25701252, https://pubmed.ncbi.nlm.nih.gov/21521773/, https://pubmed.ncbi.nlm.nih.gov/25845827/","Inhibitor, ATP competitive",6 nM,"assayed at Invitrogen using the Z'-LYTE platform, Lanthascreen",60 nM CD86; 350 nM CD63; 380 nM CD69,"cell based CD86 assay, whole blood inhibition of both anti-IgE stimulated CD63 expression and anti-IgD stimulated CD69 expression",EC50,Other,30-100 mg/Kg,
WZ4002,3.0,3.0,3.0,No,https://www.chemicalprobes.org/wz4002,EGFR,Protein kinase,RTK,2020-11-25,P00533,ITTRLTNMFYIYPA-UHFFFAOYSA-N,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc2Cl)c1,No,Yes,CHEMBL1229592,633821,"http://www.nature.com/nature/journal/v462/n7276/full/nature08622.html, https://www.ncbi.nlm.nih.gov/pubmed/?term=20033049","Covalent Inhibitor, Mutant Selective","14 WT,  2.2 T790M, 1.5 L858R, 0.13 L858R/T790M nM",EGFR kinase assays,2 nM EGFR-L858R; 8 nM  EGFR-L858R/T790M; 3 nM EGFR (del); 2 nM EGFR (del/T790M),"pERK1/2, pAKT Western blot in PC9 GR lung cancer cells",IC50,Other,"1 mg/Kg IV, 10-25 mg/Kg PO",
CFI-402257,4.0,4.0,2.0,No,https://www.chemicalprobes.org/cfi-402257,TTK,Kinase,Ser/Thr Kinase,2021-02-02,P33981,PMQUGSPFUBGJCZ-CHOKWEPUSA-N,Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1,No,No,CHEMBL4469414,3164072,"http://www.pnas.org/content/114/12/3127, http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00485, https://www.ncbi.nlm.nih.gov/pubmed/27437075, https://www.ncbi.nlm.nih.gov/pubmed/28270606","Type 1.5 Inhibitor, ATP competitive","0.09 Â± 0.02 nM, 1.7 nM",TTK Inhibition Assay,"2 nM, 4 nM, 6,5 nM","Cell Viability Assay, Autophosphorylation inhibition assay","EC50, GI50",Other,"1 mg/Kg IV, 5 mg/Kg PO",
Tubastatin-A,3.0,3.0,2.0,No,https://www.chemicalprobes.org/tubastatin,"HDAC6, HDAC10","Epigenetic, Epigenetic","HDAC, HDAC",2017-07-20,"Q9UBN7, Q969S8",GOVYBPLHWIEHEJ-UHFFFAOYSA-N,CN1CCc2c(c3ccccc3n2Cc2ccc(C(=O)NO)cc2)C1,Yes,Yes,CHEMBL2018302,1730991,"http://pubs.acs.org/doi/abs/10.1021/ja102758v, http://mcb.asm.org/content/31/10/2066, www.doi.org/10.1021/acs.jmedchem.8b01936, www.doi.org/10.1074/jbc.M117.803775, https://www.ncbi.nlm.nih.gov/pubmed/20614936, https://www.ncbi.nlm.nih.gov/pubmed/21444725, https://www.ncbi.nlm.nih.gov/pubmed/30964290, https://www.ncbi.nlm.nih.gov/pubmed/28887310","Inhibitor, Class IIB","15 nM, 12.6 nM","Enzyme inhibition assays were performed by the Reaction Biology Corporation, Malvern, PA, using the Reaction Biology HDAC Spectrum platform and by TR-FRET following the displacement of radio-labelled compound., Enzyme inhibition assays were performed by the Reaction Biology Corporation, Malvern, PA, 
using the Reaction Biology HDAC Spectrum platform and by TR-FRET following displacement of radio-labeled compound.","100 nM, 12.5 nM",A bioluminescence resonance energy transfer (BRET) assay that measures displacement of a fluorescently-labeled ligand was used with cells that overexpress nano-luciferase-tagged HDAC10.,IC 50,Mouse,"5 mg/Kg IV, 30 mg/Kg Oral",Compound 27 (4-((2-(tert-Butyl)-1H-indol-1-yl)methyl)-N-hydroxybenzamide)
Tubacin,3.3,3.0,3.0,No,https://www.chemicalprobes.org/tubacin,HDAC6,Epigenetic,HDAC,2017-04-10,Q9UBN7,BHUZLJOUHMBZQY-YXQOSMAKSA-N,O=C(CCCCCCC(=O)Nc1ccc([C@@H]2O[C@H](c3ccc(CO)cc3)C[C@H](CSc3nc(-c4ccccc4)c(-c4ccccc4)o3)O2)cc1)NO,No,Yes,CHEMBL356769,959554,"http://www.pnas.org/content/100/8/4389.long, http://www.cell.com/cell-chemical-biology/abstract/S1074-5521(03)00095-4, http://www.nature.com/nchembio/journal/v6/n3/full/nchembio.313.html, https://www.ncbi.nlm.nih.gov/pubmed/12677000, https://www.ncbi.nlm.nih.gov/pubmed/12770821, https://www.ncbi.nlm.nih.gov/pubmed/?term=20139990","Selective, Reversible Inhibitor",0.016 uM,Biochemical enzyme assay with synthetic substrates (see Nature Chemical Biology paper),2.5 uM,Tubulin acetylation assays,EC50,,,niltubacin
UNC1999,3.3,2.0,3.0,No,https://www.chemicalprobes.org/unc1999,"EZH2, EZH1","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2015-10-02,"Q15910, Q92800",DPJNKUOXBZSZAI-UHFFFAOYSA-N,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(N3CCN(C(C)C)CC3)nc2)cc2c1cnn2C(C)C,No,No,CHEMBL3414619,873612,"www.doi.org/10.1021/cb400133j, http://www.ncbi.nlm.nih.gov/pubmed/23614352","Protein substrate noncompetitive inhibitor, SAM competitive inhibitor","10 nM, 4.6 nM., 45 nM","Transfer of 3H from SAM to peptide substrate in in vitro enzymatic assay. 
UNC1999's Ki for EZH2/SAM = 4.6 nM., Transfer of 3H from SAM to peptide substrate in in vitro enzymatic assay.",124 nM,in-cell western to detect protein substrate methylation in MCF10A cells,"IC 50, IC50",Mouse,"15, 50 or 150 mg/kg",UNC2400
Bistramide A,3.0,1.0,3.0,No,https://www.chemicalprobes.org/bistramide,ACTG2,Structural protein,Cytoskeleton,2017-06-27,P63267,HXZRMADPDYFMEB-FTTMEYFSSA-N,C/C=C/C(=O)C[C@H]1CC[C@H](C)[C@H](CC(=O)NC[C@H](O)[C@H](C)C(=O)NCCC[C@H]2O[C@@]3(CCC[C@H](CC[C@H](C)/C=C(\C)[C@H](C)O)O3)CC[C@@H]2C)O1,No,Yes,CHEMBL1221600,947606,"http://www.nature.com/nchembio/journal/v1/n7/full/nchembio748.html, http://pubs.acs.org/doi/abs/10.1021/ja058319c, http://www.pnas.org/content/105/11/4088.long, https://www.ncbi.nlm.nih.gov/pubmed/16372404, https://www.ncbi.nlm.nih.gov/pubmed/16551075, https://www.ncbi.nlm.nih.gov/pubmed/18334642","Severs actin filaments, Covalent sequestration of G-actin",7 nM,"Isothermal calorimetry (ITC) assays with G-actin and ATP. 
In G-actin polymerization experiments, Bistramide A decreased polymerization at concentrations 50-400 nM. In F-actin depolymerization assays, Bistramide A increased depolymerization at concentrations 120-450 nM. These results were confirmed in later experiments using TIRF microscopy (see PNAS paper).",,"In A549 cell lysates, biotinylated Bistramide A interacted with a single protein that was shown to be beta-actin by MS. Covalently modified actin was detected in A549 cells treated with BODIPY-conjugated Bistramide A.",,,,
AZD-6482,3.0,3.3,3.0,No,https://www.chemicalprobes.org/azd-6482,PIK3CB,Lipid kinase,Class I,2020-10-26,P42338,IRTDIKMSKMREGO-OAHLLOKOSA-N,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,No,No,CHEMBL2165191,295376,"www.doi.org/10.1158/2159-8290.CD-12-0003, www.doi.org/10.1111/j.1538-7836.2012.04898.x, https://pubmed.ncbi.nlm.nih.gov/22588880/, https://pubmed.ncbi.nlm.nih.gov/22906130/","Inhibitor, ATP competitive",0.69 nM,In Vitro kinase assay measurements against recombinant PI3Ks and PIKK using SelectScreen (Invitrogen),100-500 nM,TR-FRETâbased assay termed LanthaScreen,IC50,Other,"1 mg/Kg (IV), 10 mg/Kg (PO), 10 mg/Kg (IP)",
A-196,4.0,3.0,3.0,No,https://www.chemicalprobes.org/a-196,"KMT5B, KMT5C","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2015-11-09,"Q4FZB7, Q86Y97",ABGOSOMRWSYAOB-UHFFFAOYSA-N,Clc1cc2c(NC3CCCC3)nnc(-c3ccncc3)c2cc1Cl,No,No,CHEMBL4521971,2972225,"www.doi.org/10.1038/nchembio.2282, https://www.ncbi.nlm.nih.gov/pubmed/28114273","Substrate-competitive inhibitor, SAM non-competitive inhibitor","25 nM, 144 nM",Scintillation proximity assay - Methyltransferase activity assays for SUV420H1 and SUV420H2 were performed by monitoring the incorporation of tritium-labeled methyl group to monomethylated lysine 20 of peptide H4(1-24) (H4K20Me1). The experiments were performed in triplicate.,740 nM (activating H4K20me1); 262 nM (inhibiting H4K20me2); 370 nM (inhibiting H4K20me3),"In U2OS cells, EC50s were determined by western blot after treating the cells for 48 hours. Comparable results were obtained in LnCaP cells. 
The cellular effects were also evaluated using high-content microscopy, which allowed the simultaneous assessment of two methyl marks.  In the assay (in U2OS cells), IC50 for H4K20me1=1.91 uM (activation), H4K20me3=0.502 uM (inhibition). Comparable data were obtained in PC3 cells.",EC 50,,,"SGC2043, A-197"
AZD9496,4.0,3.3,3.0,No,https://www.chemicalprobes.org/azd9496,ESR1,Other,NR3 Subfamily,2020-12-02,P03372,DFBDRVGWBHBJNR-BBNFHIFMSA-N,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F,Yes,Yes,CHEMBL3623004,469255,"www.doi.org/10.1021/acs.jmedchem.5b00984, www.doi.org/10.1158/0008-5472.CAN-15-2357, https://pubmed.ncbi.nlm.nih.gov/26407012/, https://pubmed.ncbi.nlm.nih.gov/27020862/","Antagonist, Downregulator, Inhibitor",9.17 (0.8 nm),ERÎ± LanthaScreen Assay to Measure ERÎ± Binding,9.86 (0.11 nM) ER downregulation; 9.55 (0.28 nM) PR antagonism; 10.4 (0.04 nM) anti-proliferation,"Measurement of Endogenous ERÎ± and PR Levels in a Multiplexed Cell Assay, ERÎ± Functional Antagonism Cell Assay cell proliferation assay",pIC50,Other,5-100 mg/Kg,
UNC0638,2.8,3.0,4.0,No,https://www.chemicalprobes.org/unc0638,"EHMT2, EHMT1","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2015-10-02,"Q96KQ7, Q9H9B1",QOECJCJVIMVJGX-UHFFFAOYSA-N,COc1cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2cc1OCCCN1CCCC1,No,No,CHEMBL1231795,727620,"www.doi.org/10.1021/jm401480r, www.doi.org/10.1038/nchembio.599, http://www.ncbi.nlm.nih.gov/pubmed/24102134, http://www.ncbi.nlm.nih.gov/pubmed/21743462","protein substrate competitive inhibitor, SAM noncompetitive inhibitor","27 nM, <15 nM, 19 nM","SPR, Fluorescence-based SAHH coupled assay.",81 nM,In-cell western of protein substrate methylation assay,IC 50,Mouse,1 mg/mL,UNC0737
Niraparib,4.0,3.7,3.0,No,https://www.chemicalprobes.org/niraparib,"PARP1, PARP2","Other post-translational modification, Other post-translational modification","PARP, PARP",2016-07-29,"P09874, Q9UGN5",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,No,No,CHEMBL1094636,1512158,"http://pubs.acs.org/doi/abs/10.1021/jm901188v, http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00990, http://www.ncbi.nlm.nih.gov/pubmed/19873981, https://www.ncbi.nlm.nih.gov/pubmed/?term=28001384","Catalytic inhibitor, PARP-DNA complex trapping","3.2 nM, 3.8 nM, 16.7 nM, 2.1 nM, 15.3 nM","SPA assay., TCA precipitation assays, ADP ribosylation assays PARP1 (full length), ADP ribosylation assays PARP2 (full length)",4 nM,"In HeLa cells, activity was assessed in a general PARylation assay. 
In HeLa cell proliferation assays, loss of BRCA1 sensitized cells to MK-4827 (IC50 BRCA1- 33 nM, BRCA1+ 860 nM). 
In MDA-MB-436 cells (BRCA1-), CC50 = 18 nM. 
In CAPAN-1 cells (BRCA2-), CC50 = 90 nM. 
Normal human prostate and mammary epithelial cells were resistant to MK-4827.",EC 50,Other,,
Olaparib,3.0,3.0,3.0,No,https://www.chemicalprobes.org/olaparib,"PARP1, PARP2","Other post-translational modification, Other post-translational modification","PARP, PARP",2016-07-29,"P09874, Q9UGN5",FDLYAMZZIXQODN-UHFFFAOYSA-N,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,No,No,CHEMBL521686,422599,"http://pubs.acs.org/doi/abs/10.1021/jm8001263, http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00990, http://www.ncbi.nlm.nih.gov/pubmed/18800822, https://www.ncbi.nlm.nih.gov/pubmed/?term=28001384","Catalytic inhibitor, PARP-DNA complex trapping","5 nM, 1.4 nM, 1 nM, 12.3 nM","In vitro biochemical assays using 3H-NAD or biotinylated-NAD., ADP ribosylation assays, PARP1 (full-length), In vitro biochemical assays using 3H-NAD or biotinylated-NAD, ADP ribosylation assays, oliparib , PARP2 (full length)",6 nM,"Ex vivo PARylation assay in SW620 cell extracts. 
Olaparib also sensitized cells to methylmethane sulfonate in cellular sensitization assay (PF50 = IC50 with MMS/IC50 with PARP inhibitor: 25.8).",IC 50,Other,"10 mg/kg (mouse)  , 15 mg/kg (rat), 2.5 mg/kg (dog)",
Veliparib,4.0,4.0,3.0,No,https://www.chemicalprobes.org/veliparib,"PARP1, PARP2","Other post-translational modification, Other post-translational modification","PARP, PARP",2016-07-29,"P09874, Q9UGN5",JNAHVYVRKWKWKQ-CYBMUJFWSA-N,C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,No,No,CHEMBL506871,1081646,"http://clincancerres.aacrjournals.org/content/13/9/2728.long, http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00990, https://pubchem.ncbi.nlm.nih.gov/compound/11960529#section=Top, https://www.ncbi.nlm.nih.gov/pubmed/?term=28001384","Catalytic inhibitor, PARP-DNA complex trapping","5.2 nM, 3.3 nM, 2.9 nM, 17.5 nM","Biochemical Assay, ADP ribosylation assays, PARP1 (full length), In vitro Biochemical assay, ADP ribosylation assays, PARP2 (full length)","5.9 nM, PARP 5.9 nM","In LoVo cells, PAR synthesis assay.","IC 50, IC50",Other,"10 mg/kg (mice), 5 mg/kg (rat)",
GPR40ant39,2.3,2.0,3.0,No,https://www.chemicalprobes.org/gpr40ant39,FFAR1,GPCR,Free fatty acid receptors,2017-05-10,O14842,QKPUKWQKXUUTOK-UHFFFAOYSA-N,CC1(C#N)CN(c2cc(COc3ccc(F)c(F)c3F)nc(-c3ccccn3)n2)C1,No,No,CHEMBL3740291,308448,http://pubs.rsc.org/en/Content/ArticleLanding/2015/MD/c5md00037h#!divAbstract,"Antagonist, Allosteric (predicted)",160 nM,"HEK cells were stably transfected with GPR40, stimulated with elaidic acid and measuring the secondary messenger IP1 by time resolved fluorescence resonance energy transfer as an endpoint, full details are in the ESI of the paper.",160 nM,"HEK cells were stably transfected with GPR40, stimulated with elaidic acid and measuring the secondary messenger IP1 by time resolved fluorescence resonance energy transfer as an endpoint, full details are in the ESI of the paper.",IC50,Other,80 mg/kg,
CPI-0610,4.0,4.0,3.0,No,https://www.chemicalprobes.org/cpi-0610,"BRD2, BRD4, BRD3, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2017-04-24,"P25440, O60885, Q15059, Q58F21",GCWIQUVXWZWCLE-INIZCTEOSA-N,Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=N[C@H]2CC(N)=O,No,No,CHEMBL4303404,1693860,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01882, https://www.ncbi.nlm.nih.gov/pubmed/26815195",Inhibitor,"160 nM BD1, 25 nM BD2, 39 nM, 120 nM BD1, 18 nM BD2, 170 nM BD1, 21 nM BD2, 220nM BD1, 130 nM BD2","Alphalisa assay, Time-resolved FRET assay",180 nM,Quantigene MYC cellular assay (Affymetrix),"EC50, EC 50",Mouse,"30 mg/kg (oral), 10 mg/kg (SC)",
Prednisolone,0.0,0.0,0.0,No,https://www.chemicalprobes.org/prednisolone,NR3C1,Nuclear Receptor,Nuclear hormone receptor,2017-07-20,P04150,OIGNJSKKLXVSLS-VWUMJDOOSA-N,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,No,Yes,CHEMBL131,1688668,,"Glucocorticoid competitive, Agonist",2.5 nM,GR binding assays,"110 nM, 40 nM","transactivation assay, Repression activity of compounds, assessed as inhibition of AP-1 signaling in ChaGoK1 cells","EC50, IC50",,,
A-366,4.0,2.5,3.0,No,https://www.chemicalprobes.org/a-366,"EHMT2, EHMT1","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2015-10-02,"Q96KQ7, Q9H9B1",BKCDJTRMYWSXMC-UHFFFAOYSA-N,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,No,No,CHEMBL3109630,1550951,"www.doi/org/10.1021/ml400496h, http://www.ncbi.nlm.nih.gov/pubmed/24900801","protein substrate competitive inhibitor, SAM uncompetitive inhibitor","3.6 nM, 38 nM","Peptide-based AlphaLISA, measuring the levels of H3K9 dimethylation",~50 at 3 uM,"A-366 produced a dose-dependent reduction in cellular levels of H3K27Me in PC3 cells, with levels reduced ~50% at 3 uM.",% in,,,DS607
BI-9564,3.0,3.0,3.0,No,https://www.chemicalprobes.org/bi-9564,"BRD9, BRD7","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2016-07-29,"Q9H8M2, Q9NPI1",BJFSUDWKXGMUKA-UHFFFAOYSA-N,COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C,No,No,CHEMBL3823101,1780473,"http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b01865, http://www.ncbi.nlm.nih.gov/pubmed/?term=26914985","Antagonist, Inhibits interaction between BRD9/7 and acetylated histone","BRD9 14 nM, 6 nM, 239 nM","Isothermal titration calorimetry, DiscoveRx",275 nM,"BRD9 FRAP assay ~90%  inhibition at 100 nM 
Recovery After Photobleaching (FRAP) assay U2OS cells transfected with GFP-BRD9: measurement of recovery half times of wild-type cells treated with DMSO in the absence or presence of 2.5 ÂµM SAHA or treated with BI-9564 at different concentrations, BRD7 FRAP assay full  inhibition at 1ÂµM in
Recovery After Photobleaching (FRAP) assay U2OS cells transfected with GFP-BRD7: measurement of recovery half times of wild-type cells treated with DMSO in the absence or presence of 2.5 ÂµM SAHA or treated with BI-9564",IC 50,Mouse,180 mg/kg,Not available
EED226,3.8,3.7,4.0,No,https://www.chemicalprobes.org/eed226,EED,Epigenetic,Polycomb family,2017-03-30,O75530,DYIRSNMPIZZNBK-UHFFFAOYSA-N,CS(=O)(=O)c1ccc(-c2cnc(NCc3ccco3)n3cnnc23)cc1,No,No,CHEMBL4065484,1783947,"http://www.nature.com/nchembio/journal/vaop/ncurrent/full/nchembio.2304.html, https://www.ncbi.nlm.nih.gov/pubmed/28135235","Allosteric, Noncompetitive with SAM and peptide substrate","82 nM, 23.4 nM","Isothermal titration calorimetry (ITC), In in vitro enzyme assays",,"In G401 cells, EED226 dose-dependently decreased global H3K27me3 and H3K27me2 levels.",,Mouse,4 and 40 mg/kg,
(R)-PFI-2,4.0,0.0,3.0,No,https://www.chemicalprobes.org/r-pfi-2,SETD7,Epigenetic,Protein methyltransferase,2015-10-02,Q8WTS6,JCKGSPAAPQRPBW-OAQYLSRUSA-N,O=C([C@@H](Cc1cccc(C(F)(F)F)c1)NS(=O)(=O)c1cc(F)c2c(c1)CCNC2)N1CCCC1,No,No,CHEMBL3414622,623531,"www.doi.org/10.1073/pnas.1407358111, http://www.ncbi.nlm.nih.gov/pubmed/25136132","SAM uncompetitive inhibitor, Peptide competitive inhibitor (in the presence of SAM)",0.33 nM,"IC50 = 2 nM in radioactive methyltransferase assay, transfer of 3H from 3H-SAM to peptide substrate",submicromolar,CETSA,IC50,,,(S)-PFI-2
BAY-598,4.0,4.0,3.0,No,https://www.chemicalprobes.org/bay-598,SMYD2,Epigenetic,Protein methyltransferase,2015-11-09,Q9NRG4,OTTJIRVZJJGFTK-SFHVURJKSA-N,CCN(C(=O)CO)[C@H]1CN(/C(=N\C#N)Nc2cccc(OC(F)F)c2)N=C1c1ccc(Cl)c(Cl)c1,No,Yes,CHEMBL3818617,661904,"www.doi.org/10.1021/acs.jmedchem.5b01890, https://www.ncbi.nlm.nih.gov/pubmed/?term=27075367","protein-substrate competitive inhibitor, SAM uncompetitive inhibitor",27 nM,Scintillation proximity assay,58 nM,in-cell quantification of substrate methylation by FLAG-tagged SMYD2,IC50,Other,"0.8 mg/kg (rat), 10-100 mg/kg (mouse)",BAY-369
AMG232,4.0,3.7,3.0,No,https://www.chemicalprobes.org/amg232,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,DRLCSJFKKILATL-YWCVFVGNSA-N,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,No,No,CHEMBL3125702,738542,"http://pubs.acs.org/doi/abs/10.1021/jm401753e, https://www.ncbi.nlm.nih.gov/pubmed/24456472","Antagonist, Competitive inhibitor of MDM2-p53 interaction","0.045 nM, 0.6 nM","Surface plasmon resonance assay, HTRF assay","9.1 nM, 10 nM","In SJSA-1 EdU proliferation assay., In HCT-116 cells, AMG232 selectively inhibited the proliferation of p53 wild-type cells (IC50=10 nM compared with >25 uM for mutant p53 cells).",IC50,Other,0.5 mg/kg (rat),
AS-99,4.0,3.3,3.0,No,https://www.chemicalprobes.org/99,ASH1L,Epigenetic,HMT,2021-05-25,Q9NR48,VPQCHIWQHIOPQS-UHFFFAOYSA-N,CN1CC(C(=O)NCc2ccc3c(-c4cccc(C(N)=S)c4)cn(C4CCN(S(=O)(=O)C(F)(F)F)CC4)c3c2)C1,No,Yes,CHEMBL5085204,3313085,"www.doi.org/10.1038/s41467-021-23152-6, https://pubmed.ncbi.nlm.nih.gov/33990599/","Inhibitor, SET non-competitive",790 nM; 890 nM,"Histone methyltransferase radioactivity assay, ITC",1800 - 3600ânM,"down-regulation expression of MLL fusion target genes, reduction of H3K36 dimethylation,
cell proliferation inhibition in leukemia cells with MLL1 translocations: assay performed in mouse bone marrow (BM) progenitor cells derived from the WT or âSET Ash1l mice and transduced with MLL-AF9, MLL-AF6, HOXA9/MEIS1 (HM-2), E2A-HLF or vector alone (MSCV)",GI50,Mouse,"15 mg/Kg IV, 30 mg/Kg IP",AS-NC
UNC0642,4.0,2.7,3.0,No,https://www.chemicalprobes.org/unc0642,"EHMT2, EHMT1","Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase",2016-08-08,"Q96KQ7, Q9H9B1",RNAMYOYQYRYFQY-UHFFFAOYSA-N,COc1cc2c(NC3CCN(C(C)C)CC3)nc(N3CCC(F)(F)CC3)nc2cc1OCCCN1CCCC1,No,No,CHEMBL2441082,878306,"http://pubs.acs.org/doi/abs/10.1021/jm401480r, http://www.ncbi.nlm.nih.gov/pubmed/?term=24102134","Peptide substrate competitive inhibitor, SAM noncompetitive inhibitor","3.7 nM, <2.5 nM",Enzymatic activity assays.,110 nM,"Inhibition of protein substrate (H3K9) methylation assessed by in cell western in MDA-MB-231 cells. Comparable results were also obtained in U2OS, PC3 and PANC-1 cells.",IC 50,Mouse,5 mg/kg,
GSK2033,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsk2033,"NR1H2, NR1H3","NHR, NHR","NR1 Subfamily, NR1 Subfamily",2017-07-27,"P55055, Q13133",PSOXOVKYGWBTPB-UHFFFAOYSA-N,Cc1cc(C)c(S(=O)(=O)N(Cc2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)Cc2ccc(C(F)(F)F)o2)c(C)c1,No,No,CHEMBL1093266,820132,"www.doi.org/10.1021/jm901797p, https://www.ncbi.nlm.nih.gov/pubmed/20345102, https://pubmed.ncbi.nlm.nih.gov/27680310/","Antagonist, Inverse Agonist, mix Agonist/Antagonist in vivo",31.6 nM,LXR LEADseeker binding assay,"17, 52 nM, 9, 10 nM","Co-transfection using Luciferase reporter assay, basal gene expression suppression for ABCA1 and SREBP-1c genes",IC 50,Mouse,"30 mg/Kg, 40 mg/Kg, 50 mg/Kg",
Selumetinib,3.3,3.0,3.0,No,https://www.chemicalprobes.org/selumetinib,MAP2K1,Kinase,STE,2015-12-10,Q02750,CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,No,No,CHEMBL1614701,1897397,"http://clincancerres.aacrjournals.org/content/13/5/1576.long, http://www.ncbi.nlm.nih.gov/pubmed/17332304","Covalent, ATP noncompetitive inhibitor",14 nM,Radiometric kinase assay,10 nM,Inhibition of substrate phosphorylation in Malme-3M cells,IC50,Mouse,10-100 mg/kg,
STM2457,3.7,3.3,3.0,No,https://www.chemicalprobes.org/stm2457,METTL3,Epigenetic,Methyltransferase,2021-05-06,Q86U44,DTBGJTHCIGPRDA-UHFFFAOYSA-N,O=C(NCc1cn2cc(NCCC3CCCCC3)ccc2n1)c1cc(=O)n2ccccc2n1,No,No,,3313073,"www.doi.org/10.1038/s41586-021-03536-w, https://pubmed.ncbi.nlm.nih.gov/33902106/","Inhibitor, SAM competitive","16.9 nM, 1.4 nM","METTL3/14 RF/MS methyltransferase assay, SPR","1520 nM, 2810 nM","InCell Pulse Assay in HeLa cells transfected with human protein, InCell Pulse Assay in HeLa cells transfected with mouse protein",IC50,Mouse,30-50 mg/Kg,STM2120
EPZ015666,4.0,4.0,3.0,No,https://www.chemicalprobes.org/epz015666,PRMT5,Epigenetic,Protein methyltransferase,2016-01-25,O14744,ZKXZLIFRWWKZRY-KRWDZBQOSA-N,O=C(NC[C@H](O)CN1CCc2ccccc2C1)c1cc(NC2COC2)ncn1,No,No,CHEMBL4060831,135764,,"Protein substrate competitive inhibitor, SAM uncompetitive inhibitor",5 nM,Homogeneous time-resolved fluorescence (HTRF) assay under balanced conditions to monitor the monomethylation of H4R3 on a histone H4 peptide by PRMT5:MEP50,9 nM,In-cell western (ICW) assay following inhibition of symmetric dimethylation of arginine-containing substrates in Z-138 cells over 4 days.,IC50,Mouse,"10 mg/kg, 2 mg/kg (IV)",EPZ019896
Atorvastatin,0.0,0.0,0.0,No,https://www.chemicalprobes.org/atorvastatin,HMGCR,Lipid metabolism,Sterol biosynthesis,2017-07-19,P04035,XUKUURHRXDUEBC-KAYWLYCHSA-N,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,No,No,CHEMBL1487,840349,"https://doi.org/10.1021/jm800001n, https://doi.org/10.1124/dmd.113.054783, https://pubmed.ncbi.nlm.nih.gov/18412317/, https://pubmed.ncbi.nlm.nih.gov/24194513/","Inhibitor, Prodrug","8 nM, 6.2 nM","Inhibition of HMG-CoA Reductase , 6.2 nM (Ki, Rat homolog), Inhibition of HMG-CoA Reductase (Rat homolog)",,,,Mouse,"10 mg/kg (IV), 300 mg/kg (PO)","3S, 5S-Atorvastatin"
AZD9833,0.0,0.0,0.0,No,https://www.chemicalprobes.org/azd9833,ESR1,Other,Hormone Receptor,2021-08-11,P03372,WDHOIABIERMLGY-CMJOXMDJSA-N,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,No,No,CHEMBL4650365,3323307,"https://doi.org/10.1021/acs.jmedchem.0c01163, https://pubmed.ncbi.nlm.nih.gov/32910656/","Degrader, Antagonist",2.5 nM,ER Binding Assay,9.8; 99 %,Measurement of Endogenous ERÎ± and PR Levels in a Multiplexed Cell Assay,"pIC50, Dmax",Other,"2/5 IV/PO mg/Kg (M), 0.5/1 IV/PO mg/Kg (R)",
PZ2891,4.0,4.0,1.0,No,https://www.chemicalprobes.org/pz2891,"PANK1, PANK2, PANK3","Kinase, Kinase, Kinase","Pantothenate kinase, Pantothenate kinase, Pantothenate kinase",2021-04-19,"Q8TE04, Q9BZ23, Q9H999",LGWDVWIZDPGCFG-UHFFFAOYSA-N,CC(C)c1ccc(CC(=O)N2CCN(c3ccc(C#N)nn3)CC2)cc1,No,No,CHEMBL5077276,2982200,"www.doi.org/10.1038/s41467-018-06703-2, https://pubmed.ncbi.nlm.nih.gov/30352999/","Allosteric Activator, Orthosteric Inhibitor","40.2 Â± 4.4 nM, 0.7 Â± 0.08 nM, 1.3 Â± 0.2 nM, 0.203 nM","SPR, radiochemical kinase assay, SPR",8.7 Â± 2.6 uM,"TLC with Radio-labelled Panthotenate, CETSA",K 0.5,Mouse,"2 (IV), 10 (PO) mg/Kg",PZ-3067
Cabozantinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/cabozantinib,KDR,Kinase,TK,2021-02-17,P35968,ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,No,No,CHEMBL2105717,735720,"http://mct.aacrjournals.org/content/10/12/2298.long, https://www.ncbi.nlm.nih.gov/pubmed/?term=21926191","Inhibitor, ATP Competitive",0.035 nM,AlphaScreen Assay,"6.7 nM, 4.1-7.7 nM, 31 nM, 9 nM","Phosphorylation Inhibition Assay, Inhibition of tubule formation in response to conditioned media derived from various cell cultures (MDA-MB-231 (IC50 = 5.1 nmol/L), A431 (IC50 = 4.1 nmol/L), HT1080 (IC50 = 7.7 nmol/L), and B16F10), Inhibition of HGF-induced migration, Inhibition HGF-induced invasion",IC50,Mouse,100 mg/Kg,
Brivanib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/brivanib,KDR,Kinase,TK,2021-02-16,P35968,WCWUXEGQKLTGDX-LLVKDONJSA-N,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,No,No,CHEMBL377300,1807068,"www.di.org/10.1021/jm051106d, www.doi.org/10.1007/s00280-009-1002-0, https://pubmed.ncbi.nlm.nih.gov/16570908/, https://pubmed.ncbi.nlm.nih.gov/19396600/","Inhibitor, ATP competitive","26 nM, 25 nM","Kinase Assay using [Î³-33P]-ATP IC50; 25 nM Ki, Kinase Assay using [Î³-33P]-ATP","40 nM, 276 nM","Inhibition of cell Proliferation VEGF stimulated, Inhibition of cell Proliferation FGF stimulated",IC50,Other,"10, 60, 90 Mg/Kg",
BRD4770,0.0,0.0,0.0,No,https://www.chemicalprobes.org/brd4770,EHMT2,Epigenetic,Protein methyltransferase,2017-07-19,Q96KQ7,UCGWYCMPZXDHNR-UHFFFAOYSA-N,COC(=O)c1ccc2c(c1)nc(NC(=O)c1ccccc1)n2CCCc1ccccc1,No,No,CHEMBL3970748,445749,"http://pubs.acs.org/doi/abs/10.1021/cb300139y, http://www.ncbi.nlm.nih.gov/pubmed/?term=22536950","SAM mimetic, possible prodrug for BRD9539",6300 nM,"In vitro enzyme activity assays on the related compound BRD9539. BRD4770 activity was reported to be lower in vitro, but the authors suggest BRD9539 is the active agent in cells.",5000 nM,"In PANC-1 cells, BRD4770 decreased substrate methylation (H3K9), and BRD4770 phenocopies EHMT2 knockdown (morphological changes and senescence-associated beta-galactosidase staining).",EC50,,,
AZD1332,4.0,4.0,2.0,No,https://www.chemicalprobes.org/azd1332,"NTRK1, NTRK2","Kinase, Kinase","TK, TK",2021-02-22,"P04629, Q16620",LBVKEEFIPBQIMD-JTQLQIEISA-N,CC(C)Oc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)ncc2Cl)[nH]n1,No,No,,1988291,"www.doi.org/10.1021/jm800343j, www.doi.org/10.1158/1535-7163.MCT-09-0036, https://pubmed.ncbi.nlm.nih.gov/18646745/, https://pubmed.ncbi.nlm.nih.gov/19509272/","Inhibitor, ATP competitive","2 nM, 8 nM",AlphaScreen and HTRF phosphorylation assay,1.2 nM,"Modified TRF-based TrkA intact cell assay, multiple phosphospecific cellular end point assays (ELISA-based)",EC 50,Other,"3 mg/Kg IV, 10 mg/Kg PO, Reviewer suggest 50-100 mg/Kg",
Tacrolimus,3.5,3.5,2.0,No,https://www.chemicalprobes.org/tacrolimus,FKBP1A,Other,Immunophilin Protein Family ,2021-02-04,P62942,QJJXYPPXXYFBGM-LFZNUXCKSA-N,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,No,No,"CHEMBL269732, CHEMBL4564923",979085,"www.doi.org/10.1021/jm980307x, www.doi.org/10.1073/pnas.89.9.3686, www.doi.org/10.2133/dmpk.22.328, www.doi.org/10.1021/jm031101l, https://pubmed.ncbi.nlm.nih.gov/7530743/, https://pubmed.ncbi.nlm.nih.gov/9857082/, https://pubmed.ncbi.nlm.nih.gov/1373887/, https://pubmed.ncbi.nlm.nih.gov/17965516/, https://pubmed.ncbi.nlm.nih.gov/15369399/","FKBP-Tacrolimus inhibitor complex, Molecular Glue",0.4 nM,Spectrophotometric Assay (Fisher Assay),"0.19ânM, 0.29 nM, 0.18 nM, 0.06 nM, 0.95 nM","IL-2 reporter gene assay, Murine MLR assay, PPD-induced proliferation of HPBMNC isolated from blood,, IL-5 production assay (WB), IFN-Î³ production assay (WB), Macrophilin-12 (FKBP-12) binding assay",IC50,Rat,"1, 2, 5, 10 mg/Kg",
AGI-6780,2.0,1.0,3.0,No,https://www.chemicalprobes.org/agi-6780,IDH2,Other,Dehydrogenase,2017-03-14,P48735,CCAWRGNYALGPQH-UHFFFAOYSA-N,O=C(Nc1cccc(C(F)(F)F)c1)Nc1cc(S(=O)(=O)NC2CC2)ccc1-c1ccsc1,No,No,CHEMBL3392845,466009,"http://science.sciencemag.org/content/340/6132/622.long, https://www.ncbi.nlm.nih.gov/pubmed/23558173","Allosteric inhibitor, uncompetitive with NADPH, noncompetitive with alphaKG substrate",23 nM R140Q,Enzymatic assay,11 nM,"In U87 cells expressing the mutant protein, AGI-6780 dose-dependently decreased 2HG levels.",IC 50,,,
BAZ2-ICR,3.0,2.0,3.0,No,https://www.chemicalprobes.org/baz2-icr,"BAZ2A, BAZ2B","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2016-07-29,"Q9UIF9, Q9UIF8",RRZVGDGTWNQAPW-UHFFFAOYSA-N,Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(C#N)cc2)cn1,No,No,CHEMBL4296718,1887473,"http://pubs.acs.org/doi/10.1021/jm501963e, http://www.ncbi.nlm.nih.gov/pubmed/?term=25719566","Antagonist, Mimics acetylated lysine","109 nM, 130 nM, 170 nM, 180 nM","Isothermal Titration Calorimetry., Alphascreen, Isothermal Titration Calorimetry",,"In FRAP assay in U2OS cells, BAZ2-ICR displaced the targets from chromatin.",,Mouse,5 mg/kg,
CC-90009,3.5,3.5,2.0,No,https://www.chemicalprobes.org/cc-90009,GSPT1,Other,Translation Termination Factor,2021-03-15,P15170,PWBHUSLMHZLGRN-UHFFFAOYSA-N,O=C1CCC(N2Cc3cc(CNC(=O)C(F)(F)c4ccc(Cl)cc4)ccc3C2=O)C(=O)N1,No,Yes,CHEMBL4742712,3312892,"www.doi.org/10.1021/acs.jmedchem.0c01489, www.doi.org/10.1182/blood.2020008676, https://pubmed.ncbi.nlm.nih.gov/33591756/, https://pubmed.ncbi.nlm.nih.gov/33197925/","Molecular Glue, Degrader",,,"9 nM, 88% @ 20 h, 200 nM","ePL Degradation Assay (ePL tagged GSPT1), Western Blot","DC50, Dmax",Other,"2 mg/Kg (M, R); 1 mg/Kg (Cyno)",
SGC-CLK-1,3.0,2.0,2.0,No,https://www.chemicalprobes.org/sgc-clk-1,"CLK1, CLK2, CLK4","Kinase, Kinase, Kinase","CMGC, CMGC, CMGC",2021-01-30,"P49759, P49760, Q9HAZ1",GJYVLTPTDBQQCY-UHFFFAOYSA-N,COc1cc(Nc2nccc(-c3cnn4nc(OC)ccc34)n2)cc(C(F)(F)F)c1,No,No,CHEMBL187139,240606,"www.doi.org/10.3390/ijms21207549, https://pubmed.ncbi.nlm.nih.gov/33066143/","Inhibitor, ATP Competitive","13 nM, 4 nM, 46 nM",Luceome Biotechnology Binding assay,"165 nM, 100 nM, 70 nM",NanoBRET,IC50,,,SGC-CKL-1N
BAY-3827,3.3,0.0,3.0,No,https://www.chemicalprobes.org/bay-3827,"PRKAA1, RPS6KA1","Kinase, Kinase","CAMK, CAMK",2020-08-03,"Q13131, Q15418",OZFFKOSQNBBYCA-UHFFFAOYSA-N,CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12,No,No,CHEMBL4580220,3048723,"www.doi.org/10.1007/s13402-020-00584-8, https://pubmed.ncbi.nlm.nih.gov/33492659/","Inhibitor, ATP competitor","1.4, 15 nM (High/Low ATP), 7 nM, 9.1 nM","High potency in biochemical PRKAA1 assay with IC50 = 1.4 nM @ 10 ÂµM ATP; 15 nM @ 2 mM ATP (Bayer in house), Eurofins @ 1 ÂµM","150 nM, 390 nM","Active in cellular mechanistic assay (150 nM) demonstrating cellular target engagement 
Additional proof for on target activity: ATP-competitive binding mode demonstrated., Cellular mechanistic pACC assay using Colo-320 cells",IC 50,,,BAY-974
Capmatinib,4.0,4.0,2.0,No,https://www.chemicalprobes.org/capmatinib,MET,Kinase,TK,2020-10-26,P08581,LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,No,No,CHEMBL3188267,387343,"www.doi.org/10.1158/1078-0432.CCR-11-1157, www.doi.org/10.1158/1078-0432.CCR-18-2814, https://pubmed.ncbi.nlm.nih.gov/21918175/, https://pubmed.ncbi.nlm.nih.gov/30674502/","Inhibitor, ATP competitive","0.13 nM, 0.31 nM","Cell-Free Assay, Dose-response experiment",0.3-1.1 nM,"Western blot of phospho c-MET and downstream targets ERK1/2, AKT, FAK, GAB1, STAT3/5; ELISA-based detections of phospho-c-MET in cell protein extracts. Detailed IC50 in nM per cell line: SNU-5 (gastric) 1.1, S114 (transfected) 0.9, A549 (lung) 0.7, U-87MG (glioblastoma) 1, 786-0 (kidney) 0.6, H441 (lung) 0.7, H596 (lung) 0.4, H1437 (lung) 0.3 (596 and H1437 express mutant c-MET due to an exon 14 deletion and the R988C mutation, respectively)",IC50,Mouse,"0.03, 0.1, 0.3, 1, 3, or 10 mg/kg, Reviewer suggested: 3, 10, and 30 mg/kg BID",
NVP-2,4.0,0.0,1.0,No,https://www.chemicalprobes.org/nvp-2,CDK9,Kinase,CMGC,2021-05-11,P50750,XWQVQSXLXAXOPJ-QNGMFEMESA-N,COC[C@@H](C)NC1CCC(Nc2cc(-c3cccc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1,No,No,,3313070,"www.doi.org10.1038/nchembio.2538, https://pubmed.ncbi.nlm.nih.gov/29251720/","Inhibitor, ATP competitive",0.514 nM,Cdk9/CyclinT1 IMAP,"9 nM, 92-574 nM","Cell Apoptosis, anti-proliferation of leukemia cells",IC50,,,
AMG-337,3.7,4.0,3.0,No,https://www.chemicalprobes.org/amg-337,MET,Kinase,TK,2020-11-26,P08581,WKIALOXOAZXGMG-UHFFFAOYSA-N,C=C1c2cc(OCCOC)cnc2C=CN1C(C)c1nnc2c(F)cc(-c3cnn(C)c3)cn12,No,No,,3313065,"www.doi.org/10.1158/1535-7163.MCT-15-0871, www.doi.org/10.1021/acs.jmedchem.5b01716, https://www.ncbi.nlm.nih.gov/pubmed/?term=27196782, https://pubmed.ncbi.nlm.nih.gov/26812066/","Inhibitor, ATP Competitive",1 nM,TR-FRET (WT MET),5 nM,"Quantitative electrochemiluminescence immunoassay, CellTiter-Glo Luminescent Cell Viability Assay.",IC50,Other,0.1-10 mg/Kg,
Afatinib,2.7,2.7,3.0,No,https://www.chemicalprobes.org/afatinib,"EGFR, ERBB2","Kinase, Kinase","RTK, RTK",2015-12-10,"P00533, P04626",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,No,Yes,CHEMBL1173655,576596,"http://www.nature.com/onc/journal/v27/n34/full/onc2008109a.html, http://www.ncbi.nlm.nih.gov/pubmed/18408761","ATP-competitive inhibitor, covalent inhibitor","0.5 nM, 14 nM",In vitro kinase assays,13-71 nM,"In cell autophosphorylation detected by ELISA. Cells assayed include: A431, NIH-3T3, BT-474, NCI-N87; IC50 varied by cell type.",EC 50,Mouse,20 mg/kg,
MK-8033,3.5,3.5,2.0,No,https://www.chemicalprobes.org/mk-8033,"MET, MST1R","Kinase, Kinase","TK, TK",2020-11-26,"P08581, Q04912",VMJFTOSOFDEKTM-UHFFFAOYSA-N,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,No,No,CHEMBL2323775,597001,"www.doi.org/10.1021/jm301619u, www.doi.org/10.1097/JTO.0b013e318257cc89, https://pubmed.ncbi.nlm.nih.gov/23379595/, https://pubmed.ncbi.nlm.nih.gov/22617250/","Inhibitor, ATP Competitive","1 nM, 3.2 nM, 7 nM","In Vitro Kinase Assays, BIAcore-based direct binding assay.","29 nM, 580 nM","Inhibition MET/HGF-dependent cellular phenotypes, Cell Proliferation Assay","IC50, IC 50",Other,"10, 30, 100 mg/Kg",
SGC-CK2-1,3.0,0.0,2.0,No,https://www.chemicalprobes.org/sgc-ck2-1,"CSNK2A1, CSNK2A2","Kinase, Kinase","CMGC, CMGC",2021-01-30,"P68400, P19784",YKDZIFFKQUNVHH-UHFFFAOYSA-N,CCC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C,No,No,,2849516,"www.doi.org/10.1016/j.chembiol.2020.12.013, https://pubmed.ncbi.nlm.nih.gov/33484635/","Inhibitor, ATP competitive","4.2 nM @ 10ÂµM ATP, 2.3 nM @ 10ÂµM ATP",Enzymatic Assay (Eurofin),"36 nM, 16 nM",NanoBRET,IC 50,,,SGC-CK2-1N
MEZIGDOMIDE,3.0,3.0,2.0,No,https://www.chemicalprobes.org/mezigdomide,CRBN,post-translational modification,E3 Ligase,2022-10-21,Q96SW2,YTINZZFBHWSAGL-NDEPHWFRSA-N,N#Cc1ccc(N2CCN(Cc3ccc(COc4cccc5c4CN([C@H]4CCC(=O)NC4=O)C5=O)cc3)CC2)c(F)c1,No,No,CHEMBL4648616,3339798,,"Degrader, CELMoD",37.2 nM,FRET Binding affinity assay,"2.3 nM, 3 nM","Growth Inhibition Assay, ePL Degradation assay; cpd shows fast kinetik with complete degradation of Aiolos after 3 h treatment at concentrations below 1 nM","IC50, EC50","Rat, Monkey (Cynomolgus)","2 mg/Kg, 10 mg/Kg, 3 mg/Kg",CANSAR3333581
TH257,3.7,0.0,3.0,No,https://www.chemicalprobes.org/th257,"LIMK1, LIMK2","Kinase, Kinase","TKL, TKL",2023-01-26,"P53667, P53671",VNCIWNGCMAKKEO-UHFFFAOYSA-N,CCCCN(Cc1ccccc1)C(=O)c1ccc(S(=O)(=O)Nc2ccccc2)cc1,No,No,CHEMBL4790618,3590579,,Inhibitor,"84 nM, 39 nM",RapidFire MS assay,"250 nM, 257 nM, 150 nM","NanoBRET, AlphaLISA SureFire Assay for the Detection of Phospho-Cofilin Ser3",IC50,,,CANSAR3579025
ML352,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ml352,SLC5A7,Transporter,Solute carrier ,2022-07-06,Q9GZV3,WBLVOWHFRUAMCP-UHFFFAOYSA-N,COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1,No,No,CHEMBL3304438,118241,,"Inhibitor, non-competitive",,,"90 - 266 nM, 3% remaining, 72 nM","Radiolabeled choline chloride uptake experiments in HEK 293 cells stably transfected with an endocytic mutant of human CHT.
Tested at high (10 uM)  and  low (100 nM) Choline concentrations., Radiolabeled choline chloride uptake experiments in HEK 293 cells stably transfected with an endocytic mutant of human CHT
Tested at low (100 nM) and high (10 uM) Choline concentrations., Single-point [3H]choline SPA assay at 100 nM Choline conc","IC50, Activity","Rat, Mouse","1 mg/Kg, 1 mg/kg",CANSAR1840627
AZ-960,3.3,0.0,3.0,No,https://www.chemicalprobes.org/az-960,JAK2,Kinase,TK,2020-11-27,O60674,SUNXHXDJOIXABJ-NSHDSACASA-N,Cc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cc3)c(C#N)cc2F)n[nH]1,No,No,CHEMBL1774055,1711060,"http://www.jbc.org/content/283/47/32334.long, https://www.ncbi.nlm.nih.gov/pubmed/?term=18775810","Inhibitor, ATP Competitive",0.45 nM (Ki); 3 nM (IC50) @ Km ATP,Enzymatic Biochemical Competitive Assay,"15 Â± 6 nM, 25 Â± 1 nM","Western immunoblotting determination of phospho-STAT5 and phospho-STAT3 levels., Anti-Proliferation assay using BIOSOURCE AlamarBlue Assay","IC50, GI50",,,
Phenylbutyrate,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/phenylbutyrate,,,,2023-03-31,,OBKXEAXTFZPCHS-UHFFFAOYSA-N,O=C(O)CCCc1ccccc1,No,No,CHEMBL1469,7664,,,,,,,,,,
AZD4547,3.5,4.0,2.0,No,https://www.chemicalprobes.org/azd4547,"FGFR1, FGFR2, FGFR3","Kinase, Kinase, Kinase","TK, TK, TK",2020-12-03,"P11362, P21802, P22607",VRQMAABPASPXMW-HDICACEKSA-N,COc1cc(CCc2cc(NC(=O)c3ccc(N4C[C@H](C)N[C@H](C)C4)cc3)[nH]n2)cc(OC)c1,No,No,,2011599,"www.doi.org/10.1158/0008-5472.CAN-11-3034, https://www.ncbi.nlm.nih.gov/pubmed/?term=22369928",Inhibitor,"0.2 nM, 1.8 nM, 2.5 nM",Enzymatic assay,"12 nM, 18 nM, 2 nM, 41 nM, 40 nM, 281 nM","Cellular Phosphorylation assay, Cos-1 transfected with FGFR1, Cell Proliferation Assay with KG1a with deregulated FGFR1, Cellular Phosphorylation assay,  Cos-1 transfected with FGFR2, Cell Proliferation Assay with Sum52-PE with deregulated FGFR2, Cellular Phosphorylation assay,  Cos-1 transfected with FGFR3, Cell Proliferation Assay with KMS11 with deregulated FGFR3",IC50,,,
PFI-5,3.0,0.0,2.0,No,https://www.chemicalprobes.org/pfi-5,SMYD2,Epigenetic,Methyltransferase,2023-01-25,Q9NRG4,AVKAVKZKOFSSMY-DEOSSOPVSA-N,Cc1cc2c(ncn2C2(C)CN(C(=O)c3ccn(CC4CCN([C@H]5C=CCCCC5)CC4)c3)C2)c(N)n1,No,No,CHEMBL4520134,2920724,,Inhibitor,"16 nM, 8 nM","SMYD2 Activity Assay with 20 uM SAM, SMYD2 Activity Assay with 70 nM SAM",130 nM,p53 methylation at K370 in MCF7 cells,EC50,,,CANSAR3139360
MSC1186,3.0,0.0,1.0,No,https://www.chemicalprobes.org/msc1186,"SRPK1, SRPK2, SRPK3","Kinase, Kinase, Kinase","CMGC, CMGC, CMGC",2022-03-25,"Q96SB4, P78362, Q9UPE1",WBFJDKLBAAHKIL-UHFFFAOYSA-N,CN(c1ncccc1CNc1ccnc(-c2nc3c(F)c(Cl)ccc3[nH]2)n1)S(C)(=O)=O,No,No,,3550539,,Inhibitor,"2.7 nM, 81 nM, 145 nM, 0.59 nM","Biochemical activity assay performed at Reaction Biology, biochemical activity assay performed at Reaction Biology, ITC","98 nM, 44 nM, 149 nM, 40 nM, 20 nM","NanoBRET assay on intact cells, NanoBRET assay on cell lysate",IC50,,,CANSAR3550540
SGC-iMLLT,3.5,0.0,2.0,No,https://www.chemicalprobes.org/sgc-imllt,"MLLT1, MLLT3","Epigenetic, Epigenetic","YEATS, YEATS",2021-03-16,"Q03111, P42568",QGNDVASWIHEXCL-AWEZNQCLSA-N,C[C@H]1CCCN1Cc1nc2cc(NC(=O)c3ccc4c(cnn4C)c3)ccc2[nH]1,No,No,CHEMBL4552313,3210317,"www.doi.org/10.1002/anie.201810617, www.doi.org/10.1101/2021.02.08.430291, https://pubmed.ncbi.nlm.nih.gov/30288907/",Inhibitor,"260 nM, 129 nM, 77 nM","Alpha-Screen, ITC",400 nM,NanoBRET,IC 50,,,SGCâiMLLTâN
PFI-4,3.3,0.0,3.0,No,https://www.chemicalprobes.org/pfi-4,BRPF1,Epigenetic,Bromodomain,2022-06-13,P55201,QCIJLRJBZDBVDB-UHFFFAOYSA-N,COc1ccccc1C(=O)Nc1cc2c(cc1N1CCCC1)n(C)c(=O)n2C,No,No,CHEMBL3356143,120324,,Inhibitor,"13 nM, 172 nM, 9.4 Celciuys","ITC, Alpha Screen competitive assay with tetraacetylated histone 4 and  monoacetylated  K14  histone  3  for  TRIM24., Thermal Shift assay",240 nM,"NanoBRET cellular target engagement assay evaluating the interaction of BRPF1B with histones, In a FRAP assay PFI-4 recovery time in U2OS cells transfected with a BRPF1B triple BRD construct with a nuclear localisation signal (NLS) at 500 nM.","IC50, Activity",,,
TP-030-2,4.0,0.0,1.0,No,https://www.chemicalprobes.org/tp-030-2,RIPK1,Kinase,TKL,2022-02-20,Q13546,KHVVJKLNKLQLJZ-SFHVURJKSA-N,CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21,No,No,CHEMBL4549667,3183084,,Inhibitor,0.43 nM,TR-FRET (human RIPK1),1.3 nM,HT29 necroptosis assay,IC50,,,TP-030n
GNE-886,3.5,0.0,2.0,No,https://www.chemicalprobes.org/gne-886,CECR2,Epigenetic,Bromodomain,2023-01-26,Q9BXF3,ZKIRTFGYQVXNGL-UHFFFAOYSA-N,C=CCn1cc(C(=O)N(C)C2CCN(c3cc(-c4cccc(OC)c4)ncn3)CC2)c2cc[nH]c2c1=O,No,No,CHEMBL4073178,750804,,Inhibitor,"16 nM, 42 nM","TR-FRET, BromoSCAN",370 nM,Bromodomain chromatin-release (âdotâ) assay,EC50,,,
SGC-SMARCA-BRDVIII,3.7,0.0,3.0,No,https://www.chemicalprobes.org/sgc-smarca-brdviii,"SMARCA2, SMARCA4, PBRM1","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2021-02-26,"P51531, P51532, Q86U86",AQTNUGRRZDRZIA-UHFFFAOYSA-N,CC(C)(C)OC(=O)N1CCN(c2cc(-c3ccccc3O)nnc2N)CC1,No,No,CHEMBL4780617,3059760,"www.doi.org/10.1021/acs.jmedchem.0c01242, https://pubmed.ncbi.nlm.nih.gov/33216538/",Inhibitor,"35 nM, 36 nM, 13 nM",ITC,< 1 uM,adipogenesis cell differentiation assay,EC50,,,SGC-BRDVIII-NC
SMG1i,3.0,0.0,3.0,No,https://www.chemicalprobes.org/smg1i,SMG1,Kinase,PI3/PI4,2022-10-17,Q96Q15,RZFJBSIAXYEPBX-UHFFFAOYSA-N,CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl,No,No,CHEMBL2158866,867113,,Inhibitor,0.11 nM,Biochemical assay,"100%, 75 nM","Inhibition of UPF1 phosphorylation, Cell proliferation assay","Inhibition, IC50",,,CANSAR1854626
TAO Kinase inhibitor 1,3.0,0.0,2.0,No,https://www.chemicalprobes.org/tao_kinase_inhibitor_1,"TAOK1, TAOK2","Kinase, Kinase","STE, STE",2022-07-28,"Q7L7X3, Q9UL54",WQKXOAJVNFOHNZ-UHFFFAOYSA-N,O=C(CNC(=O)c1ccc(-c2ccccc2)cc1)NC1CCCc2ccccc21,No,No,CHEMBL3717933,218601,,Inhibitor,"11 nM, 15 nM",Inhibition of MBP phosphorylation by TAOK,10 uM,Inhibition of phosphorylation and activation of JNK by TAOKs in cells,IC50,,,
PFI-6,3.0,0.0,1.0,No,https://www.chemicalprobes.org/pfi-6,"MLLT1, MLLT3","Epigenetic, Epigenetic","YEATS, YEATS",2021-03-16,"Q03111, P42568",IXWUILRSNIQHDM-QGZVFWFLSA-N,CN(C)C(=O)c1ccc(-c2cc(C(=O)N[C@@H]3CCc4ccccc43)no2)cc1O,No,No,CHEMBL4752253,3313071,https://doi.org/10.1101/2021.02.08.430291,Inhibitor,"140 nM, 82 nM, 160 nM, 76 nM","Homogeneous Time-Resolved Fluorescence assay, Biolayer Interferometry assay, ITC",760 nM,Fluorescence Recovery After Photobleaching (FRAP) assay,IC 50,,,PFI-6N
PFI-3,3.3,2.0,3.0,No,https://www.chemicalprobes.org/pfi-3,"SMARCA2, SMARCA4, PBRM1","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2017-03-07,"P51531, P51532, Q86U86",INAICWLVUAKEPB-QSTFCLMHSA-N,O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O,No,Yes,CHEMBL3752911,1574321,"http://advances.sciencemag.org/content/1/10/e1500723, http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b00012, www.doi.org/10.1172/JCI123557, www.doi.org/10.1158/0008-5472.CAN-14-3798, https://www.ncbi.nlm.nih.gov/pubmed/26702435, https://www.ncbi.nlm.nih.gov/pubmed/27115555, https://www.ncbi.nlm.nih.gov/pubmed/26139243, https://www.ncbi.nlm.nih.gov/pubmed/30496141",Antagonist,"81-86 nM, 97 nM, 54 nM",ITC assay,,"In U2OS cells, PFI-3 increased fluorescence recovery of GFP-tagged, full-length BRM protein in FRAP assay including wild-type but not mutant version of BRM (N1464F), which does not bind acetylated chromatin.",,,,PFI-oMet
IMR-687,2.0,0.0,1.0,No,https://www.chemicalprobes.org/imr-687,PDE9A,Nucleic acid metabolism,Phosphodiesterase,2017-07-20,O76083,GWGNPYYVGANHRJ-GDBMZVCRSA-N,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(C3CCOCC3)ncc2c(=O)[nH]1,No,No,CHEMBL4297290,232973,,Inhibitor,9 nM,Phosphodiesterase enzyme (PDE) inhibition IC50 values were determined for IMR-687 using recombinant human PDE enzymes in a radiometric assay,,"cGMP levels were assessed using a non-radioactive cGMP enzyme immunoassay with the acetylation protocol and protein levels were quantified by the BCA assay. Treatment for 6 hours (h) in erythroid K562 cells increases cGMP in a dose-dependent manner. treatment in erythroid K562 cells for 72 h induced HbF (fetal hemoglobin) in a dose-dependent manner, evaluated by an ELISA assay.",,,,
SGC-GAK-1,3.0,0.0,3.0,No,https://www.chemicalprobes.org/sgc-gak-1,GAK,Kinase,Ser/Thr Kinase,2022-06-08,O14976,AUOSKLDNVNGKRR-UHFFFAOYSA-N,COc1cc(Nc2ccnc3ccc(Br)cc23)cc(OC)c1OC,No,No,CHEMBL4443342,3137904,,Inhibitor,1.9 nM,Competition binding assay (DiscoverX),"110 nM, 650 nM, 170 nM","NanoBRET against ectopically expressed full-length GAK-Nluc fusion, Prostate Cancer Cell Line Viability at 72 h",IC50,,,"SGC-GAK-1N, KA2"
FMF-03-145-1,3.7,0.0,3.0,No,https://www.chemicalprobes.org/fmf-03-145-1,"AURKA, AURKB, AURKC","Kinase, Kinase, Kinase","Ser/Thr kinase, Ser/Thr kinase, Ser/Thr kinase",2022-12-20,"O14965, Q96GD4, Q9UQB9",KGXBCWANASZZQG-UHFFFAOYSA-N,CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1,No,No,CHEMBL4206831,837250,,Inhibitor,"52 nM, 41 nM, 53 nM",ZâLYTE kinase assay,"38 nM, 500 nM, 11 nM","Cellular EC50 based on 4 h treatment followed by western blot analysis of pAurora A and histone H3 pS10, Cell cycle analysis by FACS","EC50, Inhibition",,,
NVS-MLLT-1,3.7,0.0,3.0,No,https://www.chemicalprobes.org/nvs-mllt-1,"MLLT1, MLLT3","Epigenetic, Epigenetic","YEATS, YEATS",2021-03-16,"Q03111, P42568",ZRTFTZCKJUNZIU-HNNXBMFYSA-N,C[C@H]1CCCN1Cc1nc2cc(NC(=O)c3ccc4cnccc4c3)ccc2[nH]1,No,No,CHEMBL4800073,3313072,www.doi.org/10.1101/2021.02.08.430291,Inhibitor,"150 nM, 109 nM, 254 nM","TR-FRET, ITC",500 nM,NanoBRET cellular target engagement assay,IC50,,,NSV-MLLT-C
NR162,3.3,0.0,3.0,No,https://www.chemicalprobes.org/nr162,CASK,Kinase,CAMK,2022-03-25,O14936,BPLPIBNWDLPUKP-UHFFFAOYSA-N,Cc1cc(Br)c(CNc2ncc(C(=O)NCCCN3CCOC3=O)c(NC3CCCC3)n2)cc1Br,No,No,CHEMBL4850857,3317313,,Inhibitor,22 nM,ITC,80 nM,NanoBRET assay using HEK923T cells,IC50,,,CANSAR3550554
SB-216763,3.0,0.0,2.0,No,https://www.chemicalprobes.org/sb-216763,"GSK3A, GSK3B","Kinase, Kinase","CMGC, CMGC",2023-01-24,"P49840, P49841",JCSGFHVFHSKIJH-UHFFFAOYSA-N,Cn1cc(C2=C(c3ccc(Cl)cc3Cl)C(=O)NC2=O)c2ccccc21,No,Yes,CHEMBL102714,1588366,,Inhibitor,"34 nM, 9 nM, 96%","Biochemical assay in presence of 0.010 mM ATP, In the presence of 0.1 mM ATP at 10 Î¼M of SB-216763",3.6 uM,Stimulation of glycogen synthesis in the Chang human liver cell line,EC50,,,
TTT20171,1.0,1.0,3.0,No,https://www.chemicalprobes.org/ttt20171,SDHC,Other,TCA cycle,2017-06-27,Q99643,CZKPAGLXQOQNEI-UHFFFAOYSA-N,CCCCCCCCCCCCC(=O)c1c(O)c(OC)c(OC)[nH]c1=O,No,Yes,,2982640,"http://onlinelibrary.wiley.com/doi/10.1002/cmdc.201700196/abstract;jsessionid=E1DA8D079D35506DB622BB1A87D3121B.f02t01, https://www.ncbi.nlm.nih.gov/pubmed/28523727",Inhibitor,3.3 nM,Spectrophotometric assay in isolated rat heart mitochondria (rate of succinate-driven coenzyme Q2-linked reduction of DCPIP).,5400 nM,"In 22Rv cells, TTT20171 dose-dependently decreased the oxygen consumption rate, basal respiration, ATP production and decreased maximal respiration.",IC50,,,"(rac)-2,3-dimethoxy-5-(1-methoxyhexyl)pyridin-4-ol (Compound 24)"
KT109,3.0,2.0,1.0,No,https://www.chemicalprobes.org/kt109,"DAGLB, ABHD6","Enzyme, Enzyme","Lipase, Lipase",2023-02-13,"Q8NCG7, Q9BV23",JKJMWHULJIOKPJ-UHFFFAOYSA-N,O=C(N1CCCCC1Cc1ccccc1)n1cc(-c2ccc(-c3ccccc3)cc2)nn1,No,No,CHEMBL2144065,457169,,Inhibitor,"82 nM, 42 nM, 16 nM","SAG substrate assay, Competitive ABPP assay","14 nM, 500 nM, 50 nM, 1 nM","quantitative mass spectrometryâbased proteomic method ABPP-SILAC, Concentration-dependent inhibition of human DAGLÎ² activity detected via competitive ABPP with with the HT-01 probe (1 ÂµM), Conversion of DAG lipids containing an sn-2 C20:4 (arachidonoyl) acyl chain to  2-arachidonoylglycerol after treatment of cells for 4 h with inhibitor., competitive ABPP assay with HT-01 (1 ÂµM)","IC50, INH",Mouse,0.1 - 10 mg/Kg,KT195
RSL3,2.3,2.0,4.0,No,https://www.chemicalprobes.org/rsl3,GPX4,Lipid metabolism,Glutathione Peroxidase,2016-10-14,P36969,TXJZRSRTYPUYRW-GHTZIAJQSA-N,COC(=O)c1ccc([C@@H]2c3[nH]c4ccccc4c3C[C@@H](C(=O)OC)N2C(=O)CCl)cc1,Yes,Yes,CHEMBL3182405,387211,"http://www.sciencedirect.com/science/article/pii/S1074552108000835, http://www.cell.com/cell/abstract/S0092-8674(13)01544-4, http://www.ncbi.nlm.nih.gov/pubmed/18355723, http://www.ncbi.nlm.nih.gov/pubmed/24439385",Inhibitor,111 nM,RSL3 was evaluated for binding using Microscale thermophoresis (MST) with labelled His-tagged GPX4(U46C) protein. The Kd is defined as the concentration of ligands at which the binding site on GPX4 protein is half occupied.,100 nM,"HT-1080 cells were treated with a serial dilution of RSL3. Viability was assayed using Alamar Blue reagent. The EC50 is defined as the concentration that results in 50% viability. Chemoproteomic affinity capture with a modified version of RSL3 identified GPX4 as a cellular protein target.  
In lysates from a COH BR1 breast cancer cell line overexpressing GPX4, RLS3 inhibited the reduction of 7Î±-cholesterol hydroperoxide to 7Î±-cholesterol-OH. siRNA-mediated knockdown of GPX4 sensitized cells to RSL3, whereas overexpression of GPX4 rendered cells insensitive to RSL3.",EC50,Other,100 mg/kg,
PHENANTHROLINE,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/phenanthroline,,,,2023-05-09,,DGEZNRSVGBDHLK-UHFFFAOYSA-N,c1cnc2c(c1)ccc1cccnc12,No,No,CHEMBL415879,31029,,,,,,,,,,
VU0361737,2.7,1.7,3.0,No,https://www.chemicalprobes.org/vu0361737,GRM4,GPCR,Glutamate receptor,2023-02-13,Q14833,ARYUXFNGXHNNDM-UHFFFAOYSA-N,COc1cc(NC(=O)c2ccccn2)ccc1Cl,No,No,CHEMBL562551,1078770,,Modulator,,,"240 nM, GluMax 182 h","Calcium mobilization assays, Thallium flux assays",EC50,Rat,10 mg/Kg,
AZD5305,4.0,4.0,2.0,No,https://www.chemicalprobes.org/azd5305,PARP1,Other post-translational modification,PARP,2022-08-22,P09874,WQAVGRAETZEADU-UHFFFAOYSA-N,CCc1cc2ncc(CN3CCN(c4ccc(C(=O)NC)nc4)CC3)cc2[nH]c1=O,No,No,,3872894,,Inhibitor,"3 nM, 0.13 nM","PARP Fluorescence Anisotropy Binding Assays, Total Internal Fluorescence (TIRF) microscopy","2 nM, 2.3 nM","Cell Proliferation, PARylation assay",IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","10, 1, 0.1, and 0.03 mg/kg",
MU1742,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mu1742,"CSNK1D, CSNK1E","Kinase, Kinase","CK1, CK1",2023-05-18,"P48730, P49674",SWOIFXHMBKFCRM-UHFFFAOYSA-N,CN1CCC(F)(Cn2cnc(-c3ccc(F)cn3)c2-c2ccnc3[nH]ccc23)CC1,Yes,No,,3935390,,Inhibitor,"6.1 nM, 27.7 nM",Reaction biology assay at 10 mM ATP,"47 Â± 6.9 nM, 500 nM, 220 Â± 14 nM","NanoBRET, Autophosphorylation inhibition assay using CK1 delta and epsilon KO cell lines, respectively","EC50, IC50",Mouse,20 mg/Kg,MU2027
SGC-UBD253,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sgc-ubd253,HDAC6,Epigenetic,HDAC,2023-05-18,Q9UBN7,YLHSFRZHEMHKAF-UHFFFAOYSA-N,COc1ccccc1CNC(=O)Cn1c(CCC(=O)O)nc2c(Cl)cccc2c1=O,No,No,,3932768,,Inhibitor,"84 nM, 80 nM, 95 nM","SPR with HDAC6 Ubiquitin Binding Domain, ITC, Fluorescence Polarisation Assay",1900 Â± 600 nM,NanoBRET,EC50,,,SGC-UBD253N
SGC-PIKFYVE-1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sgc-pikfyve-1,PIKFYVE,Kinase,Serine kinase,2023-05-18,Q9Y2I7,DORZPJWJOBMQKC-UHFFFAOYSA-N,CN(C)CC#Cc1ccc2[nH]c3c(c2c1)-c1nc(N)ncc1CCC3,No,No,,3935393,,Inhibitor,6.9 nM,Enzymatic assay (SignalChem),4.0 nM,NanoBRET,IC50,,,SGC-PICFYVE-NC
SKI-73,3.0,0.0,3.0,No,https://www.chemicalprobes.org/ski-73,CARM1,Epigenetic,Methyltransferase,2023-01-26,Q86X55,HZHUKQLWLNDVDZ-IBDVCRJISA-N,COc1ccc(CCNC(=O)[C@H](CC[C@H](CNCc2ccccc2)C[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)NC(=O)CC(C)(C)C2=C(C)C(=O)C(C)=C(C)C2=O)cc1,Yes,Yes,,3935382,,Inhibitor,"275 nM, 1100 Â± 100 nM","SPR, Radiometric filter paper assay","+4.3 ÂºC, 450 Â± 140 nM, 750 Â± 40 nM, 1300 Â± 200 nM","CETSA, Arg1064 methylation of BAF155, Arg455/Arg460 methylation of PABP1, Invasion inhibition assay","ÎTm, EC50",,,SKI-73N
SGC3027,3.0,0.0,1.0,No,https://www.chemicalprobes.org/sgc3027,PRMT7,Epigenetic,Methyltransferase,2023-05-18,Q9NVM4,MLJVGAYSVYMPSB-MSUKGTQXSA-N,CC1=C(C)C(=O)C(C(C)(C)CC(=O)N(CCCCSC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)Cc2cccc(-c3ccc(Cl)cc3)c2)=C(C)C1=O,Yes,Yes,CHEMBL5094158,3894180,,Inhibitor,"<2.4 nM, 6.4âÂ±â1.2ânM","Scintillation proximity assay (SPA) against PRMT7 using 3H-SAM and a histone H2B peptide (residues 23â37) as a substrate (testing SGC8158), SPR using SGC8158","294âÂ±â26ânM, 2400âÂ±â100ânM","Inhibition of PRMT7 methylation of full-length HSPA8, HSP70 monomethylation in C2C12 cells",IC50,,,CANSAR3883275
ART558,4.0,0.0,1.0,No,https://www.chemicalprobes.org/art558,POLQ,Enzyme,DNA Polymerase,2022-07-21,O75417,YHMDHAMZFMNMTF-MSOLQXFVSA-N,Cc1cccc(N(C)C(=O)[C@@H]2[C@H](O)CCN2c2nc(C)cc(C(F)(F)F)c2C#N)c1,No,No,,3451465,,Allosteric Inhibitor,"7.9 nM, 3.37 - 4.65 nM, 10 uM","Primer extension assay, Primer extension assay: dNTPs non-competitive and DNA uncompetitive inhibition, DSF assay: DNA-dependent thermal stabilisation of PolÎ¸","3000 nM, 135 nM",Theta-mediated end joining (TMEJ) reporter assay,Activity,,,"(2R,4R)-1-(3-Cyano-6-methyl-4-(trifluoromethyl)pyridin-2-yl)-4-hydroxy-N-methyl-N-(m-tolyl)pyrrolidine-2-carboxamide"
(R)-9s,3.7,3.7,3.0,No,https://www.chemicalprobes.org/r-9s,ADRA1D,GPCR,Alpha-Adrenergic Receptor,2020-01-31,P25100,CDJPHTNUARAVMH-SECBINFHSA-N,C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N,No,No,CHEMBL3799292,1300914,https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01528,Antagonist,1.9 nM,Cell Free Activity Assay,15 nM,Organ bath,IC30,Rat,1 mg/kg,(S)-9s
Ruxolitinib,4.0,4.0,3.0,No,https://www.chemicalprobes.org/ruxolitinib,"JAK1, JAK2","Kinase, Kinase","TK, TK",2015-12-10,"P23458, O60674",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,Yes,No,CHEMBL1789941,1406851,"http://www.bloodjournal.org/content/early/2010/02/03/blood-2009-04-214957, http://www.ncbi.nlm.nih.gov/pubmed/20130243",Inhibitor,"3.3 nM, 2.8 nM",Kinase Enzymatic assay,280 nM,Inhibition of substrate phosphorylation in whole blood.,IC 50,Mouse,90 mg/kg,
DCLK1-IN-1,4.0,4.0,1.0,No,https://www.chemicalprobes.org/dclk1-in-1,"DCLK1, DCLK2","Kinase, Kinase","CAMK, CAMK",2023-02-13,"O15075, Q8N568",OQFCHSFVWSLDAO-UHFFFAOYSA-N,COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2CC(F)(F)F,No,No,CHEMBL4639395,3315025,,Inhibitor,"109 nM, 9.5 nM, 57.2 nM, 31 nM, 103 nM","ITC, DCLK1 KINOMEscan binding assay, 33P-ATP DCLK1 kinase assay. Assays were performed at an ATP concentration of 50âÎ¼M (Km), DCLK2 KINOMEscan binding assay, 33P-ATP DCLK2 kinase assay. Assays were performed at an ATP concentration of 100âÎ¼M (Km)",279 nM,DCLK1 nanoBRET assay,IC50,Mouse,"10 mg/Kg, 2 mg/Kg",DCLK1-NEG
ESCITALOPRAM,4.0,4.0,2.0,No,https://www.chemicalprobes.org/escitalopram,SLC6A4,Transporter,Serotonin transporter ,2022-06-14,P31645,WSEQXVZVJXJVFP-FQEVSTJZSA-N,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,No,No,CHEMBL1508,1516244,,Inhibitor,"2.1 nM, 0.89 nM","Radioligand assay, Radioligand binding displacement",89-3% residual activity,"Escitalopram significantly decreased cell viability in a dose-dependent manner (25, 50, 100 and 125 Î¼M)",Activity,Rat,1.6 mg/Kg,
MRS 1754,0.0,0.0,0.0,No,https://www.chemicalprobes.org/mrs-1754,ADORA2B,GPCR,Adenosine receptor,2022-07-07,P29275,AJBBEYXFRYFVNM-UHFFFAOYSA-N,CCCn1c(=O)c2[nH]c(-c3ccc(OCC(=O)Nc4ccc(C#N)cc4)cc3)nc2n(CCC)c1=O,No,No,CHEMBL273807,679096,,Antagonist,,,"0%, 2 nM","Functional assay (inhibiting the effects of NECA), Radioligand binding assay","Activity, Ki",,,CANSAR690755
MU1210,2.0,0.0,1.0,No,https://www.chemicalprobes.org/mu1210,"CLK1, CLK2, CLK4","Kinase, Kinase, Kinase","CMGC, CMGC, CMGC",2023-05-18,"P49759, P49760, Q9HAZ1",HEAGNKNMQVIVMM-UHFFFAOYSA-N,Cn1cc(-c2ccc3occ(-c4cccc(-c5ccncc5)c4)c3n2)cn1,No,No,CHEMBL4754195,3445603,,Inhibitor,"8 nM, 20 nM, 12 nM",Biochemical assay,"84 nM, 91 nM, 23 nM",NanoBRET,Ki,,,MU140
JNJ-6204,4.0,3.0,1.0,No,https://www.chemicalprobes.org/jnj-6204,"CSNK1D, CSNK1E","Kinase, Kinase","CK1, CK1",2023-05-18,"P48730, P49674",WZMIWVZGYMKUDV-WFGJKAKNSA-N,[2H]C([2H])([2H])C1(C([2H])([2H])[2H])Cn2nc(-c3ccc(F)cn3)c(-c3ccnc4[nH]ncc34)c2CO1,No,No,CHEMBL5081774,3889447,,Inhibitor,"2.3 nM, 137 nM",ADP-Glo assay using recombinant proteins,"72 nM, 542 nM","BRET, PER2 translocation whole cell assay",IC50,Mouse,"1 mg/Kg IV, 5 mg/Kg PO",CANSAR3893768
Spastazolin,3.0,0.0,1.0,No,https://www.chemicalprobes.org/spastazolin,SPAST,Enzyme,ATPase,2022-10-05,Q9UBP0,HNOLTAKAPDKZRY-AWEZNQCLSA-N,CC(C)[C@@H]1CN(c2nc(Nc3cc(C(C)(C)C)[nH]n3)c3cc[nH]c3n2)CCN1,No,No,,3935384,,Inhibitor,99âÂ±â18 nM,Inhibition of recombinant h-spastin,~2-fold,"Phenotypic assay: ~2-fold increase in the number of cells with intercellular bridges compared with DMSO control, mimicking RNAi-mediated spastin knockdown  phenotype",,,,
TAK-243,3.3,3.3,3.0,No,https://www.chemicalprobes.org/tak-243,UBA1,Other post-translational modification,Ubiquitin-conjugating enzyme,2020-11-17,P22314,KJDAGXLMHXUAGV-DGWLBADLSA-N,NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(-c4cccc(SC(F)(F)F)c4)nn23)[C@H](O)[C@@H]1O,No,Yes,CHEMBL4297405,613948,"www.doi.org/10.1038/nm.4474, www.doi.org/10.1016/j.str.2017.05.001, www.doi.org/10.1038/s41375-018-0167-0, https://pubmed.ncbi.nlm.nih.gov/29334375/, https://pubmed.ncbi.nlm.nih.gov/28578874, https://pubmed.ncbi.nlm.nih.gov/29884901",Inhibitor,">0.75 nM, 1 Â± 0.2 nM","E1âUBL-dependent pyrophosphate exchange (PPiX) activity, UBCH10 E2 transthiolation assay",12-20 nM (48-72h),"Western blotting, Cellular thioester assays, Lys48 immunofluorescence assay in tumor tissue",EC50,Mouse,"12.5, 18.8, 25 mg/Kg",
CP-96345,2.3,0.0,3.0,No,https://www.chemicalprobes.org/cp-96345,TACR1,GPCR,NK-1 Receptor,2023-02-08,P25103,FLNYLINBEZROPL-NSOVKSMOSA-N,COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,No,No,CHEMBL16192,322202,,Antagonist,"0.2 nM, 0.4 nM","displacement of 125I-labelled substance P from cloned receptor expressed in CHO cells, Radioligand Binding Affinity of NK Antagonists in Membrane Preparations from HEK293 Cells Transiently Expressing hNK1-WT",4.0 nM,Inhibition of substance P induced IL-6 secretion in U-373 MG astrocytoma cells,Ki,,,CANSAR335710
3-AMINOBENZAMIDE,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/3-aminobenzamide,,,,2017-02-01,,GSCPDZHWVNUUFI-UHFFFAOYSA-N,NC(=O)c1cccc(N)c1,No,No,CHEMBL81977,67064,,,,,,,,,,
DDR-TRK-1,3.0,4.0,1.0,No,https://www.chemicalprobes.org/ddr-trk-1,"DDR1, DDR2, NTRK1, NTRK2, NTRK3","Kinase, Kinase, Kinase, Kinase, Kinase","Tyrosine kinase, Tyrosine kinase, Tyrosin kinase, Tyrosine kinase, Tyrosine kinase",2023-05-18,"Q08345, Q16832, P04629, Q16620, Q16288",CMJJZRAAQMUAFH-INIZCTEOSA-N,Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)CN(c3cncnc3)C[C@@H]4C)cc(C(F)(F)F)c2)cn1,No,No,CHEMBL4553037,3213765,,Inhibitor,"9.4 Â± 1.7 nM, 4.7 Â± 0.8 nM, 27 nM, 4.5 nM, 188 Â± 23 nM, 43 nM, 100 Â± 17.5 nM, 3.6 nM, 22 Â± 0.5 nM, 2.9 nM, 18 Â± 1.5 nM","LANCE ULTRA kinase assay, DiscoverX profiling, In an activity assay at RBC (10Î¼M ATP)","104 nM, 175 nM, 448 nM, 14.2 nM",NanoBRET,IC50,"Mouse, Rat","4 mg/Kg, 1 mg/Kg, 20 mg/Kg",CANSAR3203052
TP-238,3.0,0.0,1.0,No,https://www.chemicalprobes.org/tp-238,"CECR2, BPTF","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2023-05-18,"Q9BXF3, Q12830",MSIJJXOWLFOYIN-UHFFFAOYSA-N,CN(C)CCCOc1ccc(-c2cc(NCCCn3cccn3)nc(S(C)(=O)=O)n2)cc1,No,Yes,CHEMBL4461619,3156773,,Inhibitor,"30 nM, 10 nM, 350 nM, 120 nM","Alphascreen assay, ITC","289 nM, 228 nM","NanoBRET, FRAP assay shows significant inhibition",EC50,,,TP-422
TM-04-176-01,3.0,0.0,2.0,No,https://www.chemicalprobes.org/tm-04-176-01,"PIP4K2C, PIP4K2A, PIP4K2B","Kinase, Kinase, Kinase","Lipid kinase, Lipid Kinase, Lipid Kinase",2023-02-13,"Q8TBX8, P48426, P78356",KKMZWHRTQLNOCF-UHFFFAOYSA-N,CS(=O)(=O)Nc1ccc(-c2cncc(-c3cccc4[nH]ccc34)c2)cc1,No,No,CHEMBL4455633,3150449,,Inhibitor,"3.4 nM, 2000 Â± 450 nM, 9400 Â± 7100 nM","KdELECT binding assay, Transcreener assay",5 uM,CETSA,,,,
SGC-CK2-2,3.0,0.0,1.0,No,https://www.chemicalprobes.org/sgc-ck2-2,"CSNK2A1, CSNK2A2","Kinase, Kinase","Ser/Thr kinase, Ser/Thr kinase",2023-05-18,"P68400, P19784",HEVVNKYNJCSHFA-UHFFFAOYSA-N,O=C(O)c1ccc2c(c1)nc(NCc1ccccc1)c1ncncc12,No,No,,3929850,,Inhibitor,"3.0 nM, <1.0 nM",DiscoverX assay,"920 nM, 200 nM",NanoBRET,IC50,,,SGC-CK2-2N
MRK-990,3.0,0.0,1.0,No,https://www.chemicalprobes.org/mrk-990,"PRMT9, PRMT5","Epigenetic, Epigenetic","Methyltransferase, Methyltransferase",2023-05-18,"Q6P2P2, O14744",PYMRXCFAOAFTGR-DYVMYPEFSA-N,Cc1cn([C@@H]2O[C@H](CSCCNCc3cccnc3C(C)(C)C)[C@@H](O)[C@H]2O)c2ncnc(N)c12,Yes,No,,3935395,,Inhibitor,"10 nM, 30 nM",Biochemical assay,"145 nM, 519 nM","Inhibition of the methylation of SAP145 (PRMT9) after 2 days of treatment, Inhibition of methylation of Rme2/smBB (PRMT5) after 2 days of treatment",IC50,,,
MU1700,2.5,2.5,2.0,No,https://www.chemicalprobes.org/mu1700,"ACVRL1, ACVR1","Kinase, Kinase","TKL, TKL",2023-05-18,"P37023, Q04771",FFLJVBPCONQSQW-UHFFFAOYSA-N,c1ccc2c(-c3coc4cc(-c5ccc(N6CCNCC6)cc5)cnc34)ccnc2c1,No,No,CHEMBL5083143,3886767,,Inhibitor,"13 nM, 6 nM",Biochemical assay,"225 nM, 100 nM, 27 nM","NanoBRET, phosphorylation of SMAD1/5/8 in western blot","IC50, INH",Mouse,20 mg/Kg,MU1700NC
SGC-PI5P4Kg/MYLK-1,4.0,0.0,1.0,No,https://www.chemicalprobes.org/sgc-pi5p4kgmylk-1,"PIP4K2C, MYLK4","Kinase, Kinase","Lipid kinase, CAMK",2023-05-19,"Q8TBX8, Q86YV6",VGFHPNRWHOQLEB-UHFFFAOYSA-N,Nc1ncc2c(n1)-c1c([nH]c3ccc(C4=CCOCC4)cc13)CCC2,No,No,,3935396,,Inhibitor,"19 nM, 12 nM",DiscoverX scanMAX assay,"67 nM, 14 nM",NanoBRET,IC50,,,SGC-PI5P4KÎ³/MYLK4-1N
LDN-57444,0.0,0.0,0.0,Yes,https://www.chemicalprobes.org/unsuitables/ldn-57444,,,,2023-06-19,,OPQRFPHLZZPCCH-PGMHBOJBSA-N,CC(=O)O/N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc21,No,Yes,CHEMBL3407553,1660579,,,,,,,,,,
BAY-390,3.0,3.0,2.0,No,https://www.chemicalprobes.org/bay-390,TRPA1,Transient Receptor,,2022-02-20,O75762,IESAJAZKMLPVIB-VXGBXAGGSA-N,O[C@]1(C(F)(F)F)CCCC[C@H]1Nc1ccc(F)cc1,No,No,CHEMBL4514203,3173350,,Inhibitor,,,"16 nM, 82 nM","FLIPR Ca2+ assay (human TRAP1), Ephys (human TRPA1)",IC50,Rat,30-90 mg/Kg,BAY-9897
Pictilisib,2.8,2.5,4.0,No,https://www.chemicalprobes.org/pictilisib,"PIK3CA, PIK3CD","Lipid kinase, Lipid kinase","Class I, Class I",2015-12-10,"P42336, O00329",LHNIIDJUOCFXAP-UHFFFAOYSA-N,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,No,No,CHEMBL521851,627580,"www.doi.org/10.1021/jm800295d, http://www.ncbi.nlm.nih.gov/pubmed/18754654",ATP-competitive inhibitor,"3 nM, 10.2 nM","Scintillation proximity assays, Scintillation proximity assay",28-46 nM,"Inhibition of protein substrate phosphorylation in MDA-MB-361, PC3, and U87MG cells.",IC 50,Mouse,75 ng/kg,
PALBOCICLIB,4.0,3.0,3.0,No,https://www.chemicalprobes.org/palbociclib,"CDK4, CDK6","Kinase, Kinase","CMGC, CMGC",2015-12-10,"P11802, Q00534",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,No,No,CHEMBL189963,495280,"http://mct.aacrjournals.org/content/3/11/1427.long, http://www.ncbi.nlm.nih.gov/pubmed/15542782",ATP-competitive inhibitor,"11 nM, 16 nM",Inhibition of substrate-GST fusion phosphorylation,66 nM,Inhibition of Rb phosphorylation at Ser780 in MDA-MB-435 breast carcinoma cells,IC 50,,,
MRTX849,4.0,4.0,3.0,No,https://www.chemicalprobes.org/mrtx849,KRAS,Enzyme,GTPase ,2020-06-10,P01116,PEMUGDMSUDYLHU-ZEQRLZLVSA-N,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,No,Yes,CHEMBL4594350,2948441,"https://doi.org/10.1021/acs.jmedchem.9b02052, www.doi.org/10.1158/2159-8290.CD-19-1167, https://pubmed.ncbi.nlm.nih.gov/32250617/, https://pubmed.ncbi.nlm.nih.gov/31658955/",Covalent Inhibitor,low uM,LCMS measurement of the pepsin-derived Cys12-containing peptide fragments,14 nM; 4.7 nM (24h),NCI-H358 cellular pERK inhibition at 3 h,IC50,Other,"3 mg/Kg IV, 3 to 100 mg/Kg PO",Compound-21
AMG-510,4.0,4.0,3.0,No,https://www.chemicalprobes.org/amg-510,KRAS,Enzyme,GTPase,2020-06-10,P01116,NXQKSXLFSAEQCZ-SFHVURJKSA-N,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,No,Yes,CHEMBL4535757,2942155,"https://doi.org/10.1021/acs.jmedchem.9b01180, https://doi.org/10.1038/s41586-019-1694-1, https://pubmed.ncbi.nlm.nih.gov/31820981/, https://pubmed.ncbi.nlm.nih.gov/31666701/",Covalent Inhibitor,9900 Â± 1800  Mâ1 sâ1,Mass Spectroscopy (Kinact/Ki),68 nM,ERK1/2 phosphorylation assay,IC 50,Other,"1 mg/Kg IV, 10 mg/Kg PO, Reviewer suggest 30 and 100 mg/Kg PO",Compound-8
CST967,3.0,0.0,1.0,No,https://www.chemicalprobes.org/cst967,USP7,Enzyme,Peptidase,2022-08-03,Q93009,QIMGOEDDLLNUNK-UHFFFAOYSA-N,O=C1CCC(N2C(=O)c3ccc(N4CCN(C(=O)CCc5ccc(NC(=O)c6ccc(C(=O)NC7(O)CCN(C(=O)OCc8ccccc8)CC7)c(Cl)c6)cc5)CC4)cc3C2=O)C(=O)N1,No,Yes,,3872896,,Degrader (PROTAC),1600 nM,Fluorogenic substrate (Ub-AMC) assay,17 nM,western blot analysis performed in the multiple myeloma cell line MM.1S with Dmax of 85% reached in 24h,DC50,,,
MRK952,3.0,0.0,1.0,No,https://www.chemicalprobes.org/mrk952,NUDT5,Epigenetic,Nudix hydrolase,2023-06-12,Q9UKK9,CAPZLSKZPWSIKV-LJQANCHMSA-N,Cn1cnc2ncnc(N3CC[C@@]4(CCN(c5ccc(C(F)(F)F)c(Cl)c5)C4)C3)c21,No,No,,3935412,,Inhibitor,"85 nM, 31 Â± 18 nM","AMP-GLO assay, SPR",23.5 Â± 4 nM,NanoBRET,EC50,,,
JNJ-9350,3.0,2.5,2.0,No,https://www.chemicalprobes.org/jnj-9350,SMOX,Enzyme,Oxidase,2023-05-18,Q9NWM0,RIGHCDSORZCRDE-UHFFFAOYSA-N,O=C(NCCCn1ccnc1)c1cc2nc(-c3ccccc3)cc(-c3ccccc3)n2n1,No,No,CHEMBL5094181,3895457,,Inhibitor,"10 nM, 9.9 nM","SMOX enzymatic assay using HyPerBlu, Horseradish Peroxidase (HRP) Fluorescence Assay",1200 nM,CETSA: 91 - 108 % recovery of SMOX (54 Â°C),IC50,Mouse,"2 mg/Kg IV, 10 mg/Kg",CANSAR3894094
ERKi,3.0,2.0,3.0,No,https://www.chemicalprobes.org/erki,"MAPK1, MAPK3","Kinase, Kinase","CMGC, CMGC",2022-01-31,"P28482, P27361",RAXZSEGXMBWYQK-SNVBAGLBSA-N,C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1,No,No,CHEMBL4538174,3196879,,Inhibitor,"1.8 nM, 4 nM","ERK Biochemical Assay, Invitrogen kinase screen (MAPK1)","280 nM, 850 nM, 91-305, 6690 nM","Inhibition of RSK phosphorylation (pRSK A375SM), NanoBRET (MAPK1), Anti proliferation assay IC50s: 
Colo 205 - 91 nM
A375SM - 214 nM
SK-MEL 30 - 305 nM
Lovo - 201 nM, NanoBRET",IC50,"Rat, Dog","1 mg/Kg PO, 0.5 mg/Kg IV, 0.5 mg/Kg PO, 0.25 mg/Kg IV",ERKi-NC
DORAMAPIMOD,1.5,1.5,2.0,No,https://www.chemicalprobes.org/doramapimod,MAPK14,Kinase,CMGC,2022-06-08,Q16539,MVCOAUNKQVWQHZ-UHFFFAOYSA-N,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,No,No,CHEMBL103667,792243,,Inhibitor,"38 nM, 0.45 nM, 8 nM","Biochemical assay, Competition binding assay, Fluorescence assay, measured after 2 h; apparent inhibitory potency of BIRB 796 as a function of the preincubation time in a standard IC50 experiment ranges from 97 nM to 8 nM after 2 h .",780 nM,inhibitinâofâTNF-Î±âin humanâwholeâblood,EC50,"Mouse, Rat","1 mg/Kg (IV), 10 mg/Kg (PO)",
GNE-3511,3.0,3.0,3.0,No,https://www.chemicalprobes.org/gne-3511,MAP3K12,Protein kinase,STE,2021-02-03,Q12852,RHFIAUKMKYHHFA-UHFFFAOYSA-N,N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)cc(N3CCC(F)(F)C3)n2)c1,No,No,CHEMBL3393333,466313,"www.doi.org/10.1021/jm5013984, www.doi.org/10.1021/acs.jmedchem.5b01072, https://pubmed.ncbi.nlm.nih.gov/25341110/, https://pubmed.ncbi.nlm.nih.gov/26431428/",Inhibitor,0.5 nM,DLK Biochemical Assay,30 nM,In cell substrate protein phosphorylation assay,IC50,Other,"0.4-1 mg/kg (IV), 5 mg/Kg (PO)",
GSK-J4,3.3,3.0,3.0,No,https://www.chemicalprobes.org/gsk-j4,"KDM6A, KDM6B","Epigenetic, Epigenetic","Lysine demethylase, Lysine demethylase",2015-11-04,"O15550, O15054",WBKCKEHGXNWYMO-UHFFFAOYSA-N,CCOC(=O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,No,No,CHEMBL3183531,387221,"www.doi.org/10.1038/nature11262, http://www.ncbi.nlm.nih.gov/pubmed/22842901",Inhibitor,60 nM,Alpha screen,9000 nM,Inhibition of TNF alpha release in primary human macrophages,IC 50,,,GSK-J5
JNJ-4355,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jnj-4355,MCL1,Other,BCL2 family,2023-10-04,Q07820,LUVOYGUFQRWXGQ-UHFFFAOYSA-N,COCCOCCn1nc(C)c2c1CSCc1cc(n(C)n1)CCc1cc(c3ccc(F)cc3c1)OCCCn1c(C(=O)O)c(C)c3c-2c(Cl)ccc31,Yes,No,,3935431,,Inhibitor,0.015 nM,HTRF assay,"AC50: 12 nM, AC50: 69 nM","Caspase Glo MOLP-8 assay, Caspase Glo KMS12PE assay",,"Mouse, Rat",1 mg/Kg,JNJ-78732576
SGC-CAF382-1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sgc-caf382-1,CDKL5,Kinase,CMGC,2023-10-04,O76039,MCLDWKVRXDHDEI-UHFFFAOYSA-N,CC(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,No,No,,3935429,,Inhibitor,6.7 nM,ADP Glo Assay,10 nM,NanoBRET,IC50,Mouse,2.29 mg/kg,SGC-CAF268-1N
TDI-10229,2.0,2.0,1.0,No,https://www.chemicalprobes.org/tdi-10229,ADCY10,Enzyme,Adenylyl Cyclase,2023-08-10,Q96PN6,VSMTYSWGHKYXOF-UHFFFAOYSA-N,Cc1c(Cc2ccccc2)c(-c2cc(Cl)nc(N)n2)nn1C,No,No,CHEMBL4854762,3453318,,Inhibitor,195 nM,In-Vitro Cyclase Activity Assay,92 nM,cAMP accumulation assay,IC50,Mouse,"20 mg/kg, 20 mg/Kg",CANSAR3453338
CDD-1653,0.0,0.0,0.0,No,https://www.chemicalprobes.org/cdd-1653,BMPR2,Kinase,TKL,2023-08-10,Q13873,MHMPZSOMHQSWEN-UHFFFAOYSA-N,COc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1N1CCN(c2ccccc2)C(=O)C1,No,No,,3935433,,Inhibitor,2.8 nM,Kinase-Glo Assay using recombinant BMPR2,"6920 nM, 25 ÂµM","Inhibition of BMP-stimulated luciferase transactivation in HEK293T BMP reporter (293T BRE-R) cells treated with 5 ng/mL BMP2 for 6 h, cells were pretreated with 25 Î¼M CDD-1653 for 30 min followed by stimulation with 5 ng/mL BMP2 for 15 min. as used to detect phosphorylated SMAD1/5., Cells were pretreated with 25 Î¼M CDD-1653 followed by stimulation with 0.5 ng/mL BMP9 for 15 min. Western blot detection of phosphorylated SMAD1/5 (pSMAD1/5)","IC50, Activity",,,
QC-01-175,2.3,0.0,3.0,No,https://www.chemicalprobes.org/qc-01-175,MAPT,Extracellular protein,Microtubule Associated Protein ,2023-08-10,P10636,NWTCZTAQSRLSCP-UHFFFAOYSA-N,O=C(CCc1ccc2c(c1)[nH]c1ccncc12)NCCOCCOCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,No,Yes,CHEMBL4465176,3160151,,Degrader (PROTAC),1.2 ÂµM,"BLI measuring the interaction with wild-type tau, or mutant tau: A152T (KD1.7 Î¼M) and P301L (KD2.5 Î¼M)",70-80%,Reduction in total tau and P-tau levels followed by western blotting after 24h treatment,Dmax,,,QC-03-075
TC-G-1008,3.0,2.5,2.0,No,https://www.chemicalprobes.org/tc-g-1008,GPR39,GPCR,,2023-08-10,O43194,DRSZMILOMUPIBJ-UHFFFAOYSA-N,CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1,No,No,CHEMBL3342358,1902215,,Agonist,,,"60 nM, 20 nM, 0.8 nM","cAMP assay (64% of efficiency) with hGPR39, Cytokine assay: Caspase 3/7 activity was measured in cytokine-treated rat insulinoma INS-1E cells, GLP1 secretion assay, IP1 assay with hGPR39",EC50,Mouse,"10, 30. 100 mg/Kg",
TIVOZANIB,2.0,2.0,1.0,No,https://www.chemicalprobes.org/krn-951,"FLT1, KDR, FLT4","Kinase, Kinase, Kinase","Tyrosine kinase, Tyrosine kinase, Tyrosine kinase",2023-08-10,"P17948, P35968, P35916",SPMVMDHWKHCIDT-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,No,No,CHEMBL1289494,436369,,Inhibitor,"30.6 nM, 6.5 nM, 15 nM",activity based assay,"0.21 nM, 0.16 nM, 0.24 nM","ligand-induced VEGFR1 receptor phosphorylation, followed by immunoprecipitation and immunoblotting, ligand-induced VEGFR2 receptor phosphorylation, followed by immunoprecipitation and immunoblotting, ligand-induced VEGFR3 receptor phosphorylation, followed by immunoprecipitation and immunoblotting",IC50,Rat,"0.04 mg/Kg, 0.2 mg/Kg, 1 mg/Kg, 5 mg/mL",
ALISERTIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/alisertib,AURKA,Kinase,Ser/Thr Kinase,2023-08-10,O14965,ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,No,No,CHEMBL483158,721492,,Inhibitor,"3.5 nM, 1.2 nM","Radiometric assays containing 100 Î¼M [Î³-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting, Assayed using recombinant protein",6.7 nM,Levels of autophosphorylation of Aurora A on threonine 288,IC50,Mouse,"5, 10, 30 mg/Kg",
JNK3-IN-8,2.3,2.0,3.0,No,https://www.chemicalprobes.org/jnk3-in-8,MAPK10,Kinase,CMGC,2023-08-10,P53779,CWLAIOPWFOOJHQ-QHCPKHFHSA-N,CNC(=O)Oc1cc(F)c2nc(-c3ccc4ccccc4c3)n(-c3ccnc(N[C@H]4CCCN(C(=O)C5CC5)C4)n3)c2c1,No,No,,3935434,,Inhibitor,21 nM,Enzymatic assay,"Fold decrease = 2, >85% @ 24h, 20 ÂµM","Inhibition of JNK3 activation induced by AÎ², by measuring reduction in c-Jun phosphorylation levels, Cell viability assay (MTT assay), Western blot assessing c-Jun phosphorylation induced by anisomycin",,Mouse,3 mg/Kg,
AZD-4017,3.0,0.0,1.0,No,https://www.chemicalprobes.org/azd-4017,HSD11B1,Enzyme,Dehydrogenase,2023-08-10,P28845,NCDZABJPWMBMIQ-INIZCTEOSA-N,CCCSc1nc(N2CCC[C@@H](CC(=O)O)C2)ccc1C(=O)NC1CCCCC1,No,No,CHEMBL2153191,278210,,Inhibitor,7 nM,cortisol competitive homogeneous time-resolved fluorescence assay (HTRF) assay,2 nM,Measurement of 11-Î²HSD1 Activity in Isolated Human Adipocytes using radiolabelled steroids.,IC50,"Mouse, Rat, Dog",,
Firazorexton,4.0,3.5,2.0,No,https://www.chemicalprobes.org/firazorexton,HCRTR2,GPCR,Orexin receptor,2023-08-10,O43614,VOSAWOSMGPKQEQ-OALUTQOASA-N,CC(C)(O)C(=O)N1CC[C@H](NS(C)(=O)=O)[C@@H]1Cc1cccc(-c2cc(F)cc(F)c2)c1F,No,No,,3935413,,Agonist,85 nM,"Radioligand Binding Assay (Saturation Binding assay), Bmax of 4.03 pmol/mg protein","19 nM, 37 nM, 170 nM, 100 nM, 19.7 nM","calcium mobilization assay in hOX2R/CHO-K1 cells, IP1 production activation assay, Induction of phosphorylation of ERK1/2, Increased Î²-arrestin recruitment, Patch clamp assay",EC50,Mouse,"10 mg/Kg, 30 mg/Kg, 3 mg/Kg",
PF-06263276,2.0,1.5,2.0,No,https://www.chemicalprobes.org/pf-06263276,"JAK1, JAK2, JAK3, TYK2","Kinase, Kinase, Kinase, Kinase","Tyrosine kinase, Tyrosine kinase, Tyrosine kinase, Tyrosine kinase",2023-06-14,"P23458, O60674, P52333, P29597",XDJGNPSZQSWJCV-UHFFFAOYSA-N,CCc1cc(O)c(F)cc1-c1ccc2c(-c3nc4c([nH]3)CCN(C(=O)c3cnc(N5CCCCC5)cn3)C4)n[nH]c2c1,No,No,CHEMBL3644620,874973,,Inhibitor,"2.2 nM, 23.1 nM, 59.9 nM, 29.7 nM",Caliper microfluidic assays measuring the potency of inhibition of phosphorylation of a peptide substrate at 1 mM ATP concentration,"70.3 nM, 620 nM, 1800 nM, 2100 nM, 4200 nM, 5200 nM","inhibition of interferon Î³ (IFNÎ³) release following stimulation with interleukin 2 (IL2), inhibition of STAT phosphorylation induced by IFNalpha, inhibition of STAT phosphorylation induced by IL-4, inhibition of STAT phosphorylation induced by IL-6, inhibition of STAT phosphorylation induced by IL-23, inhibition of STAT phosphorylation induced by GM-CSF",IC50,"Rat, Dog","0.5 mg/kg, 1 mg/Kg, 0.1 mg/Kg",
ABEMACICLIB,2.5,3.0,2.0,No,https://www.chemicalprobes.org/abemaciclib,"CDK4, CDK6","Kinase, Kinase","CMGC, CMGC",2023-06-12,"P11802, Q00534",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,No,No,CHEMBL3301610,718414,,Inhibitor,"2 nM, 0.6 nM, 10 nM, 2.4 nM",radiometric-filter binding assay,"120 nM, 72 nM, 60 nM, 20 nM, 90 nM","concentration-dependent inhibition of p-Rb, G1 arrest, pRb inhibition (pSer780), Cell viability","IC50, EC50",Mouse,>12.5 mg/Kg,
OSMI-4,0.0,0.0,0.0,No,https://www.chemicalprobes.org/osmi-4,OGT,Enzyme,Glycosyltransferase,2023-06-12,O15294,STPSLAZMEWZDAJ-AREMUKBSSA-N,CCOC(=O)CN(Cc1cccs1)C(=O)[C@H](NS(=O)(=O)c1cc2ccc(=O)[nH]c2cc1Cl)c1ccccc1OC,No,No,,3935408,,Inhibitor,8 nM,MST (microscale thermophoresis) of active form 4a,~3000 nM,O-GlcNAcylation levels after 24h treatment,EC50,,,
ARUK2002821,0.0,0.0,0.0,No,https://www.chemicalprobes.org/aruk2002821,PIP4K2A,Kinase,PIP family,2023-06-12,P48426,DZIHITUUUPJMOQ-UHFFFAOYSA-N,COc1ccc(Nc2ncnc3c2ccn3-c2ccc(C)c(C)c2)cc1Cl,Yes,No,,3929995,,Inhibitor,10 nM,ADP-Glo assay,250 nM,InCELL Pulse thermal stabilisation assay (DiscoverX),IC50,,,
MK-2894,3.3,3.7,3.0,No,https://www.chemicalprobes.org/mk-2894,PTGER4,GPCR,Prostaglandin receptor,2023-06-12,P35408,QJZQFVRFJCGDKF-UHFFFAOYSA-N,Cc1sc(C)c(C(=O)NC2(c3ccc(C(=O)O)cc3)CC2)c1Cc1ccc(C(F)(F)F)cc1,No,No,CHEMBL597997,578727,,Antagonist,0.56âÂ±â0.10 nM,Radio ligand binding assays performed on HEK293 membranes,"2.5âÂ± 0.7 nM, 11 Â± 9 nM","The EP4 functional assay measured the inhibition of PGE2-induced cAMP accumulation in HEK 293 cells, blockade of inhibition of TNFÎ±-induced IP-10 release",IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","5 mg/Kg IV, 20 mg/Kg PO, 5 mg/Kg IV, 20 mg/Kg, 1 mg/Kg IV, 5 mg/Kg PO",
APITOLISIB,3.0,3.0,2.0,No,https://www.chemicalprobes.org/gdc-0980,"PIK3CA, PIK3CB, PIK3CG, PIK3CD, MTOR","Kinase, Kinase, Kinase, Kinase, Kinase","PI3/PI4, PI3/PI4, PI3/PI4, PI3/PI4, PI3/PI4",2023-06-12,"P42336, P42338, P48736, O00329, P42345",YOVVNQKCSKSHKT-HNNXBMFYSA-N,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,No,No,CHEMBL1922094,643373,,Inhibitor,"4.8 nM, 27 nM, 14 nM, 6.7 nM, 17 nM",fluorescence polarization assay,"307 nM, 255 nM","Cell Proliferation assay, Cell Proliferation assay; activating mutation of PI3KÎ±",IC50,Mouse,"1 mg/Kg, 5 mg/Kg, 50 mg/Kg",
Idelalisib,4.0,0.0,2.0,No,https://www.chemicalprobes.org/idelalisib,PIK3CD,Kinase,PI3/PI4 family,2023-06-12,O00329,IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,No,No,CHEMBL2216870,379664,,Inhibitor,2.5 nM,Enzymatic assay using recombinant protein at Km ATP,8 nM,PI3K class I isoform-specific cell-based assay. Basophil activation was measured in isolated peripheral blood mononuclear cell or whole blood p110Î´ was activated with anti-FCÏµRI.,EC50,,,
(R)-SKBG-1,3.0,0.0,2.0,No,https://www.chemicalprobes.org/r-skbg-1,NONO,DNA Binding,,2023-05-18,Q15233,SXQZEMXQTRNLRZ-HXUWFJFHSA-N,COc1ccc(CNC(=O)[C@H]2CN(C(=O)CCl)CCN2S(=O)(=O)c2ccc(OC)cc2)cc1,No,Yes,,3935410,,Covalent Binder,,,"3100 nM, 5500 nM, 630 nM, 20 ÂµM","Depletion of AR-FL mRNA (QuantiGene assay), Depletion of AR-V7 mRNA measured by QuantiGene assays, Effects of (R)-SKBG-1 on the growth of 22Rv1 cells expressing exogenous NONO-WT (NONO-C145S EC50 3900 nM), induction","IC50, EC50, Activity",,,(S)-SKBG-1N
PRALSETINIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pralsetinib,RET,Kinase,Tyrosine Kinase,2023-05-17,P07949,GBLBJPZSROAGMF-RWYJCYHVSA-N,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,No,No,CHEMBL4582651,3218777,,Inhibitor,0.78 nM,In Vitro Biochemical Activity Assay,17 nM,Inhibition of cell proliferation transfected with NSCLC related KIF5B-RET fusion,IC50,Mouse,10 mg/Kg,
LAROTRECTINIB,4.0,4.0,1.0,No,https://www.chemicalprobes.org/larotrectinib,"NTRK1, NTRK2, NTRK3","Kinase, Kinase, Kinase","Tyr kinase, Tyr kinase, Tyr kinase",2023-05-17,"P04629, Q16620, Q16288",NYNZQNWKBKUAII-KBXCAEBGSA-N,O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1,No,No,CHEMBL3889654,401319,,Inhibitor,"1.2 nM, 2.1 nM",Activity assay using 10 ÂµM ATP,"8 nM, 1.9 nM, 6 nM, 8.1 nM, 10.6 nM","MTS assay measuring anti-proliferation of Ba/F3 cells expressing the MPRIP-NTRK1, Inhibition of activation of TRKA, downstream signalling, in cells expressing CD74-NTRK1 (CD74-TRKA), Inhibition of activation of TRKA in KM12 cells expressing endogenous TPM3-NTRK1, downstream signalling, and proliferation",IC50,Mouse,30 mg/Kg BID,
BI-5524,4.0,3.3,3.0,No,https://www.chemicalprobes.org/bi-5524,ELANE,Enzyme,peptidase S1 family,2023-05-17,P08246,DOVSNSDMRJVTMR-JOCHJYFZSA-N,CC(C)(O)CNC(=O)N1C(=O)N(c2cccc(C(F)(F)F)c2)C2=C(C(=O)CC2)[C@H]1c1ccc(C#N)cc1,No,No,CHEMBL4112323,751766,,Inhibitor,0.5 nM,hNE inhibitor assay,0.4 nM,Inhibition of zymosan-stimulated NE activity in human plasma,EC50,"Mouse, Rat",1 uM/Kg,CANSAR748058
GW0742,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gw0742,PPARD,Nuclear Hormone Receptor,Nuclear Receptor 1C2,2023-05-15,Q03181,HWVNEWGKWRGSRK-UHFFFAOYSA-N,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)c(F)c3)nc2C)ccc1OCC(=O)O,No,No,CHEMBL38508,322852,,Agonist,"0.4 nM, 1 nM","competitive TR-FRET assay, Inhibition of human PPARD","1 nM, 30 Â± 3.6 nM","cell-based transactivation assay, Transactivation assays of human and mouse variant in transfected cells",EC50,,,
XL01126,0.0,0.0,0.0,No,https://www.chemicalprobes.org/xl01126,LRRK2,Kinase,TKL,2023-04-02,Q5S007,HKSBXNVKPFTBIG-WUEKOBJSSA-N,CNc1nc(Nc2ccc(C(=O)N3CCN(CC4CCC(CSC(C)(C)[C@H](NC(=O)C5(F)CC5)C(=O)N5C[C@H](O)C[C@H]5C(=O)NCc5ccc(-c6scnc6C)cc5)CC4)CC3)cc2OC)ncc1Cl,No,Yes,,3935385,,Degrader (PROTAC),12.4 nM,kinase activity assay,"32 nM, 14 nM, 54 nM, 15 nM, 1.4 ÂµM","Degradation of WT-LRRK2 Dmax 82% after 4 h, Degradation of G2019S-LRRK2 Dmax 90% after 4h, Time-dependent pRab10 dephosphorylation (WT-pRab10 after 4 h), Time-dependent pRab10 dephosphorylation (G2019S-pRab10 after 4h), NanoBRET target engagement assay","DC50, EC50, IC50",Mouse,"5 mg/Kg, 30 mg/Kg",cis-XL01126
AZD8055,4.0,4.0,2.0,No,https://www.chemicalprobes.org/azd8055,MTOR,Kinase,PI3/PI4,2023-04-02,P42345,KVLFRAWTRWDEDF-IRXDYDNUSA-N,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,No,No,CHEMBL1801204,574349,,Inhibitor,"0.13 Â± 0.05 nM, 0.8 Â± 0.2 nM, 1.3nM","Alpha-screen using truncated recombinant mTOR enzyme, Alpha-Screen using native mTOR enzyme complexes extracted from HeLa cells., enzymatic assay using different ATP concentrations","24 Â± 9 nM, 27 Â± 3 nM, 1 ÂµM","High-throughput immunocytochemical screening assay in MDA-MB-468 cells detecting phosphorylation of AKT at Ser473 (mTORC2 substrate), High-throughput immunocytochemical screening assay in MDA-MB-468 cells detecting phosphorylation of ribosomal protein S6 at Ser235/236 (indirect substrate of mTORC1), Western blot assessing phosphorylation of the SGK substrate NDRG1, autophagy assay assessing increase of LC3","IC50, INH, Activity",Mouse,2.5 and 10 mg/Kg,
SN-011,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sn-011,STING1,Transmembrane protein,STING family,2023-04-02,Q86WV6,GPXQUPCJIJBXHJ-UHFFFAOYSA-N,O=C(Nc1ccc(O)c(NS(=O)(=O)c2ccc(F)cc2)c1)c1ccc(-c2ccccc2)cc1,No,Yes,,3935387,,Inhibitor,4.03 nM,surface plasmon resonance (SPR) measuring the binding affinity and kinetics between SN-011 and soluble human STING,"127.5 nM, 107.1 nM, 502.8 nM, 76 nM, 1 ÂµM","inhibit 2â²3â²-cGAMP-induced Ifnb mRNA expression in MEFs, 2â²3â²-cGAMP-induced Ifnb mRNA expression in mouse bone marrow-derived macrophages (BMDMs), inhibit 2â²3â²-cGAMP-induced Ifnb mRNA expression in human foreskin fibroblasts (HFFs), Quantitative PCR of Ifnb mRNA after 6 h treatment with SN-011 and subsequent stimulation with HT-RNA.
No effect on basal Ifnb mRNA expression., suppression of the induction of Ifnb, Cxcl10, and Il6 mRNA activated by various canonical STING stimulators (ISD, HT-DNA, HSV-1, c-di-GMP, and 2â²3â²-cGAMP.","IC50, INH",Mouse,5 mg/Kg,SN-100
KHK-IN-1,4.0,3.0,1.0,No,https://www.chemicalprobes.org/khk-in-1,KHK,Kinase,Carbohydrate kinase,2023-10-09,P50053,HFLMLZKGLUEWBU-UHFFFAOYSA-N,CSc1ccccc1Nc1nc(N2CCNCC2)nc2c(NCC3CC3)ncnc12,No,No,CHEMBL2017214,293552,,Inhibitor,12 nM,Inhibition of recombinant human hepatic KHK (KHK-C) Fluorescence Polarization (FP) Assay,400 nM,Inhibition of F1P production in HepG2 cell lysates,IC50,Rat,10 mg/Kg,
Ervogastat,4.0,4.0,2.0,No,https://www.chemicalprobes.org/ervogastat,DGAT2,Enzyme,Acyltransferase,2023-10-09,Q96PD7,UKBQFBRPXKGJPY-INIZCTEOSA-N,CCOc1cccnc1Oc1cncc(-c2ncc(C(=O)N[C@H]3CCOC3)cn2)c1,No,No,CHEMBL4760665,2865424,,Inhibitor,17.2 nM,Radiolabelled incorporation assay,2.79 nM,Inhibition of [14C]-glycerol incorporation into triglycerides in primary hepatocytes,IC50,"Rat, Monkey (Cynomolgus)","1 mg/Kg, 5 mg/Kg",
TP-060,1.0,0.0,1.0,No,https://www.chemicalprobes.org/tp-060,UGCG,Enzyme,Glycosyltransferase,2023-10-06,Q16739,OAZAPIKYVGRNCO-UHFFFAOYSA-N,CC(C)(O)c1ccc(N2Cc3c(ccnc3-c3ccc(F)cc3OCC(F)(F)F)C2=O)cc1,No,No,CHEMBL5078078,3886348,,Inhibitor,31 nM,Enzymatic assay,7.6 nM,Cellular GlcCer reduction,EC50,Mouse,"0.5 mg/Kg, 5 mg/Kg",CANSAR3897548
YKL-01-116,3.0,0.0,1.0,No,https://www.chemicalprobes.org/ykl-01-116,CDK7,Kinase,CMGC,2023-03-02,P50613,VBYGXNURPHQSPG-MUUNZHRXSA-N,C=CC(=O)Nc1ccc(C(=O)Nc2cccc(Nc3n[nH]c4c3CN(C(=O)N[C@H](CN(C)C)c3ccccc3)C4(C)C)c2)cc1,No,Yes,CHEMBL4434871,3129634,,Inhibitor,7.6 nM,Biochemical Radioactivity Assay,,"YKL-1-116 dose-dependently targets CDK7 in HCT116, Jurkat, Kuramochi, OVCAR8, and COV362 cancer cells as assessed by intracellular target engagement",,,,
AZD5153,3.5,3.0,2.0,No,https://www.chemicalprobes.org/azd5153,"BRD4, BRD2, BRDT, BRD3","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2023-03-02,"O60885, P25440, Q58F21, Q15059",RSMYFSPOTCDHHJ-GOSISDBHSA-N,COc1nnc2ccc(N3CCC(c4ccc(OCCN5CCN(C)C(=O)[C@H]5C)cc4)CC3)nn12,No,No,CHEMBL4078100,668436,,Inhibitor,"5 nM, 100 nM, 50 nM","BRD4 Fluorescence Polarization Assay, Bromoscan","25 nM, 12.6 nM, 5 nM","Estrogen Receptor Downregulation Assay, c-Myc Downregulation Assay, Cell Viability Assay","IC50, GI50","Rat, Dog",unknown,
LP-935509,3.0,2.5,2.0,No,https://www.chemicalprobes.org/lp-935509,AAK1,Kinase,Ser/Thr kinase,2023-03-01,Q2M2I8,GOOYSJIWTIHOGW-UHFFFAOYSA-N,COc1ncccc1-c1cnn2ccc(N3CCN(C(=O)OC(C)C)CC3)nc12,No,No,CHEMBL4127773,230769,,Inhibitor,"3.3 Â± 0.7 nM, 0.9 nM","phosphorylation of peptide inhibition, Enzymatic assay",2.8 Â± 0.4 nM,In cell phosphorylation inhibition,IC50,"Mouse, Rat",10 mg/Kg,
ZIMLOVISERTIB,3.0,2.0,1.0,No,https://www.chemicalprobes.org/zimlovisertib,IRAK4,Kinase,TKL,2023-03-01,Q9NWZ3,JKDGKIBAOAFRPJ-ZBINZKHDSA-N,CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F,No,No,CHEMBL4081711,1785299,,Inhibitor,0.2 Â± 0.1 nM,"DELFIA assay using activated full-length IRAK4 protein in the presence of 600 Î¼M ATP (i.e., ATP Km) and assessing phosphorylation of a peptide substrate",2.4 Â± 1.9 nM,R848-stimulated TNFÎ± production in peripheral blood mononuclear cells (PBMCs) isolated from human blood,IC50,"Rat, Dog","1 mg/Kg, 5 mg/Kg",CANSAR1682746
Emavusertib,3.0,3.0,1.0,No,https://www.chemicalprobes.org/emavusertib,IRAK4,Kinase,TKL,2023-03-01,Q9NWZ3,SJHNWSAWWOAWJH-MRXNPFEDSA-N,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1,No,No,CHEMBL4783351,3316728,,Inhibitor,31.7 nM,TR-FRET assay using recombinant IRAK4 kinase,"514 nM, 270 nM, 696-1375 nM","Inhibition of LTA induced TNFÎ± in THP-1 Cells, pIRAK1 modulation in MV4-11 cell-line, Modulation of IL6 in human whole blood assay 
TLR2 (LTA) induced	989 Â± 686 nM,
IL-1R (IL-1Î²) induced	1375 Â± 272 nM,
TLR5 (FLA-ST) induced	696 nM",IC50,"Mouse, Rat, Dog","3 mg/Kg, 10 mg/Kg, 1 mg/Kg",
IRAK4-IN-28,3.0,2.0,2.0,No,https://www.chemicalprobes.org/irak4-in-28,"IRAK4, IRAK1","Kinase, Kinase","TKL, TKL",2023-03-01,"Q9NWZ3, P51617",DJVYXMINSBMUHH-QAQDUYKDSA-N,c1nc(N[C@H]2CC[C@H](N3CCOCC3)CC2)c2c(C3CCOCC3)c[nH]c2n1,Yes,No,CHEMBL4064608,135759,,Inhibitor,"5 nM, 0.7 nM, 23 nM","Enzymatic Assay, DiscoverX Kd ELECT, enzymatic assay","52 nM, ~ 1000 nM","IRAK4 Cell Potency Assay (FACS) after stimulation with 25 ng/mL recombinant IL-1 and staining for anti-pIRAK4, Dose-dependent inhibition of IÎºBÎ± phosphorylation in OCI-LY10 cells upon treatment of cells with compound 28 for 14 h",IC50,"Rat, Dog","2 mg/kg, 5 mg/kg, 1 mg/kg",CANSAR137197
SR-4835,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sr-4835,"CDK12, CDK13","Kinase, Kinase","CMGC, CMGC",2023-02-24,"Q9NYV4, Q14004",FSELUFUYNUNZKD-UHFFFAOYSA-N,Cn1cc(-n2cnc3c(NCc4nc5cc(Cl)c(Cl)cc5[nH]4)nc(N4CCOCC4)nc32)cn1,No,No,CHEMBL4877117,3652871,,Inhibitor,"98 nM, 99.0 Â± 10.5 nM, 4.9 nM","Binding affinity (DiscoverX), ADP-glo kinase assay","105.5 Â± 5.50 nM, 15-25 nM","percentage of the ratio of pSer2 of Pol II CTD signal versus total Pol II CTD signal relative to DMSO control (In Cell Western), Anti-proliferative activity",EC50,Mouse,20 mg/Kg,
ALW-II-49-7,3.0,0.0,1.0,No,https://www.chemicalprobes.org/alw-ii-49-7,"DDR2, DDR1","Kinase, Kinase","Tyrosine kinase, Tyrosine kinase",2023-02-13,"Q16832, Q08345",SAAYRHKJHDIDPH-UHFFFAOYSA-N,Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1cncc(C(N)=O)c1,No,No,CHEMBL552425,255911,,Inhibitor,"18.6 nM, 12.4 nM",KinomeSCAN,1 ÂµM,Decreasing level of DDR2 Phosphorylation,INH,,,
TES-1025,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tes-1025,ACMSD,Enzyme,Carboxylase,2023-02-13,Q8TDX5,CDQQWCLOMUMQMM-UHFFFAOYSA-N,N#Cc1c(-c2cccs2)nc(SCc2cccc(C(=O)NO)c2)[nH]c1=O,Yes,Yes,CHEMBL4082726,1785169,,Inhibitor,13 Â± 3 nM,ACMSD enzymatic assay,40%,increase in intracellular NAD+ levels,% in,Mouse,"0.5 mg/Kg, 5 mg/Kg",
EPZ005687,3.0,0.0,1.0,No,https://www.chemicalprobes.org/epz005687,EZH2,Epigenetic,Methyltransferase ,2023-01-26,Q15910,ZOIBZSZLMJDVDQ-UHFFFAOYSA-N,Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(CN4CCOCC4)cc3)cc3c2cnn3C2CCCC2)c(O)n1,No,No,,3444996,,Inhibitor,"24 Â± 7 nM, 54 Â± 5 nM","Biochemical Enzyme Assay, Flashplate assay",80 Â± 30 nM,Methylation of substrate H3K27 detected by Western,IC50,,,
PF-367,3.7,3.0,3.0,No,https://www.chemicalprobes.org/pf-367,"GSK3A, GSK3B","Kinase, Kinase","CMGC, CMGC",2023-01-25,"P49840, P49841",RQFYFNAGNBUGFC-UHFFFAOYSA-N,COc1ccc(-c2ocnc2C(=O)NCCCn2cncn2)cc1Cl,No,No,,2976831,,Inhibitor,"10 nM, 9.0 nM, 1.1 nM, 2.1 nM","Mobility shift assay, ADP-Glo assay, GSK-3Î² enzyme assay",466 nM,Inhibition of Tau phosphorylation assay,IC50,Rat,50 mg/Kg,
MFH290,4.0,3.0,1.0,No,https://www.chemicalprobes.org/mfh290,"CDK12, CDK13","Kinase, Kinase","CMGC, CMGC",2023-01-25,"Q9NYV4, Q14004",COGUZYALRYMQTD-LJQANCHMSA-N,C=CC(=O)Nc1ccc(C(=O)N2CCC[C@@H](Nc3ncc(SCc4ncc(C(C)(C)C)o4)s3)C2)cc1,No,Yes,CHEMBL4647764,3339086,,Inhibitor,"25 nM, 49 nM",Biochemical assay,"10.15 nM, 0%","Cell Proliferation assay, Pulldown assay (remaining CDK12 percentage)",IC50,Mouse,"1 mg/Kg, 5 mgKg, 10 mg/Kg",CANSAR3329968
JH-X-119-01,2.5,3.0,2.0,No,https://www.chemicalprobes.org/jh-x-119-01,IRAK1,Kinase,TKL,2023-01-25,P51617,WQVPGYMGERDXLH-UHFFFAOYSA-N,C=CC(=O)Nc1cccc(C(=O)Nc2ccc(NC(=O)c3cccc(-c4ccn[nH]4)n3)cc2)c1,No,Yes,CHEMBL4782804,3580467,,Inhibitor,9 nM,Enzymatic assay,,JH-X-119-01 (10 Î¼M) decreases phosphorylation of NF-ÎºB and mRNA levels of IL-6 and TNFÎ± in LPS-treated macrophages in vitro,,Mouse,5 mg/kg,
LRRK2-IN1,3.0,3.0,1.0,No,https://www.chemicalprobes.org/lrrk2-in-1,LRRK2,Kinase,TKL,2023-01-24,Q5S007,IWMCPJZTADUIFX-UHFFFAOYSA-N,COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C,No,No,CHEMBL2012582,870554,,Inhibitor,"6 nM, 13 nM, 20 nM","Enzymatic activity of GST-LRRK2[G2019S] (1,326â2,527), Enzymatic activity of GST-LRRK2 (1,326â2,527), Binding Assay (Ambit)",,Near-maximal effects of 1 Î¼M LRRK2-IN-1 on dephosphorylation of Ser910 and Ser935 and 14-3-3 binding to wild-type LRRK2 and LRRK2[G2019S] were observed within 15 min and sustained for at least 2 h,INH,Mouse,"1 mg/Kg, 10 mg/Kg",
ML5,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ml5,S1PR1,GPCR,Sphingosine receptor,2023-01-24,P21453,FWJRVGZWNDOOFH-OAHLLOKOSA-N,CCCCCCc1cccc(NC(=O)[C@H](N)CCP(=O)(O)O)c1,No,Yes,CHEMBL1221649,1421673,,Antagonist,77 nM,GTP-Î³S binding assay using CHO cell membranes,18 nM,Antagonist activity at human S1P1 receptor expressed in CHO cells assessed as inhibition of SEW2871-induced [35S]GTPgamma binding,Ki,Rat,1 mg/Kg,CANSAR1421688
AZ2858,0.0,0.0,0.0,No,https://www.chemicalprobes.org/az2858,GSK3B,Kinase,CMGC,2023-01-24,P49841,FHCSBLWRGCOVPT-UHFFFAOYSA-N,CN1CCN(S(=O)(=O)c2ccc(-c3cnc(N)c(C(=O)Nc4cccnc4)n3)cc2)CC1,No,No,CHEMBL2177161,455810,,Inhibitor,4.9 nM,Biochemical Assay,76 nM,Inhibition of Tau phosphorylation,IC50,,,
PT-65,2.0,0.0,2.0,No,https://www.chemicalprobes.org/pt-65,"GSK3A, GSK3B","Kinase, Kinase","CMGC, CMGC",2023-01-24,"P49840, P49841",QJSFLEBIQZMJQF-UHFFFAOYSA-N,Nc1ncc(-c2ccc(S(=O)(=O)N3CCN(CCCCc4cn(CCOCCOCCOCCOCCOCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)nn4)CC3)cc2)nc1C(=O)Nc1cccnc1,No,Yes,CHEMBL5084520,3900947,,Degrader (PROTAC),12.41 nM,SPR,"28.3 nM, 94.3 Â± 2.2%, 34.2 nM, 90.8 Â± 2.9%","Degradation of GSK3B in SH-SY5Y cells after 24 h treatment, max degradation in cell @ 1 uM, max degradation in cells @ 1 uM","DC50, Dmax",,,
BAY-6035,4.0,0.0,2.0,No,https://www.chemicalprobes.org/bay-6035,SMYD3,Epigenetic,Methyltransferase,2023-01-23,Q9H7B4,CKFRXCBNKKOFGO-IGEOTXOUSA-N,C[C@H]1CC(=O)Nc2cc(C(=O)NCCC3CC3)ccc2N1C(=O)N1CC2CC2C1,No,No,CHEMBL4746525,3558528,,Inhibitor,"8.34 K, 88 nM, 133 nM, 97 nM","Thermal Shift Assay, Scintillation Proximity Assay, ITC, SPR",183 Â± 13 nM,Inhibition of SMYD3-dependent MAP3K2 methylation in cells,IC50,,,BAY-444
SGC6870,4.0,0.0,2.0,No,https://www.chemicalprobes.org/sgc6870,PRMT6,Epigenetic,Methyltransferase,2023-01-23,Q96LA8,NIPTUMFVYBXSMZ-JOCHJYFZSA-N,Cc1cc(C)cc([C@@H]2c3cc(C)ccc3NC(=O)CN2C(=O)c2ccc(Br)s2)c1,No,No,CHEMBL5070897,2855705,,Inhibitor,77 nM,Biochemical assay (radiometric method),"900 Â± 100 nM, 600 Â± 100 nM","SGC6870 potently and concentration-dependently reduced cellular levels of H3R2me2a, SGC6870 potently and concentration-dependently reduced cellular levels of H4R3me2a",IC50,,,SGC6870N
DGY-09-192,4.0,4.0,2.0,No,https://www.chemicalprobes.org/dgy-09-192,"FGFR1, FGFR2","Kinase, Kinase","TK, TK",2022-12-21,"P11362, P21802",WDBUEMWHXKHQNB-NNAUULPKSA-N,COc1cc(OC)c(Cl)c(/N=C(\O)N(C)c2cc(Nc3ccc(N4CCN(C/C(O)=N/[C@H](C(=O)N5C[C@H](O)C[C@H]5/C(O)=N\[C@H](C)c5ccc(-c6scnc6C)cc5)C(C)(C)C)CC4)cc3)ncn2)c1Cl,Yes,Yes,,3445795,,Degrader (PROTAC),"23.8 nM, 34 nM",Zâ-LYTE kinase assay by Invitrogen,"4.35 nM, 85%, 17 nM, 70 nM, 74%, 1 nM","Target degradation, Anti-proliferation activity (CellTiter-Glo assay), Target degradation after 6 h treatment","DC50, Dmax, IC50",Mouse,"1 mg/Kg, 3 mg/Kg, 10 mg/Kg",DGY-09-192-Neg
BSJ-04-122,2.5,0.0,2.0,No,https://www.chemicalprobes.org/bsj-04-122,"MAP2K4, MAP2K7","Kinase, Kinase","STE, STE",2022-12-21,"P45985, O14733",LWXOPXNDPRPGMJ-UHFFFAOYSA-N,C=C/C(O)=N/c1ccccc1Nc1ncnc2[nH]cc(Cl)c12,No,Yes,,3445418,,Inhibitor,"4 nM, 181 nM, 707 nM","Lanthascreen binding assay; covalent binding to CYS247, located before the highly conserved DFG motif, was confirmed by LC-MS, Radioisotope binding assay ([32P]ATP kinase assay); covalent binding to CYS261, located before the highly conserved DFG motif, was confirmed by LC-MS, Capillary microfluidic electrophoretic mobility shift assay","87.0%, ~100%, 90.2%","Kinativ, JNK1/2 phosphorylation inhibition",% in,,,"N-(2-((5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)propionamide"
UNC6934,4.0,0.0,3.0,No,https://www.chemicalprobes.org/unc6934,NSD2,Epigenetic,Methyltransferase,2022-12-20,O96028,KOZGEDUWAQFVAV-UHFFFAOYSA-N,O=C1COc2cc(C(=O)N(Cc3ccc(C(=O)Nc4ccncn4)cc3)C3CC3)ccc2N1,No,No,CHEMBL5200945,2888304,,Antagonist,"91 Â± 8 nM, 104 Â± 13 nM, 78 Â± 29 nM","SPR binding, Binding of NSD2-PWWP1 to nucleosomal H3K36me2 by Alphascreen of N-terminal domain, Binding of NSD2-PWWP1 to nucleosomal H3K36me2 by Alphascreen of Full length NSD-2",1230 Â± 250 nM,"NanoBRET PPI assay, based on interaction between NSD2-PWWP1âNanoLuc and histone H3.3âHaloTag",EC50,,,UNC7145
BSJ-4-116,3.0,0.0,2.0,No,https://www.chemicalprobes.org/bsj-4-116,CDK12,Kinase,CMGC,2022-12-20,Q9NYV4,YJOJMGTVKMABKQ-FIQOPJFZSA-N,CC(C)S(=O)(=O)c1ccccc1Nc1nc(N[C@@H]2CCCN(CCCCCCCNC(=O)COc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)ncc1Cl,No,Yes,CHEMBL4870240,3314963,,Degrader (PROTAC),6 nM,radioactive CDK12/Cyclin K in vitro kinase assay,250 nM,Degradation assessed by western blot for CDK12,Activity,,,BSJ-4-116-NC
BSJ-01-175,2.0,2.0,1.0,No,https://www.chemicalprobes.org/bsj-01-175,"CDK12, CDK13","Kinase, Kinase","CMGC, CMGC",2022-11-22,"Q9NYV4, Q14004",DMUSMYYDKCXFKR-MRJIRHQNSA-N,CN(C)C/C=C/C(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1,No,Yes,CHEMBL4754873,3567225,,Inhibitor,"156 nM, 282.6 nM","Biochemical Activity, Biochemical assay","42 nM, 160 nM, 0.5 to 5 ÂµM","Anti-proliferation activity of BSJ-01â175 on Kelly cells with WT CDK12 or C1039F mutant: cell bearing C1039F mutation IC50 225.3 nM, antiproliferative activity in Ewing sarcoma cells, Competitive pull-down experiment and washout experiments followed by WB for Cyclin K, Western blot for phosphorylated RNA pol II CTD","IC50, Activity, INH",Mouse,"3 mg/Kg, 10 mg/Kg",
FMF-02-063-1,2.0,0.0,1.0,No,https://www.chemicalprobes.org/fmf-02-063-1,"PIK3CD, PIK3CG","Kinase, Kinase","PI3/PI4-kinase, PI3/PI4-kinase",2022-11-22,"O00329, P48736",GHKMIOAEPALCFS-UHFFFAOYSA-N,Cc1ccc2c(c1)C(=O)N(C)c1cnc(Nc3cccc(S(=O)(=O)N4CCC(O)CC4)c3)nc1N2C,No,No,CHEMBL3959351,706860,,Inhibitor,"2.1 nM, 6.5 nM","ADAPTA assay, homogenous, fluorescence-based immunoassay for the detection of ADP","1.4 ÂµM, 1.3 ÂµM, 0.62 ÂµM, 1.0 ÂµM, 0.35 ÂµM","AKT and S6RP phosphorylation in isogenic HMEC lines expressing CA-p110Î±, CA-p110Î², or CA-p110Î´, Cell Viability Assays",IC50,,,CANSAR807724
AR-C141990,3.0,3.0,1.0,No,https://www.chemicalprobes.org/ar-c141990,SLC16A1,Solute carrier,Monocarboxylate porter,2023-10-16,P53985,JOFQERPJMGKMMX-QGZVFWFLSA-N,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21,No,No,CHEMBL205742,618499,,Inhibitor,4.8 nM,Scintillation Proximity Assay,3.2 nM,Human Lymphocyte proliferation assay,IC50,Rat,,
AVL-292,2.7,3.5,3.0,No,https://www.chemicalprobes.org/avl-292,BTK,Protein kinase,TK,2015-12-10,Q06187,KXBDTLQSDKGAEB-UHFFFAOYSA-N,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,No,Yes,CHEMBL3301625,388399,"www.doi.org/10.1124/jpet.113.203489, http://www.ncbi.nlm.nih.gov/pubmed/23709115","ATP-competitive inhibitor, Covalent inhibitor",7.69 x 10^4 per M per sec,IC50 (app) < 0.5 nM,8 nM,Autophosphorylation in Ramos cells. EC50 for occupancy with a biotinylated derivative of AVL-292 was 6 nM.,EC50,Other,50 mg/kg,
SGC-STK-17B-1,4.0,0.0,2.0,No,https://www.chemicalprobes.org/sgc-stk17b-1,STK17B,Kinase,CAMK,2022-06-08,O94768,BNYXRPMABDQJJR-UHFFFAOYSA-N,O=C(O)CSc1ncnc2cc(-c3cc4ccccc4s3)sc12,No,No,CHEMBL4752776,2968658,,Inhibitor,34 nM,KinaseSeeker Split Luciferase Assay,190 nM,NanoBRET,IC50,,,SGC-STK17B-1N
SGC-CAMKK2-1,3.0,0.0,2.0,No,https://www.chemicalprobes.org/sgc-camkk2-1,"CAMKK1, CAMKK2","Kinase, Kinase","Other STK, Other STK",2022-03-25,"Q8N5S9, Q96RR4",TXIYVFVMXNFNRX-UHFFFAOYSA-N,Cc1cccc(-c2cnc3occ(-c4ccc(C(=O)O)c(C5CCCC5)c4)c3c2)c1,No,No,CHEMBL4745471,3550555,,Inhibitor,"12 Percent of Control, 30 nM","KINOMEscan assay at 1 ÂµM, Biochemical Assay",1603 nM,"C4-2 cells (a prostate cancer cell line). Expression levels of CaMKK2, p-AMPK and AMPK were measured by Western Blot",IC50,,,CANSAR3550556
YX968,4.0,0.0,1.0,No,https://www.chemicalprobes.org/yx968,"HDAC3, HDAC8","Epigenetic, Epigenetic","HDAC, HDAC",2023-10-05,"O15379, Q9BY41",,,No,No,,,,Degrader (PROTAC),"283.8 Â± 50.6 nM, 740.1 Â± 302.7 nM",HDAC activity assays,"1.7 nM, 95%, 6.1 nM","Degradation detected by WB over 8 h, Western blot after treatment for 8h at 50 nM, Degradation detected via WB after 8h","DC50, Dmax",,,YC968-NC
PF-9363,3.3,3.0,3.0,No,https://www.chemicalprobes.org/pf-9363,"KAT6A, KAT6B","Epigenetic, Epigenetic","MYST family, MYST family",2023-10-06,"Q92794, Q8WYB5",,,No,No,,,,Inhibitor,"0.27 nM, 2.4 nM",SPR,"0.85 nM, 370 nM","H3K23Ac sandwich ELISA assay, Cell proliferation assay",IC50,Mouse,"1.0 mg/Kg, 1 mg/Kg",Ctx-533
ALKBH5-IN-1,2.0,0.0,1.0,No,https://www.chemicalprobes.org/alkbh5-in-1,ALKBH5,Enzyme,Dioxygenase,2023-10-09,Q6P6C2,VBTBURGKMCKOJC-UHFFFAOYSA-N,O=C(O)c1cc(O)n(-c2cccc(C(F)(F)F)c2)n1,No,No,CHEMBL5203605,4004004,,Inhibitor,"21 nM, 8.75 Celsius","Fluorescence Polarization assay, DSF assay with 100 ÂµM compound","~10 Celsius, > 1 ÂµM","CETSA using 100 ÂµM compound, Dot blot monitoring the methylation of adenosine in intact cells in dose dependent manner (1 ÂµM to 10 ÂµM)",ÎTm,,,cpd 20n
SGC-GSK3-1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sgc-gsk3-1,"GSK3A, GSK3B","Kinase, Kinase","CMGC, CMGC",2023-10-04,"P49840, P49841",OCQCKUTZHBQNEI-UHFFFAOYSA-N,O=C(NCC1CCOCC1)c1n[nH]cc1NC(=O)c1c(F)cccc1F,No,No,,3935430,,Inhibitor,"1.0 nM, 2.0 nM",Enzymatic assay,"4.6 nM, 12 nM",NanoBRET,IC50,,,SGC-CDKL5/GSK3-1N
BAY-805,4.0,0.0,2.0,No,https://www.chemicalprobes.org/bay-805,USP21,Enzyme,USP subfamily,2023-06-12,Q9UK80,LXRBPWHQMGKMRT-GOSISDBHSA-N,CC(C)C[C@@H](NC(=O)C1(C(F)(F)F)CCCCC1)C(=O)Nc1nnc(Cc2ccc(C#N)cc2)s1,No,No,,3935406,,Inhibitor,"6 nM, 95, 2 nM, 85%, 2.2 nM","hUSP21 HTRF Interference Assay, Enzymatic efficacy in hUSP21 HTRF Interference Assay, Ubiquitin (Ub) Rhodamine 110 Assays, Enzymatic efficacy in Ubiquitin (Ub) Rhodamine 110 Assays, SPR",17 nM,HiBiT CETSA,EC50,,,BAY-728
CVN417,0.0,3.0,1.0,No,https://www.chemicalprobes.org/cvn417,CHRNA6,Ion Channel,Nicotinic Acetylcholine Receptor,2023-10-09,Q15825,,,No,No,,,,Antagonist,,,86 nM,"Calcium flux assay in human Î±6*-nAChR containing channels
whereas Î±6-containing nAChRs (Î±6*-nAChRs; asterisk (*) denotes possible presence of additional subunits) Î±6* = Î±6-Î±3/Î²2/Î²3V273S",IC50,"Rat, Dog","0.5 mg/Kg, 10 mg/Kg, 1 mg/Kg, 3 mg/Kg",
IACS-52825,3.0,3.0,1.0,No,https://www.chemicalprobes.org/iacs-52825,MAP3K12,Kinase,STE,2023-10-09,Q12852,,,No,No,,,,Inhibitor,1.3 nM,Biochemical assay (KINOMEscan KdELECT),107 Â± 22 nM,Phospho-c-Jun cellular assay,IC50,"Mouse, Rat, Dog, Monkey (Cynomolgus)","0.3/10 mpk IV/PO, 1/3 mpk IV/PO, 0.3/1 mpk IV/PO",
JNJ-42226314,4.0,4.0,2.0,No,https://www.chemicalprobes.org/jnj-42226314,MGLL,Enzyme,Lipase,2023-10-06,Q99685,IVOACCSOISMVBL-UHFFFAOYSA-N,O=C(c1ccc2c(ccn2-c2ccc(F)cc2)c1)N1CC(N2CCN(C(=O)c3nccs3)CC2)C1,No,No,CHEMBL3658400,659577,,Inhibitor,< 5 nM,Fluorometric Assay (Inhibition of 4MU-B cleavage),"1.13 Â± 0.05 nM, up to 10 ÂµM",[3H] 2-OG cleavage activity assay,IC50,"Rat, Dog, Monkey (Cynomolgus)",10 mg/Kg,JN8034
BI-3231,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi-3231,HSD17B13,Enzyme,Dehydrogenases,2023-11-03,Q7Z5P4,,,No,No,,,,Inhibitor,"0.7 Â± 0.2 nM, 1 Â± 0.5 nM, 16.7 K","Enzymatic assay, Thermal Shift Assay experiments (nanoDSF)",11 nM,Custom-made stably overexpressing hHSD17B13-Myc/DDK HEK293 cells,IC50,Mouse,"5 umol/Kg, 50 umol/Kg, 80 umol/Kg",BI-0955
ABT-100,2.5,3.5,2.0,No,https://www.chemicalprobes.org/abt-100,FNTB,Other post-translational modification,Transferase,2020-05-21,P49356,HEUVRFNVTLGKMZ-SANMLTNESA-N,Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1,No,No,CHEMBL4586794,2920851,"www.doi.org/10.1158/1078-0432.CCR-04-2041, www.doi.org/10.1158/1078-0432.CCR-04-2386, www.doi.org/10.1016/j.healun.2004.06.006, www.doi.org/10.1126/science.1124875, www.doi.org/10.1097/00001813-200511000-00004, https://pubmed.ncbi.nlm.nih.gov/15837760/, https://pubmed.ncbi.nlm.nih.gov/15930366/, https://pubmed.ncbi.nlm.nih.gov/16143263/, https://pubmed.ncbi.nlm.nih.gov/16484451/, https://pubmed.ncbi.nlm.nih.gov/16222147/",Inhibitor,0.05 nM,Scintillation proximity assay,0.73 nM,Ras and Rap 1A processing assay,EC50,Other,"5 mg/kg (Rat), 2.5 mg/kg (Dog), up to 25 mg/kg (PO)",ABT-108
JQ1,4.0,3.0,3.0,No,https://www.chemicalprobes.org/jq1,"BRD2, BRD4, BRD3, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2015-07-13,"P25440, O60885, Q15059, Q58F21",DNVXATUJJDPFDM-KRWDZBQOSA-N,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,No,No,CHEMBL1957266,375603,"www.doi.org/10.1038/nature09504, http://www.ncbi.nlm.nih.gov/pubmed/20871596",Inhibitor,"128 nM, 76.9 BD1, 32.6 BD2 nM, 49.0 BD1, 90.1 BD2 nM, 17.7 nM, 59.1 BD1, 82.0 BD2 nM, 190.2 BD1 nM","ITC assay, alpha screen, ITC assay
IC50: BRD2 17.7 nM, BRD4 (N) 76.9 nM,  BRD4 (C) 32.6 nM, alpha screen",,"Human osteosarcoma cells (U2OS) transfected with GFPâBRD4 show a time-dependent recovery of fluorescence intensity in Fluorescence recovery after photobleaching (FRAP) assay. In the presence of JQ1 (500 nM), the observed recovery is immediate, indicating displaced and freely diffusing nuclear BRD4. Cellular FRAP studies confirmed that the effects on the mobile fraction of BRD4 are limited to the biochemically active (1)-JQ1 stereoisomer.",,Mouse,50 mg/kg,(-)-JQ1
MRK-740,3.5,0.0,2.0,No,https://www.chemicalprobes.org/mrk-740,PRDM9,Epigenetic,Histone methyltransferase,2020-05-29,Q9NQV7,NZYTZRHHBAJPKN-UHFFFAOYSA-N,COc1cc(OC)cc(-c2noc(N3CCN(C)C4(CCN(c5ccnc(C)c5)CC4)C3)n2)c1,No,No,CHEMBL4791017,2897449,"www.doi.org/10.1038/s41467-019-13652-x, https://pubmed.ncbi.nlm.nih.gov/31848333",Inhibitor,80 Â±â16ânM,,0.8 uM,H3K4 methylation assay,IC50,,,MRK-740-NC
MS023,4.0,0.0,3.0,No,https://www.chemicalprobes.org/ms023,"PRMT1, PRMT6, CARM1, PRMT8, PRMT3","Epigenetic, Epigenetic, Epigenetic, Epigenetic, Epigenetic","Protein methyltransferase, Protein methyltransferase, Protein methyltransferase, Protein methyltransferase, Protein methyltransferase",2015-11-05,"Q99873, Q96LA8, Q86X55, Q9NR22, O60678",FMTVWAGUJRUAKE-UHFFFAOYSA-N,CC(C)Oc1ccc(-c2c[nH]cc2CN(C)CCN)cc1,No,No,CHEMBL3901808,1301406,"www.doi.org/10.1021/acschembio.5b00839, http://www.ncbi.nlm.nih.gov/pubmed/26598975",Noncompetitive inhibitor,"11 nM, 0.8 nM, 23 nM, 1.3 nM, 55 nM",Potency was quantified in several in vitro assays including scintillation proximity assay and ITC.,"9 nM, 56 nM","Methylation of PRMT1 protein substrate in MCF7 cells, and methylation of PRMT6 protein substrate in PRMT6-overexpressing HEK293 cells.",IC50,,,MS094
NVS-PAK1-1,3.7,1.3,3.0,No,https://www.chemicalprobes.org/nvs-pak1-1,PAK1,Kinase,STE,2016-11-29,Q13153,OINGHOPGNMYCAB-INIZCTEOSA-N,CC(C)NC(=O)N1CC[C@H](NC2=Nc3cc(F)ccc3N(CC(F)F)c3ccc(Cl)cc32)C1,No,No,CHEMBL3609372,536057,"http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00102, https://www.ncbi.nlm.nih.gov/pubmed/?term=26191365",Allosteric inhibitor,"5 nM, 7 nM","Caliper IC50 assay. IC50 values were derived from % inhibition values at different compound concentrations by non-linear regression analysis., DiscoverX",200 nM,"In the pancreatic cell line Su86.86, NVS-PAK1-1 dose-dependently inhibited PAK1/PAK2 signalling. There is no cellular assay presently available that can distinguish inhibitors of PAK1 and PAK2. Inhibition of the shared downstream substrate (MEK1 Ser289) was evident between 6 and 20 uM, but this number reflects inhibition of both enzymes and NVS-PAK1-1 is highly selective for PAK1. A combination of NVS-PAK1-1 and shRNA targeting PAK2 revealed inhibition of substrate phosphorylation at 0.2 uM NVS-PAK1-1.",IC50,Other,,
Taxol,4.0,4.0,1.0,No,https://www.chemicalprobes.org/taxol,TUBB,Enzyme,GTPase,2017-06-10,P07437,RCINICONZNJXQF-MZXODVADSA-N,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,No,No,CHEMBL428647,991478,"https://www.nature.com/nature/journal/v277/n5698/abs/277665a0.html, http://www.jbc.org/content/269/5/3132.long, http://www.cell.com/cell/fulltext/S0092-8674(14)00483-8?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867414004838%3Fshowall%3Dtrue, http://www.sciencedirect.com/science/article/pii/S0022283617300153, http://www.pnas.org/content/96/8/4256.long, https://www.ncbi.nlm.nih.gov/pubmed/423966, https://www.ncbi.nlm.nih.gov/pubmed/7906266, https://www.ncbi.nlm.nih.gov/pubmed/24855948, https://www.ncbi.nlm.nih.gov/pubmed/28104363, https://www.ncbi.nlm.nih.gov/pubmed/9491787, https://www.ncbi.nlm.nih.gov/pubmed/10200249",Inhibitor,,,9 nM,Mitotic cell cycle arrest in A431 cells,EC50,Other,2-36 mg/kg,
Imatinib,1.0,1.0,3.0,No,https://www.chemicalprobes.org/imatinib,"ABL1, KIT","Kinase, Kinase","TK, TK",2015-12-10,"P00519, P10721",KTUFNOKKBVMGRW-UHFFFAOYSA-N,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,No,No,CHEMBL941,713353,"www.doi.org/10.1038/nm0596-561, http://www.ncbi.nlm.nih.gov/pubmed/10910906, http://www.ncbi.nlm.nih.gov/pubmed/8548747, http://www.ncbi.nlm.nih.gov/pubmed/8616716",ATP-competitive inhibitor,"38 nM, 100 nM",In vitro assays of protein kinase inhibition,100-300 nM,Imatinib inhibits autophosphorylation of ABL and PDGFR as well as substrate phosphorylation by KIT,IC 50,,,
GSK343,4.0,0.0,3.0,No,https://www.chemicalprobes.org/gsk343,EZH2,Epigenetic,Protein methyltransferase,2015-10-02,Q15910,ULNXAWLQFZMIHX-UHFFFAOYSA-N,CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccnc(N3CCN(C)CC3)c2)cc2c1cnn2C(C)C,No,No,CHEMBL2204995,826223,"www.doi.org/10.1021/ml3003346, http://www.ncbi.nlm.nih.gov/pubmed/24900432",SAM competitive inhibitor,1.2 nM,Ki app for SAM binding,174 nM,in-cell protein substrate methylation assay,IC50,,,
GSK484,3.7,2.0,3.0,No,https://www.chemicalprobes.org/gsk484,PADI4,Epigenetic,Arginine deaminase,2015-11-09,Q9UM07,BDYDINKSILYBOL-WMZHIEFXSA-N,COc1cc(C(=O)N2CC[C@@H](O)[C@@H](N)C2)cc2nc(-c3cc4ccccc4n3CC3CC3)n(C)c12,No,No,CHEMBL4539512,2905553,"www.doi.org/10.1038/nchembio.1735, http://www.ncbi.nlm.nih.gov/pubmed/25622091",Mixed-mode inhibitor,"50 nM, 250 nM","Fluorescence polarization binding assay with no Ca2+, Fluorescence polarization binding assay with 2 mM Ca2+",,Dose-dependent activity against target in human and mouse neutrophils detected in a citrullination assay,,,,GSK106
GSK6853,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsk6853,BRPF1,Epigenetic,Bromodomain,2023-02-13,P55201,FQWDVNSBYDXPIO-CQSZACIVSA-N,COc1ccccc1/C(O)=N/c1cc2c(cc1N1CCNC[C@H]1C)n(C)c(=O)n2C,No,Yes,,3449780,,Inhibitor,"7.9 nM, 0.31 nM","TR-FRET, BromoSCAN","20 nM, 2.5 nM","NanoBRET using isolated BRPF1B BRD with NLS and Halo-tagged histone H3.3, chemoproteomic competition binding assay",IC50,Mouse,"1 mg/Kg, 3 mg/Kg",8VI
GSK864,3.0,2.5,2.0,No,https://www.chemicalprobes.org/gsk864,IDH1,Kinase,Dehydrogenase,2015-11-10,O75874,DUCNNEYLFOQFSW-PMERELPUSA-N,COc1c(C)cc(NC(=O)c2nn(Cc3ccc(F)cc3)c3c2CN(C(=O)c2ccc[nH]2)C[C@]3(C)C(N)=O)cc1C,No,No,CHEMBL4565370,2942156,"www.doi.org/10.1038/nchembio.1930, http://www.ncbi.nlm.nih.gov/pubmed/26436839",Inhibitor,"15 nM R132H, 8.8 nM R132C, 16.6 nM R132G",NADPH production and thermal shift assay,320 nM,LC/MS/MS analysis from HT-1080 fibrosarcoma cells,EC 50,Other,150 mg/kg,GSK990
PPTN,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pptn,P2RY14,GPCR,Purinergic Receptor,2021-12-07,Q15391,FOECKIWHCOYYFL-UHFFFAOYSA-N,O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,No,No,CHEMBL1800685,630519,,Antagonist,"0.5 nM, 2.3 nM, 35 nM","FLIPR assay, Binding assay (no HSA), Binding assay with 2% HSA",>20 uM,NanoBRET (SGC Frankfurt) (Indirect assessment via MAPK14),IC50,Mouse,25 - 75 mg/kg,PPTN-NC
TP-064,3.0,0.0,1.0,No,https://www.chemicalprobes.org/tp-064,CARM1,Epigenetic,Methyltransferase,2022-07-21,Q86X55,VUIITYLFSAXKIQ-UHFFFAOYSA-N,CNCCN1CCC(c2cc(CN(C)C(=O)c3cccc(Oc4ccccc4)c3)ccn2)CC1,No,No,CHEMBL4559961,2897274,,Inhibitor,"7.1 Â± 1.8 nM, + 6 Â°C","SPR, Differential static light scattering (DSLS), aggregation temperature","340 nM, 42 nM","dimethyl-BAF155 inhibition, dimethyl-MED12 inhibition",IC50,,,N-((2-(1-(2-methoxyethyl)piperidin-4-yl)pyridin-4-yl)methyl)-N-methyl-3-phenoxybenzamide
TP-472,3.5,0.0,2.0,No,https://www.chemicalprobes.org/tp-472,"BRD9, BRD7","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2022-07-01,"Q9H8M2, Q9NPI1",RPBMXJHQYJLPDN-UHFFFAOYSA-N,CC(=O)c1cc(-c2cc(C(=O)NC3CC3)ccc2C)c2ncccn12,No,No,CHEMBL4065619,1681330,,Inhibitor,"9.9 Â°C, 82 nM, 9.6 Â°C, 556 nM","DSF, ITC",320 nM,NanoBRET,EC50,,,TP-472N
Borussertib,3.0,3.0,1.0,No,https://www.chemicalprobes.org/borussertib,"AKT2, AKT1","Kinase, Kinase","AGC, AGC",2022-02-11,"P31751, P31749",HXBRBOYWXDLHDC-UHFFFAOYSA-N,C=C/C(O)=N/c1ccc2nc(O)n(C3CCN(Cc4ccc(-c5nc6ccnc(O)c6cc5-c5ccccc5)cc4)CC3)c2c1,No,No,,3450313,,Covalent-allosteric inhibitor,"59 nM, 0.8 nM","Homogeneous Time Resolved Fluorescence (HTRF) assay (AKT2), Homogeneous Time Resolved Fluorescence (HTRF) assay (AKT1)","68 nM, 21 nM, 5 nM, 50 nM, 190 nM","NanoBRET assay (AKT2), NanoBRET assay (AKT1), CellTiter-Glo luminescent cell viability assay (CTG) with ZR-75-1 cells, CellTiter-Glo luminescent cell viability assay (CTG) with T-47D cells, CellTiter-Glo luminescent cell viability assay (CTG) with AN3-CA cells","IC50, EC50",Mouse,"2 mg/Kg, 20 mg/Kg",RL2578
BI2536,2.0,2.0,3.0,No,https://www.chemicalprobes.org/bi2536,"PLK1, PLK2, PLK3","Kinase, Kinase, Kinase","Other, Other, Other",2015-12-10,"P53350, Q9NYY3, Q9H4B4",XQVVPGYIWAGRNI-JOCHJYFZSA-N,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,No,No,CHEMBL513909,763292,"www.doi.org/10.1016/j.cub.2006.12.037, http://www.ncbi.nlm.nih.gov/pubmed/17291758",ATP-competitive inhibitor,"0.83 nM, 3.5 nM, 9 nM","in Vitro Kinase assay, In Vitro Kinase Assay",,"In HeLa cells, BI2536 dose-dependently inhibited substrate phosphorylation, caused G2/M arrest and led to PARP p85 fragment formation, with activity saturating between 10-100 nM",,,,
URMC-099,1.3,1.3,3.0,No,https://www.chemicalprobes.org/urmc-099,"MAP3K9, MAP3K10, MAP3K11","Kinase, Kinase, Kinase","TKL, TKL, TKL",2015-12-10,"P80192, Q02779, Q16584",QKKIWEILHCXECO-UHFFFAOYSA-N,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,No,No,CHEMBL2436978,461444,"www.doi.org/10.1021/jm401094t, http://www.ncbi.nlm.nih.gov/pubmed/24044867",Inhibitor,"19 nM, 42 nM, 14 nM",Kinase assay,0.51 uM,TNFalpha release from microglia,"IC50, IC 50",Mouse,10 mg/kg,
APREPITANT,0.0,0.0,0.0,No,https://www.chemicalprobes.org/aprepitant,TACR1,GPCR,NK-1 Receptor,2023-11-03,P25103,ATALOFNDEOCMKK-OITMNORJSA-N,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,No,No,CHEMBL1471,716719,,Antagonist,0.2 nM,Saturation binding analysis with increasing concentrations of [3H]-Aprepitant using Sf9 membranes,0.09 nM,Displacement of 125I-labeled SP from the human NK-1 receptor expressed in CHO cells,IC50,"Other, Rat, Dog","0.3-3.0 mg/Kg, 0.1-3.0 mg/Kg, 2 and 5 mg/Kg, 0.5, 2.0 mg/Kg",
ISPINESIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ispinesib,KIF11,Motor protein,Kinesin family,2023-11-03,P52732,QJZRFPJCWMNVAV-HHHXNRCGSA-N,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,No,No,CHEMBL228814,716535,,Inhibitor,1.7 Â± 0.1 nM,MT-stimulated KSP ATPase activity,"45 nM, 19 nM",Cell proliferation assay,GI50,Mouse,,
Capzimin,2.0,0.0,1.0,No,https://www.chemicalprobes.org/capzimin,PSMD14,Enzyme,Peptidase,2023-11-03,O00487,RNEOHKZPZKEZCQ-UHFFFAOYSA-N,O=C(NCCc1nccs1)c1cnc2c(SSc3cccc4cc(C(=O)NCCc5nccs5)cnc34)cccc2c1,No,Yes,CHEMBL4073553,877101,,Inhibitor,360 nM,Fluorescence polarization assays,"600 nM, ~2000 nM","Cycloheximide chase assay. HeLa cells stably expressing proteasome reporter UbG76V-GFP treated with 5 uM Capzimin show accumulation of UbG76V-GFP., Cell proliferation assay","IC50, GI50",,,
SHR1653,0.0,0.0,0.0,No,https://www.chemicalprobes.org/shr1653,OXTR,GPCR,Oxytocin receptor,2023-10-31,P30559,UYKVJQCPBDDIFD-ZSEKCTLFSA-N,COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,No,No,CHEMBL4591825,3245128,,Antagonist,,,15 nM,Calcium flux assay,IC50,"Rat, Mouse, Dog","2 mg/Kg, 1 mg/Kg, 4 mg/Kg, 30 mg/Kg, 20 mg/Kg",
AK-42,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ak-42,CLCN2,Ion Channel,Chloride channel,2022-08-02,P51788,AYGDOYFDJDUPSS-UHFFFAOYSA-N,O=C(O)c1cccnc1Nc1c(Cl)ccc(OCc2ccccc2)c1Cl,No,No,,3452398,,Inhibitor,,,"17 nM, 2.5 ÂµM","Patch clamp assay, Whole-cell patch-clamp electrophysiology measuring CLC-2 currents. AK-42 attenuated steady-state currents and eliminated relaxation currents in recorded neurons","IC50, INH",,,"2-(3-benzyloxy-2,6-dichloro-anilino)benzoic acid"
TTBK1-IN-1,4.0,3.0,1.0,No,https://www.chemicalprobes.org/ttbk1-in-1,"TTBK1, TTBK2","Kinase, Kinase","CK1, CK1",2023-05-11,"Q5TCY1, Q6IQ55",HPJVZSVEIGCFJP-SFHVURJKSA-N,CC[C@](C)(O)C#Cc1cc2c(ccn2-c2cc(OC)nc(N)n2)cn1,No,No,,3935416,,Inhibitor,"2.7 nM, 1.6 nM",Biochemical assay (TR-FRET assay),315 nM,Tau-pSer 422-HTRF Assay,IC50,"Rat, Mouse","up to 80 mg/Kg, 2.5, 7, 20, 60, and 180 mg/kg",
SB-714786,4.0,0.0,1.0,No,https://www.chemicalprobes.org/sb-714786,HTR1D,GPCR,Serotonin Receptor,2022-08-03,P28221,RMCSKUADBRROSI-UHFFFAOYSA-N,Cc1ccc2c(OCCN3CCN(Cc4cccc5cccnc45)CC3)cccc2n1,No,No,CHEMBL425190,338263,,Antagonist,0.8 nM,Radioligand binding assay,,[35S]GTPÎ³S binding assay in the human receptor cell lines,,,,CANSAR149525
TTBK1-IN-2,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ttbk1-in-2,TTBK1,Kinase,CK1,2023-06-30,Q5TCY1,RWRSKMSFZCQDMQ-UHFFFAOYSA-N,Clc1ccc(Oc2ccc(Nc3ncnc4[nH]ccc34)cc2)cc1,Yes,No,,3931021,,Inhibitor,240 nM,Biochemical assay,5 ÂµM,TDP-43 phosphorylation of cells treated with ethacrynic acid,,Mouse,"5 mg/Kg, 10 mg/Kg",
DDC-03-024-01,2.0,0.0,2.0,No,https://www.chemicalprobes.org/ddc-03-024-01,EGFR,Kinase,TK,2022-06-08,P00533,ZPNTXOKOIHPCLI-UHFFFAOYSA-N,CN1CCN(c2ccc(Oc3ccc4c(c3)C(=O)N(Cc3ccccc3)c3cc(F)ccc3N4)cc2)CC1,No,No,CHEMBL4558528,3217678,,Allosteric Inhibitor,"11 nM, 13 nM","IC50 values were measured at varying ATP concentrations spanning 1 to 1000 Î¼M against mutant L858R/T790M using homogeneous
time-resolved fluorescence (HTRF) KinEASE-TK (Cisbio) assay, IC50 values were measured at varying ATP concentrations spanning 1 to 1000 Î¼M against mutant L858R/T790M/C797S using homogeneous time-resolved fluorescence (HTRF) KinEASE-TK (Cisbio) assay.","200 nM, 360 nM","CellTiter-Glo Luminescent Cell Viability Assay using cell bearing L858R/T790M mutation, CellTiter-Glo Luminescent Cell Viability Assay using cells bearing L858R/T790M/C797S mutation",IC50,,,
M4K2234,3.0,2.3,3.0,No,https://www.chemicalprobes.org/m4k2234,"ACVRL1, ACVR1","Kinase, Kinase","TKL, TKL",2022-06-08,"P37023, Q04771",RIWTUJFFSTVYPW-UHFFFAOYSA-N,COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O,No,No,CHEMBL4548795,3196344,,Inhibitor,"7 nM, 14 nM","Reaction Biology, at 10 mM ATP conc.","83 nM, 100 nM, 13 nM","NanoBRET, Western blot; modulation of phosphorylation of SMAD1/5/8 that corresponds to BMP branch of signalling which is mediated, besides others, also by ALK1/2 kinases","IC50, INH",Mouse,10 mg/Kg,M4K2234-NC
INCB085660,0.0,0.0,0.0,No,https://www.chemicalprobes.org/incb086550,CD274,Receptor ligand,Cell death receptor ligand ,2022-10-07,Q9NZQ7,QARLNMDDSQMINK-BVRKHOPBSA-N,Cc1c(Nc2nccc3cc(CN4CC[C@@H](O)C4)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CC[C@@H](C(=O)O)C4)cc(C#N)c3o2)c1C,No,No,,3060670,,Inhibitor,3.1 nM,Homogeneous time-resolved fluorescence (HTRF)âbased PD-L1/PD-1 interaction assay,"13 nM, 6.3 nM, 21.4 nM","Inhibition of binding of phycoerythrin (PE)-labeled PD-1 (PD-1/PE) to cell-surface PD-L1, PD-1âSHP Reporter Assay, NFAT Reporter Assay","IC50, EC50",Mouse,"2, 20, 200 mg/Kg",
BI-5756,2.0,3.0,2.0,No,https://www.chemicalprobes.org/bi-5756,CETP,Transporter,BPI/LBP family,2022-06-08,P11597,HKASDKLLEVWKJA-YADARESESA-N,CC(C)c1nc2c(c3c1[C@@H](c1ccc(C(F)(F)F)cc1)OC31CCOCC1)[C@@H](O)CC(C)(C)C2,No,No,CHEMBL3360279,577259,,Inhibitor,"151 nM, 18 nM","Inhibition of the transfer of a fluorescence labelled lipid from donor vesicles to acceptor vesicles in the presence of human plasma, TF_ROAR assay, measuring the transfer of a neutral fluorescence labeled lipid from donor vesicles to acceptor vesicles by CETP",,,,Mouse,"10 uM/Kg, 1 uM/Kg",CANSAR577267
GPX4-IN-5,2.3,2.0,3.0,No,https://www.chemicalprobes.org/gpx4-in-5,GPX4,Enzyme,Glutathione Peroxidase,2023-10-06,P36969,,,No,No,,,,Covalent Inhibitor,120 Â± 10 nM,GPX4 inhibition assay,"6.5, 10-75 nM","CETSA, Cell Proliferation assay","ÎTm, IC50",Mouse,10 mg/Kg,ferrostatin-1
PF-06835919,0.0,0.0,0.0,No,https://www.chemicalprobes.org/pf-06835919,KHK,Kinase,Sugar Kinase,2023-10-11,P50053,MDUYWDNWFXSMJJ-XWLWVQCSSA-N,C[C@H]1CCN1c1nc(N2C[C@H]3[C@H](CC(=O)O)[C@H]3C2)cc(C(F)(F)F)n1,No,No,CHEMBL4549658,2979899,,Inhibitor,"28 nM, 170 nM, 4.53 nM, 10 nM","Biochemical assay, measured at 2 mM ATP and 8 mM fructose for Isoform C (KHK-C), Biochemical assay, measured at 2 mM ATP and 8 mM fructose for Isoform A (KHK-A), Biochemical Assay, Biochemical assay, measured at [ATP], [fructose] at Km for Isoform C (KHK-C)",232 nM,dose-dependent inhibition of fructose-1-phosphate in primary human hepatocytes,IC50,"Rat, Dog","1 mg/Kg, 5 mg/Kg",
GNE-617,4.0,3.0,1.0,No,https://www.chemicalprobes.org/gne-617,NAMPT,Enzyme,Phosphoribosyltransferase,2023-10-13,P43490,XRDVXQQZLHVEQZ-UHFFFAOYSA-N,O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1,No,No,CHEMBL2420629,300539,,Inhibitor,5 nM,Nampt biochemical inhibition.,"2 nM, 1.8-7.4 nM, 1.1 nM, 1.3 nM","A2780 cell proliferation inhibition. This inhibition can be reversed by addition of 0.33 mM of NMN, Cell Proliferation assay, NAD reduction; intracellular compound levels were confirmed, NAD reduction in mouse cells; intracellular compound levels were confirmed","IC50, EC50",Mouse,"5 mg/Kg, 10 mg/Kg",
VU69,0.0,0.0,0.0,No,https://www.chemicalprobes.org/vu69,PLD1,Enzyme,Phospholipase,2023-10-16,Q13393,DRIMIUYGTDAQOX-KRWDZBQOSA-N,C[C@@H](CN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)NC(=O)c1ccc2ccccc2c1,No,No,CHEMBL492572,534216,,Inhibitor,46 nM,In vitro PLD activity assay,11 nM,mass spectrometric analysis of the levels of individual PtdBuOH-d9 species,IC50,,,
SB-258719,3.0,0.0,1.0,No,https://www.chemicalprobes.org/sb-258719,HTR7,GPCR,Serotonin receptor,2023-10-16,P34969,AGVNHDNTFYHZNL-QGZVFWFLSA-N,Cc1cccc(S(=O)(=O)N(C)[C@H](C)CCN2CCC(C)CC2)c1,No,No,CHEMBL12264,1390754,,Antagonist,31.6 nM,Radio ligand binding assay,20 nM,Adenylyl cyclase functional assay (Inhibition of basal adenylyl cyclase activity),EC50,,,
MI-888,3.0,3.0,3.0,No,https://www.chemicalprobes.org/mi-888,MDM2,Other post-translational modification,E3 ubiquitin ligase,2017-06-06,Q00987,MZBOZBMARIQZGX-GRRGFIRHSA-N,CC(C)(C)C[C@@H]1N[C@@H](C(=O)N[C@H]2C[C@@](C)(O)C2)[C@H](c2cccc(Cl)c2F)[C@]12C(=O)Nc1cc(Cl)ccc12,No,No,CHEMBL2396674,737489,"http://pubs.acs.org/doi/abs/10.1021/jm4005708, https://www.ncbi.nlm.nih.gov/pubmed/23786219",Antagonist,0.44 nM,Fluorescence polarization assay with MDM2 protein and p53 peptide.,0.08 uM,"In SJSA-1 cells, MI-888 dose dependently decreased cell growth.",IC50,Other,25 mg/kg (rat),
VUBI1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/vubi1,SOS1,Enzyme,Nucleotide exchange factor,2021-11-24,Q07889,JWZAQUXBYYOGFA-UHFFFAOYSA-N,Cc1cc(Cn2c(N3CC4(CNC4)C3)nc3c(N4CCN(C)CC4)cc(Cl)cc32)cc(C)c1F,No,No,CHEMBL4213025,611302,,Activator,44 nM,Fluorescence Polarization Anisotropy (FPA) competition binding assay,94 nM,HRAS Nucleotide Exchange,EC50,,,BI-9930
ABPA3,2.0,2.0,3.0,No,https://www.chemicalprobes.org/abpa3,"UBA1, UBA3","Enzyme, Enzyme","Ubiquitin-conjugating enzyme, Ubiquitin-conjugating enzyme",2016-07-29,"P22314, Q8TBC4",LZNFQRSVDZCPTR-SCFUHWHPSA-N,C#Cc1cccc(Nc2ncnc3c2ncn3[C@@H]2O[C@H](COS(N)(=O)=O)[C@@H](O)[C@H]2O)c1,No,No,,2870539,"http://pubs.rsc.org/is/content/articlelanding/2015/sc/c5sc01351h#!divAbstract, http://pubs.acs.org/doi/abs/10.1021/ja4099643, https://www.ncbi.nlm.nih.gov/pubmed/24138456",Covalent Inhibitor,43 nM,"Different doses of ABP A3 were incubated with UBA1 (0.5 uM), ATP (50 uM) and Ub (50 uM), for 2 hours at room temperature. The amount of formed ABP A3-Ub covalent adduct is then quantified using click chemistry. IC50 is the concentration of ABP A3 at which half maximal amount of ABP A3-Ub covalent adduct is formed.","2500 nM, 80 nM",CellTiterGlo viability assay. A549/MM1S cells were treated with ABP A3 for 48h.,IC 50,,,N/A
AZ0108,2.7,2.0,3.0,No,https://www.chemicalprobes.org/az0108,"PARP1, PARP2, PARP6","Other post-translational modification, Other post-translational modification, Other post-translational modification","PARP, PARP, PARP",2016-07-29,"P09874, Q9UGN5, Q2NL67",NWGMIELHSCQGOG-ZDUSSCGKSA-N,C[C@H]1Cn2c(nnc2C(C)(F)F)CN1C(=O)c1cccc(C(F)(F)c2n[nH]c(=O)c3ccccc23)c1,No,No,CHEMBL3740897,703029,"http://www.sciencedirect.com/science/article/pii/S0960894X15301888, http://www.ncbi.nlm.nih.gov/pubmed/26546219",NAD+ competitive inhibitor,"<30nM, <30 nM, 83 nM",All PARP enzyme assays were done by following the BPS PARP assay kit protocols.,53 nM,"EC50s were measured in a high-content phenotypic assay that was also used to screen for small molecules that block centrosome clustering and cause a multi-polar spindle phenotype. 
This cell-based centrosome declustering assay begins with treatment of HeLa cells with increasing concentrations of compound. After 24 h, the cells are fixed and then the mitotic cells are identified 
by treatment with a cyclin B antibody. Next, the cells are treated with an antibody towards pericentrin to label the centrosomes. After that, an automated process generates an overlay of the two 
images and analyzes it to calculate the number of centrosomes observed in each mitotic cell. Mitotic cells with greater than four centrosomes are then assumed to have a multi-polar spindle phenotype Finally, a declustering EC50 is calculated from a doseresponse 
curve generated from a plot of the percentage of mitotic cells with a multi-polar spindle phenotype at eight concentrations ranging from 3 nM to 10 uM.",EC50,Other,,
DS-1558,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ds-1558,FFAR1,GPCR,Free fatty acid receptor,2017-07-21,O14842,YHLQVQKZDZYMIP-MOPGFXCFSA-N,CCO[C@@H](CC(=O)O)c1ccc(O[C@@H]2CCc3c2cccc3C(F)(F)F)cc1,No,No,CHEMBL3427712,120344,https://www.ncbi.nlm.nih.gov/pubmed/16702999,Agonist,,,3.7 nM,Calcium flux assay in transfected-GPR40 CHO cells,EC50,"Rat, Dog, Monkey (Cynomolgus)","1 mg/Kg, 0.5 mg/Kg",
VT104,4.0,4.0,2.0,No,https://www.chemicalprobes.org/vt104,"TEAD1, TEAD2, TEAD3, TEAD4","Transcription factor, Transcription factor, Transcription factor, Transcription factor","TEA Domain, TEA Domain, TEA Domain, TEA Domain",2021-05-26,"P28347, Q15562, Q99594, Q15561",AAZUPSFRSHFTGV-INIZCTEOSA-N,C[C@H](NC(=O)c1ccc2c(-c3ccc(C(F)(F)F)cc3)cccc2c1)c1ccccn1,No,No,,3313086,"www.doi.org/10.1158/1535-7163.MCT-20-0717, https://pubmed.ncbi.nlm.nih.gov/33850002/",Inhibitor,"8.6 Celsius, 5.4 Celsius, 8.2 Celsius, 4.3 Celsius","Thermal Shift Assays (TSA), Cell-free TEAD palmitoylation assay","10.4 Â± 0.8 nM, 16-98 nM","YAP reporter assay, Cell proliferation assay","IC 50, GI 50",Mouse,10 mg/Kg,VT106
AZD-5672,0.0,0.0,0.0,No,https://www.chemicalprobes.org/azd-5672,CCR5,GPCR,Chemokine receptor,2023-10-13,P51681,AESXAJXKMUNYJP-ZWFIUULVSA-N,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCC(S(C)(=O)=O)CC2)CC1,No,No,CHEMBL2178577,888515,,Antagonist,0.26 nM,Radioligand displacement assay using CHO membranes,"0.69 nM, 0.76 nM","inhibition of MIP-1beta-induced chemotaxis in allo T cells, Receptor internalization in human whole blood","IC50, Activity","Rat, Dog","1-2 mg/Kg, 2-5 mg/Kg",
Lirafugratinib,0.0,0.0,0.0,No,https://www.chemicalprobes.org/lirafugratinib,FGFR2,Kinase,TK,2023-10-06,P21802,,,No,No,,,,Covalent Inhibitor,"3 nM, kinact/KI = 43.45*10-2 per s/umol/L","Biochemical Assay, mass spectrometry","6 nM, 3 nM","Phospho-FGFR2 (Tyr653/654) Cellular HTRF detected via Western Blot, Phospho-ERK (Thr202/Tyr204) Cellular HTRF detected via Western Blot, RLY-4008 concentration-dependent modification rate against FGFR2 (red) and FGFR1 (blue). RLY-4008 against FGFR2: kinact = 6.45*10-2 per second; KI = 1.87 uM; kinact/KI = 3.45*10-2 per second/(uM). RLY-4008 against FGFR1: kinact = 2.33*10-3 per second; KI = 6.14 uM; kinact/KI = 3.79*10-4 per second/(uM).",IC50,Mouse,30 mg/kg twice daily,
GNE-7883,3.0,3.0,1.0,No,https://www.chemicalprobes.org/gne-7883,"TEAD1, TEAD2, TEAD3, TEAD4","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Transcription factor, Transcription factor, Transcription factor, Transcription factor",2023-07-25,"P28347, Q15562, Q99594, Q15561",UNRTVIQQMJRQLZ-UHFFFAOYSA-N,Cc1nccnc1-c1nn2c(=O)cc(-c3ccc(C4CCCCC4)cc3)[nH]c2c1C(=O)N1CC(CF)C1,No,No,,3931189,,Inhibitor,"4 nM, 5 nM, 2 nM, 1 nM, 55 uM, 9 nM, 10 nM, 3 nM","TEADâYAP TR-FRET assay, TEADâTAZ TR-FRET assay, TEAD lipid pocket TR-FRET assay, increase in the 1 D19F signal of free peptide S2, but not of  of free peptide S3","170 nM, 290 nM, 3 uM","Cell viability, IP assay; displacement of YAP, TAZ from TEAD","EC50, INH",Mouse,250 mg/Kg,
GSM1,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gsm1,PSEN1,Enzyme,Gamma-Secretase Complex,2021-12-01,P49768,AAHNBILIYONQLX-UHFFFAOYSA-N,COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,No,No,CHEMBL3609637,741271,,Modulator,,,"31 nM, 131 nM","A-beta 42 inhibition assay, A-Beta 40 inhibition assay",IC50,"Rat, Dog","1 IV, 2 PO mg/Kg, 0.2 IV; 0.5 PO mg/Kg",GSM-NC
BiBET,3.3,2.0,3.0,No,https://www.chemicalprobes.org/bibet,"BRD2, BRD4, BRD3, BRDT","Epigenetic, Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain, Bromodomain",2016-12-12,"P25440, O60885, Q15059, Q58F21",LQHDIGAYVSAVRJ-UHFFFAOYSA-N,COc1nnc2ccc(N(C)CCOc3ccc(C4CCN(c5ccc6nnc(OC)n6n5)CC4)cc3)nn12,No,No,,2933153,"http://www.nature.com/nchembio/journal/vaop/ncurrent/full/nchembio.2210.html, https://www.ncbi.nlm.nih.gov/pubmed/?term=27775716",Bivalent inhibitor,"25 nM BD1, 63 nM BD2, 0.01 nM, 39.8 nM BD2, 7.9 nM BD1, 5 nM BD1, 199 nM BD2, 2.5 nM BD1, 316 nM BD2","BromoSCAN, Full-length BRD4 protein (Bromoscan DiscoveRx)",0.1 nM,"BiBET disrupted BRD4-mediator complex foci with pIC50=10 in U2OS cells.   
Other cellular endpoints are characterized extensively including nanoBRET target engagement and growth inhibition assays with consistent potency values. Potencies in cells against all BET proteins are 100 pM. 
Mutations in BRD4(2) confirmed bivalent mechanism of action in BRET assay (pIC50 for full-length BRD4=9.6, BRD4(1)=5.6 and pIC50 mutant full-length BRD4=6.6, BRD4(1)=6.8).",IC50,,,"(S)-6-(4-(4-(2-(2,4-dimethyl-3-oxopiperazin-1-yl)ethoxy)phenyl)piperidin-1-yl)-2-methyl-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one"
CS640,3.0,3.0,2.0,No,https://www.chemicalprobes.org/cs640,CAMK1D,Kinase,CAMK,2023-11-01,Q8IU85,BWBUPDTUXQDHSX-AWEZNQCLSA-N,CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1,No,No,CHEMBL4635883,2855624,,Inhibitor,8 nM,ADP-Glo assay (Reaction Biology),29 nM,NanoBRET,IC50,"Mouse, Rat","2 mg/Kg, 10 mg/Kg, 20 mg/Kg, 40 mg/Kg",CS640s
BI-3231,4.0,4.0,1.0,No,https://www.chemicalprobes.org/bi-3231,HSD17B13,Enzyme,SDR,2023-10-04,Q7Z5P4,XKDHFIPNTTUSIA-UHFFFAOYSA-N,CCn1c(=O)c(C)cn(Cc2nnc(-c3ccc(F)c(O)c3F)s2)c1=O,No,No,,3935414,,Inhibitor,"Ki = 0.7 Â± 0.2 nM, 16.7 K","Enzymatic assay, nanoDSF in presence of NAD+",11 Â± 5 nM,Cellular hHSD17B13 assay,IC50,Mouse,"5 uM/Kg, 50 uM/Kg, 80 uM/Kg",BI-0955
PCS1055,3.0,1.0,1.0,No,https://www.chemicalprobes.org/pcs1055,CHRM4,GPCR,Muscarinic receptor,2023-10-16,P08173,POOQAGFAYZUAOY-UHFFFAOYSA-N,Cl.Cl.O.c1ccc(CN2CCC(CCNc3cc4c(nn3)-c3ccccc3CCC4)CC2)cc1,No,No,CHEMBL1202865,568649,,Antagonist,6.53 Â± 0.797 nM,Competitive radioligand binding assays,18.1 Â± 0.658 nM,GTP-Î³-[35S] binding assays,IC50,Mouse,30 mg/Kg,
ABL127,4.0,2.0,1.0,No,https://www.chemicalprobes.org/abl127,PPME1,Enzyme,Serine hydrolase,2023-10-16,Q9Y570,ZRHWCAFAIHTQKD-QGZVFWFLSA-N,COC(=O)N1C(=O)[C@@](c2ccccc2)(C2CCCC2)N1C(=O)OC,No,No,CHEMBL1524542,1534082,,Covalent Inhibitor,"4.2 nM, 500 nM","Gel-based competitive ABPP with FP-Rh (2 Î¼M) in the soluble proteome (1 mg/mL protein) of MDA-MB-231 cells., inhibition of demethylated PP2A using Western of lysate of HEK293T cells spiked with recombinant PME-1","11.1 nM, 6.4 nM",gel-based competitive ABPP,IC50,Mouse,50 mg/Kg,CANSAR1531928
T-690,3.0,3.0,1.0,No,https://www.chemicalprobes.org/t-690,UGCG,Enzyme,Glycosyltransferase,2023-10-11,Q16739,CQAPXPSWLDAVEG-UHFFFAOYSA-N,CC(C)(O)c1ccc(NC(=O)c2ccnn(-c3ccccc3OCC(F)(F)F)c2=O)cc1,No,No,CHEMBL5085509,3891163,,Inhibitor,15 nM,GCS enzymatic assay,4.4 nM,Cell-Based Glucosylceramide Lowering Assay,EC50,Mouse,"0.5 mg/Kg, 5 mg/Kg",
HS665,3.0,3.0,1.0,No,https://www.chemicalprobes.org/hs665,OPRK1,GPCR,Opioid receptor,2023-10-31,P41145,YNVKFHIWFDRVNY-UHFFFAOYSA-N,Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1,No,No,CHEMBL2180639,1448719,,Agonist,0.49 Â± 0.20 nM,Scintillation proximity assay,3.62 Â± 1.87 nM,guanosine 5â²-O-(3-[35S]thio)triphosphate ([35S]GTPÎ³S) binding assays,EC50,Mouse,2.5 mg/kg,
SGK1-IN-1,2.0,0.0,1.0,No,https://www.chemicalprobes.org/sgk1-in-1,SGK1,Kinase,AGC,2023-11-01,O00141,DDKHTWASHUKHLD-UHFFFAOYSA-N,Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12,No,No,CHEMBL3092468,114504,,Inhibitor,1 or 41 nM,"enzymatic potency using 10 or 500 uM ATP, respectively",690 nM,SGK1-dependent phosphorylation of GSK3Î² assay,IC50,,,
THZ1,3.3,3.0,3.0,No,https://www.chemicalprobes.org/thz1,CDK7,Kinase,CMGC,2015-12-10,P50613,OBJNFLYHUXWUPF-IZZDOVSWSA-N,CN(C)C/C=C/C(=O)Nc1ccc(C(=O)Nc2cccc(Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)c2)cc1,No,Yes,CHEMBL3603847,853184,"www.doi.org/10.1038/nature13393, http://www.ncbi.nlm.nih.gov/pubmed/25043025",Covalent Inhibitor,3.2 nM,Time-dependent binding established supporting covalent mechanism,"~20 nM, 55 nM, 0.50 nM","In Jurkat cells, THZ1 inhibited CDK7 substrate phosphorylation in a dose-dependent and time-dependent manner. Expression of a THZ1-resistant mutant CDK7 C312S restored CDK7 activity., Anti-proliferative assay",IC50,,,V0G
ARUK2001607,3.0,3.0,2.0,No,https://www.chemicalprobes.org/aruk2001607,PIP4K2C,Kinase,Phosphatidylinositol Kinase,2023-10-31,Q8TBX8,QVQHWPLHUNEREE-UHFFFAOYSA-N,Cc1cc2c(Nc3ccc(S(C)(=O)=O)cc3)ncnc2s1,No,No,,3929729,,Inhibitor,"79.4 nM, 7.1 nM","ADP-Glo assay, Lipid kinase binding assay",250 nM,InCell Pulse thermal stabilization assay (DiscoverX) (target engagement),IC50,Mouse,5 mg/Kg,
UNMCK90,1.5,1.5,2.0,No,https://www.chemicalprobes.org/unmck90,AKR1C3,Enzyme,Hydroxysteoid dehydrogenase,2023-11-01,P42330,,,No,No,,,,Inhibitor,51 Â± 6 nM,Inhibition of the NADP+-dependent oxidation of S-tetralol catalyzed by AKR1C3.,,,,Mouse,50 mg/Kg,UNMCK90E
SIAIS001,4.0,3.0,1.0,No,https://www.chemicalprobes.org/siais001,ALK,Kinase,TK,2022-03-08,Q9UM73,OGAOHACYLUBWJQ-UHFFFAOYSA-N,CCc1cc2c(cc1N1CCC(N3CCN(CCCC#Cc4cccc5c4CN(C4CCC(=O)NC4=O)C5=O)CC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,No,No,CHEMBL4851806,3314930,,Degrader (PROTAC),0.9 nM,Inhibition of recombinant ALK,"3.9 nM, 70.3%, 0.9 nM","Degradation of ALK in SR cells, Inhibit the proliferation of SR cells","DC50, Dmax, IC50",Rat,"2 mg/Kg, 10 mg/Kg",
CAPIVASERTIB,2.0,1.0,1.0,No,https://www.chemicalprobes.org/capivasertib,"AKT1, AKT2, AKT3","Kinase, Kinase, Kinase","AGC, AGC, AGC",2023-11-22,"P31749, P31751, Q9Y243",JDUBGYFRJFOXQC-KRWDZBQOSA-N,NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1,No,No,CHEMBL2325741,297861,,Inhibitor,"3 nM, 8 nM",Caliper Off-Chip Incubation Mobility Shift assay,89 nM,Cellular inhibition of AKT via detection of pGSK3Î²,IC50,"Mouse, Rat, Dog",,
BI-3406,4.0,4.0,3.0,No,https://www.chemicalprobes.org/bi-3406,SOS1,Enzyme,Nucleotide exchange factor,2022-06-08,Q07889,XVFDNRYZXDHTHT-PXAZEXFGSA-N,COc1cc2nc(C)nc(N[C@H](C)c3cc(N)cc(C(F)(F)F)c3)c2cc1O[C@H]1CCOC1,No,No,CHEMBL4519023,3178755,,Inhibitor,"5 nM, 9.7 nM","Biochemical Protein-Protein Interaction assay, SPR using recombinant SOS1","28 nM, 31.9 nM","pERK modulation in MIA-PaCa-2 cells with SOS1 transgene expression, Cell proliferation assay using MIA PaCa-2 transgenic cell pools expressing the indicated FLAGâSOS1 transgenes",IC50,"Mouse, Rat",,BI-0178
GSK1016790A,3.5,0.0,2.0,No,https://www.chemicalprobes.org/gsk1016790a,TRPV4,Ion Channel,Ca transporter,2023-11-03,Q9HBA0,IVYQPSHHYIAUFO-VXKWHMMOSA-N,CC(C)C[C@H](NC(=O)c1cc2ccccc2s1)C(=O)N1CCN(C(=O)[C@H](CO)NS(=O)(=O)c2ccc(Cl)cc2Cl)CC1,No,No,CHEMBL4461515,3156595,,Agonist,,,"3.0 nM, 5.0 nM","Patch clamp assay, FLIPR assay",EC50,Other,,
BAY-7081,2.0,2.0,1.0,No,https://www.chemicalprobes.org/bay-7081,PDE9A,Nucleic acid metabolism,Phosphodiesterase,2023-10-04,O76083,RVOZYMPVGIVNJX-UHFFFAOYSA-N,CCCC1CNCc2c1[nH]c(=O)c(C#N)c2N1CCC2(CC1)CC2.Cl,No,No,CHEMBL5198935,3935432,,Inhibitor,15 nM,PDE activity assays,995 nM,Cellular PDE9A assay,EC50,"Rat, Dog","0.3 mg/Kg IV, 10 mg/Kg PO",BAY-7424
FIBOFLAPON,3.3,3.3,3.0,No,https://www.chemicalprobes.org/fiboflapon,ALOX5AP,Enzyme,5-lipoxygenase,2023-10-31,P20292,DFQGDHBGRSTTHX-UHFFFAOYSA-N,CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,No,No,CHEMBL1922660,917167,,Inhibitor,"2.9 Â± 1.0 nM, 0.7 Â± 03 nM","FLAP binding assay (inhibition of 3H-ligand binding to FLAP membranes), Human Leukocyte Inhibition Assay (hLA)",76 Â± 15 nM (5h),Human Blood LTB4 Inhibition Assay (hWB),IC50,Rat,"2 mg/Kg IV, 10 mg/Kg PO",
PF-3274167,2.7,2.7,3.0,No,https://www.chemicalprobes.org/pf-3274167,OXTR,GPCR,Oxytocin receptor,2023-10-31,P30559,HNIFCPBQMKPRCX-UHFFFAOYSA-N,COCc1nnc(N2CC(Oc3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,No,No,CHEMBL594828,173082,,Antagonist,,,9.5 nM,Cell based Î² lactamase assay,Ki,"Rat, Dog","2 mg/Kg, 0.2 mg/Kg",
ZIRITAXESTAT,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ziritaxestat,ENPP2,Enzyme,pyrophosphatase/phosphodiesterase,2023-12-20,Q13822,REQQVBGILUTQNN-UHFFFAOYSA-N,CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,No,No,CHEMBL3828074,875576,,Inhibitor,"15 nM, 131 nM","Human ATX biochemical assay using LPC 16:0 as substrate., biochemical assays with human enzyme",242 nM,Human plasma assay (inhibition of ATX-induced LPA 18:2 production in healthy donor plasma in a concentration-dependent manner),IC50,Mouse,"3 mg/Kg, 10 mg/Kg, 30 mg/Kg",
WLB-89462,0.0,0.0,0.0,No,https://www.chemicalprobes.org/wlb-89462,TMEM97,Orphan receptor,Sigma receptor,2023-12-20,Q5BJF2,,,No,No,,,,Modulator,,,13 Â± 5 nM,Binding affinity to Ï2R in human Ï2/TMEM97 cloned receptor enriched membranes using DTG as the radioligand.,Ki,Rat,"10 mg/Kg, 1 mg/Kg",
SGC-CDKL5_GSK3,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sgc-cdkl5_gsk3,"CDKL5, GSK3A, GSK3B","Kinase, Kinase, Kinase","CMGC, CMGC, CMGC",2023-12-20,"O76039, P49840, P49841",,,No,No,,,,Inhibitor,"6.5 nM, 4.0 nM, 9.0","CDKL5 Split luciferase assay, enzymatic assay","3.5 nM, 10 nM, 35 nM",NanoBRET,IC50,,,CANSAR3935430
PPM-3,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ppm-3,MAPK7,Kinase,CMGC,2023-12-21,Q13164,,,No,No,,,,Degrader (PROTAC),62.4 Â± 18.6 nM,ADP-Glo Assay,"17 nM, <45 nM","Degradation levels detected via Western blot, Degradation of ERK5 in various cancer cells; Dmax was between 86.7 and 94.7 in teh cell lines tested",DC50,,,
TP-050,0.0,0.0,0.0,No,https://www.chemicalprobes.org/tp-050,GRIN2A,Ion Channel,Glutamate receptor,2023-12-21,Q12879,BEBDKSYNJJVZSO-SECBINFHSA-N,Cc1cn([C@H](C)CC#N)c(=O)c2cc(Cn3nc(C(F)F)cc3Cl)nn12,No,No,CHEMBL5092058,3897346,,Modulator,,,510 nM,"Ca2+ influx assay using CHO cells.
Max. potentiation at 30 ÂµM: 350 %",EC50,Rat,"1 mg/Kg IV, 10 mg/Kg PO",CANSAR3880517
KS176,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ks176,ABCG2,Transporter,ABCG family,2023-12-22,Q9UNQ0,LTWQQWSXYYXVGA-UHFFFAOYSA-N,O=C(Nc1ccccc1C(=O)Nc1ccc(CCO)cc1)c1ccc([N+](=O)[O-])cc1,No,No,CHEMBL4303487,238828,,Inhibitor,,,"590 nM, 1.39Â±0.26 ÂµM","Pheo A assay, Hoechst 33342 assay",IC50,,,
GNE-064,0.0,0.0,0.0,No,https://www.chemicalprobes.org/gne-064,"SMARCA4, SMARCA2, PBRM1","Epigenetic, Epigenetic, Epigenetic","Bromodomain, Bromodomain, Bromodomain",2023-12-22,"P51532, P51531, Q86U86",FHRKRGDHMCCDEO-LLVKDONJSA-N,CC(=O)N1CCN(c2cc(-c3ccccc3O)nnc2N)C[C@H]1C,No,No,,3059884,,Inhibitor,"35 Â± 1 nM, 47 nM, 10 nM, 16 nM, 18 nM, 490 nM","TR-FRET, ITC, BromoSCAN, BromoSCAN of BD5, BromoSCAN of DB2",100 nM,"Cellular target engagement (""dot"") assay",EC50,Mouse,"0.5 (IV), 1.0 (PO) mg/Kg",
NGB2904,4.0,4.0,2.0,No,https://www.chemicalprobes.org/ngb2904,DRD3,GPCR,Dopamine receptor,2023-10-31,P35462,YJPWVCIGSHWNON-UHFFFAOYSA-N,O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2,No,No,CHEMBL300780,564583,,Antagonist,1.4 Â± 0.6 nM,Radioligand binding assay,5.0 nM,Antagonism assay 100 nM quinpirole stimulated mitogenesis,IC50,Rat,"10 mg/kg, 10 mg/Kg",
d9A-2,3.0,0.0,1.0,No,https://www.chemicalprobes.org/d9a-2,SLC9A1,Ion Channel,Cation Proton Antiporter,2020-05-29,P19634,WMBSSRAFHKGIRA-UHFFFAOYSA-N,Cc1cc(-c2ccc(C(=O)NCCOCCOCCOCCOCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)cc2N2CCC(c3[nH]cnc3C)CC2)ccc1F,No,Yes,,3313080,"https://doi.org/10.1016/j.chembiol.2020.04.003, https://pubmed.ncbi.nlm.nih.gov/32386596/",Degrader (PROTAC),,,< 1uM,Cell Viability,EC50,,,
IRAK3-PROTAC 23,4.0,0.0,2.0,No,https://www.chemicalprobes.org/irak3-protac,IRAK3,Kinase,TKL,2023-10-09,Q9Y616,ZUODKONSNNHSAJ-AMLBMYBGSA-N,CC(C)c1ccn2ncnc(N[C@H]3CC[C@@H](N4CCN(C(=O)CCC(=O)N5CCC(CCN6CCN(c7ccc8c(c7)C(=O)N(C7CCC(=O)NC7=O)C8=O)CC6)CC5)CC4)CC3)c12,No,Yes,CHEMBL4749646,3314425,,Degrader (PROTAC),4.9 nM,Enzymatic binding assay,2 nM,"Degradation of IRAK3 in THP1 cells after 16 h treatment, Western blot; maximum degradation measured (Dmax) 98%",DC50,,,CANSAR3575573
ERTUGLIFLOZIN,4.0,4.0,2.0,No,https://www.chemicalprobes.org/ertugliflozin,SLC5A2,Transporter,Solute carrier,2023-10-16,P31639,MCIACXAZCBVDEE-CUUWFGFTSA-N,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,No,No,CHEMBL1770248,288905,,Inhibitor,,,0.927 Â± 0.369 nM,inhibition of methyl Î±-d-glucopyranoside (AMG) uptake via the SGLT transporter,IC50,Rat,"2 mg/Kg, 5.0 mg/Kg",
ABBV-CLS-484,4.0,4.0,1.0,No,https://www.chemicalprobes.org/abbv-cls-484,"PTPN2, PTPN1","Enzyme, Enzyme","Phosphatase, Phosphatase",2023-12-21,"P17706, P18031",DVFCRTGTEXUFIN-GFCCVEGCSA-N,CC(C)CCN[C@@H]1CCc2cc(O)c(N3CC(=O)NS3(=O)=O)c(F)c2C1,No,No,CHEMBL5095164,3879279,,Inhibitor,"1.8 nM, 2.5 nM",Mobility shift assay,"176 nM, 64 nM","B16 pSTAT1 FRET assay, Growth inhibition of B16 tumour cells treated with AC484 with IFNÎ³ (0.5ângâmlâ1)","EC50, IC50",Mouse,"1, 10 mg/Kg",
MRTX0902,4.0,4.0,1.0,No,https://www.chemicalprobes.org/mrtx0902,SOS1,Enzyme,Nucleotide,2023-12-21,Q07889,ILPWEAHQRAWJIU-OAHLLOKOSA-N,Cc1c(C#N)cccc1[C@@H](C)Nc1nnc(C)c2cnc(N3CCOCC3)cc12,No,No,CHEMBL5192659,3932205,,Inhibitor,1.9 nM,HTRF displacement assay,29 nM,In-Cell Western Assay quantifying phosphorylated ERK1/2 (pERK) modulation in MKN1 cells,IC50,"Mouse, Rat, Dog","3 mg/Kg IV, 30 mg/Kg PO, 1 mg/Kg IV, 10 mg/Kg PO, 2 mg/Kg IV, 10 mg/Kg PO",
MK-3697,4.0,4.0,1.0,No,https://www.chemicalprobes.org/mk-3697,HCRTR2,GPCR,Orexin receptor,2023-12-22,O43614,VSOUDUXMPUHJEU-UHFFFAOYSA-N,COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC,No,No,CHEMBL3338865,414493,,Antagonist,1.1 nM,Radioligand Binding Assay,16 nM,FLIPR Assay,IC50,"Rat, Dog, Mouse","2 mg/Kg, 5 mg/Kg, 1 mg/Kg, 3 mg/Kg, 100 mg/Kg, 15 mg/Kg",
BN-81644,3.0,0.0,2.0,No,https://www.chemicalprobes.org/bn81644,SSTR3,GPCR,Somatostatin receptor,2023-11-03,P32745,FOBFICSYUINKAA-XMMPIXPASA-N,CCCCC1(CCCC)N[C@@H](c2nc(-c3ccccc3)c[nH]2)Cc2c1[nH]c1ccccc21,No,No,CHEMBL2069499,454421,,Antagonist,0.64 Â±â0.12 nM,Radioligand binding assay,2.7âÂ±â0.7 nM,Inhibition of SRIF-14 decreased cAMP accumulation induced by forskolin,IC50,,,
KW-6356,4.0,0.0,1.0,No,https://www.chemicalprobes.org/kw-6356,ADORA2A,GPCR,Adenosine receptor,2023-06-30,P29274,KMFLQPJJHQNKKF-UHFFFAOYSA-N,Cc1ccc(C(=O)Nc2nc(-c3ccco3)c(C(=O)C3CCOCC3)s2)cn1,No,No,,3932029,,Antagonist/inverse agonist,0.13 nM,[3H]-KW-6356 binding to human A2A receptor,"0.12 nM, pKB: 10.00 Â± 0.31, pEC50 (âlog of EC50) = 8.46","Radioligand binding assays, cAMP accumulation assay of cells treated with  CGS21680 and KW-6356, inhibition of  constitutive A2A receptor activity",Ki,,,
BIBO3304,3.0,3.0,1.0,No,https://www.chemicalprobes.org/bibo3304,NPY1R,GPCR,Neuropeptide Y receptor,2022-12-20,P25929,TVMJSGGZULFVCZ-XMMPIXPASA-N,N=C(N)NCCC[C@@H](/N=C(\O)C(c1ccccc1)c1ccccc1)/C(O)=N/Cc1ccc(CNC(=N)O)cc1,No,Yes,,3446866,,Antagonist,,,"pKb 9.1, 0.38 nM, 0. 69 nM","cAMP assay, NPY induced inhibition of cAMP synthesis was antagonized by 100 nM BIBO 3304 with a pKb of 9.1 Â± 0.4, Radioligand displacement assay in SK-N-MC transfected cells, Radioligand displacement assay in BHK transfected cells",IC50,Rat,30 Âµg,BIBO3457
VZ185,3.7,0.0,3.0,No,https://www.chemicalprobes.org/vz185,"BRD7, BRD9","Epigenetic, Epigenetic","Bromodomain, Bromodomain",2020-11-12,"Q9NPI1, Q9H8M2",ZAGCLFXBHOXXEN-JPTLTNPLSA-N,COc1cc(-c2cn(C)c(=O)c3cnccc23)cc(OC)c1CN1CCN(CCCCCOc2cc(-c3scnc3C)ccc2CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)CC1,No,Yes,,3312898,"www.doi.org/10.1021/acs.jmedchem.8b01413, https://pubmed.ncbi.nlm.nih.gov/30540463/",Degrader (PROTAC),"26 Â± 9 nM binary, 27 Â± 3nM Ternary",ITC,"4.5 nM, 95%, 1.8 nM",Quantitative Live Cell Kinetic Analysis of BRD7 and BRD9 Degradation,"DC 50, Dmax",,,cis-VZ185
INY-06-061,0.0,0.0,0.0,No,https://www.chemicalprobes.org/iny-06-061,MAPK7,Kinase,CMGC,2024-01-18,Q13164,,,No,No,,,,Degrader (PROTAC),12 nM,Biochemical binding to recombinant ERK5 measured via KdELECT assay (Eurofins),21 nM,Normalized luminescence intensity of MOLT4 ERK5-HiBiT cells treated with indicated compounds and concentrations for 5 hours,DC50,,,INY-06-089
ELIMUSERTIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/elimusertib,ATR,Kinase,PI3/PI4,2024-01-18,Q13535,YBXRSCXGRPSTMW-CYBMUJFWSA-N,C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1,No,No,CHEMBL4647810,3339609,,Inhibitor,7 nM,Biochemical Assay,"36 nM, 9 nM, 71 nM, 160 nM","Phospho-H2AX Assay (Mechanistic assay), Antiproliferative activity, Antiproliferation activity assay",IC50,"Mouse, Rat, Dog",4 mg/Kg,
SOS1-IN-1-15,0.0,0.0,0.0,No,https://www.chemicalprobes.org/sos1-in-15,SOS1,Enzyme,Nucleotide exchange factor,2024-01-18,Q07889,KKFFOOWORPUAJB-NVXWUHKLSA-N,Cc1nc(N[C@H](C)c2cccc(C(F)F)c2F)c2cc3c(cc2n1)OC[C@H]1CN(C(=O)C2(C#N)CC2)CCN31,No,No,CHEMBL5184590,3985626,,PPI Inhibitor,3.9 nM,Biochemical assay (SOS1::KRAS(G12C) HTRF Assay),"178 Â± 42 nM, 21 nM","Anti-proliferation activity, phosphorylation of extracellular regulated protein kinases (ERK)",IC50,"Mouse, Rat, Dog","20 mg/Kg, 2 mg/Kg, 10 mg/Kg",
AZD9574,0.0,0.0,0.0,No,https://www.chemicalprobes.org/azd9574,PARP1,Other post-translational modification,PARP,2024-01-18,P09874,WXRCLFFPZXJCLS-UHFFFAOYSA-N,CNC(=O)c1ccc(N2CCN(Cc3ccc4nc(C)c(=O)[nH]c4c3F)CC2)c(F)n1,No,No,CHEMBL5095223,3879341,,Inhibitor,5.5 nM,fluorescence anisotropy assay,"1.5 nM, 2 nM, 4.7 nM","PARylation assay, Colony formation assay",IC50,Mouse,"0.3, 3.0, 30.0 mg/Kg",
KMI169,0.0,0.0,0.0,No,https://www.chemicalprobes.org/kmi169,N6AMT1,Epigenetic,,2024-01-18,Q9Y5N5,,,No,No,,,,Inhibitor,"25 nM, 12.5 K, 50 nM","Microscale thermophoresis (MST), Fluorescence Thermal Shift Assay (FTSA), KMT9 methyltransferase inhibition assays","9.8 K, 8.3 K, 150 nM, 1 ÂµM","Cellular Thermal Shift Assay (CETSA), MTT cell viability assays, Western blot assessing levels of H4K12me1","ÎTm, GI50, INH",,,KMI169Ctrl
BI-2081,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bi-2081,FFAR1,GPCR,Free fatty acid receptor,2024-01-18,O14842,VXNAMCLMCBLNOL-NFQMXDRXSA-N,Cc1cc(OCCC(C)(C)O)cc(C)c1-c1ccc(F)c2c1CC[C@H]2Oc1ccc2c(c1)OC[C@H]2CC(=O)O,No,No,CHEMBL5075693,3881267,,Agonist,23 nM,Biochemical assay,3-5 nM,"human IPOne assay: Stimulation of 1321N1 cells, which express FFAR1 followed by measurement of the IP1 accumulation by fluorescence",EC50,Rat,"1 mg/Kg IV, 10 mg/Kg PO",CANSAR3894697
BAY-289,0.0,0.0,0.0,No,https://www.chemicalprobes.org/bay-298,LHCGR,GPCR,Luteinizing hormone receptor,2024-01-18,P22888,FMQWOAKTQPLQBR-SANMLTNESA-N,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1,No,No,CHEMBL4537998,3196383,,Antagonist,,,96 nM,Frozen cell assay (TR-FRET),IC50,Rat,"0.5 mg/Kg, 2.0 mg/Kg",
CAMONSERTIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/camonsertib,ATR,Kinase,PI3/PI4,2024-01-18,Q13535,YIHHYCIYAIVQKX-MBIULKOWSA-N,C[C@@H]1COCCN1c1cc([C@]2(O)C[C@H]3CC[C@@H](C2)O3)c2cnn(-c3cc[nH]n3)c2n1,No,No,CHEMBL5095260,3879371,,Inhibitor,"1.0 nM, 0.022 nM","ATR kinase assay at 3 ÂµM ATP, ATR/ATRIP Biochemical assay",0.33 nM,Inhibition of gemcitabine-stimulated ATR phosphorylation of substrate pCHK1(Ser345) during early treatment (up to 3 h),IC50,Mouse,3 mg/Kg,
CERALASERTIB,0.0,0.0,0.0,No,https://www.chemicalprobes.org/ceralasertib,ATR,Kinase,PI3/PI4,2024-01-18,Q13535,RHGZXPKHVAHQJO-BIIHCSGHSA-N,C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(C2CCNC3NCCC32)n1,No,Yes,CHEMBL4285417,3546672,,Inhibitor,1 nM,Biochemical assay using 32P radioactive assays,76 nM,ATR kinase-dependent CHK1 phosphorylation in cells,IC50,"Rat, Dog","8.55 (IV), 20.3 (PO) Î¼mol/kg, 10.5 (IV), 15.1 (PO) Î¼mol/kg",
JRD-SIK1/2i-4,0.0,0.0,0.0,No,https://www.chemicalprobes.org/jrd-sik1-2i-4,"SIK1, SIK2","Kinase, Kinase","CAMK, CAMK",2024-01-18,"P57059, Q9H0K1",,,No,No,,,,Inhibitor,"143 nM, 3.1 nM, 76 nM, 1.9 nM","ADP-Gloâ¢ Max assay at high ATP, Eurofins Cerep KinaseProfiler assay at Km ATP","700 nM, 110 nM, 250 nM, 2910 nM","IL-10 elevation, TNF suppression in R848 stimulated macrofages, IL-12/23 p40 suppression in R848 stimulated macrophages, CRTC3 nuclear translocation assay","EC50, IC50","Rat, Mouse","1 mg/Kg IV, 5 mg/Kg PO, 20 and 80 mg/Kg",
YKL-5-124,3.0,0.0,2.0,No,https://www.chemicalprobes.org/ykl-5-124,CDK7,Kinase,CMGC,2023-12-21,P50613,KPABJHHKKJIDGX-JOCHJYFZSA-N,C=CC(=O)Nc1ccc(C(=O)Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)cc1,No,Yes,CHEMBL4450322,3145566,,Covalent Inhibitor,"9.7 nM, 53.3 nM, 2.2 nM","Invitrogen, biochemical assay, Geyer, P32 biochemical assay, Westover, enzyme kinetics using mobility shift assay
(Kinact 228 us-1, kinact/Ki 103 us-1 nM-1)",<62.5 nM,Inhibition of RNA Pol II phosphorylation,IC50,,,"N-[(1S)-2-(dimethylamino)-1-phenyl-ethyl]-6,6-dimethyl-3-[[4-(propanoylamino)benzoyl]amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide"
AZD0156,4.0,3.0,1.0,No,https://www.chemicalprobes.org/azd0156,ATM,Kinase,PI3/PI4,2024-01-18,Q13315,AOTRIQLYUAFVSC-UHFFFAOYSA-N,CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1,No,No,"CHEMBL3960662, CHEMBL4297899",607333,,Inhibitor,0.04 nM,Enzymatic assay (HTRF),0.57 nM,Detection of pATM via western blot,IC50,Mouse,5 mg/Kg,
DKY709,0.0,0.0,0.0,No,https://www.chemicalprobes.org/dky709,IKZF2,Transcription factor,Zinc Finger,2024-01-26,Q9UKS7,OMISHRJQMYQPMG-UHFFFAOYSA-N,O=C1CCC(N2Cc3cc(C4CCN(Cc5ccccc5)CC4)ccc3C2=O)C(=O)N1,No,No,CHEMBL5077506,3882367,,Degrader (PROTAC),"130 nM, 190 nM","Biochemical CBRN binding assay, SPR of the trimeric complex with ZF2 and 3","4 nM, 73 nM, 11 nM","Cellular degradation assay Dmax 53%, CRBN cellular engagement, Degradation of endogenous IKZF2 (Dmax 69% after 20h)","DC50, IC50","Mouse, Monkey (Cynomolgus)","2 mg/Kg, 3 mg/Kg, 0.3 mg/Kg, 1.0 mg/Kg",
BAY-8400,2.0,1.0,1.0,No,https://www.chemicalprobes.org/bay-8400,PRKDC,Kinase,PI3/PI4,2024-01-18,P78527,ATKHYZXUMVNCIO-UHFFFAOYSA-N,FC(F)c1cncc(-c2ccc3ncc4nnc(C5=CCCOCC5)n4c3c2)c1,No,No,CHEMBL4851439,3634675,,Inhibitor,81 nM,Biochemical DNA-PK Activity Assay (TR-FRET),69 nM,Phospho-H2AX Assay to Determine Inhibition of DNA-PK,IC50,"Rat, Mouse","0.3 mg/kg IV, 0.6 mg/kg PO, 0.3 mg/kg",
BI-8668,3.0,3.0,1.0,No,https://www.chemicalprobes.org/bi-8668,"SCNN1A, SCNN1B, SCNN1G","Ion Channel, Ion Channel, Ion Channel","Sodium channel, Sodium Channel, Sodium channel ",2024-01-18,"P37088, P51168, P51170",,,No,No,,,,Inhibitor,,,"81%, 6.2 nM, 16.8 nM","Inhibition of M-1 water resorption (Measurement of ENaC-mediated water permeability through cell monolayers of M-1 cells and the blocking capacity of ENaC-inhibitors. The transported volume is determined with tritiated water. A potent ENaC-inhibitor results in reduced water transport leading to more remaining liquid in the apical (upper) compartment of the cell layer.), Inhibition of Na + transport in mouse renal collecting duct cell line M1 (ussing chamber assay), Ussing Chamber applying P0 cells","% in, IC50","Mouse, Rat","0.5 umol/kg, 0.5 umol/Kg",BI-0337
